

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, consisting of vertical black bars of varying widths on a white background.

(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72781 A2

- (51) International Patent Classification⁷: C07K 14/00
(21)- International Application Number: PCT/US01/09952
(22) International Filing Date: 27 March 2001 (27.03.2001)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/192,583 28 March 2000 (28.03.2000) US
(71) Applicants (*for all designated States except US*): CHIRON CORPORATION [US/US]; 4560 Horton Street-R440, Emeryville, CA 04608 (US). HYSEQ INC. [US/US]; 675 Almanor Avenue, Sunnyvale, CA 94086 (US).
(72) Inventors; and
(75) Inventors/Applicants (*for US only*): WILLIAMS, Lewis, T. [US/US]; 3 Miroflores, Tiburon, CA 94920 (US). ESCOBEDO, Jaime [CL/US]; 1470 Lavora Road, Alamo, CA 94507 (US). INNIS, Michael, A. [US/US]; 315 Constance Place, Moraga, CA 94556 (US). GARCIA, Pablo, Dominguez [CL/US]; 882 Chenery Street, San Francisco, CA 94131 (US). SUDDUTH-KLINGER, Julie [US/US]; 280 Lexington Road, Kensington, CA 94707 (US). REINHARD, Christoph [DE/US]; 1633 Clinton Avenue, Alameda, CA 94501 (US). HE, Zhijun [US/US]; Union City, CA (US). RANDAZZO, Filippo [US/US]; 690 Chestnut Street, Apt. 403, San Francisco, CA 94133 (US). KENNEDY, Giulia, C. [US/US]; 360 Castaneda Avenue, San Francisco, CA 94116 (US). POT, David [CA/US]; 1565 5th Avenue #102, San Francisco, CA 94112 (US). KASSAM, Altaf [US/US]; 2659 Harold Street, Oakland, CA 94602 (US). LAMSON, George [US/US]; 232 Sandringham Drive, Moraga, CA 94556 (US). DRMANAC, Radoje [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). CRKVENJAKOV,

[Continued on next page]

(54) Title: HUMAN GENES AND GENE EXPRESSION PRODUCTS XVI

(57) Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variant thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. This invention also relates to diagnostic and therapeutic agents employing such novel polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.



Radomir [YU/US]; 762 Haverhill Drive, Sunnyvale, CA 94068 (US). **DICKSON, Mark** [US/US]; 1411 Gibilan Drive #B, Hollister, CA 95025 (US). **DRMANAC, Snezana** [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). **LABAT, Ivan** [YU/US]; 140 Acalanes Drive, Sunnyvale, CA 94086 (US). **LESHKOWITZ, Dena** [US/US]; 678 Durshire Way, Sunnyvale, CA 94087 (US). **KITA, David** [US/US]; 899 Bounty Drive, Foster City, CA 94404 (US). **GARCIA, Veronica** [ES/US]; 396 Ano Nuevo, Apt. 412, Sunnyvale, CA 94086 (US). **JONES, Lee, William** [US/US]; 396 Ano Nuevo #412, Sunnyvale, CA 94086 (US). **STACHE-CRAIN, Birgit** [DE/US]; 345 South Mary Avenue, Sunnyvale, CA 94086 (US).

- (74) Agent: **BLACKBURN, Robert, P.**; Chief Patent Counsel, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

HUMAN GENES AND GENE EXPRESSION PRODUCTS XVI

Field of the Invention

The present invention relates to polynucleotides of human origin and the encoded gene products.

Background of the Invention

Identification of novel polynucleotides, particularly those that encode an expressed gene product, is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer. Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences.

This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.

Summary of the Invention

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS:1-316.

Various aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.

Brief Description of the Figures

Figures 1A-1B is a comparison of SEQ ID NO:315 and clone H72034 (SEQ ID NO:317).
Figure 2 is a comparison of SEQ ID NO:316 and clone AA707002 (SEQ ID NO:318).

Detailed Description of the Invention

The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA genomic sequences, and genes corresponding to these sequences and degenerate variants thereof, and to polypeptides encoded by the polynucleotides of the invention and polypeptide variants. The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA

encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding 5 polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.

Polynucleotide Compositions

The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of SEQ ID NOS:1-10 316; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency); genes corresponding to the provided polynucleotides; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a 15 biological activity of the encoded gene product (e.g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family(ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here. 20 “Polynucleotide” and “nucleic acid” as used herein with reference to nucleic acids of the composition is not intended to be limiting as to the length or structure of the nucleic acid unless specifically indicated.

The invention features polynucleotides that are expressed in human tissue, specifically human colon, breast, and/or lung tissue. Novel nucleic acid compositions of the invention of 25 particular interest comprise a sequence set forth in any one of SEQ ID NOS:1-316 or an identifying sequence thereof. An “identifying sequence” is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, e.g., exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 30 80 nt. Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of SEQ ID NOS: 1-316.

The polynucleotides of the invention also include polynucleotides having sequence 35 similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1XSSC.

Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1XSSC (9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, e.g., USPN 5,707,829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences (SEQ ID NOS:1-316) under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e.g. primate species, particularly human; rodents, such as rats and mice; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.

Preferably, hybridization is performed using at least 15 contiguous nucleotides (nt) of at least one of SEQ ID NOS:1-316. That is, when at least 15 contiguous nt of one of the disclosed SEQ ID NOS. is used as a probe, the probe will preferentially hybridize with a nucleic acid comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids that uniquely hybridize to the selected probe. Probes from more than one SEQ ID NO. can hybridize with the same nucleic acid if the cDNA from which they were derived corresponds to one mRNA. Probes of more than 15 nt can be used, e.g., probes of from about 18 nt to about 100 nt, but 15 nt represents sufficient sequence for unique identification.

The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e.g., degenerate variants, allelic variants, etc.). Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions. For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30% base pair (bp) mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% bp mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% bp mismatches, as well as a single bp mismatch.

The invention also encompasses homologs corresponding to the polynucleotides of SEQ ID NOS:1-316, where the source of homologous genes can be any mammalian species, e.g., primate species, particularly human; rodents, such as rats; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e.g., human and mouse, homologs generally have substantial sequence similarity, e.g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete

sequence that is being compared. Algorithms for sequence analysis are known in the art, such as gapped BLAST, described in Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402.

In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith-Waterman algorithm, using the following. Global DNA sequence identity must be greater than 65% as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty, 12; and gap extension penalty, 1.

The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e.g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3' and 5' untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' and 3' end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' and 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease-state specific expression.

The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 15, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nt selected from the polynucleotide sequences as shown in SEQ ID NOS:1-316. For the most part,

fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least 12 nt selected from the group consisting of the polynucleotides shown in SEQ ID NOS:1-316.

- 5 Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in SEQ ID NOS:1-316. The probes are preferably at least about a 12, 15, 16, 18, 20, 22, 24, or 25 nt fragment of a corresponding contiguous sequence of SEQ ID NOS:1-316, and can be less than 2, 1, 0.5, 0.1, or 0.05 kb in length. The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes.
- 10 The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of SEQ ID NOS:1-316. More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (*e.g.*, XBLAST) to the sequence., *i.e.*, one would select an unmasked 15 region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.

The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, 20 generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *e.g.*, flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule, and can be provided within autonomously replicating molecules (vectors) or 25 within molecules without replication sequences. Expression of the polynucleotides can be regulated by their own or by other regulatory sequences known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex 30 beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

The subject nucleic acid compositions can be used to, for example, produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (*e.g.*, extracts of human 35 cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides. The probes described herein can be used to, for example, determine the presence or absence of the

polynucleotide sequences as shown in SEQ ID NOS:1-316 or variants thereof in a sample. These and other uses are described in more detail below.

Use of Polynucleotides to Obtain Full-Length cDNA, Gene, and Promoter Region

Full-length cDNA molecules comprising the disclosed polynucleotides are obtained as follows. A polynucleotide having a sequence of one of SEQ ID NOS:1-316, or a portion thereof comprising at least 12, 15, 18, or 20 nt, is used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection techniques such as those described in USPN 5,654,173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent. Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA libraries, the libraries are prepared from mRNA of human colon cells, more preferably, human colon cancer cells, even more preferably, from a highly metastatic colon cell, Km12L4-A.

Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. The cDNA can be prepared by using primers based on sequence from SEQ ID NOS:1-316. In one embodiment, the cDNA library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.

Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows. Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretic mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. In order to obtain additional sequences 5' to the end of a partial cDNA, 5' RACE (*PCR Protocols: A Guide to Methods and Applications*, (1990) Academic Press, Inc.) can be performed.

Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, 5 the genomic DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as P1 or YAC, as described in detail in Sambrook *et al.*, 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntsville, Alabama, USA, for example. In order to obtain additional 5' or 3' sequences, 10 chromosome walking is performed, as described in Sambrook *et al.*, such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.

Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using 15 either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA libraries are taught in Sambrook *et al.*, *supra*. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be 20 produced using the instant sequences as primers.

PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector 25 then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library 30 vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber *et al.*, WO 95/04745 and Gruber *et al.*, USPN 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.

“Rapid amplification of cDNA ends,” or RACE, is a PCR method of amplifying cDNAs 35 from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant

polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this methods is reported in WO 97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, *Biotechniques* 5 (1993) 15:890-893; Edwards *et al.*, *Nuc. Acids Res.* (1991) 19:5227-5232). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

Another PCR-based method generates full-length cDNA library with anchored ends 10 without needing specific knowledge of the cDNA sequence. The method uses lock-docking primers (I-VI), where one primer, poly TV (I-III) locks over the polyA tail of eukaryotic mRNA producing first strand synthesis and a second primer, polyGH (IV-VI) locks onto the polyC tail produced by terminal deoxynucleotidyl transferase (TdT)(see, e.g., WO 96/40998).

The promoter region of a gene generally is located 5' to the initiation site for RNA 15 polymerase II. Hundreds of promoter regions contain the "TATA" box, a sequence such as TATTA or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5' RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence, and the region 5' to the coding region is identified by "walking up." If the gene is highly expressed or differentially expressed, the promoter from the 20 gene can be of use in a regulatory construct for a heterologous gene.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook *et al.*, 15.3-15.63. The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.

As an alternative method to obtaining DNA or RNA from a biological material, nucleic 25 acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nt (corresponding to at least 15 contiguous nt of one of SEQ ID NOS:1-316) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic 30 acid having the size of a full gene, and comprising at least one of SEQ ID NOS:1-316; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b); and (e) a recombinant viral particle comprising (a) or (b). Once provided 35 with the polynucleotides disclosed herein, construction or preparation of (a) - (e) are well within the skill in the art.

The sequence of a nucleic acid comprising at least 15 contiguous nt of at least any one of SEQ ID NOS:1-316, preferably the entire sequence of at least any one of SEQ ID NOS:1-316, is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will 5 depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of SEQ ID NOS:1-316 is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of SEQ ID NOS:1-316.

Expression of Polypeptide Encoded by Full-Length cDNA or Full-Length Gene

10 The provided polynucleotides (e.g., a polynucleotide having a sequence of one of SEQ ID NOS:1-316), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of SEQ ID NOS:1-316 can also be generated synthetically. Alternatively, single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e.g., Stemmer *et al.*, 15 *Gene (Amsterdam)* (1995) 164(1):49-53. In this method, assembly PCR (the synthesis of long DNA sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA shuffling (Stemmer, *Nature* (1994) 370:389-391), and does not rely on DNA ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process.

20 Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Vectors, host cells and methods for obtaining expression in same are well known in the art. Suitable vectors and host cells are described in USPN 5,654,173.

25 Polynucleotide molecules comprising a polynucleotide sequence provided herein are generally propagated by placing the molecule in a vector. Viral and non-viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available 30 commercially. Methods for preparation of vectors comprising a desired sequence are well known in the art.

The polynucleotides set forth in SEQ ID NOS:1-316 or their corresponding full-length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The 5 promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.

When any of the above host cells, or other appropriate host cells or organisms, are used to 10 replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.

Once the gene corresponding to a selected polynucleotide is identified, its expression can 15 be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in USPN 5,641,670.

Identification of Functional and Structural Motifs of Novel Genes Screening Against Publicly Available Databases

Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full 20 genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention. Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences.

The full length sequences and fragments of the polynucleotide sequences of the nearest 25 neighbors can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides.

Typically, a selected polynucleotide is translated in all six frames to determine the best 30 alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5' to 3' orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences. Databases with individual sequences are described in "Computer Methods for Macromolecular Sequence Analysis" *Methods in Enzymology* (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co.,

San Diego, California, USA. Databases include GenBank, EMBL, and DNA Database of Japan (DDBJ).

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST 2.0, available over the world wide web at a site supported by 5 the National Center for Biotechnology Information, which is supported by the National Library of Medicine and the National Institutes of Health. See also Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in Doolittle, *supra*. Preferably, an 10 alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See *Meth. Mol. Biol.* (1997) 70: 173-187. Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on 15 a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases. Incorporated herein by reference are all sequences that have been made public as of the filing date of this application by any of the DNA or protein sequence databases, including 20 the patent databases (*e.g.*, GeneSeq). Also incorporated by reference are those sequences that have been submitted to these databases as of the filing date of the present application but not made public until after the filing date of the present application.

Results of individual and query sequence alignments can be divided into three categories: high similarity, weak similarity, and no similarity. Individual alignment results ranging from high 25 similarity to weak similarity provide a basis for determining polypeptide activity and/or structure. Parameters for categorizing individual results include: percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value. The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, *e.g.*, contiguous region of the individual 30 sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query 35 sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11

amino acid stretch. The percentage of the alignment region length is: 11 (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%.

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90.9%

P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin *et al.*, *Proc. Natl. Acad. Sci.* (1990) 87:2264 and Karlin *et al.*, *Proc. Natl. Acad. Sci.* (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul *et al.*, *Nat. Genet.* (1994) 6:119. Alignment programs such as BLAST program can calculate the p value. See also Altschul *et al.*, *Nucleic Acids Res.* (1997) 25:3389-3402.

Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle, *supra*; BLAST 2.0 (see, e.g., Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402) or FAST programs; or by determining the area where sequence identity is highest.

High Similarity. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about 55% of total length query sequence; more typically, at least about 58%; even more typically; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62%; more usually, as much as about 64%; even more usually, as much as about 66%. Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity; more typically, at least about 78%; even more typically; at least about 80% sequence identity. Usually, percent sequence identity can be as much as about 82%; more usually, as much as about 84%; even more usually, as much as about 86%.

The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about 10^{-2} ; more usually; less than or equal to about 10^{-3} ; even more usually; less than or equal to about 10^{-4} . More typically, the p value is no more than about 10^{-5} ; more typically; no more than or equal to about 10^{-10} ; even more typically; no more than or equal to about 10^{-15} for the query sequence to be considered high similarity.

Weak Similarity. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length; more typically, at least about 20; even more typically; at 5 least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues; more usually, as much as about 40; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically, exhibits at least about 35% of sequence identity; more typically, at least about 40%; even more typically; at least about 45% sequence identity. Usually, percent sequence identity can be as 10 much as about 50%; more usually, as much as about 55%; even more usually, as much as about 60%.

If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about 10^{-2} ; more usually; less than or equal to about 10^{-3} ; even more usually; less than or equal to about 10^{-4} . More typically, the p 15 value is no more than about 10^{-5} ; more usually; no more than or equal to about 10^{-10} ; even more usually; no more than or equal to about 10^{-15} for the query sequence to be considered weak similarity.

Similarity Determined by Sequence Identity Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of 20 the sequence. Such an alignment, preferably, permits gaps to align sequences. Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15%; more typically, at least about 20%; even more typically, at least about 25%; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length; more usually, 90 residues; 25 even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length; more preferably, 120 residues in length; even more preferably, 150 amino acid residues in length.

Alignments with Profile and Multiple Aligned Sequences. Translations of the provided 30 polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs. Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs. Similarity or identity with profile sequences or MSAs can be used to determine the activity of the gene products (e.g., polypeptides) encoded by the provided polynucleotides or 35 corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA can exhibit chemokine activities.

Profiles can be designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney *et al.*, *Nucl. Acid Res.* (1996) 24(14): 2730-2739. MSAs of some protein families and motifs are publicly available. For example, the Genome Sequencing Center at the Washington University School of Medicine provides a web set (Pfam) which includes MSAs of 547 different families and motifs. These MSAs are described also in Sonnhammer *et al.*, *Proteins* (1997) 28: 405-420. Other sources over the world wide web include the site supported by the European Molecular Biology Laboratories in Heidelberg, Germany. A brief description of these MSAs is reported in Pascarella *et al.*, *Prot. Eng.* (1996) 9(3):249-251. Techniques for building profiles from MSAs are described in Sonnhammer *et al.*, *supra*; Birney *et al.*, *supra*; and "Computer Methods for Macromolecular Sequence Analysis," *Methods in Enzymology* (1996) 266, Doolittle, Academic Press, Inc., San Diego, California, USA.

Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Searchwise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile (see Birney *et al.*, *supra*). Other techniques to compare the sequence and profile are described in Sonnhammer *et al.*, *supra* and Doolittle, *supra*.

Next, methods described by Feng *et al.*, *J. Mol. Evol.* (1987) 25:351 and Higgins *et al.*, *CABIOS* (1989) 5:151 can be used to align the query sequence with the members of a family or motif, also known as a MSA. Sequence alignments can be generated using any of a variety of software tools. Examples include PileUp, which creates a multiple sequence alignment, and is described in Feng *et al.*, *J. Mol. Evol.* (1987) 25:351. Another method, GAP, uses the alignment method of Needleman *et al.*, *J. Mol. Biol.* (1970) 48:443. GAP is best suited for global alignment of sequences. A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith *et al.*, *Adv. Appl. Math.* (1981) 2:482. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists: (1) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence, (3) number of frameshifts, and (4) spacing between conserved residues.

Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from

two frameshifts. Preferably, three or fewer frameshifts are found in an alignment; more preferably two or fewer frameshifts; even more preferably, one or fewer frameshifts; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs.

Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.

Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A residue is considered conserved when three unrelated amino acids are found at a particular position in the some or all of the members; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA; more usually, at least about 30%; even more usually; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45% of the conserved residues of the profile or MSA; more typically, at least about 50%; even more typically; at least about 55%.

Identification of Secreted & Membrane-Bound Polypeptides

Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, prostatic fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides. Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides.

- A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane-bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & Woods, *Proc. Natl. Acad. Sci. USA* (1981) 78:3824-3828; Kyte & Doolittle, *J. Mol. Biol.* (1982) 157: 105-132; and RAOAR algorithm, Degli Esposti *et al.*, *Eur. J. Biochem.* (1990) 190: 207-219.
- Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic amino acids are present. Those translated polypeptides with at least 8; more typically, 10; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine.

Identification of the Function of an Expression Product of a Full-Length Gene

Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein. These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function. Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage *et al.*, *Tet. Lett.* (1981) 22:1859 and USPN 4,668,777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, California, USA; and Expedite by Perceptive Biosystems, Framingham, Massachusetts, USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attached to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, California, USA.

Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A sulfurizing reagent, such as tetraethylthiuram disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard

phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.

Oligonucleotides of up to 200 nt can be synthesized, more typically, 100 nt, more typically 50 nt; even more typically 30 to 40 nt. These synthetic fragments can be annealed and ligated 5 together to construct larger fragments. See, for example, Sambrook *et al.*, *supra*. Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein 10 expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect. One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, as well as therapeutic uses of ribozymes, are disclosed in Usman *et al.*, *Current Opin. Struct. Biol.* (1996) 15 6:527. Methods for production of ribozymes, including hairpin structure ribozyme fragments, methods of increasing ribozyme specificity, and the like are known in the art.

The hybridizing region of the ribozyme can be modified or can be prepared as a branched structure as described in Horn and Urdea, *Nucleic Acids Res.* (1989) 17:6959. The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and 20 chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh *et al.*, *Eur. J. Biochem.* (1997) 245:1.

Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or 25 messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed 30 polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.

Given the extensive background literature and clinical experience in antisense therapy, one 35 skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics. The choice of polynucleotide can be narrowed by first testing them for binding to

"hot spot" regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a "hot spot", testing the polynucleotide as an antisense compound in the corresponding cancer cells is warranted.

As an alternative method for identifying function of the gene corresponding to a 5 polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer. Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain. Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such 10 an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e.g., Herskowitz, *Nature* (1987) 329:219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.

Polypeptides and Variants Thereof

15 The polypeptides of the invention include those encoded by the disclosed polynucleotides, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ ID NOS:1-316 or a variant thereof.

20 In general, the term "polypeptide" as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof. "Polypeptides" also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurring protein, and can be of an origin of the same or different species as the naturally occurring protein (e.g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 25 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by BLAST 2.0 using the parameters described above. The variant polypeptides can be naturally or 30 non-naturally glycosylated, i.e., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring protein.

The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, i.e. other animal or plant species, where such homologs, usually mammalian species, e.g. rodents, such as mice, rats; domestic 35 animals, e.g., horse, cow, dog, cat; and humans. By "homolog" is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid

sequence identity to a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST 2.0 algorithm, with the parameters described *supra*.

In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, e.g. are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control. As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of non-differentially expressed polypeptides.

Also within the scope of the invention are variants; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/ hydrophilicity, and/or steric bulk of the amino acid substituted. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Selection of amino acid alterations for production of variants can be based upon the accessibility (interior vs. exterior) of the amino acid (see, e.g., Go *et al.*, *Int. J. Peptide Protein Res.* (1980) 15:211), the thermostability of the variant polypeptide (see, e.g., Querol *et al.*, *Prot. Eng.* (1996) 9:265), desired glycosylation sites (see, e.g., Olsen and Thomsen, *J. Gen. Microbiol.* (1991) 137:579), desired disulfide bridges (see, e.g., Clarke *et al.*, *Biochemistry* (1993) 32:4322; and Wakarchuk *et al.*, *Protein Eng.* (1994) 7:1379), desired metal binding sites (see, e.g., Toma *et al.*, *Biochemistry* (1991) 30:97, and Haezerbrouck *et al.*, *Protein Eng.* (1993) 6:643), and desired substitutions within proline loops (see, e.g., Masul *et al.*, *Appl. Env. Microbiol.* (1994) 60:3579). Cysteine-depleted mutoins can be produced as disclosed in USPN 4,959,314.

Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any SEQ ID NOS:1-316, or a

homolog thereof. The protein variants described herein are encoded by polynucleotides that are within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.

Computer-Related Embodiments

5 In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (*e.g.*, as a collection of polynucleotide molecules), or in electronic form (*e.g.*, as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, *e.g.*, as a resource for
10 gene discovery, as a representation of sequences expressed in a selected cell type (*e.g.*, cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (*e.g.*, a cell of the same or similar type that is not substantially affected by disease). For example, a polynucleotide sequence in a library can be a
15 polynucleotide that represents an mRNA, polypeptide, or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (*i.e.*, substantially disease-free) breast cell.

The nucleotide sequence information of the library can be embodied in any suitable form, *e.g.*, electronic or biochemical forms. For example, a library of sequence information embodied in
20 electronic form comprises an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (*e.g.*, overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell; ii) a cancerous cell and a dysplastic cell; iii) a cancerous cell and a cell affected by a disease or condition other than cancer; iv) a metastatic cancerous cell and a
25 normal cell and/or non-metastatic cancerous cell; v) a malignant cancerous cell and a non-malignant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the
30 nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.

The polynucleotide libraries of the subject invention generally comprise sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of SEQ ID NOS:1-316. By plurality is meant at least 2, usually at least 3
35 and can include up to all of SEQ ID NOS:1-316. The length and number of polynucleotides in the

library will vary with the nature of the library, *e.g.*, if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.

Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media. "Media" refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention. Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, *e.g.* the nucleic acid sequences of any of the polynucleotides of SEQ ID NOS:1-316, can be recorded on computer readable media, *e.g.* any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. "Recorded" refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, *e.g.* word processing text file, database format, *etc.* In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-readable files (*e.g.*, searchable files, executable files, *etc.*, including, but not limited to, for example, search program software, *etc.*).

By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the gapped BLAST (Altschul *et al. Nucleic Acids Res.* (1997) 25:3389-3402) and BLAZE (Brutlag *et al. Comp. Chem.* (1993) 17:203) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.

As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture.

"Search means" refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif, or expression levels of a polynucleotide in a sample, with the stored sequence information. Search means can be used to identify fragments or regions of the genome that match a particular target sequence or target motif.

- 5 A variety of known algorithms are publicly known and commercially available, e.g. MacPattern (EMBL), BLASTN and BLASTX (NCBI). A "target sequence" can be any polynucleotide or amino acid sequence of six or more contiguous nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nt. A variety of comparing means can be used to accomplish comparison of sequence information from a sample (e.g., to analyze target 10 sequences, target motifs, or relative expression levels) with the data storage means. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention to accomplish comparison of target sequences and motifs. Computer programs to analyze expression levels in a sample and in controls are also known in the art.

- 15 A "target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target 20 motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.

- A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks the relative expression levels of different polynucleotides. Such presentation 25 provides a skilled artisan with a ranking of relative expression levels to determine a gene expression profile.

- As discussed above, the "library" of the invention also encompasses biochemical libraries of the polynucleotides of SEQ ID NOS:1-316, e.g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e.g., a solution of 30 cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (*i.e.*, an array) and the like. Of particular interest are nucleic acid arrays in which one or more of SEQ ID NOS:1-316 is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10 nt, usually at 35 least 20 nt and often at least 25 nt. A variety of different array formats have been developed and are known to those of skill in the art. The arrays of the subject invention find use in a variety of

applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.

In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the polypeptides of the library will represent at least a portion of the

5 polypeptides encoded by SEQ ID NOS:1-316.

Utilities

Use of Polynucleotide Probes in Mapping, and in Tissue Profiling

Polynucleotide probes, generally comprising at least 12 contiguous nt of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping 10 of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.

15 Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for *in situ* 20 hybridization to cells to detect expression. Probes can also be used *in vivo* for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in WO92/02526 and USPN 5,124,246.

Alternatively, the Polymerase Chain Reaction (PCR) is another means for detecting small 25 amounts of target nucleic acids (see, e.g., Mullis *et al.*, *Meth. Enzymol.* (1987) 155:335; USPN 4,683,195; and USPN 4,683,202). Two primer polynucleotides nucleotides that hybridize with the target nucleic acids are used to prime the reaction. The primers can be composed of sequence 30 within or 3' and 5' to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3' and 5' to these polynucleotides, they need not hybridize to them or the complements. After amplification of the target with a thermostable polymerase, the amplified target nucleic acids can be detected by methods known in the art, e.g., Southern blot. mRNA or cDNA can also be detected by traditional blotting techniques (e.g., Southern blot, Northern blot, etc.) described in Sambrook *et al.*, "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory, 1989) (e.g., without PCR amplification). In general, mRNA or cDNA generated from mRNA using 35 a polymerase enzyme can be purified and separated using gel electrophoresis, and transferred to a

solid support, such as nitrocellulose. The solid support is exposed to a labeled probe, washed to remove any unhybridized probe, and duplexes containing the labeled probe are detected.

Mapping. Polynucleotides of the present invention can be used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in USPN 5,783,387. An exemplary mapping method is fluorescence in situ hybridization (FISH), which facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA sequences (see, e.g., Valdes *et al.*, *Methods in Molecular Biology* (1997) 68:1). Polynucleotides can also be mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels. See Leach *et al.*, *Advances in Genetics*, (1995) 33:63-99; Walter *et al.*, *Nature Genetics* (1994) 7:22; Walter and Goodfellow, *Trends in Genetics* (1992) 9:352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Alabama, USA. Databases for markers using various panels are available via the world wide web at sites supported by the Stanford Human Genome Center (Stanford University) and the Whitehead Institute for Biomedical Research/MIT Center for Genome Research. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RHMAP is available via the world wide web at a site supported by the Center for Statistical Genetics at the University of Michigan School of Public Health. In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer.

Tissue Typing or Profiling. Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific. This variation of mRNA levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA.

Tissue typing can be used to identify the developmental organ or tissue source of a metastatic lesion by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide can be assayed by detection of either the corresponding mRNA or the protein product. As would be readily apparent to any forensic scientist, the sequences disclosed herein are useful in differentiating human tissue from non-human tissue. In particular, these

sequences are useful to differentiate human tissue from bird, reptile, and amphibian tissue, for example.

Use of Polymorphisms. A polynucleotide of the invention can be used in forensics, genetic analysis, mapping, and diagnostic applications where the corresponding region of a gene is

- 5 polymorphic in the human population. Any means for detecting a polymorphism in a gene can be used, including, but not limited to electrophoresis of protein polymorphic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to allele-specific probes.

Antibody Production

- Expression products of a polynucleotide of the invention, as well as the corresponding 10 mRNA, cDNA, or complete gene, can be prepared and used for raising antibodies for experimental, diagnostic, and therapeutic purposes. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and 15 can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.

Methods for production of antibodies that specifically bind a selected antigen are well known in the art. Immunogens for raising antibodies can be prepared by mixing a polypeptide encoded by a polynucleotide of the invention with an adjuvant, and/or by making fusion proteins 20 with larger immunogenic proteins. Polypeptides can also be covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously, or intramuscularly to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Monoclonal antibodies can be. Monoclonal antibodies can be generated by isolating spleen cells and fusing myeloma cells to form hybridomas. 25 Alternatively, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo. The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.

Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies 30 specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. Epitopes that involve non-contiguous amino acids may require a longer polypeptide, e.g., at least 15, 25, or 50 amino acids. Antibodies that specifically bind to human 35 polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies that specifically bind polypeptides of the

invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.

The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, serum antibodies to a polypeptide of the invention in a human population can be purified by methods well known in the art, e.g., by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example using a buffer with a high salt concentration.

In addition to the antibodies discussed above, the invention also contemplates genetically engineered antibodies, antibody derivatives (e.g., single chain antibodies, antibody fragments (e.g., Fab, etc.)), according to methods well known in the art.

Polynucleotides or Arrays for Diagnostics

Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotide sequences in a sample. This technology can be used as a diagnostic and as a tool to test for differential expression, e.g., to determine function of an encoded protein. Arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocelllose, etc.) in a two-dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP 799 897; WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; USPN 5,593,839; USPN 5,578,832; EP 728 520; USPN 5,599,695; EP 721 016; USPN 5,556,752; WO 95/22058; and USPN 5,631,734. Arrays can be used to, for example, examine differential expression of genes and can be used to determine gene function. For example, arrays can be used to detect differential expression of a polynucleotide between a test cell and control cell (e.g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific gene product. Exemplary uses of arrays are further described in, for example, Pappalarado *et al.*, *Sem. Radiation Oncol.* (1998) 8:217; and Ramsay *Nature Biotechnol.* (1998) 16:40.

Differential Expression in Diagnosis

The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e.g., as a method to identify abnormal or diseased tissue in a human. For polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to

a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example an intestinal polyp or other abnormal growth should be compared with normal 5 intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example in molecular weight, amino acid or 10 nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in USPNs 5,688,641 and 5,677,125.

A genetic predisposition to disease in a human can also be detected by comparing 15 expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this purpose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo. The comparable normal polynucleotide-related gene is obtained from any tissue. The mRNA or protein is obtained from a normal tissue of a human in which the 20 polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. In general, diagnostic, prognostic, and other methods of the 25 invention based on differential expression involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e.g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereof), and comparing the detected levels to those levels found in normal cells (e.g., cells substantially unaffected by cancer) and/or other control cells (e.g., to differentiate a 30 cancerous cell from a cell affected by dysplasia). Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially gene product associated with varying degrees of severity of disease. It should be noted that use of the term "diagnostic" herein is not necessarily meant to exclude "prognostic" or "prognosis," but rather is used as a matter of 35 convenience.

The term "differentially expressed gene" is generally intended to encompass a polynucleotide that can, for example, include an open reading frame encoding a gene product (*e.g.*, a polypeptide), and/or introns of such genes and adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, *i.e.*, a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1 ½-fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1,000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, *i.e.*, an overexpressed or up-regulated gene.

"Differentially expressed polynucleotide" as used herein means a nucleic acid molecule (RNA or DNA) comprising a sequence that represents a differentially expressed gene, *e.g.*, the differentially expressed polynucleotide comprises a sequence (*e.g.*, an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample. "Differentially expressed polynucleotides" is also meant to encompass fragments of the disclosed polynucleotides, *e.g.*, fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (*e.g.*, having about 90% sequence identity) to the disclosed polynucleotides.

"Diagnosis" as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, as well as to the prognosis of a subject affected by a disease or disorder (*e.g.*, identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy). The present invention particularly encompasses diagnosis of subjects in the context of breast cancer (*e.g.*, carcinoma in situ (*e.g.*, ductal carcinoma in situ), estrogen receptor (ER)-positive breast cancer, ER-negative breast cancer, or other forms and/or stages of breast cancer), lung cancer (*e.g.*, small cell carcinoma, non-small cell carcinoma, mesothelioma, and other forms and/or stages of lung cancer), and colon cancer (*e.g.*, adenomatous polyp, colorectal carcinoma, and other forms and/or stages of colon cancer).

"Sample" or "biological sample" as used throughout here are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with the disease for which the diagnostic application is designed (*e.g.*,

ductal adenocarcinoma), and the like. "Samples" is also meant to encompass derivatives and fractions of such samples (e.g., cell lysates). Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.

Methods of the subject invention useful in diagnosis or prognosis typically involve
5 comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually; by
10 using a technique such as densitometry, with or without computerized assistance; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample; or by using an array to detect relative levels
15 of hybridization to a selected sequence or set of sequences, and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art (see, e.g., WO 97/27317).

In general, diagnostic assays of the invention involve detection of a gene product of a the
20 polynucleotide sequence (e.g., mRNA or polypeptide) that corresponds to a sequence of SEQ ID NOS:1-316. The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e.g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.

25 Diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in SEQ ID NOS:1-316, and can involve detection of expression of genes corresponding to all of SEQ ID NOS:1-316 and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the
30 diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. Examples of such differentially expressed polynucleotides are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such
35 polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan.

Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes, (e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA)), radioactive labels, (e.g. ^{32}P , ^{35}S , ^3H , etc.), and the like. The detectable label can involve a two stage systems (e.g., biotin-avidin, haptens-anti-hapten antibody, etc.)

Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample. Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.

Polypeptide detection in diagnosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods. Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can be used for qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotides of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, *in situ* hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One

of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. mRNA expression levels in a sample can also be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST library is representative of sequences present in the sample (Adams, et al., (1991) *Science* 252:1651). Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein.

Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (e.g., Velculescu et al., *Science* (1995) 270:484) or differential display (DD) methodology (see, e.g., U.S. 5,776,683; and U.S. 5,807,680).

Alternatively, gene expression can be analyzed using hybridization analysis. Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

Use of a single gene in diagnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymorphism of such a gene (e.g., a polymorphism in an coding region or control region), that is associated with disease. Disease-associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e.g. a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (e.g., using a detectably labeled

primer or detectably labeled oligonucleotides) to facilitate detection. Alternatively, various methods are also known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, see e.g., Riley *et al.*, *Nucl. Acids Res.* (1990) 18:2887; and Delahunty *et al.*, *Am. J. Hum. Genet.* (1996) 58:1239.

5 The amplified or cloned sample nucleic acid can be analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, *e.g.*, to a wild-type sequence. Hybridization with the polymorphic or variant sequence can also be used to determine its presence in a sample (*e.g.*, by Southern blot, dot blot, *etc.*). The hybridization pattern of a polymorphic or variant 10 sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505, can also be used as a means of identifying polymorphic or variant sequences associated with disease. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence 15 variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

20 Screening for mutations in a gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening 25 tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.

30 Pattern matching in diagnosis using arrays. In another embodiment, the diagnostic and/or prognostic methods of the invention involve detection of expression of a selected set of genes in a test sample to produce a test expression pattern (TEP). The TEP is compared to a reference expression pattern (REP), which is generated by detection of expression of the selected set of genes in a reference sample (*e.g.*, a positive or negative control sample). The selected set of genes includes at least one of the genes of the invention, which genes correspond to the polynucleotide sequences of SEQ ID NOS:1-316. Of particular interest is a selected set of genes that includes gene differentially expressed in the disease for which the test sample is to be screened.

35 "Reference sequences" or "reference polynucleotides" as used herein in the context of differential gene expression analysis and diagnosis/prognosis refers to a selected set of

polynucleotides, which selected set includes at least one or more of the differentially expressed polynucleotides described herein. A plurality of reference sequences, preferably comprising positive and negative control sequences, can be included as reference sequences. Additional suitable reference sequences are found in GenBank, Unigene, and other nucleotide sequence databases (including, e.g., expressed sequence tag (EST), partial, and full-length sequences).

"Reference array" means an array having reference sequences for use in hybridization with a sample, where the reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Usually such an array will include at least 3 different reference sequences, and can include any one or all of the provided differentially expressed sequences. Arrays of interest can further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for screening for a disease or disorder (e.g., cancer, dysplasia, or other related or unrelated diseases, disorders, or conditions). The oligonucleotide sequence on the array will usually be at least about 12 nt in length, and can be of about the length of the provided sequences, or can extend into the flanking regions to generate fragments of 100 nt to 200 nt in length or more. Reference arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U.S. 5,134,854, and U.S. 5,445,934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers. Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505.

A "reference expression pattern" or "REP" as used herein refers to the relative levels of expression of a selected set of genes, particularly of differentially expressed genes, that is associated with a selected cell type, e.g., a normal cell, a cancerous cell, a cell exposed to an environmental stimulus, and the like. A "test expression pattern" or "TEP" refers to relative levels of expression of a selected set of genes, particularly of differentially expressed genes, in a test sample (e.g., a cell of unknown or suspected disease state, from which mRNA is isolated).

REPs can be generated in a variety of ways according to methods well known in the art. For example, REPs can be generated by hybridizing a control sample to an array having a selected set of polynucleotides (particularly a selected set of differentially expressed polynucleotides), acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the REP with a TEP. Alternatively, all expressed sequences in a control sample can be isolated and sequenced, e.g., by isolating mRNA from a control sample, converting the mRNA into cDNA, and sequencing the cDNA. The resulting sequence information roughly or precisely reflects the identity and relative number of expressed sequences in the sample. The

sequence information can then be stored in a format (e.g., a computer-readable format) that allows for ready comparison of the REP with a TEP. The REP can be normalized prior to or after data storage, and/or can be processed to selectively remove sequences of expressed genes that are of less interest or that might complicate analysis (e.g., some or all of the sequences associated with housekeeping genes can be eliminated from REP data).

TEPs can be generated in a manner similar to REPs, e.g., by hybridizing a test sample to an array having a selected set of polynucleotides, particularly a selected set of differentially expressed polynucleotides, acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the TEP with a REP. The REP and TEP to be used in a comparison can be generated simultaneously, or the TEP can be compared to previously generated and stored REPs.

In one embodiment of the invention, comparison of a TEP with a REP involves hybridizing a test sample with a reference array, where the reference array has one or more reference sequences for use in hybridization with a sample. The reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Hybridization data for the test sample is acquired, the data normalized, and the produced TEP compared with a REP generated using an array having the same or similar selected set of differentially expressed polynucleotides. Probes that correspond to sequences differentially expressed between the two samples will show decreased or increased hybridization efficiency for one of the samples relative to the other.

Methods for collection of data from hybridization of samples with a reference arrays are well known in the art. For example, the polynucleotides of the reference and test samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label using, for example, a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in USPN 5,631,734. A scanning laser microscope is described in Shalon et al., *Genome Res.* (1996) 6:639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample (e.g., a test sample) is compared to the fluorescent signal from another sample (e.g., a reference sample), and the relative signal intensity determined.

Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, i.e. data deviating from a predetermined statistical distribution,

and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes.

In general, the test sample is classified as having a gene expression profile corresponding to
5 that associated with a disease or non-disease state by comparing the TEP generated from the test sample to one or more REPs generated from reference samples (*e.g.*, from samples associated with cancer or specific stages of cancer, dysplasia, samples affected by a disease other than cancer, normal samples, *etc.*). The criteria for a match or a substantial match between a TEP and a REP include expression of the same or substantially the same set of reference genes, as well as
10 expression of these reference genes at substantially the same levels (*e.g.*, no significant difference between the samples for a signal associated with a selected reference sequence after normalization of the samples, or at least no greater than about 25% to about 40% difference in signal strength for a given reference sequence. In general, a pattern match between a TEP and a REP includes a match in expression, preferably a match in qualitative or quantitative expression level, of at least one of,
15 all or any subset of the differentially expressed genes of the invention.

Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (*e.g.*, arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for
20 example, U.S. 5,800,992.

Diagnosis, Prognosis and Management of Cancer

The polynucleotides of the invention and their gene products are of particular interest as genetic or biochemical markers (*e.g.*, in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or to monitor the efficacy of various therapies and preventive
25 interventions. For example, the level of expression of certain polynucleotides can be indicative of a poorer prognosis, and therefore warrant more aggressive chemo- or radio-therapy for a patient or vice versa. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients can define prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting and gene
30 therapy. Determining expression of certain polynucleotides and comparison of a patients profile with known expression in normal tissue and variants of the disease allows a determination of the best possible treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient. Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer.
35 Two classifications widely used in oncology that can benefit from identification of the expression

levels of the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.

The polynucleotides of the invention can be useful to monitor patients having or susceptible to cancer to detect potentially malignant events at a molecular level before they are 5 detectable at a gross morphological level. Furthermore, a polynucleotide of the invention identified as important for one type of cancer can also have implications for development or risk of development of other types of cancer, e.g., where a polynucleotide is differentially expressed across various cancer types. Thus, for example, expression of a polynucleotide that has clinical implications for metastatic colon cancer can also have clinical implications for stomach cancer or 10 endometrial cancer.

Staging. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Staging systems vary with the types of cancer, but generally involve the following "TNM" system: the type of tumor, indicated by T; whether the 15 cancer has metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to more distant parts of the body, indicated by M. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. 20 Cancers that have spread to a distant part of the body, such as the liver, bone, brain or other site, are Stage IV, the most advanced stage.

The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggressivity of a cancer, e.g. the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a 25 high metastatic potential cancer can be used to change a borderline Stage II tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor.

Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. The microscopic appearance of a tumor is used to identify tumor 30 grade based on parameters such as cell morphology, cellular organization, and other markers of differentiation. As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness, with undifferentiated or high-grade tumors being more aggressive than well differentiated or low-grade tumors. The following guidelines are generally used for grading tumors: 1) GX Grade cannot be assessed; 2) G1 Well differentiated; G2 Moderately well differentiated; 3) 35 G3 Poorly differentiated; 4) G4 Undifferentiated. The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining

the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressiveness of a tumor, such as metastatic potential.

Detection of lung cancer. The polynucleotides of the invention can be used to detect lung cancer in a subject. Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma) usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer. 10 Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large. Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is 15 usually fairly large when diagnosed. Other less common forms of lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignant mesothelioma.

The polynucleotides of the invention, e.g., polynucleotides differentially expressed in normal cells versus cancerous lung cells (e.g., tumor cells of high or low metastatic potential) or between types of cancerous lung cells (e.g., high metastatic versus low metastatic), can be used to 20 distinguish types of lung cancer as well as identifying traits specific to a certain patient's cancer and selecting an appropriate therapy. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal 25 of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.

Detection of breast cancer. The majority of breast cancers are adenocarcinomas subtypes, which can be summarized as follows: 1) ductal carcinoma in situ (DCIS), including comedocarcinoma; 2) infiltrating (or invasive) ductal carcinoma (IDC); 3) lobular carcinoma in situ 30 (LCIS); 4) infiltrating (or invasive) lobular carcinoma (ILC); 5) inflammatory breast cancer; 6) medullary carcinoma; 7) mucinous carcinoma; 8) Paget's disease of the nipple; 9) Phyllodes tumor; and 10) tubular carcinoma;

The expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer, as well as to distinguish between types of breast cancer. Detection of 35 breast cancer can be determined using expression levels of any of the appropriate polynucleotides of the invention, either alone or in combination. Determination of the aggressive nature and/or the

metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e.g. ER expression. In addition, development of breast cancer can be detected by examining the ratio of expression of a differentially expressed polynucleotide to the levels of 5 steroid hormones (e.g., testosterone or estrogen) or to other hormones (e.g., growth hormone, insulin). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

Detection of colon cancer. The polynucleotides of the invention exhibiting the appropriate 10 expression pattern can be used to detect colon cancer in a subject. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia. Prevention and early detection are key factors in controlling and curing colorectal cancer. Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional 15 mutations and become cancerous. Multiple familial colorectal cancer disorders have been identified, which are summarized as follows: 1) Familial adenomatous polyposis (FAP); 2) Gardner's syndrome; 3) Hereditary nonpolyposis colon cancer (HNPCC); and 4) Familial colorectal cancer in Ashkenazi Jews. The expression of appropriate polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. Detection of colon cancer 20 can be determined using expression levels of any of these sequences alone or in combination with the levels of expression. Determination of the aggressive nature and/or the metastatic potential of a colon cancer can be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e.g., expression of p53, DCC ras, or FAP (see, e.g., Fearon ER, *et al.*, *Cell* (1990) 61(5):759; Hamilton 25 SR *et al.*, *Cancer* (1993) 72:957; Bodmer W, *et al.*, *Nat Genet.* (1994) 4(3):217; Fearon ER, *Ann N Y Acad Sci.* (1995) 768:101). For example, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e.g. ras) or tumor suppressor genes (e.g. FAP or p53). Thus expression of specific marker 30 polynucleotides can be used to discriminate between normal and cancerous colon tissue, to discriminate between colon cancers with different cells of origin, to discriminate between colon cancers with different potential metastatic rates, etc.

Detection of prostate cancer. The polynucleotides and their corresponding genes and gene products exhibiting the appropriate differential expression pattern can be used to detect prostate cancer in a subject. Over 95% of primary prostate cancers are adenocarcinomas. Signs and 35 symptoms may include: frequent urination, especially at night, inability to urinate, trouble starting

or holding back urination, a weak or interrupted urine flow and frequent pain or stiffness in the lower back, hips or upper thighs.

Many of the signs and symptoms of prostate cancer can be caused by a variety of other non-cancerous conditions. For example, one common cause of many of these signs and symptoms 5 is a condition called benign prostatic hypertrophy, or BPH. In BPH, the prostate gets bigger and may block the flow of urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between prostate cancer and such non-cancerous conditions. The methods of the invention can be used in conjunction with conventional methods of diagnosis, e.g., digital rectal exam and/or detection of the level of prostate specific antigen (PSA), a substance 10 produced and secreted by the prostate.

Use of Polynucleotides to Screen for Peptide Analogs and Antagonists

Polypeptides encoded by the instant polynucleotides and corresponding full length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides. Peptide libraries can be synthesized according to methods known in the 15 art (see, e.g., USPN 5,010,175, and WO 91/17823). Agonists or antagonists of the polypeptides if the invention can be screened using any available method known in the art, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The assay conditions ideally should resemble the conditions under which the native activity is exhibited *in vivo*, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or 20 antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.

Such screening and experimentation can lead to identification of a novel polypeptide 25 binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of 30 genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor.

Pharmaceutical Compositions and Therapeutic Uses

Pharmaceutical compositions of the invention can comprise polypeptides, antibodies, or 35 polynucleotides (including antisense nucleotides and ribozymes) of the claimed invention in a therapeutically effective amount. The term "therapeutically effective amount" as used herein refers

to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will 5 depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For purposes of the present invention, an effective dose will generally be from about 0.01 mg/kg to 50 mg/kg or 10 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the 15 individual receiving the composition, and which can be administered without undue toxicity.

Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such 20 as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

25 Pharmaceutically acceptable salts can also be present in the pharmaceutical composition, e.g., mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., N.J. 1991).

30 Delivery Methods. Once formulated, the compositions of the invention can be (1) administered directly to the subject (e.g., as polynucleotide or polypeptides); or (2) delivered ex vivo, to cells derived from the subject (e.g., as in *ex vivo* gene therapy). Direct delivery of the compositions will generally be accomplished by parenteral injection, e.g., subcutaneously, intraperitoneally, intravenously or intramuscularly, intratumoral or to the interstitial space of a 35 tissue. Other modes of administration include oral and pulmonary administration, suppositories,

and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.

Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., International Publication No. WO 93/14778. Examples of 5 cells useful in ex vivo applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of 10 the DNA into nuclei, all well known in the art.

Once a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hyperplasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided 15 polynucleotide, corresponding polypeptide or other corresponding molecule (e.g., antisense, ribozyme, etc.).

The dose and the means of administration of the inventive pharmaceutical compositions are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. For example, administration of polynucleotide therapeutic compositions agents of the invention includes local or 20 systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic polynucleotide composition contains an expression construct comprising a promoter operably linked to a polynucleotide of at least 12, 22, 25, 30, or 35 contiguous nt of the polynucleotide disclosed herein. Various methods can be used to administer the therapeutic composition directly to a specific site in the body. For 25 example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries which serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is 30 directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods.

Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues can also be used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis *et al.*, *Trends 35 Biotechnol.* (1993) 11:202; Chiou *et al.*, *Gene Therapeutics: Methods And Applications Of Direct Gene Transfer* (J.A. Wolff, ed.) (1994); Wu *et al.*, *J. Biol. Chem.* (1988) 263:621; Wu *et al.*, *J. Biol.*

Chem. (1994) 269:542; Zenke *et al.*, *Proc. Natl. Acad. Sci. (USA)* (1990) 87:3655; Wu *et al.*, *J. Biol. Chem.* (1991) 266:338. Therapeutic compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 µg to about 2 mg, about 5 µg to about 500 µg, and about 20 µg to about 100 µg of DNA can also be used during a gene therapy protocol. Factors such as method of action (e.g., for enhancing or inhibiting levels of the encoded gene product) and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides. Where greater expression is desired over a larger area of tissue, larger amounts of antisense 5 subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic 10 effect. For polynucleotide related genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in USPN 5,654,173.

The therapeutic polynucleotides and polypeptides of the present invention can be delivered using gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, *Cancer Gene Therapy* (1994) 1:51; Kimura, *Human Gene Therapy* (1994) 5:845; Connelly, *Human Gene Therapy* (1995) 1:185; and Kaplitt, *Nature Genetics* (1994) 6:148). Expression of such coding sequences can be induced using endogenous mammalian or heterologous 20 promoters. Expression of the coding sequence can be either constitutive or regulated.

Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; 25 USPN 5,219,740; WO 93/11230; WO 93/10218; USPN 4,777,127; GB Patent No. 2,200,651; EP 0 345 242; and WO 91/02805), alphavirus-based vectors (e.g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532), and adeno-associated virus (AAV) vectors (see, e.g., WO 94/12649, WO 93/03769; WO 30 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655). Administration of DNA linked to killed adenovirus as described in Curiel, *Hum. Gene Ther.* (1992) 3:147 can also be employed.

Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, *Hum. Gene Ther.* (1992) 3:147); ligand-linked DNA (see, e.g., Wu, *J. Biol. Chem.* (1989) 264:16985); eukaryotic cell delivery vehicles (see, e.g., USPN 5,814,482; WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with

cell membranes. Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and USPN 5,580,859. Liposomes that can act as gene delivery vehicles are described in USPN 5,422,120; WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968. Additional approaches are described in Philip, *Mol. Cell Biol.* (1994) 14:2411, and in 5 Woffendin, *Proc. Natl. Acad. Sci.* (1994) 91:1581

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al.*, *Proc. Natl. Acad. Sci. USA* (1994) 91(24):11581.

Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials or use of ionizing radiation (see, e.g., USPN 10 5,206,152 and WO 92/11033). Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun (see, e.g., USPN 5,149,655); use of ionizing radiation for activating transferred gene (see, e.g., USPN 5,206,152 and WO 92/11033).

The present invention will now be illustrated by reference to the following examples which 15 set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.

EXAMPLES

The following examples are offered primarily for purposes of illustration. It will be readily 20 apparent to those skilled in the art that the formulations, dosages, methods of administration, and other parameters of this invention may be further modified or substituted in various ways without departing from the spirit and scope of the invention.

Example 1: Source of Biological Materials and Overview of Novel Polynucleotides Expressed 25 by the Biological Materials

cDNA libraries were constructed from mRNA isolated from the GRRpz or and WOca cells, which were provided by Dr. Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz cells were primary cells derived from normal prostate epithelium. The WOca cells were prostate epithelial cells derived from prostate cancer Gleason Grade 4+4. 30 Polynucleotides expressed by these cells were isolated and analyzed; the sequences of these polynucleotides were about 275-300 nucleotides in length.

The sequences of the isolated polynucleotides were first masked to eliminate low complexity sequences using the XBLAST masking program (Claverie "Effective Large-Scale Sequence Similarity Searches," In: Computer Methods for Macromolecular Sequence Analysis, 35 Doolittle, ed., *Meth. Enzymol.* 266:212-227 Academic Press, NY, NY (1996); see particularly Claverie, in "Automated DNA Sequencing and Analysis Techniques" Adams *et al.*, eds., Chap. 36,

p. 267 Academic Press, San Diego, 1994 and Claverie *et al.* *Comput. Chem.* (1993) 17:191).

Generally, masking does not influence the final search results, except to eliminate sequences of relative little interest due to their low complexity, and to eliminate multiple "hits" based on similarity to repetitive regions common to multiple sequences, e.g., Alu repeats. The remaining sequences were then used in a BLASTN vs. GenBank search; sequences that exhibited greater than 70% overlap, 99% identity, and a p value of less than 1×10^{-40} were discarded. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.

The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a BLASTX vs. NRP (non-redundant proteins) database search: (1) unknown (no hits in the GenBank search), (2) weak similarity (greater than 45% identity and p value of less than 1×10^{-5}), and (3) high similarity (greater than 60% overlap, greater than 80% identity, and p value less than 1×10^{-5}). Sequences having greater than 70% overlap, greater than 99% identity, and p value of less than 1×10^{-40} were discarded.

The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a BLAST vs. EST database search was performed and sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1×10^{-40} were discarded. Sequences with a p value of less than 1×10^{-65} when compared to a database sequence of human origin were also excluded. Second, a BLASTN vs. Patent GeneSeq database was performed and sequences having greater than 99% identity, p value less than 1×10^{-40} , and greater than 99% overlap were discarded.

The remaining sequences were subjected to screening using other rules and redundancies in the dataset. Sequences with a p value of less than 1×10^{-111} in relation to a database sequence of human origin were specifically excluded. The final result provided the 316 sequences listed as SEQ ID NOS:1-316 in the accompanying Sequence Listing and summarized in Table 1 (inserted prior to claims). Each identified polynucleotide represents sequence from at least a partial mRNA transcript. Many of the sequences include the sequence ggcacgag at the 5' end; this sequence is a sequencing artifact and not part of the sequence of the polynucleotides of the invention.

Table 1 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each sequence for use in the present specification; 2) the Cluster Identification No. ("CLUSTER"); 3) the sequence name ("SEQ NAME") used as an internal identifier of the sequence; 4) the orientation of the sequence ("ORIENT"); 5) the name assigned to the clone from which the sequence was isolated ("CLONE ID"); and the name of the library from which the sequence was isolated ("LIBRARY"). CH22PRC indicates the sequence was isolated from Library 22; CH21PRN indicates the sequence was isolated from Library 21. A description of the libraries is provided in Table 3 below. Because the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides of the invention

may represent different regions of the same mRNA transcript and the same gene. Thus, if two or more SEQ ID NOS: are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene.

5 Example 2: Results of Public Database Search to Identify Function of Gene Products

SEQ ID NOS:1-316 were translated in all three reading frames, and the nucleotide sequences and translated amino acid sequences used as query sequences to search for homologous sequences in either the GenBank (nucleotide sequences) or Non-Redundant Protein (amino acid sequences) databases. Query and individual sequences were aligned using the BLAST 2.0 programs, available over the world wide web at a saite sponsored by the National Center for Biotechnology Information, which is supported by the National Library of Medicine and the National Institutes of Health (see also Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402). The sequences were masked to various extents to prevent searching of repetitive sequences or poly-A sequences, using the XBLAST program for masking low complexity as described above in

10 Example 1.

15

Table 2 (inserted before the claims) provide the alignment summaries having a p value of 1 x 10⁻² or less indicating substantial homology between the sequences of the present invention and those of the indicated public databases. Specifically, Table 2 provides the SEQ ID NO of the query sequence, the accession number of the GenBank database entry of the homologous sequence, and the p value of the alignment. Table 2 also provides the SEQ ID NO of the query sequence, the accession number of the Non-Redundant Protein database entry of the homologous sequence, and the p value of the alignment. The alignments provided in Table 2 are the best available alignment to a DNA or amino acid sequence at a time just prior to filing of the present specification. The activity of the polypeptide encoded by the SEQ ID NOS listed in Table 2 can be extrapolated to be substantially the same or substantially similar to the activity of the reported nearest neighbor or closely related sequence. The accession number of the nearest neighbor is reported, providing a publicly available reference to the activities and functions exhibited by the nearest neighbor. The public information regarding the activities and functions of each of the nearest neighbor sequences is incorporated by reference in this application. Also incorporated by reference is all publicly available information regarding the sequence, as well as the putative and actual activities and functions of the nearest neighbor sequences listed in Table 2 and their related sequences. The search program and database used for the alignment, as well as the calculation of the p value are also indicated.

20

25

30

Full length sequences or fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence of the corresponding polynucleotide. The nearest neighbors can indicate a tissue or cell type to be used to

35

construct a library for the full-length sequences of the corresponding polynucleotides.

Example 3: Differential Expression of Polynucleotides of the Invention: Description of Libraries and

5 Detection of Differential Expression

The relative expression levels of the polynucleotides of the invention was assessed in several libraries prepared from various sources, including primary cells, cell lines and patient tissue samples. Table 3 provides a summary of these libraries, including the shortened library name (used hereafter), the mRNA source used to prepared the cDNA library, the "nickname" of the library that 10 is used in the tables below (in quotes), and the approximate number of clones in the library.

Table 3. Description of cDNA Libraries

Library (Lib#)	Description	Number of Clones in Library
1	Human Colon Cell Line Km12 L4: High Metastatic Potential (derived from Km12C)	308731
2	Human Colon Cell Line Km12C: Low Metastatic Potential	284771
3	Human Breast Cancer Cell Line MDA-MB-231: High Metastatic Potential; micro-mets in lung	326937
4	Human Breast Cancer Cell Line MCF7: Non Metastatic	318979
8	Human Lung Cancer Cell Line MV-522: High Metastatic Potential	223620
9	Human Lung Cancer Cell Line UCP-3: Low Metastatic Potential	312503
12	Human microvascular endothelial cells (HMVEC) - UNTREATED (PCR (OligodT) cDNA library)	41938
13	Human microvascular endothelial cells (HMVEC) – bFGF TREATED (PCR (OligodT) cDNA library)	42100
14	Human microvascular endothelial cells (HMVEC) – VEGF TREATED (PCR (OligodT) cDNA library)	42825
15	Normal Colon - UC#2 Patient (MICRODISSECTED PCR (OligodT) cDNA library)	282722
16	Colon Tumor - UC#2 Patient (MICRODISSECTED PCR (OligodT) cDNA library)	298831
17	Liver Metastasis from Colon Tumor of UC#2 Patient	303467

Library (Lib#)	Description	Number of Clones in Library
	(MICRODISSECTED PCR (OligodT) cDNA library)	
18	Normal Colon - UC#3 Patient (MICRODISSECTED PCR (OligodT) cDNA library)	36216
19	Colon Tumor - UC#3 Patient (MICRODISSECTED PCR (OligodT) cDNA library)	41388
20	Liver Metastasis from Colon Tumor of UC#3 Patient (MICRODISSECTED PCR (OligodT) cDNA library)	30956
21	GRRpz Cells derived from normal prostate epithelium	164801
22	WOca Cells derived from Gleason Grade 4 prostate cancer epithelium	162088
23-	Normal Lung Epithelium of Patient #1006 (MICRODISSECTED PCR (OligodT) cDNA library)	306198
24	Primary tumor, Large Cell Carcinoma of Patient #1006 (MICRODISSECTED PCR (OligodT) cDNA library)	309349

The KM12L4 cell line is derived from the KM12C cell line (Morikawa, et al., *Cancer Research* (1988) 48:6863). The KM12C cell line, which is poorly metastatic (low metastatic) was established in culture from a Dukes' stage B₂ surgical specimen (Morikawa et al. *Cancer Res.* 5 (1988) 48:6863). The KML4-A is a highly metastatic subline derived from KM12C (Yeatman et al. *Nucl. Acids. Res.* (1995) 23:4007; Bao-Ling et al. *Proc. Annu. Meet. Am. Assoc. Cancer. Res.* (1995) 21:3269). The KM12C and KM12C-derived cell lines (e.g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e.g., Moriakawa et al., *supra*; Radinsky et al. *Clin. Cancer Res.* (1995) 1:19; Yeatman et al., (1995) *supra*; Yeatman et al. *Clin. Exp. Metastasis* (1996) 14:246). The MDA-MB-231 cell line (Brinkley et al. *Cancer Res.* 10 (1980) 40:3118-3129) was originally isolated from pleural effusions (Cailleau, *J. Natl. Cancer. Inst.* (1974) 53:661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma grade II in nude mice consistent with breast carcinoma.

The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non-metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, e.g., Chandrasekaran et al., *Cancer Res.* (1979) 39:870 (MDA-MB-231 and MCF-7); Gastpar et al., *J Med Chem* (1998) 41:4965 (MDA-

MB-231 and MCF-7); Ranson *et al.*, *Br J Cancer* (1998) 77:1586 (MDA-MB-231 and MCF-7); Kuang *et al.*, *Nucleic Acids Res* (1998) 26:1116 (MDA-MB-231 and MCF-7); Varki *et al.*, *Int J Cancer* (1987) 40:46 (UCP-3); Varki *et al.*, *Tumour Biol.* (1990) 11:327; (MV-522 and UCP-3); Varki *et al.*, *Anticancer Res.* (1990) 10:637; (MV-522); Kelner *et al.*, *Anticancer Res* (1995) 15:867

5 (MV-522); and Zhang *et al.*, *Anticancer Drugs* (1997) 8:696 (MV522)). The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3). The bFGF-treated HMVEC were prepared by incubation with bFGF at 10ng/ml for 2 hrs; the VEGF-treated HMVEC were prepared by incubation with 20ng/ml VEGF for 2 hrs. Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation. The GRRpz and WOca 10 cells were provided by Dr. Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz cells were derived from normal prostate epithelium. The WOca cells are Gleason Grade 4 cell line.

Each of the libraries is composed of a collection of cDNA clones that in turn are representative of the mRNAs expressed in the indicated mRNA source. In order to facilitate the 15 analysis of the millions of sequences in each library, the sequences were assigned to clusters. The concept of "cluster of clones" is derived from a sorting/grouping of cDNA clones based on their hybridization pattern to a panel of roughly 300 7bp oligonucleotide probes (see Drmanac *et al.*, *Genomics* (1996) 37(1):29). Random cDNA clones from a tissue library are hybridized at moderate stringency to 300 7bp oligonucleotides. Each oligonucleotide has some measure of specific 20 hybridization to that specific clone. The combination of 300 of these measures of hybridization for 300 probes equals the "hybridization signature" for a specific clone. Clones with similar sequence will have similar hybridization signatures. By developing a sorting/grouping algorithm to analyze these signatures, groups of clones in a library can be identified and brought together computationally. These groups of clones are termed "clusters". Depending on the stringency of the 25 selection in the algorithm (similar to the stringency of hybridization in a classic library cDNA screening protocol), the "purity" of each cluster can be controlled. For example, artifacts of clustering may occur in computational clustering just as artifacts can occur in "wet-lab" screening of a cDNA library with 400 bp cDNA fragments, at even the highest stringency. The stringency used in the implementation of cluster herein provides groups of clones that are in general from the 30 same cDNA or closely related cDNAs. Closely related clones can be a result of different length clones of the same cDNA, closely related clones from highly related gene families, or splice variants of the same cDNA.

Differential expression for a selected cluster was assessed by first determining the number of cDNA clones corresponding to the selected cluster in the first library (Clones in 1st), and the 35 determining the number of cDNA clones corresponding to the selected cluster in the second library (Clones in 2nd). Differential expression of the selected cluster in the first library relative to the

second library is expressed as a "ratio" of percent expression between the two libraries. In general, the "ratio" is calculated by: 1) calculating the percent expression of the selected cluster in the first library by dividing the number of clones corresponding to a selected cluster in the first library by the total number of clones analyzed from the first library; 2) calculating the percent expression of the selected cluster in the second library by dividing the number of clones corresponding to a selected cluster in a second library by the total number of clones analyzed from the second library; 3) dividing the calculated percent expression from the first library by the calculated percent expression from the second library. If the "number of clones" corresponding to a selected cluster in a library is zero, the value is set at 1 to aid in calculation. The formula used in calculating the ratio takes into account the "depth" of each of the libraries being compared, *i.e.*, the total number of clones analyzed in each library.

In general, a polynucleotide is said to be significantly differentially expressed between two samples when the ratio value is greater than at least about 2, preferably greater than at least about 3, more preferably greater than at least about 5, where the ratio value is calculated using the method described above. The significance of differential expression is determined using a z score test (Zar, Biostatistical Analysis, Prentice Hall, Inc., USA, "Differences between Proportions," pp 296-298 (1974)).

Using this approach, a number of polynucleotide sequences were identified as being differentially expressed between, for example, cells derived from high metastatic potential cancer tissue and low metastatic cancer cells, and between cells derived from metastatic cancer tissue and normal tissue. Evaluation of the levels of expression of the genes corresponding to these sequences can be valuable in diagnosis, prognosis, and/or treatment (*e.g.*, to facilitate rationale design of therapy, monitoring during and after therapy, *etc.*). Moreover, the genes corresponding to differentially expressed sequences described herein can be therapeutic targets due to their involvement in regulation (*e.g.*, inhibition or promotion) of development of, for example, the metastatic phenotype. For example, sequences that correspond to genes that are increased in expression in high metastatic potential cells relative to normal or non-metastatic tumor cells may encode genes or regulatory sequences involved in processes such as angiogenesis, differentiation, cell replication, and metastasis.

Detection of the relative expression levels of differentially expressed polynucleotides described herein can provide valuable information to guide the clinician in the choice of therapy. For example, a patient sample exhibiting an expression level of one or more of these polynucleotides that corresponds to a gene that is increased in expression in metastatic or high metastatic potential cells may warrant more aggressive treatment for the patient. In contrast, detection of expression levels of a polynucleotide sequence that corresponds to expression levels associated with that of low metastatic potential cells may warrant a more positive prognosis than

the gross pathology would suggest.

The differential expression of the polynucleotides described herein can thus be used as, for example, diagnostic markers, prognostic markers, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The differential expression data for polynucleotides of the invention that have been identified as being differentially expressed across various combinations of the libraries described above is summarized in Table 4 (inserted prior to the claims). Table 4 provides: 1) the Sequence Identification Number ("SEQ ID") assigned to the polynucleotide; 2) the cluster ("CLUST") to which the polynucleotide has been assigned as described above; 3) the library comparisons that resulted in identification of the polynucleotide as being differentially expressed ("PairAB-text"), with shorthand names of the compared libraries provided in parentheses following the library numbers; 4) the number of clones corresponding to the polynucleotide in the first library listed ("A"); 5) the number of clones corresponding to the polynucleotide in the second library listed ("B"); 6) the "RATIO PLUS" where the comparison resulted in a finding that the number of clones in library A is greater than the number of clones in library B; and 7) the "RATIO MINUS" where the comparison resulted in a finding that the number of clones in library B is greater than the number of clones in library A.

20 Example 4: Differential Expression of a Polynucleotides Associated with Metastatic Potential in Breast Cancer

Differential expression was examined in breast cancer cells having either high metastatic potential or low metastatic potential. A single cluster, Cluster Identification No. 10154, was identified as displaying low expression in the high metastatic potential breast cancer cells (Library 25 3), and significantly increased expression – approximately 100-fold higher -- in the low metastatic potential cells (Library 4). Specifically, three clones were identified that were expressed in Library 3, the high metastatic potential breast cancer library, while 317 clones were expressed in Library 4, the low metastatic potential breast cancer library. The two sequences assigned to this particular cluster, SEQ ID NO:315 and SEQ ID NO:316, both displayed this differential expression, 30 suggesting that the two sequences are likely associated with a single transcript.

SEQ ID NO:315 and SEQ ID NO:316 were then used as query sequences to search for homologous sequences in GenBank as described in Examples 1 and 2. SEQ ID NO: 315 displayed identity to the GenBank entry H72034 (SEQ ID NO:317) and SEQ ID NO:316 displayed identity to GenBank entry AA707002 (SEQ ID NO:318). SEQ ID NO:315 displays striking identity to the 3' 35 end of SEQ ID NO:317 (See Figures 1A and 1B), while SEQ ID NO:316 displays striking identity to the 5' end of SEQ ID NO:318 (See Figure 2). Clones of H72034 and AA707002 were ordered

from the I.M.A.G.E. Consortium at the Lawrence Livermore National Laboratories (Livermore, California) for further studies.

Restriction Mapping of Clones H72034 and AA707002

- The newly identified sequences were digested with a number of different restriction
5 endonucleases to construct a restriction map of each of the clones. An appropriate amount of each
clone, SEQ ID NO:317 or SEQ ID NO:318, was digested with various enzymes, and the restriction
fragments identified as follows:

SEQ ID NO:317

	Enzyme	#Cuts	Positions					
5	AluI	5	331	1029	1422	1595	1977	
	BamHI	2	1836	2089				
	BstEII	1	936					
	BstXI	1	1033					
	HaeIII	12	145	300	453	497	582	780
			1102	1536	1561	1722	1981	2062
10	HinfI	12	5	154	205	325	397	473
		968		1295	1426	2066		610
	KpnI	1	1938					
	MspI	6	78	739	1098	2038	2077	2093
	NcoI	2	2013	2058				
	PstI	1	1501					
15	PvuII	2	331	1422				
	Sau3AI	6	1270	1813	1819	1836	1894	2089
	SphI	1	1870					
	XbaI	1	1413					

20

SEQ ID NO:318

	Enzyme	#Cuts	Positions					
25	AluI	9	19	245	367	553	586	874
		1214						904
	BamHI	1	407					
	BglI	1	1056					
	BglII	1	475					
	BstEII	1	1108					
30	HaeIII	10	153	348	485	867	518	628
		915		1016	1312			780
	HindIII	2	243	872				
	HinfI	1	1353					
	KpnI	1	132					
	MspI	2	1196	1261				
35	PstI	1	823					
	PvuII	1	996					
	Sau3AI	7	66	407	475	504	750	850
								1024

The restriction maps based on the identified sites can be used to determine the position of each clone relative to the genomic sequences, and to confirm the 5'-3' orientation of the clones.

Amplification and Purification of Transcript

A transcript in this region upregulated in low metastatic cancers which contain sequences from SEQ ID NOS: 315-318 is identified using a technique such as polymerase chain reaction (PCR) amplification. Based on the sequences identified and the original sequences of the cluster, primers can be designed to isolate the full length cDNA from a library constructed from the breast cancer cell line with low metastatic potential.

A cDNA template for use in the amplification reaction is generated from total RNA isolated from the high metastatic breast cell line. RNA is reverse transcribed using oligo-dT primer to generate first strand cDNA. cDNA is synthesized by denaturing 3 μ l of total RNA, 2 μ l oligo-dT primer at 20 μ M, and 5 μ l DEPC water for 8 minutes at 65°C followed by reverse transcription at 52°C for 1 hour in a reaction containing the denatured RNA/primer plus 4 μ l 1.5X cDNA buffer (GibcoBRL), 1 μ l 0.1 M dithiothreitol, 1 μ l 40 U/1 RNaseOUT (GibcoBRL), 1 μ l DEPC water, 2 μ l 10 mM dNTP (GibcoBRL), and 1 μ l 15 U/1 Thermoscript reverse transcriptase (GibcoBRL). The reaction was terminated by a 5-min incubation at 85°C, and the RNA was removed by 1 μ l 2 U/1 RNase H at 37°C for thirty minutes.

Based on the determined orientation of the clones, primers are designed to amplify a full-length clone corresponding to the differentially expressed transcript in this region. Forward primers that are used to amplify the full-length clone are taken from the 5' end of SEQ ID NO:17 as follows:

F1 5'- TGGGATATAAGTCTCGTGGTGCG -3' (SEQ ID NO:319)
F2 5'- TGATTCGATGTCATCAGTCCCG-3' (SEQ ID NO:320)

Primer F1 is taken from residues 51-62 of SEQ ID NO: 317, and primer F2 is taken from residues 212-233 Of SEQ ID NO:17. Both forward primers are near the 5' end of this sequence.

Reverse Primers are designed using sequences complementary to the 3' end of clone 10154-3 as follows:

R1 5'- TGTGTCACAGCCAGACATGAGC (SEQ ID NO:321)
R2 5' – TGCAAACATACACAGGGACCG (SEQ ID NO:322)

Primer R1 is based on residues 573-552 of SEQ ID NO:318, and R2 is based on residues 399-379 of SEQ ID NO:318.

PCR is performed using a 5 μ l aliquot of the first strand cDNA synthesis reaction, and a primer pair, e.g., F1 and R1, F1 and R2, F2 and R1, or F2 and R2. An open reading frame is amplified using 2 μ l of the reverse transcription product as template in a PCR reaction containing 5 μ l of 10x PCR buffer (GibcoBRL), 1 μ l 50 mM Mg₂SO₄, 1 μ l 10 mM dNTP, 1 μ l F1 or F2 primer, 5 1 μ l R1 primer, 2.5 U High Fidelity Platinum Taq DNA polymerase (GibcoBRL), and water to 50 μ l. The molecule is amplified using 30 rounds of amplification in a thermal cycler at the following temperatures: 1 minute at 95°C; 1 minute at 55°C and 2 minutes at 72°C. The 30 cycles was followed by a 10 minute extension at 72°C.

Following amplification of the sequences, the PCR products are loaded on a 1% TAE gel 10 and subjected to gel purification. One or more bands can be isolated from the gel and the DNA was purified using a QIAquick® Gel Extraction Kit (Qiagen, Valencia, CA). The purified fragment was cloned into a bacterial vector and transformed into the bacterial strain DH5 α . Following cloning of the purified fragment(s), the DNA can be isolated and sequenced to confirm that a band corresponds to a transcript from this genetic region.

15 The reactions are carried out with two different 5' and 3' primers to increase the likelihood that the reaction will yield an amplification product. Other primers may also be designed from the predicted 5' and/or 3' end of the sequence, as will be apparent to one skilled in the art upon reading this disclosure, and thus other primers may be designed from the general region of SEQ ID NOS:317 and 318 that may yield better results than the disclosed primers.

20 In order to obtain additional sequences 5' to the end of a partial cDNA, 5' rapid amplification of cDNA ends (RACE) can be performed to ensure that the entire transcript has been identified. See *PCR Protocols: A Guide to Methods and Applications*, (1990) Academic Press, Inc. Following isolation of a cDNA using the F1-R1 or F2-R1 primer pairs, additional primers can be designed to perform RACE. The primers can be designed from the sequence of 10154-1 as 25 follows:

5'-TTTAGCAGCACTAATGACTGTGGC-3' (SEQ ID NO:323)
5'-CGCCGTGAATTACTGTGGATGG-3' (SEQ ID NO:324)

30 The two RACE primers are designed based residues 286-263 and 396-375 of SEQ ID NO:317, respectively.

These sequences can be used to obtain any transcript sequences 5' to the amplification products obtained using the PCR protocol described above.

35 Northern Analysis

Other techniques can be used for confirming differential expression of the full-length transcript. For example, a Northern Blot can be used to verify differential expression of SEQ ID

NOS:317 and 318 in a breast cancer cells with low metastatic potential compared to breast cancer cells with high metastatic potential. Northern analysis can be accomplished by methods well-known in the art. Briefly, RNA is individually isolated from breast cancer cells having high metastatic potential and breast cancer cells having low metastatic potential, e.g., a product such as RNeasy

- 5 Mini Kits (Qiagen, CA) or NucleoSpin® RNA II Kit (Clontech, Palo Alto, CA). The isolated RNA samples are For Northern analysis, RNA isolated from the cells was electrophoresed on a denaturing formaldehyde agarose gel and transferred onto a membrane such as a supported nitrocellulose membrane (Schleicher & Schuell).

Rapid-Hyb buffer (Amersham Life Science, Little Chalfont, England) with 5 mg/ml
10 denatured single stranded sperm DNA is pre-warmed to 65°C and the RNA blots are pre-hybridized in the buffer with shaking at 65°C for 30 minutes. Gene-specific DNA probes (50 ng per reaction) labeled with [α -³²P]dCTP (3000Ci/mmol, Amersham Pharmacia Biotech Inc., Piscataway, NJ)
(Prime-It RmT Kit, Stratagene, La Jolla, CA) and purified with ProbeQuant™ G-50 Micro
Columns (Amersham Pharmacia Biotech Inc.) are added and hybridized to the blots with shaking at
15 65°C for overnight. The blots are washed in 2x SSC; 0.1% (w/v) SDS at room temperature for 20 minutes, twice in 1x SSC, 0.1% (w/v) SDS at 65°C for 15 minutes, then exposed to Hyperfilms
(Amersham Life Science).

Example 6: Identification of Differentially Expressed Genes by Array Analysis with Patient Tissue
20 Samples

Differentially expressed genes corresponding to the polynucleotides described herein were also identified by microarray hybridization analysis using materials obtained from patient tissue samples. The biological materials used in these experiments are described below.

Source of patient tissue samples

25 Normal and cancerous tissues were collected from patients using laser capture microdissection (LCM) techniques, which techniques are well known in the art (see, e.g., Ohshima et al. (2000) *Biotechniques* 29:530-6; Curran et al. (2000) *Mol. Pathol.* 53:64-8; Suarez-Quian et al. (1999) *Biotechniques* 26:328-35; Simone et al. (1998) *Trends Genet.* 14:272-6; Conia et al. (1997) *J. Clin. Lab. Anal.* 11:28-38; Emmert-Buck et al. (1996) *Science* 274:998-1001). Table 8
30 (inserted following the last page of the Examples) provides information about each patient from which the samples were isolated, including: the Patient ID and Path ReportID, numbers assigned to the patient and the pathology reports for identification purposes; the anatomical location of the tumor (AnatomicalLoc); The Primary Tumor Size; the Primary Tumor Grade; the Histopathologic Grade; a description of local sites to which the tumor had invaded (Local Invasion); the presence of
35 lymph node metastases (Lymph Node Metastasis); incidence of lymph node metastases (provided as number of lymph nodes positive for metastasis over the number of lymph nodes examined)

(Incidence Lymphnode Metastasis); the Regional Lymphnode Grade; the identification or detection of metastases to sites distant to the tumor and their location (Distant Met & Loc); a description of the distant metastases (Description Distant Met); the grade of distant metastasis (Distant Met Grade); and general comments about the patient or the tumor (Comments). Adenoma was not 5 described in any of the patients. ; adenoma dysplasia (described as hyperplasia by the pathologist) was described in Patient ID No. 695. Extranodal extensions were described in two patients, Patient ID Nos. 784 and 791. Lymphovascular invasion was described in seven patients, Patient ID Nos. 128, 278, 517, 534, 784, 786, and 791.. Crohn's-like infiltrates were described in seven patients, Patient ID Nos. 52, 264, 268, 392, 393, 784, and 791.

10 Source of polynucleotides on arrays

Polynucleotides on arrays

Polynucleotides spotted on the arrays were generated by PCR amplification of clones derived from cDNA libraries. The clones used for amplification were either the clones from which the sequences described herein (SEQ ID NOS:1-316) were derived, or are clones having inserts 15 with significant polynucleotide sequence overlap with the sequences described herein (SEQ ID NO:1-316) as determined by BLAST2 homology searching.

Microarray Design

Each array used in the examples below had an identical spatial layout and control spot set. Each microarray was divided into two areas, each area having an array with, on each half, twelve 20 groupings of 32 x 12 spots for a total of about 9,216 spots on each array. The two areas are spotted identically which provide for at least two duplicates of each clone per array. Spotting was accomplished using PCR amplified products from 0.5kb to 2.0 kb and spotted using a Molecular Dynamics Gen III spotter according to the manufacturer's recommendations. The first row of each of the 24 regions on the array had about 32 control spots, including 4 negative control spots and 8 25 test polynucleotides.

The test polynucleotides were spiked into each sample before the labeling reaction with a range of concentrations from 2-600 pg/slide and ratios of 1:1 . For each array design, two slides 30 were hybridized with the test samples reverse-labeled in the labeling reaction. This provided for about 4 duplicate measurements for each clone, two of one color and two of the other, for each sample.

Microarray analysis

cDNA probes were prepared from total RNA isolated from the patient cells described in above (Table 8). Since LCM provides for the isolation of specific cell types to provide a substantially homogenous cell sample, this provided for a similarly pure RNA sample.

35 Total RNA was first reverse transcribed into cDNA using a primer containing a T7 RNA polymerase promoter, followed by second strand DNA synthesis. cDNA was then transcribed in

vitro to produce antisense RNA using the T7 promoter-mediated expression (see, e.g., Luo *et al.* (1999) *Nature Med* 5:117-122), and the antisense RNA was then converted into cDNA. The second set of cDNAs were again transcribed *in vitro*, using the T7 promoter, to provide antisense RNA. Optionally, the RNA was again converted into cDNA, allowing for up to a third round of 5 T7-mediated amplification to produce more antisense RNA. Thus the procedure provided for two or three rounds of *in vitro* transcription to produce the final RNA used for fluorescent labeling. Fluorescent probes were generated by first adding control RNA to the antisense RNA mix, and producing fluorescently labeled cDNA from the RNA starting material. Fluorescently labeled cDNAs prepared from the tumor RNA sample were compared to fluorescently labeled cDNAs 10 prepared from normal cell RNA sample. For example, the cDNA probes from the normal cells were labeled with Cy3 fluorescent dye (green) and the cDNA probes prepared from the tumor cells were labeled with Cy5 fluorescent dye (red).

The differential expression assay was performed by mixing equal amounts of probes from tumor cells and normal cells of the same patient. The arrays were prehybridized by incubation for 15 about 2 hrs at 60°C in 5X SSC/0.2% SDS/1 mM EDTA, and then washed three times in water and twice in isopropanol. Following prehybridization of the array, the probe mixture was then hybridized to the array under conditions of high stringency (overnight at 42°C in 50% formamide, 5X SSC, and 0.2% SDS. After hybridization, the array was washed at 55°C three times as follows: 1) first wash in 1X SSC/0.2% SDS; 2) second wash in 0.1X SSC/0.2% SDS; and 3) third wash in 20 0.1X SSC.

The arrays were then scanned for green and red fluorescence using a Molecular Dynamics Generation III dual color laser-scanner/detector. The images were processed using BioDiscovery Autogene software, and the data from each scan set normalized to provide for a ratio of expression relative to normal. Data from the microarray experiments was analyzed according to the algorithms 25 described in U.S. application serial no. 60/252,358, filed November 20, 2000, by E.J. Moler, M.A. Boyle, and F.M. Randazzo, and entitled "Precision and accuracy in cDNA microarray data," which application is specifically incorporated herein by reference.

The experiment was repeated, this time labeling the two probes with the opposite color in order to perform the assay in both "color directions." Each experiment was sometimes repeated 30 with two more slides (one in each color direction). The level fluorescence for each sequence on the array expressed as a ratio of the geometric mean of 8 replicate spots/genes from the four arrays or 4 replicate spots/gene from 2 arrays or some other permutation. The data were normalized using the spiked positive controls present in each duplicated area, and the precision of this normalization was included in the final determination of the significance of each differential. The fluorescent intensity 35 of each spot was also compared to the negative controls in each duplicated area to determine which spots have detected significant expression levels in each sample.

A statistical analysis of the fluorescent intensities was applied to each set of duplicate spots to assess the precision and significance of each differential measurement, resulting in a p-value testing the null hypothesis that there is no differential in the expression level between the tumor and normal samples of each patient. For initial analysis of the microarrays, the hypothesis was accepted if $p > 10^{-3}$, and the differential ratio was set to 1.000 for those spots. All other spots have a significant difference in expression between the tumor and normal sample. If the tumor sample has detectable expression and the normal does not, the ratio is truncated at 1000 since the value for expression in the normal sample would be zero, and the ratio would not be a mathematically useful value (e.g., infinity). If the normal sample has detectable expression and the tumor does not, the ratio is truncated to 0.001, since the value for expression in the tumor sample would be zero and the ratio would not be a mathematically useful value. These latter two situations are referred to herein as "on/off." Database tables were populated using a 95% confidence level ($p > 0.05$).

Table 9 below summarize the results of the differential expression analysis. Each table provides: the SEQ ID NO of the polynucleotide corresponding to the polynucleotide on the spot on the array; the Spot ID (an identifier assigned to the spot so as to distinguish it from spots on the same and different arrays), the number of patients for whom there was information obtained from the array (Num Ratios), and the percentage of patients in which expression was detected at greater than or equal to a two-fold increase ($\geq 2x$), greater than or equal to a five-fold increase ($\geq 5x$), or less than or equal to a 1/2 -fold decrease ($\leq \text{half}x$) relative to matched normal control tissue.

In general, a polynucleotide is said to represent a significantly differentially expressed gene between two samples when there is detectable levels of expression in at least one sample and the ratio value is greater than at least about 1.2 fold, preferably greater than at least about 1.5 fold, more preferably greater than at least about 2 fold, where the ratio value is calculated using the method described above.

A differential expression ratio of 1 indicates that the expression level of the gene in the tumor cell was not statistically different from expression of that gene in normal colon cells of the same patient. A differential expression ratio significantly greater than 1 in cancerous colon cells relative to normal colon cells indicates that the gene is increased in expression in cancerous cells relative to normal cells, indicating that the gene plays a role in the development of the cancerous phenotype, and may be involved in promoting metastasis of the cell. Detection of gene products from such genes can provide an indicator that the cell is cancerous, and may provide a therapeutic and/or diagnostic target.

Likewise, a differential expression ratio significantly less than 1 in cancerous colon cells relative to normal colon cells indicates that, for example, the gene is involved in suppression of the cancerous phenotype. Increasing activity of the gene product encoded by such a gene, or replacing such activity, can provide the basis for chemotherapy. Such gene can also serve as markers of

cancerous cells, e.g., the absence or decreased presence of the gene product in a colon cell relative to a normal colon cell indicates that the cell may be cancerous.

Table 9.

SEQ ID NO:	SpotID	Num Ratios	>=2x	>=5x	<=halfx
8	579	33	87.88	39.39	3.03
12	22300	33	33.33	18.18	6.06
26	21886	33	33.33	0.00	3.03
64	9487	33	33.33	12.12	3.03
248	28179	28	32.14	0.00	0.00
253	28179	28	32.14	0.00	0.00
272	28179	28	32.14	0.00	0.00
292	9111	33	33.33	18.18	3.03
295	19980	33	33.33	6.06	0.00
309	23993	33	42.42	3.03	3.03

5

Deposit Information. The following materials were deposited with the American Type Culture Collection (CMCC = Chiron Master Culture Collection).

Table 5. Cell Lines Deposited with ATCC

Cell Line	Deposit Date	ATCC Accession No.	CMCC Accession No.
KM12L4-A	March 19, 1998	CRL-12496	11606
Km12C	May 15, 1998	CRL-12533	11611
MDA-MB-231	May 15, 1998	CRL-12532	10583
MCF-7	October 9, 1998	CRL-12584	10377

10 In addition, pools of selected clones, as well as libraries containing specific clones, were assigned an "ES" number (internal reference) and deposited with the ATCC. Table 6 below provides the ATCC Accession Nos. of the ES deposits, all of which were deposited on or before May 13, 1999. The names of the clones contained within each of these deposits are provided in the Table 7 (inserted before the claims).

15 Table 6: Pools of Clones and Libraries Deposited with ATCC on or before March 28, 2000

Cell Line	CMCC	ATCC
ES75	5140	PTA-1102
ES76	5141	PTA-1103
ES77	5142	PTA-1104
ES78	5143	PTA-1105
ES79	5144	PTA-1106
ES80	5145	PTA-1107
ES81	5146	PTA-1108
ES82	5147	PTA-1109
ES83	5148	PTA-1110
ES84	5149	PTA-1111

The deposits described herein are provided merely as convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained within the deposited material, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the written description of sequences herein. A license may be required to make, use, or sell the deposited material, and no such license is granted hereby.

Retrieval of Individual Clones from Deposit of Pooled Clones. Where the ATCC deposit is composed of a pool of cDNA clones or a library of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. The clones in the pool or library were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e.g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID NO). The probe should be designed to have a T_m of approximately 80°C (assuming 2°C for each A or T and 4°C for each G or C). Positive colonies can then be picked, grown in culture, and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e.g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.

Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
1	819545	RTA22200265F.k.06.1.P.Seq	F	M00064554D:A03	CH22PRC
2	377944	RTA22200251F.j.02.1.P.Seq	F	M00063482A:A08	CH21PRN
3	818497	RTA22200252F.a.13.1.P.Seq	F	M00063514C:D03	CH21PRN
4	819498	RTA22200252F.n.05.1.P.Seq	F	M00063638C:G12	CH21PRN
5	455465	RTA22200264F.e.16.1.P.Seq	F	M00064454A:H10	CH22PRC
6	819069	RTA22200255F.f.01.1.P.Seq	F	M00063940D:F09	CH21PRN
7	672003	RTA22200265F.b.09.1.P.Seq	F	M00064517C:F11	CH22PRC
8	728115	RTA22200253F.o.24.1.P.Seq	F	M00063838B:G08	CH21PRN
9	372700	RTA22200260F.b.20.1.P.Seq	F	M00063580C:A06	CH22PRC
10	818056	RTA22200266F.c.13.1.P.Seq	F	M00064593D:C01	CH22PRC
11	818497	RTA22200255F.a.17.1.P.Seq	F	M00063920D:H02	CH21PRN
12	729832	RTA22200267F.l.21.1.P.Seq	F	M00064714A:G03	CH22PRC
13	505514	RTA22200251F.b.21.1.P.Seq	F	M00063158A:A01	CH21PRN
14	376488	RTA22200254F.c.05.1.P.Seq	F	M00063852B:D08	CH21PRN
15	376488	RTA22200260F.b.09.1.P.Seq	F	M00063578C:A06	CH22PRC
16	748572	RTA22200254F.c.07.1.P.Seq	F	M00063852D:F07	CH21PRN
17	549934	RTA22200253F.k.18.1.P.Seq	F	M00063801B:D04	CH21PRN
18	819069	RTA22200255F.e.24.1.P.Seq	F	M00063940D:F09	CH21PRN
19	817618	RTA22200253F.n.16.1.P.Seq	F	M00063828D:E05	CH21PRN
20	124396	RTA22200263F.a.11.2.P.Seq	F	M00064375B:G07	CH22PRC
21	404375	RTA22200260F.m.08.1.P.Seq	F	M00063967D:G02	CH22PRC
22	391820	RTA22200261F.f.02.1.P.Seq	F	M00064000B:C03	CH22PRC
23	672003	RTA22200267F.i.06.1.P.Seq	F	M00064693D:F08	CH22PRC
24	830620	RTA22200263F.n.09.1.P.Seq	F	M00064424B:C12	CH22PRC
25	450399	RTA22200251F.f.23.1.P.Seq	F	M00063467D:H07	CH21PRN
26	450982	RTA22200261F.n.18.1.P.Seq	F	M00064307B:G02	CH22PRC
27	819894	RTA22200264F.h.18.1.P.Seq	F	M00064467B:D06	CH22PRC
28	379302	RTA22200257F.j.02.3.P.Seq	F	M00064178C:C04	CH21PRN
29	379746	RTA22200256F.e.16.1.P.Seq	F	M00064086C:E01	CH21PRN
30	124863	RTA22200265F.m.06.1.P.Seq	F	M00064564A:C02	CH22PRC
31	379154	RTA22200257F.c.11.1.P.Seq	F	M00064151B:C07	CH21PRN
32	830620	RTA22200262F.l.23.1.P.Seq	F	M00064358C:D09	CH22PRC
33	389409	RTA22200266F.l.24.1.P.Seq	F	M00064631A:C07	CH22PRC
34	397284	RTA22200262F.i.22.1.P.Seq	F	M00064346C:B09	CH22PRC
35	819440	RTA22200264F.e.19.1.P.Seq	F	M00064454C:B06	CH22PRC
36	389409	RTA22200266F.m.01.1.P.Seq	F	M00064631A:C07	CH22PRC
37	518848	RTA22200265F.n.15.1.P.Seq	F	M00064571C:C04	CH22PRC
38	830620	RTA22200263F.a.21.1.P.Seq	F	M00064376A:A05	CH22PRC
39	379154	RTA22200256F.f.20.1.P.Seq	F	M00064090D:D09	CH21PRN
40	818544	RTA22200256F.h.04.1.P.Seq	F	M00064105B:A03	CH21PRN
41	817375	RTA22200251F.a.15.1.P.Seq	F	M00063152C:B07	CH21PRN

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
42	455264	RTA22200259F.e.23.1.P.Seq	F	M00063539C:C11	CH22PRC
43	817503	RTA22200266F.k.11.1.P.Seq	F	M00064624D:C09	CH22PRC
44	377696	RTA22200256F.d.21.1.P.Seq	F	M00064082D:D10	CH21PRN
45	375596	RTA22200261F.h.10.1.P.Seq	F	M00064009A:C01	CH22PRC
46	817689	RTA22200263F.h.05.1.P.Seq	F	M00064399A:E01	CH22PRC
47	831867	RTA22200262F.i.15.2.P.Seq	F	M00064345A:A03	CH22PRC
48	830085	RTA22200261F.k.14.1.P.Seq	F	M00064293D:B12	CH22PRC
49	389627	RTA22200264F.c.10.1.P.Seq	F	M00064447B:C06	CH22PRC
50	397284	RTA22200259F.k.09.1.P.Seq	F	M00063555B:D01	CH22PRC
51	380063	RTA22200261F.j.02.1.P.Seq	F	M00064014D:H05	CH22PRC
52	830931	RTA22200266F.m.23.1.P.Seq	F	M00064633C:A03	CH22PRC
53	819321	RTA22200257F.I.03.3.P.Seq	F	M00064194C:D02	CH21PRN
54	475587	RTA22200261F.c.01.1.P.Seq	F	M00063990A:D05	CH22PRC
55	819046	RTA22200255F.a.18.1.P.Seq	F	M00063920D:H05	CH21PRN
56	817477	RTA22200253F.g.21.1.P.Seq	F	M00063784A:H12	CH21PRN
57	475587	RTA22200261F.b.24.1.P.Seq	F	M00063990A:D05	CH22PRC
58	728115	RTA22200253F.p.01.1.P.Seq	F	M00063838B:G08	CH21PRN
59	389627	RTA22200260F.i.24.1.P.Seq	F	M00063957A:E02	CH22PRC
60	403453	RTA22200256F.i.24.1.P.Seq	F	M00064113B:C04	CH21PRN
61	508525	RTA22200255F.d.10.1.P.Seq	F	M00063931B:F07	CH21PRN
62	819525	RTA22200261F.n.20.1.P.Seq	F	M00064307C:G03	CH22PRC
63	817618	RTA22200255F.i.03.1.P.Seq	F	M00064025D:H12	CH21PRN
64	819403	RTA22200254F.h.14.1.P.Seq	F	M00063888D:D05	CH21PRN
65	553242	RTA22200254F.g.20.1.P.Seq	F	M00063886A:B06	CH21PRN
66	817417	RTA22200255F.a.10.1.P.Seq	F	M00063919C:E07	CH21PRN
67	817618	RTA22200252F.f.13.1.P.Seq	F	M00063604A:B11	CH21PRN
68	611440	RTA22200262F.e.04.2.P.Seq	F	M00064328B:H09	CH22PRC
69	817375	RTA22200260F.m.06.1.P.Seq	F	M00063967C:A12	CH22PRC
70	213577	RTA22200255F.i.23.1.P.Seq	F	M00064033C:C11	CH21PRN
71	820061	RTA22200265F.p.10.1.P.Seq	F	M00064579D:E11	CH22PRC
72	455264	RTA22200259F.m.06.1.P.Seq	F	M00063559D:G03	CH22PRC
73	455264	RTA22200255F.o.23.1.P.Seq	F	M00064059A:C11	CH21PRN
74	380331	RTA22200255F.b.19.1.P.Seq	F	M00063926A:H04	CH21PRN
75	380331	RTA22200252F.b.19.1.P.Seq	F	M00063518D:A01	CH21PRN
76	817455	RTA22200267F.o.01.1.P.Seq	F	M00064723D:H03	CH22PRC
77	423967	RTA22200252F.a.20.1.P.Seq	F	M00063515B:H02	CH21PRN
78	220584	RTA22200261F.m.14.1.P.Seq	F	M00064302A:D10	CH22PRC
79	817688	RTA22200251F.e.20.1.P.Seq	F	M00063462D:D07	CH21PRN
80	549934	RTA22200253F.n.10.1.P.Seq	F	M00063826A:D03	CH21PRN
81	819149	RTA22200255F.e.16.1.P.Seq	F	M00063938B:H07	CH21PRN
82	817455	RTA22200267F.n.24.1.P.Seq	F	M00064723D:H03	CH22PRC

Table 1.

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
83	377696	RTA22200251F.j.03.1.P.Seq	F	M00063482A:F07	CH21PRN
84	830146	RTA22200260F.b.07.1.P.Seq	F	M00063578B:E02	CH22PRC
85	194490	RTA22200264F.l.07.1.P.Seq	F	M00064481C:F03	CH22PRC
86	819460	RTA22200257F.m.15.3.P.Seq	F	M00064200D:E08	CH21PRN
87	819018	RTA22200257F.p.01.3.P.Seq	F	M00064212D:E04	CH21PRN
88	830620	RTA22200259F.p.24.1.P.Seq	F	M00063571B:G03	CH22PRC
89	141079	RTA22200262F.k.19.1.P.Seq	F	M00064354A:A10	CH22PRC
90	376588	RTA22200256F.e.04.1.P.Seq	F	M00064083D:E05	CH21PRN
91	380604	RTA22200264F.g.05.1.P.Seq	F	M00064460C:B01	CH22PRC
92	413138	RTA22200260F.b.05.1.P.Seq	F	M00063577C:C02	CH22PRC
93	818544	RTA22200265F.e.12.1.P.Seq	F	M00064527A:H07	CH22PRC
94	647435	RTA22200257F.h.08.1.P.Seq	F	M00064172C:A02	CH21PRN
95	551785	RTA22200266F.c.09.1.P.Seq	F	M00064593A:A05	CH22PRC
96	17092	RTA22200261F.f.17.1.P.Seq	F	M00064002C:F06	CH22PRC
97	818326	RTA22200251F.i.06.1.P.Seq	F	M00063478C:D01	CH21PRN
98	377944	RTA22200262F.e.03.2.P.Seq	F	M00064328B:H04	CH22PRC
99	745559	RTA22200262F.m.04.1.P.Seq	F	M00064359B:H12	CH22PRC
100	818326	RTA22200265F.d.08.1.P.Seq	F	M00064524A:A09	CH22PRC
101	379879	RTA22200264F.b.23.1.P.Seq	F	M00064446A:D11	CH22PRC
102	819640	RTA22200257F.f.24.1.P.Seq	F	M00064165A:B12	CH21PRN
103	818326	RTA22200265F.a.14.1.P.Seq	F	M00064514D:F11	CH22PRC
104	243524	RTA22200265F.g.04.1.P.Seq	F	M00064532D:G06	CH22PRC
105	43995	RTA22200261F.l.02.1.P.Seq	F	M00064294D:F01	CH22PRC
106	597854	RTA22200262F.g.06.2.P.Seq	F	M00064337D:F01	CH22PRC
107	268290	RTA22200260F.p.14.1.P.Seq	F	M00063981D:A06	CH22PRC
108	818043	RTA22200256F.p.10.2.P.Seq	F	M00064138A:F11	CH21PRN
109	830930	RTA22200267F.b.03.1.P.Seq	F	M00064652B:D09	CH22PRC
110	389627	RTA22200260F.j.01.1.P.Seq	F	M00063957A:E02	CH22PRC
111	378730	RTA22200260F.i.07.1.P.Seq	F	M00063955C:F07	CH22PRC
112	819037	RTA22200260F.n.09.1.P.Seq	F	M00063972C:E10	CH22PRC
113	830397	RTA22200261F.g.14.1.P.Seq	F	M00064005D:A08	CH22PRC
114	450247	RTA22200261F.e.10.1.P.Seq	F	M00063998C:E09	CH22PRC
115	819273	RTA22200252F.b.09.1.P.Seq	F	M00063517A:A04	CH21PRN
116	587779	RTA22200257F.i.11.3.P.Seq	F	M00064175B:B09	CH21PRN
117	818639	RTA22200256F.j.09.1.P.Seq	F	M00064115B:E12	CH21PRN
118	615617	RTA22200261F.o.13.1.P.Seq	F	M00064309C:H09	CH22PRC
119	79309	RTA22200257F.j.13.3.P.Seq	F	M00064180A:G03	CH21PRN
120	748994	RTA22200261F.o.20.1.P.Seq	F	M00064310C:A10	CH22PRC
121	818682	RTA22200258F.h.07.1.P.Seq	F	M00064271B:D03	CH21PRN
122	373061	RTA22200253F.j.09.1.P.Seq	F	M00063795C:D09	CH21PRN
123	484413	RTA22200253F.g.09.1.P.Seq	F	M00063781B:B10	CH21PRN

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
124	819273	RTA22200258F.h.04.1.P.Seq	F	M00064270B:B03	CH21PRN
125	569532	RTA22200252F.h.18.1.P.Seq	F	M00063613D:C11	CH21PRN
126	170313	RTA22200255F.g.20.1.P.Seq	F	M00063949D:A05	CH21PRN
127	818682	RTA22200253F.p.14.1.P.Seq	F	M00063841A:B09	CH21PRN
128	377188	RTA22200255F.l.06.1.P.Seq	F	M00064043D:C09	CH21PRN
129	518848	RTA22200257F.j.22.3.P.Seq	F	M00064186C:B03	CH21PRN
130	45592	RTA22200259F.l.08.1.P.Seq	F	M00063557D:C07	CH22PRC
131	819273	RTA22200255F.n.19.1.P.Seq	F	M00064053C:G04	CH21PRN
132	397284	RTA22200251F.a.06.1.P.Seq	F	M00063151D:B10	CH21PRN
133	818326	RTA22200258F.e.14.1.P.Seq	F	M00064260C:E05	CH21PRN
134	819037	RTA22200251F.c.15.1.P.Seq	F	M00063452A:F08	CH21PRN
135	817417	RTA22200253F.m.14.1.P.Seq	F	M00063818C:A09	CH21PRN
136	819640	RTA22200254F.i.11.1.P.Seq	F	M00063891A:F11	CH21PRN
137	818771	RTA22200254F.i.19.1.P.Seq	F	M00063892B:G02	CH21PRN
138	389627	RTA22200254F.k.10.1.P.Seq	F	M00063898A:A10	CH21PRN
139	379067	RTA22200260F.e.20.1.P.Seq	F	M00063593A:D03	CH22PRC
140	818544	RTA22200251F.f.02.1.P.Seq	F	M00063463D:B05	CH21PRN
141	819440	RTA22200251F.j.22.1.P.Seq	F	M00063485A:E05	CH21PRN
142	817417	RTA22200251F.k.10.1.P.Seq	F	M00063487C:C02	CH21PRN
143	385307	RTA22200262F.k.11.1.P.Seq	F	M00064352C:H01	CH22PRC
144	611440	RTA22200263F.d.24.2.P.Seq	F	M00064386B:C02	CH22PRC
145	376056	RTA22200259F.e.16.1.P.Seq	F	M00063538D:B01	CH22PRC
146	611440	RTA22200263F.d.24.1.P.Seq	F	M00064386B:C02	CH22PRC
147	820061	RTA22200264F.f.09.1.P.Seq	F	M00064457D:C09	CH22PRC
148	617825	RTA22200264F.p.06.1.P.Seq	F	M00064508A:B09	CH22PRC
149	819440	RTA22200257F.h.17.1.P.Seq	F	M00064173B:E01	CH21PRN
150	819145	RTA22200266F.m.08.1.P.Seq	F	M00064631C:H11	CH22PRC
151	817653	RTA22200265F.p.07.1.P.Seq	F	M00064579A:C06	CH22PRC
152	611440	RTA22200263F.e.01.1.P.Seq	F	M00064386B:C02	CH22PRC
153	375958	RTA22200264F.j.22.1.P.Seq	F	M00064476D:C04	CH22PRC
154	611440	RTA22200257F.a.20.1.P.Seq	F	M00064144D:A07	CH21PRN
155	831049	RTA22200266F.o.13.1.P.Seq	F	M00064637B:F03	CH22PRC
156	818162	RTA22200266F.g.18.1.P.Seq	F	M00064610D:H01	CH22PRC
157	553200	RTA22200263F.p.02.1.P.Seq	F	M00064429D:B07	CH22PRC
158	139677	RTA22200254F.o.07.1.P.Seq	F	M00063910D:A12	CH21PRN
159	139677	RTA22200252F.c.11.1.P.Seq	F	M00063520D:E11	CH21PRN
160	397284	RTA22200262F.i.22.2.P.Seq	F	M00064346C:B09	CH22PRC
161	385810	RTA22200256F.m.04.2.P.Seq	F	M00064126C:F12	CH21PRN
162	404624	RTA22200261F.e.07.1.P.Seq	F	M00063997C:B12	CH22PRC
163	375958	RTA22200262F.b.14.2.P.Seq	F	M00064322C:A10	CH22PRC
164	616555	RTA22200265F.b.24.1.P.Seq	F	M00064520A:E04	CH22PRC

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
165	616555	RTA22200265F.c.01.1.P.Seq	F	M00064520A:E04	CH22PRC
166	295694	RTA22200260F.o.20.1.P.Seq	F	M00063978B:B06	CH22PRC
167	36113	RTA22200265F.e.06.1.P.Seq	F	M00064526D:F05	CH22PRC
168	831812	RTA22200263F.f.05.1.P.Seq	F	M00064390A:C05	CH22PRC
169	817653	RTA22200252F.g.23.1.P.Seq	F	M00063610D:C11	CH21PRN
170	397284	RTA22200252F.m.15.1.P.Seq	F	M00063636A:E01	CH21PRN
171	817979	RTA22200253F.p.15.1.P.Seq	F	M00063841A:E08	CH21PRN
172	817653	RTA22200255F.m.18.1.P.Seq	F	M00064048C:G12	CH21PRN
173	611440	RTA22200253F.f.03.1.P.Seq	F	M00063774A:D09	CH21PRN
174	386014	RTA22200261F.f.06.1.P.Seq	F	M00064001A:B03	CH22PRC
175	549981	RTA22200255F.b.10.1.P.Seq	F	M00063925B:F04	CH21PRN
176	193373	RTA22200255F.l.21.1.P.Seq	F	M00064046A:G02	CH21PRN
177	400619	RTA22200255F.g.14.1.P.Seq	F	M00063947D:D01	CH21PRN
178	831149	RTA22200261F.o.21.1.P.Seq	F	M00064310D:F03	CH22PRC
179	36113	RTA22200255F.d.16.1.P.Seq	F	M00063932D:G08	CH21PRN
180	817503	RTA22200253F.l.16.1.P.Seq	F	M00063805D:E05	CH21PRN
181	376588	RTA22200260F.i.11.1.P.Seq	F	M00063955D:F05	CH22PRC
182	141079	RTA22200252F.f.23.1.P.Seq	F	M00063606C:B04	CH21PRN
183	818063	RTA22200253F.p.04.1.P.Seq	F	M00063839A:F01	CH21PRN
184	455264	RTA22200253F.n.14.1.P.Seq	F	M00063828A:H12	CH21PRN
185	189234	RTA22200251F.f.17.1.P.Seq	F	M00063466C:C11	CH21PRN
186	295694	RTA22200265F.j.05.1.P.Seq	F	M00064550A:A07	CH22PRC
187	648679	RTA22200260F.f.06.1.P.Seq	F	M00063594B:H07	CH22PRC
188	830930	RTA22200264F.e.10.1.P.Seq	F	M00064452D:E11	CH22PRC
189	818497	RTA22200256F.d.07.1.P.Seq	F	M00064079C:A10	CH21PRN
190	373928	RTA22200256F.d.19.1.P.Seq	F	M00064082A:A08	CH21PRN
191	385307	RTA22200263F.j.12.1.P.Seq	F	M00064406B:H06	CH22PRC
192	403453	RTA22200266F.e.10.1.P.Seq	F	M00064601D:B05	CH22PRC
193	730318	RTA22200264F.c.09.1.P.Seq	F	M00064447B:A07	CH22PRC
194	44183	RTA22200271F.a.01.1.P.Seq	F	M00021929A:D03	CH03MAH
195	373928	RTA22200255F.d.22.1.P.Seq	F	M00063934B:E04	CH21PRN
196	404624	RTA22200255F.d.23.1.P.Seq	F	M00063934C:C10	CH21PRN
197	403173	RTA22200253F.a.21.1.P.Seq	F	M00063685A:C02	CH21PRN
198	372700	RTA22200253F.c.06.1.P.Seq	F	M00063689D:E12	CH21PRN
199	374343	RTA22200261F.h.04.1.P.Seq	F	M00064008A:B01	CH22PRC
200	597854	RTA22200255F.j.03.1.P.Seq	F	M00064033D:B01	CH21PRN
201	817417	RTA22200255F.a.23.1.P.Seq	F	M00063922B:A12	CH21PRN
202	818497	RTA22200257F.k.05.3.P.Seq	F	M00064188B:G08	CH21PRN
203	377696	RTA22200255F.f.15.1.P.Seq	F	M00063943B:G12	CH21PRN
204	379105	RTA22200252F.n.19.1.P.Seq	F	M00063642B:A08	CH21PRN
205	831188	RTA22200267F.o.02.1.P.Seq	F	M00064723D:H11	CH22PRC

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
206	376056	RTA22200253F.m.09.1.P.Seq	F	M00063810C:E03	CH21PRN
207	124863	RTA22200255F.n.15.1.P.Seq	F	M00064053B:D09	CH21PRN
208	376056	RTA22200254F.i.03.1.P.Seq	F	M00063890A:F11	CH21PRN
209	831812	RTA22200266F.j.10.1.P.Seq	F	M00064620C:D01	CH22PRC
210	141079	RTA22200260F.i.14.1.P.Seq	F	M00063956A:F05	CH22PRC
211	19148	RTA22200265F.o.18.1.P.Seq	F	M00064577C:B12	CH22PRC
212	124396	RTA22200252F.a.14.1.P.Seq	F	M00063514C:E08	CH21PRN
213	831026	RTA22200265F.c.03.1.P.Seq	F	M00064520A:F08	CH22PRC
214	819037	RTA22200263F.i.23.1.P.Seq	F	M00064405B:C04	CH22PRC
215	380207	RTA22200263F.i.19.1.P.Seq	F	M00064404C:G05	CH22PRC
216	819460	RTA22200255F.c.13.1.P.Seq	F	M00063928A:G09	CH21PRN
217	379067	RTA22200253F.g.23.1.P.Seq	F	M00063784C:E10	CH21PRN
218	403173	RTA22200252F.p.23.1.P.Seq	F	M00063682A:C04	CH21PRN
219	3856	RTA22200269F.a.05.1.P.Seq	F	M00003773D:H02	CH01COH
220	378551	RTA22200263F.d.17.1.P.Seq	F	M00064385D:C11	CH22PRC
221	456089	RTA22200272F.a.09.1.P.Seq	F	M00043134A:A05	CH19COP
222	549981	RTA22200267F.a.22.1.P.Seq	F	M00064650B:B07	CH22PRC
223	378551	RTA22200265F.m.21.1.P.Seq	F	M00064568A:H06	CH22PRC
224	819201	RTA22200256F.n.23.2.P.Seq	F	M00064132B:B07	CH21PRN
225	374826	RTA22200251F.c.20.1.P.Seq	F	M00063453B:F08	CH21PRN
226	389409	RTA22200253F.l.23.1.P.Seq	F	M00063807A:D12	CH21PRN
227	819149	RTA22200260F.a.17.1.P.Seq	F	M00063575B:G02	CH22PRC
228	389409	RTA22200255F.e.18.1.P.Seq	F	M00063939C:D06	CH21PRN
229	818165	RTA22200254F.h.15.1.P.Seq	F	M00063888D:F02	CH21PRN
230	817757	RTA22200252F.i.15.1.P.Seq	F	M00063617D:F09	CH21PRN
231	553242	RTA22200263F.i.20.1.P.Seq	F	M00064404D:A06	CH22PRC
232	385615	RTA22200265F.b.08.1.P.Seq	F	M00064517B:F10	CH22PRC
233	819102	RTA22200258F.h.19.1.P.Seq	F	M00064272C:G01	CH21PRN
234	817757	RTA22200255F.o.16.1.P.Seq	F	M00064057C:H10	CH21PRN
235	385615	RTA22200265F.b.07.1.P.Seq	F	M00064517B:F04	CH22PRC
236	385615	RTA22200253F.l.06.1.P.Seq	F	M00063804C:A11	CH21PRN
237	827355	RTA22200266F.n.23.1.P.Seq	F	M00064636B:A04	CH22PRC
238	817629	RTA22200259F.a.13.1.P.Seq	F	M00063165A:C09	CH22PRC
239	817514	RTA22200260F.h.02.1.P.Seq	F	M00063600C:C09	CH22PRC
240	817514	RTA22200252F.p.21.1.P.Seq	F	M00063681B:C02	CH21PRN
241	680563	RTA22200265F.f.13.1.P.Seq	F	M00064530B:H02	CH22PRC
242	827355	RTA22200255F.e.20.1.P.Seq	F	M00063939C:H01	CH21PRN
243	377286	RTA22200254F.a.04.1.P.Seq	F	M00063843B:D07	CH21PRN
244	680563	RTA22200258F.g.18.1.P.Seq	F	M00064268D:G03	CH21PRN
245	819156	RTA22200255F.h.06.1.P.Seq	F	M00064021D:H01	CH21PRN
246	220584	RTA22200261F.f.22.1.P.Seq	F	M00064003B:C10	CH22PRC

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
247	616555	RTA22200263F.o.12.1.P.Seq	F	M00064428B:A12	CH22PRC
248	819498	RTA22200254F.o.14.1.P.Seq	F	M00063912A:D06	CH21PRN
249	817508	RTA22200257F.h.01.1.P.Seq	F	M00064171D:E05	CH21PRN
250	817690	RTA22200257F.e.05.1.P.Seq	F	M00064159A:H03	CH21PRN
251	819156	RTA22200256F.h.13.1.P.Seq	F	M00064106C:G03	CH21PRN
252	830904	RTA22200266F.j.12.1.P.Seq	F	M00064620D:G05	CH22PRC
253	819498	RTA22200253F.b.04.1.P.Seq	F	M00063686B:E07	CH21PRN
254	817508	RTA22200257F.g.24.1.P.Seq	F	M00064171D:E05	CH21PRN
255	817508	RTA22200252F.a.19.1.P.Seq	F	M00063515B:F06	CH21PRN
256	831160	RTA22200267F.h.01.1.P.Seq	F	M00064690A:C04	CH22PRC
257	817762	RTA22200252F.k.13.1.P.Seq	F	M00063627C:F06	CH21PRN
258	377286	RTA22200266F.k.07.1.P.Seq	F	M00064624C:B03	CH22PRC
259	831160	RTA22200267F.g.24.1.P.Seq	F	M00064690A:C04	CH22PRC
260	819994	RTA22200256F.k.11.1.P.Seq	F	M00064119C:D12	CH21PRN
261	819994	RTA22200256F.k.09.1.P.Seq	F	M00064119B:H10	CH21PRN
262	373298	RTA22200259F.c.19.1.P.Seq	F	M00063533A:C12	CH22PRC
263	819894	RTA22200256F.m.03.2.P.Seq	F	M00064126C:C02	CH21PRN
264	372718	RTA22200260F.b.22.1.P.Seq	F	M00063580D:B06	CH22PRC
265	827355	RTA22200262F.l.20.1.P.Seq	F	M00064358A:G03	CH22PRC
266	819894	RTA22200255F.d.09.1.P.Seq	F	M00063931B:E10	CH21PRN
267	827355	RTA22200266F.e.07.1.P.Seq	F	M00064601C:G07	CH22PRC
268	372718	RTA22200256F.l.03.1.P.Seq	F	M00064122C:B06	CH21PRN
269	647435	RTA22200251F.b.10.1.P.Seq	F	M00063156D:H10	CH21PRN
270	450262	RTA22200265F.a.10.1.P.Seq	F	M00064514A:G10	CH22PRC
271	484703	RTA22200255F.i.20.1.P.Seq	F	M00064032D:G04	CH21PRN
272	819498	RTA22200256F.f.12.1.P.Seq	F	M00064089B:F09	CH21PRN
273	406043	RTA22200263F.i.12.1.P.Seq	F	M00064404A:B05	CH22PRC
274	817500	RTA22200255F.f.24.1.P.Seq	F	M00063945A:C03	CH21PRN
275	818180	RTA22200264F.o.18.1.P.Seq	F	M00064506A:C07	CH22PRC
276	818143	RTA22200251F.a.03.1.P.Seq	F	M00063151A:G06	CH21PRN
277	819756	RTA22200267F.a.18.1.P.Seq	F	M00064649A:E04	CH22PRC
278	406908	RTA22200257F.i.18.3.P.Seq	F	M00064176D:H10	CH21PRN
279	124863	RTA22200256F.o.21.2.P.Seq	F	M00064136C:D12	CH21PRN
280	429009	RTA22200257F.e.24.1.P.Seq	F	M00064161B:G04	CH21PRN
281	402586	RTA22200257F.i.24.3.P.Seq	F	M00064178B:A05	CH21PRN
282	400475	RTA22200254F.i.04.1.P.Seq	F	M00063890A:H04	CH21PRN
283	403453	RTA22200264F.d.12.1.P.Seq	F	M00064450C:E07	CH22PRC
284	383021	RTA22200259F.d.06.1.P.Seq	F	M00063534C:A02	CH22PRC
285	394913	RTA22200254F.p.10.1.P.Seq	F	M00063915C:E01	CH21PRN
286	831361	RTA22200263F.k.19.1.P.Seq	F	M00064414D:D06	CH22PRC
287	646020	RTA22200267F.n.21.1.P.Seq	F	M00064723C:H04	CH22PRC

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
288	831361	RTA22200263F.l.03.1.P.Seq	F	M00064415B:G03	CH22PRC
289	831580	RTA22200261F.f.18.1.P.Seq	F	M00064002C:H09	CH22PRC
290	402586	RTA22200257F.j.01.3.P.Seq	F	M00064178B:A05	CH21PRN
291	400475	RTA22200262F.j.21.1.P.Seq	F	M00064349D:H01	CH22PRC
292	818937	RTA22200262F.h.14.2.P.Seq	F	M00064341A:C02	CH22PRC
293	557697	RTA22200261F.j.20.1.P.Seq	F	M00064018C:E07	CH22PRC
294	831361	RTA22200265F.m.24.1.P.Seq	F	M00064569B:A09	CH22PRC
295	194490	RTA22200252F.c.10.1.P.Seq	F	M00063520D:D08	CH21PRN
296	818143	RTA22200254F.b.18.1.P.Seq	F	M00063848C:G11	CH21PRN
297	377286	RTA22200259F.a.10.1.P.Seq	F	M00063163A:G04	CH22PRC
298	831361	RTA22200265F.n.01.1.P.Seq	F	M00064569B:A09	CH22PRC
299	385307	RTA22200255F.p.07.1.P.Seq	F	M00064060B:D03	CH21PRN
300	378447	RTA22200251F.c.01.1.P.Seq	F	M00063158A:E11	CH21PRN
301	378447	RTA22200251F.b.24.1.P.Seq	F	M00063158A:E11	CH21PRN
302	817514	RTA22200260F.m.17.1.P.Seq	F	M00063968D:G08	CH22PRC
303	818942	RTA22200255F.f.03.1.P.Seq	F	M00063941B:C12	CH21PRN
304	818942	RTA22200267F.e.23.1.P.Seq	F	M00064678D:F05	CH22PRC
305	817363	RTA22200266F.f.04.1.P.Seq	F	M00064605C:G05	CH22PRC
306	818942	RTA22200255F.i.02.1.P.Seq	F	M00064025D:E07	CH21PRN
307	818942	RTA22200265F.g.23.1.P.Seq	F	M00064534D:F06	CH22PRC
308	817457	RTA22200267F.e.15.1.P.Seq	F	M00064675C:E09	CH22PRC
309	831968	RTA22200263F.f.23.1.P.Seq	F	M00064393B:H04	CH22PRC
310	530941	RTA22200253F.h.05.1.P.Seq	F	M00063785C:F03	CH21PRN
311	763446	RTA22200257F.j.05.3.P.Seq	F	M00064179A:C04	CH21PRN
312	763446	RTA22200255F.n.21.1.P.Seq	F	M00064053D:F02	CH21PRN
313	819219	RTA22200256F.f.16.1.P.Seq	F	M00064090C:A02	CH21PRN
314	763446	RTA22200258F.b.19.2.P.Seq	F	M00064248A:E02	CH21PRN
315	10154				
316	10154				

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
SEQ ID	ACCESSION	DESCRIPTION	P VALUE	ACCESSION	DESCRIPTION	P VALUE
19	<NONE>	<NONE>	<NONE>	1077580	hypothetical protein YDR125c - yeast	7
20	<NONE>	<NONE>	<NONE>	4585925	(AC007211) unknown protein	6
21	<NONE>	<NONE>	<NONE>	1085306	EVI1 protein - human	4.3
22	<NONE>	<NONE>	<NONE>	3876587	(Z81521) predicted using Genefinder; cDNA EST yk233g4.5 comes from this gene; cDNA EST yk233g4.3 comes from this gene [Caenorhabditis elegans]	0.85
23	<NONE>	<NONE>	<NONE>	1086591	(U41007) similar to S. cerevisiae nuclear protein SNF2	0.34
24	<NONE>	<NONE>	<NONE>	157272	(L11345) DNA-binding protein [Drosophila melanogaster]	0.29
25	<NONE>	<NONE>	<NONE>	2633160	(Z99108) similar to surface adhesion YfiQ [Bacillus subtilis]	0.19
26	<NONE>	<NONE>	<NONE>	755468	(U19879) transmembrane protein [Xenopus laevis]	0.042
27	<NONE>	<NONE>	<NONE>	4507339	T brachyury (mouse) homolog protein [Homo sapiens]	0.029

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
28	<NONE>	<NONE>	<NONE>	729711 PROTEASE DEGS PRECURSOR 3.4.21.-) hhoB - Escherichia coli > gi 558913 (U15661) HhoB [Escherichia coli] > gi 606174 (U18997) ORF_o355 coli] > gi 1789630 (AE000402) protease [Escherichia coli]	0.004	
29	<NONE>	<NONE>	<NONE>	3168911 (AF068718) No definition line found [Caenorhabditis elegans]	8e-013	
30	<NONE>	<NONE>	<NONE>	2832777 (AL021086) /prediction=(method:; comes from the 5' UTR [Drosophila melanogaster]	3e-040	
31	X78712	H.sapiens mRNA for glycerol kinase testis specific 2	2.1	2852449 (D88207) protein kinase [Arabidopsis thaliana] > gi 2947061 (AC002521) putative protein kinase	9.1	
32	X60760	L.esculentum TDR8 mRNA	2.1	157272 (L11345) DNA-binding protein [Drosophila melanogaster]	5	

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
33	U40853	Oryctolagus cuniculus pulmonary surfactant protein B (SP-B) gene, complete cds	2	<NONE>	<NONE>	<NONE>
34	AF083655	Homo sapiens procollagen C-proteinase enhancer protein (PCOLCE) gene, 5' flanking region and complete cds	2	<NONE>	<NONE>	<NONE>
35	AJ223776	Staphylococcus warneri hld gene	2	<NONE>	<NONE>	<NONE>
36	U40853	Oryctolagus cuniculus pulmonary surfactant protein B (SP-B) gene, complete cds	2	<NONE>	<NONE>	<NONE>
37	X04436	Clostridium tetani gene for tetanus toxin	2	<NONE>	<NONE>	<NONE>
38	Z35787	S.cerevisiae chromosome II reading frame ORF YBL026w	2	157272	(L11345) DNA-binding protein [Drosophila melanogaster]	8.4
39	X78712	H.sapiens mRNA for glycerol kinase testis specific 2	2	2852449	(D88207) protein kinase [Arabidopsis thaliana] >gi 2947061 (AC002521) putative protein kinase	8.2

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
40	Z15056	B.subtilis genes spoVD, murE, mraY, murD	2	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	2.8
41	S65623	cAMP-regulated enhancer- binding protein 1 of 3]	2	119266	PROTEIN GRAINY- HEAD (DNA- BINDING PROTEIN ELF- 1) (ELEMENT I-BINDING ACTIVITY) regulatory protein elf-1 - fruit fly (Drosophila melanogaster) >gi 7939 emb CAA33692 (X15657) Elf-1 protein (AA 1- 1063) [Drosophila melanogaster]	0.55
42	NM_004415 .1	Homo sapiens desmoplakin (DPI, DPII) (DSP) mRNA mRNA, complete cds	2	2649177	(AE001008) conserved hypothetical protein [Archaeoglobus fulgidus]	0.2
43	AF031552	Vibrio cholerae magnesium transporter (mgtE) gene, partial cds; sensor kinase (vieS), response regulator (vieA), and response regulator (vieB) genes, complete cds; and collagenase (vcc) gene.	2	2088714	(AF003139) strong similarity to NADPH oxidases; partial CDS, the gene begins in the neighboring clone	2e-013

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
		(vcc) gene, partial cds				
44	AF116852.1	Danio rerio dickkopf-1 (dkk1) mRNA, complete cds	2	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	2e-019
45	X82595	P.sativum fuc gene	1.9	<NONE>	<NONE>	<NONE >
46	AF008216	Homo sapiens candidate tumor suppressor pp32r1	1.9	<NONE>	<NONE>	<NONE >
47	AF130672.1	Felis catus clone Fca603 microsatellite sequence	1.9	<NONE>	<NONE>	<NONE >
48	AJ007044	Oryctolagus Cuniculus sod gene	1.9	388055	(L22981) merozoite surface protein- 1 [Plasmodium chabaudi]	7.8
49	AC004497	Homo sapiens chromosome 21, P1 clone LBNL#6	1.9	160925	(M94346) A.1.12/9 antigen [Schistosoma mansoni]	7.7

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
50	U30290	Rattus norvegicus galanin receptor GALR1 mRNA, complete cds	1.9	3024079	GALECTIN-4 (LACTOSE-BINDING LECTIN 4) (L-36 LACTOSE BINDING PROTEIN) (L36LBP) >gi 2281707 sapiens] >gi 2623387 (U82953) galectin-4 [Homo sapiens]	4.5
51	Y13234	Chironomus tentans mRNA for chitinase, 1695 bp	1.9	4567068	(AF125568) tumor suppressing STF cDNA 4 [Homo sapiens]	3.4
52	NM_003644 .1	Homo sapiens growth arrest-specific 7 (GAS7) mRNA > :: emb AJ224876 HSAJ4876 Homo sapience mRNA for GAS7 protein	1.9	125560	PROTEIN KINASE C, GAMMA TYPE C (EC 2.7.1.-) gamma - rabbit >gi 165652 (M19338) protein kinase delta [Oryctolagus cuniculus]	0.53
53	AB013448.1	Oryza sativa gene for Pib, complete cds	1.8	<NONE>	<NONE>	<NONE>
54	D63854	Human cytomegalovirus DNA, replication origin	1.8	<NONE>	<NONE>	<NONE>
55	AB002340	Human mRNA for KIAA0342 gene, complete cds	1.8	<NONE>	<NONE>	<NONE>
56	AF017779	Mus musculus vitamin D receptor gene, promoter region	1.8	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
57	D63854	Human cytomegalovirus DNA, replication origin	1.8	<NONE>	<NONE>	<NONE>
58	M24102	Bovine ADP/ATP translocase T1 mRNA, complete cds.	1.8	<NONE>	<NONE>	<NONE>
59	AC004497	Homo sapiens chromosome 21, P1 clone LBNL#6	1.8	<NONE>	<NONE>	<NONE>
60	M37394	Rat epidermal growth factor receptor mRNA.	1.8	<NONE>	<NONE>	<NONE>
61	AF006304	Saccharomyces cerevisiae protein tyrosine phosphatase (PTP3) gene, complete cds	1.8	<NONE>	<NONE>	<NONE>
62	D13454	Candida albicans CACHS3 gene for chitin synthase III	1.8	<NONE>	<NONE>	<NONE>
63	Y00354	Xenopus laevis gene encoding vitellogenin A2	1.8	1077580	hypothetical protein YDR125c - yeast	7.5
64	U90936	Aspergillus niger px27 gene, promoter region	1.8	4337033	(AF124138) transcriptional activator protein CdaR [Streptomyces coelicolor] transcriptional regulator [Streptomyces coelicolor]	7.3

Table 2

		Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
65	D84448	Cavia cobaya mRNA for Na+,K+-ATPase beta-3 subunit, complete cds	1.8	4704603	(AF109916) putative dehydrin	7.1	
66	AF039948	Xenopus laevis clone H-0 transcription elongation factor S-II (TFIIS) precursor RNA, isoform TFIIS.h, partial cds	1.8	1695839	(U58151) envelope glycoprotein [Human immunodeficiency virus type 1]	5.6	
67	M18061	Xenopus laevis vitellogenin gene, complete cds.	1.8	780502	(U18466) AP endonuclease class II [African swine fever virus] >gi 1097525 prf 2113434ET AP endonuclease:IS OTYPE=class II [African swine fever virus]	3.1	
68	U61112	Mus musculus Eya3 homolog mRNA, complete cds	1.8	3043646	(AB011133) KIAA0561 protein [Homo sapiens]	1.9	
69	AB018442	Oryza sativa mRNA for phytochrome C, complete cds	1.8	4455041	(AF116463) unknown [Streptomyces lincolnensis]	0.49	

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
70	D63854	Human cytomegalovirus DNA, replication origin	1.8	1169200	DNA- DAMAGE- REPAIR/TOLERATION PROTEIN DRT111 PRECURSOR >gi 421829 pir S33706 DNA-damage resistance protein - Arabidopsis thaliana and DNA-damage resistance protein (DRT111) mRNA, complete cds.], gene product [Arabidopsis thaliana]	0.22
71	D26549	Bovine mRNA for adseverin, complete cds	1.8	755468	(U19879) transmembrane protein [Xenopus laevis]	0.042
72	J05211	Human desmoplakin mRNA, 3' end.	1.8	728867	ANTER-SPECIFIC PROLINE-RICH PROTEIN APG PRECURSOR >gi 99694 pir S21961 proline-rich protein APG - Arabidopsis thaliana >gi 22599 emb CAA42925	0.015

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
73	NM_004415 .1	Homo sapiens desmoplakin (DPI, DPII) (DSP) mRNA mRNA, complete cds	1.8	728867	ANTER- SPECIFIC PROLINE- RICH PROTEIN APG PRECURSOR >gi 99694 pir S21961 proline-rich protein APG - Arabidopsis thaliana >gi 22599 em b CAA42925	0.015
74	AF038604	Caenorhabditis elegans cosmid B0546	1.8	3877951	(Z81555) predicted using Genefinder	3e-008
75	AF038604	Caenorhabditis elegans cosmid B0546	1.8	3877951	(Z81555) predicted using Genefinder	2e-011
76	U23551	Prochlorothrix hollandica phosphomannomutase	1.8	2828280	(AL021687) putative protein [Arabidopsis thaliana] >gi 2832633 emb CAA16762 (AL021711) putative protein [Arabidopsis thaliana]	2e-013
77	S60150	ORF1...ORF6 {3' terminal region} [chrysanthemum virus B CVB, Genomic RNA, 6 genes, 3426 nt]	1.8	1065454	(U40410) C54G7.2 gene product [Caenorhabditis elegans]	2e-019
78	AB014558	Homo sapiens mRNA for KIAA0658 protein, partial cds	1.8	3850072	(AL033385) DNA-directed RNA polymerase III subunit [Schizosaccharomyces pombe]	6e-027

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
79	X17191	E.gracilis chloroplast RNA polymerase rpoB-rpoC1-rpoC2 operon	1.7	<NONE>	<NONE>	<NONE>
80	X07729	R.norvegicus gene encoding neuron-specific enolase, exons 8-12	1.7	4584544	(AL049608) extensin-like protein	8.8
81	D38178	Human gene for cytosolic phospholipase A2, exon 1	1.7	73714	infected cell protein ICP34.5 - human herpesvirus 1 (strain F) >gi 330123 (M12240) infected cell protein [Herpes simplex virus type 1]	1.1
82	U23551	Prochlorothrix hollandica phosphomannomutase	1.7	2828280	(AL021687) putative protein [Arabidopsis thaliana] >gi 2832633 emb CAA16762 (AL021711) putative protein [Arabidopsis thaliana]	2e-010
83	Y00525	Klebsiella pneumoniae nifL gene for regulatory protein	1.6	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	6e-013
84	AF100170.1	Bos taurus major fibrous sheath protein precursor, mRNA, complete cds	1.5	463552	(U05877) AF-1 [Homo sapiens]	0.074
85	Y13441	Homo sapiens Rox gene, exon 2	0.74	<NONE>	<NONE>	<NONE>

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
86	L46792	Actinidia deliciosa clone AdXET-5 xyloglucan endotransglycosylase precursor (XET) mRNA, complete cds	0.73	3170252	(AF043636) circumsporozoite protein [Plasmodium chabaudi]	0.001
87	U73489	Drosophila melanogaster Nem (nem) mRNA, complete cds	0.7	3915994	HYPOTHETIC AL 53.2 KD PROTEIN IN PRC-PRPA INTERGENIC REGION	3e-005
88	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.68	157272	(L11345) DNA- binding protein [Drosophila melanogaster]	8.5
89	AF082012	Caenorhabditis elegans UDP-N- acetylglucosamine:a-3-D- mannoside b- 1,2-N- acetylglucosaminylyltransferase I (gly-14) mRNA, complete cds	0.67	2494313	PUTATIVE TRANSLATION INITIATION FACTOR EIF- 2B SUBUNIT 1 (EIF-2B GDP- GTP EXCHANGE FACTOR) eIF- 2B, subunit alpha - Methanococcus jannaschii aIF- 2B, subunit delta (aIF2BD) [Methanococcus jannaschii]	8.4
90	U04354	Mus musculus ADSEVERIN mRNA, complete cds	0.67	4755188	(AC007018) unknown protein	8e-026

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
91	M68881	S.pombe cigl+ gene, complete cds.	0.67	2078441	(U56964) weak similarity to S. cerevisiae intracellular protein transport protein US1 (SP:P25386)	2e-030
92	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.66	2829685	PROTEIN-TYROSINE PHOSPHATASE X PRECURSOR (R-PTP-X) (PTP IA-2BETA) (PROTEIN TYROSINE PHOSPHATASE E-NP) (PTP-NP) >gi 1515425 (U57345) protein tyrosine phosphatase-NP [Mus musculus]	6.2
93	Z15056	B.subtilis genes spoVD, murE, mraY, murD	0.66	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	2.1
94	M86808	Human pyruvate dehydrogenase complex (PDHA2) gene, complete cds.	0.65	<NONE>	<NONE>	<NONE>
95	J03754	Rat plasma membrane Ca2+ ATPase-isoform 2 mRNA, complete cds.	0.65	4507549	transmembrane protein with EGF-like and two follistatin-like domains 1 >gi 755466	8e-006

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
96	NM_000887 .1	Homo sapiens integrin, alpha X (antigen CD11C emb Y00093 H SP15095 H.sapiens mRNA for leukocyte adhesion glycoprotein p150,95	0.64	<NONE>	<NONE>	<NONE >
97	L27080	Human melanocortin 5 receptor (MC5R) gene, complete cds.	0.64	<NONE>	<NONE>	<NONE >
98	U07890	Mus musculus C57BL/6J epidermal surface antigen (mesa) mRNA, complete cds.	0.64	<NONE>	<NONE>	<NONE >
99	AF079139	Streptomyces venezuelae pikCD operon, complete sequence	0.64	3041869	(U96109) proline-rich transcription factor ALX3 [Mus musculus]	2.8
100	M16140	Chicken ovoinhibitor gene, exon 15.	0.64	123984	ACROSIN INHIBITORS IIA AND IIB	4e-008
101	NM_000887 .1	Homo sapiens integrin, alpha X (antigen CD11C emb Y00093 H SP15095 H.sapiens mRNA for leukocyte adhesion glycoprotein p150,95	0.63	<NONE>	<NONE>	<NONE >

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
102	Z17316	Kluyveromyces lactis for gene encoding phosphofructokinase beta subunit	0.63	<NONE>	<NONE>	<NONE>
103	Z25470	H.sapiens melanocortin 5 receptor gene, complete CDS	0.63	<NONE>	<NONE>	<NONE>
104	L19954	Bacillus subtilis feuA, B, and C genes, 3 ORFs, 2 complete cds's and 5'end.	0.63	<NONE>	<NONE>	<NONE>
105	U44405	Spiroplasma citri chromosome pre-inversion border, SPV1-like sequences, transposase gene, partial cds, adhesin-like protein P58 gene, complete cds.	0.63	2499642	SERINE/THREONINE-PROTEIN KINASE STE20 HOMOLOG >gi 1737181 (U73457) Cst20p [Candida albicans]	7.7

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
106	Z28264	S.cerevisiae chromosome XI reading frame ORF YKR039w	0.63	3880930 (AL021481) similar to Phosphoglucomutase and phosphomannomutase phosphoserine; cDNA EST EMBL:D36168 comes from this gene; cDNA EST EMBL:D70697 comes from this gene; cDNA EST yk373h9.5 comes from this gene; cDNA EST EMBL:T00805 ...	2e-014	
107	AE001107	Archaeoglobus fulgidus section 172 of 172 of the complete genome	0.62	<NONE>	<NONE>	<NONE>
108	Z14112	B.firmus TopA gene encoding DNA topoisomerase I	0.62	310115 (L02530) Drosophila polarity gene (frizzled) homologue	0.026	
109	AF118101	Toxoplasma gondii protein kinase 6 (tpk6) mRNA, complete cds	0.62	726403 (U23175) similar to anion exchange protein [Caenorhabditis elegans]	4e-018	
110	M59743	Rabbit cardiac muscle Ca-2+ release channel	0.61	<NONE>	<NONE>	<NONE>
111	M12036	Human tyrosine kinase-type receptor (HER2) gene, partial cds.	0.61	61962 (X58484) gag [Simian foamy virus]	7.5	

Table 2

		Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs.. Non- Redundant Proteins)		
112	AF043195	Homo sapiens tight junction protein ZO (ZO- 2) gene, alternative splice products, promoter and exon A	0.61	1572629	(U69699) unknown protein precursor [Mus musculus]	7.5	
113	U18178	Human HLA class I genomic survey sequence.	0.61	1336688	(S81116) properdin [guinea pigs, spleen, Peptide, 470 aa] [Cavia]	5.7	
114	U44405	Spiroplasma citri chromosome pre-inversion border, SPV1- like sequences, transposase gene, partial cds, adhesin-like protein P58 gene, complete cds.	0.61	2827531	(AL021633) hypothetical protein	3.3	
115	Z33011	M.capricolum DNA for CONTIG MC008	0.61	3915729	HYPERPLASTI C DISCS PROTEIN (HYD PROTEIN) >gi 2673887 (L14644) hyperplastic discs protein	0.26	
116	NM_001429 .1	Homo sapiens E1A binding protein p300 mRNA, complete cds. > :: gb I62297 I622 97 Sequence 1 from patent US 5658784	0.61	4204294	(AC003027) lcl prt_seq No definition line found	5e-005	

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
117	Z25418	C.familiaris MHC class Ib gene (DLA-79) gene, complete CDS	0.61	3877493 (Z48583) similar to ATPases associated with various cellular activities (AAA); cDNA EST EMBL:Z14623 comes from this gene; cDNA EST EMBL:D75090 comes from this gene; cDNA EST EMBL:D72255 comes from this gene; cDNA EST yk200e4.5 ...		1e-007
118	AB002150	Bacillus subtilis DNA for FeuB, FeuA, YbbB, YbbC, YbbD, YbzA, YbbE, YbbF, YbbH, YbbI, YbbJ, YbbK, YbbL, YbbM, YbbP, complete cds	0.6	<NONE>	<NONE>	<NONE>
119	Y07786	V.cholerae ORF's involved in lipopolysacchari de synthese	0.6	<NONE>	<NONE>	<NONE>
120	Z17316	Kluyveromyces lactis for gene encoding phosphofructoki nase beta subunit	0.6	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
121	Z71403	<i>S.cerevisiae</i> chromosome XIV reading frame ORF YNL127w	0.6	<NONE>	<NONE>	<NONE >
122	L34641	Homo sapiens platelet/endothelial cell adhesion molecule-1 (PECAM-1) gene, exon 10.	0.6	1147634	(U42213) micronemal TRAP-C1 protein homolog	9.6
123	AF070572	Homo sapiens clone 24778 unknown mRNA	0.6	399034	N- ACETYLMUR AMOYL-L- ALANINE AMIDASE AMIB PRECURSOR >gi 628763 pir S41741 N- acetyl muramoyl- L-alanine amidase (EC 3.5.1.28) - <i>Escherichia coli</i> >gi 304914 (L19346) N- acetyl muramoyl- L-alanine amidase [<i>Escherichia</i> <i>coli</i>] N- acetyl muramoyl- L-alanine amidase II; a	2.5
124	X75627	<i>C.burnetii</i> trxB, spoIIIE and serS genes	0.6	3036833	(AJ003163) apsB [<i>Emericella</i> <i>nidulans</i>]	0.28
125	Z99765	<i>Flaveria pringlei</i> gdcsH gene	0.59	<NONE>	<NONE>	<NONE >

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
126	U02538	Mycoplasma hyopneumoniae J ATCC 25934 23S rRNA gene, partial sequence	0.59	<NONE>	<NONE>	<NONE>
127	Z71403	S.cerevisiae chromosome XIV reading frame ORF YNL127w	0.59	<NONE>	<NONE>	<NONE>
128	X03942	Mouse simple repetitive DNA (sqr family) transcript (clone pmlc 2) with conserved GACA/GATA repeats	0.59	<NONE>	<NONE>	<NONE>
129	U11844	Mus musculus glucose transporter (GLUT3) gene, exon 1	0.59	<NONE>	<NONE>	<NONE>
130	D63395	Homo sapiens mRNA for NOTCH4, partial cds	0.59	4433616	(AF107018) alpha-mannosidase IIx [Mus musculus]	1.8
131	Z33011	M.capricolum DNA for CONTIG MC008	0.59	3915729	HYPERPLASTIC DISCS PROTEIN (HYD PROTEIN) >gi 2673887 (L14644) hyperplastic discs protein	0.27
132	U05670	Haemophilus influenzae DL42 Lex2A and Lex2B genes, complete cds.	0.58	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
133	L27080	Human melanocortin 5 receptor (MC5R) gene, complete cds.	0.58	123984	ACROSIN INHIBITORS IIA AND IIB	2e-006
134	AF043195	Homo sapiens tight junction protein ZO (ZO-2) gene, alternative splice products, promoter and exon A	0.57	1572629	(U69699) unknown protein precursor [Mus musculus]	6.7
135	U57707	Bos taurus activin receptor type IIB precursor	0.57	807646	(M17294) unknown protein [Human herpesvirus 4]	0.068
136	Z17316	Kluyveromyces lactis for gene encoding phosphofructokinase beta subunit	0.56	<NONE>	<NONE>	<NONE>
137	M21535	Human erg protein (ets-related gene) mRNA, complete cds.	0.56	<NONE>	<NONE>	<NONE>
138	M64932	Candida maltosa cyclohexamide resistance protein	0.56	3219524	(AF069428) NADH dehydrogenase subunit IV [Alligator mississippiensis] > gi 3367630 emb CAA73570 (Y13113) NADH dehydrogenase subunit 4 [Alligator mississippiensis]	1.3

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
139	AE000342	Escherichia coli K-12 MG1655 section 232 of 400 of the complete genome	0.56	3874685	(Z78539) Similarity to S.pombe hypothetical protein C4G8.04 (SW:YAD4_SC HPO); cDNA EST EMBL:D27846 comes from this gene; cDNA EST EMBL:D27845 comes from this gene; cDNA EST yk202h7.3 comes from this gene; cDNA EST yk202h7.5 come...	0.088
140	Z15056	B.subtilis genes spoVD, murE, mraY, murD	0.55	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	3.7
141	Z58167	H.sapiens CpG island DNA genomic Mse1 fragment, clone 30e10, forward read cpg30e10.ft1b	0.53	<NONE>	<NONE>	<NONE >
142	M27159	Rat potassium channel-Kv2 gene, partial cds.	0.53	1850920	(U21247) Bet [Human spumaretrovirus]	0.9
143	M15555	Mouse Ig germline V- kappa-24 chain (VK24C) gene, exons 1 and 2.	0.24	<NONE>	<NONE>	<NONE >

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
144	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.24	399109	TRANSCRIPTION FACTOR BF-1 (BRAIN FACTOR 1) (BF1) >gi 92020 pir JH0672 brain factor 1 protein - rat >gi 203135 (M87634) BF-1 [Rattus norvegicus]	4
145	AJ002014	Crythecodium cohnii mRNA for nuclear protein JUS1	0.24	416704	BALBIANI RING PROTEIN 3 PRECURSOR balbiani ring 3 (BR3) [Chironomus tentans]	0.36
146	L35330	Rattus norvegicus glutathione S-transferase Yb3 subunit gene, complete cds.	0.23	1388158	(U58204) myomesin [Gallus gallus]	8.8
147	NM_001432 .1	Homo sapiens epiregulin (EREG) mRNA > :: dbj D30783 D3 0783 Homo sapiens mRNA for epiregulin, complete cds	0.23	2851520	TRANSFORMING GROWTH FACTOR ALPHA PRECURSOR (TGF-ALPHA) (EGF-LIKE TGF) (ETGF) (TGF TYPE 1) precursor - rat >gi 207282 (M31076) transforming growth factor alpha precursor [Rattus norvegicus]	2e-008

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
148	U57043	Cebus apella gamma globin (gamma1) gene, complete cds	0.22	<NONE>	<NONE>	<NONE >
149	AB023188.1	Homo sapiens mRNA for KIAA0971 protein, complete cds	0.22	<NONE>	<NONE>	<NONE >
150	M18105	Yeast (S.cerevisiae) SST2 gene encoding desensitization to alpha- factor pheromone, complete cds.	0.22	<NONE>	<NONE>	<NONE >
151	AJ001113	Homo sapiens UBE3A gene, exon 16	0.22	3122961	ENHANCER OF SPLIT GROUCHO- LIKE PROTEIN 1 > gi 2408145 (U18775) enhancer of split groucho	8.5
152	L35330	Rattus norvegicus glutathione S- transferase Yb3 subunit gene, complete cds.	0.22	1388158	(U58204) myomesin [Gallus gallus]	8.1
153	D42042	Human mRNA for KIAA0085 gene, partial cds	0.22	4827063	zinc finger protein 142 (clone pHZ-49) > gi 3123312 sp P52746 Z142 HUMAN ZINC FINGER PROTEIN 142 (KIAA0236) (HA4654) > gi 1510147 dbj BAA13242	6.1

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
154	L35330	Rattus norvegicus glutathione S-transferase Yb3 subunit gene, complete cds.	0.22	2853301	(AF007194) mucin [Homo sapiens]	1.6
155	Z11653	H.sapiens DBH gene complex repeat polymorphism DNA	0.22	3819705	(AL032824) syntaxin binding protein 1; sec1 family secretory protein [Schizosaccharomyces pombe]	1.2
156	L29063	Candida albicans fatty acid synthase alpha subunit (FAS2) gene, complete cds.	0.22	3046871	(AB003753) high sulfur protein B2E [Rattus norvegicus]	0.32
157	M64865	Horse alcohol dehydrogenase-S-isoenzyme mRNA, complete cds.	0.22	2213909	(AF004874) latent TGF-beta binding protein-2 [Mus musculus]	0.037
158	Y09472	B.taurus gene encoding preprododecapeptide	0.21	2909874	(AF047829) melatonin-related receptor [Ovis aries]	7.6
159	Y09472	B.taurus gene encoding preprododecapeptide	0.21	2909874	(AF047829) melatonin-related receptor [Ovis aries]	7.5
160	X80301	N.tabacum axi 1 gene	0.21	2832715	(AJ003066) subunit beta of the mitochondrial fatty acid beta-oxydation multienzyme complex [Bos taurus]	6

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
161	AF073485	Homo sapiens MHC class I- related protein MR1 precursor (MR1) gene, partial cds	0.21	2224559	(AB002307) KIAA0309 [Homo sapiens]	3.3
162	S78251	growth hormone receptor {alternatively spliced, exon 1B} [sheep, Merino, skeletal muscle, mRNA. Partial, 438 nt]	0.21	729381	DYNAMIN-1 (DYNAMIN BREDNM19)	2
163	U16135	Synechococcus sp. Clp protease proteolytic subunit	0.21	135514	T-CELL RECEPTOR BETA CHAIN PRECURSOR precursor (ANA 11) - rabbit	0.02
164	X95601	M.hominis lmp3 and lmp4 genes	0.21	2995445	(Y10496) CDV- 1 protein [Mus musculus]	0.005
165	X95601	M.hominis lmp3 and lmp4 genes	0.21	2995447	(Y10495) CDV- 1R protein [Mus musculus]	0.005
166	AF124249.1	Homo sapiens SH2-containing protein Nsp1 mRNA, complete cds	0.21	423456	epidermal growth factor- receptor-binding protein GRB-4 - mouse (fragment)	8e-010
167	AF030282	Danio rerio homeobox protein Six7 (six7) mRNA, complete cds	0.21	3928083	(AC005770) unknown protein [Arabidopsis thaliana]	2e-014
168	X83427	O.anatinus mitochondrial DNA, complete genome	0.21	132575	RIBONUCLEA SE INHIBITOR	3e-021

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
169	AJ001113	Homo sapiens UBE3A gene, exon 16	0.2	<NONE>	<NONE>	<NONE >
170	AF081533.1	Anopheles gambiae putative gram negative bacteria binding protein gene, complete cds	0.2	<NONE>	<NONE>	<NONE >
171	U70316	Dictyostelium discoideum IonA (iona) gene, partial cds	0.2	<NONE>	<NONE>	<NONE >
172	AF009341	Homo sapiens E6-AP ubiquitin-protein ligase	0.2	<NONE>	<NONE>	<NONE >
173	L35330	Rattus norvegicus glutathione S- transferase Yb3 subunit gene, complete cds.	0.2	3702275	(AC005793) KIAA0561 protein [AA 1- 593] [Homo sapiens]	2.5
174	AE000573.1	Helicobacter pylori 26695 section 51 of 134 of the complete genome	0.2	3947855	(AL034381) putative Golgi membrane protein	2.5
175	X83230	G.gallus hsp90beta gene	0.2	3258596	(U95821) putative transmembrane GTPase [Drosophila melanogaster]	0.81
176	X57157	Chicken mRNA for Hsp47, heat shock protein 47	0.2	108325	insulin-like growth factor- binding protein 6	0.17

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
177	M58748	Chicken alpha-globin gene domain with structural matrix attachment sites.	0.2	1086863	(U41272) T03G11.6 gene product [Caenorhabditis elegans]	4e-005
178	AB016815	Anthocidaris crassispina mRNA for Src-type protein tyrosine kinase, complete cds	0.2	423456	epidermal growth factor-receptor-binding protein GRB-4 - mouse (fragment)	1e-012
179	AF030282	Danio rerio homeobox protein Six7 (six7) mRNA, complete cds	0.2	3928083	(AC005770) unknown protein [Arabidopsis thaliana]	3e-014
180	AL035559	Streptomyces coelicolor cosmid 9F2	0.2	2088714	(AF003139) strong similarity to NADPH oxidases; partial CDS, the gene begins in the neighboring clone	3e-022
181	S79641	SDH =succinate dehydrogenase flavoprotein subunit Mutant, 387 nt]	0.2	4755188	(AC007018) unknown protein	2e-022
182	X75383	H.sapiens mRNA for TFIIA-alpha	0.19	<NONE>	<NONE>	<NONE>
183	U53901	Hippopotamus amphibius b-casein gene, exon 7, partial cds	0.19	<NONE>	<NONE>	<NONE>
184	J05265	Mouse interferon gamma receptor mRNA, complete cds.	0.19	77356	hypothetical 70K protein - eggplant mosaic virus	0.0005

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
185	U72353	Rattus norvegicus lamin B1 mRNA, complete cds	0.19	3880857	(AL031633) cDNA EST yk404d1.5 comes from this gene; cDNA EST yk404d1.3 comes from this gene	2e-006
186	AB016815	Anthocidaris crassispina mRNA for Src-type protein tyrosine kinase, complete cds	0.19	3930217	(AF047487) Nck-2 [Homo sapiens]	2e-007
187	D10911	Mus musculus DNA for MS2 protein, complete cds	0.19	2662366	(D86332) membrane type-2 matrix metalloproteinase [Mus musculus]	5e-011
188	AB015345	Homo sapiens HRIHFB2216 mRNA, partial cds	0.075	3877417	(Z66564) similar to anion exchange protein	6.4
189	AF086410	Homo sapiens full length insert cDNA clone ZD77B03	0.075	3023371	PHEROMONE B BETA 1 RECEPTOR	4.9
190	K02024	Human T-cell lymphotropic virus type II env gene encoding envelope glycoprotein, complete cds.	0.075	2791527	(AL021246) PE_PGRS [Mycobacterium tuberculosis]	0.11

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
191	M10188	X.laevis mitochondrial DNA containing the D-loop, and the 12S rRNA, apocytochrome b, Glu-tRNA, Thr-tRNA, Pro-tRNA and Phe-tRNA genes.	0.074	4753163	huntingtin DISEASE PROTEIN) (HD PROTEIN) > gi 454415 (L12392) Huntington's Disease protein [Homo sapiens]	2.8
192	X85525	G.gallus AG repeat region (GgaMU130)	0.073	984339	(U20966) Rev [Simian immunodeficiency virus]	3.6
193	AJ238394.1	Homo sapiens AML2 gene (partial)	0.07	4240219	(AB020672) KIAA0865 protein [Homo sapiens]	2
194	AF039704	Homo sapiens lysosomal pepstatin insensitive protease (CLN2) gene, complete cds	0.069	2894106	(Z78279) Collagen alpha1 [Rattus norvegicus]	0.39
195	K02024	Human T-cell lymphotropic virue type II env gene encoding envelope glycoprotein, complete cds.	0.068	4504857	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 > gi 3309531 (AF031815) calcium-activated potassium channel [Homo sapiens]	0.5

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
196	Z60719	H.sapiens CpG island DNA genomic Mse1 fragment, clone 33a11, forward read cpg33a11.ft1m	0.068	4826874	nucleoporin 214kD (CAIN) PROTEIN NUP214 (NUCLEOPORIN N NUP214) (214 KD NUCLEOPORIN) transforming protein (can) - human sapiens]	0.044
197	AF053994	Lycopersicon esculentum Hcr2-0A (Hcr2-0A) gene, complete cds	0.068	2842699	PUTATIVE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE C6G9.08 (UBIQUITIN THIOLESTERASE) (UBIQUITIN-SPECIFIC PROCESSING PROTEASE)	9e-009
198	AJ233650.1	Equus caballus endogenous retroviral sequence ERV-L pol gene, clone ERV-L Horse1	0.067	<NONE>	<NONE>	<NONE>
199	M10188	X.laevis mitochondrial DNA containing the D-loop, and the 12S rRNA, apocytochrome b, Glu-tRNA, Thr-tRNA, Pro-tRNA and Phe-tRNA genes.	0.067	4753163	huntingtin DISEASE PROTEIN) (HD PROTEIN) >gi 454415 (L12392) Huntington's Disease protein [Homo sapiens]	2.5

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
200	U14646	Murine hepatitis virus Y strain S glycoprotein gene, complete cds.	0.067	3880930	(AL021481) similar to Phosphoglucomutase and phosphomannomutase phosphoserine; cDNA EST EMBL:D36168 comes from this gene; cDNA EST EMBL:D70697 comes from this gene; cDNA EST yk373h9.5 comes from this gene; cDNA EST EMBL:T00805 ...	1e-019
201	X15373	Mouse cerebellum mRNA for P400 protein	0.066	164507	(M81771) immunoglobulin gamma-chain [Sus scrofa]	9.4
202	AF086410	Homo sapiens full length insert cDNA clone ZD77B03	0.066	3023371	PHEROMONE B BETA 1 RECEPTOR	4.2
203	AL034492	Streptomyces coelicolor cosmid 6C5	0.066	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	3e-015
204	L13377	Staphylococcus aureus enterotoxin gene, 3' end.	0.065	<NONE>	<NONE>	<NONE>
205	U83478	Thelephoraceae sp. 'Taylor #13' ITS1, 5.8S ribosomal RNA gene, and ITS2, complete sequence	0.065	3877335	(Z92786) predicted using Genefinder	9.1

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
206	AJ002014	Crythecodium cohnii mRNA for nuclear protein JUS1	0.065	1213283	(U40576) SIM2 [Mus musculus]	0.47
207	AB016804	Aloe arborescens mRNA for NADP-malic enzyme, complete cds	0.065	2832777	(AL021086) /prediction=(method:; comes from the 5' UTR [Drosophila melanogaster]	5e-036
208	AJ002014	Crythecodium cohnii mRNA for nuclear protein JUS1	0.063	1213283	(U40576) SIM2 [Mus musculus]	0.45
209	AB023143.1	Homo sapiens mRNA for KIAA0926 protein, complete cds	0.024	132575	RIBONUCLEASE INHIBITOR	8e-026
210	U72966	Human hepatocyte nuclear factor 4-alpha gene, exon 7	0.022	<NONE>	<NONE>	<NONE>
211	X02801	Mouse gene for glial fibrillary acidic protein	0.022	2231607	(U85917) nef protein [Human immunodeficiency virus type 1]	7
212	AF017636	Mesocricetus auratus 3-keto-steroid reductase	0.022	2723362	(AF023459) lustrin A [Haliothis rufescens]	0.097
213	Z36879	F.pringlei gdcsPA gene for P-protein of the glycine cleavage system	0.008	<NONE>	<NONE>	<NONE>
214	X73150	P.sativum GapC1 gene	0.008	1572629	(U69699) unknown protein precursor [Mus musculus]	8.6

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
215	AJ239031.1	Homo sapiens LSS gene, partial, exons 22, 23 and joined CDS	0.008	4508019	zinc finger protein 231 protein [Homo sapiens]	0.01
216	U76602	Human 180 kDa bullos pemphigoid antigen 2/type XVII collagen (BPAG2/COL17 A1) gene, exons 49, 50, 51 and 52	0.007	3170252	(AF043636) circumsporozoit e protein [Plasmodium chabaudi]	0.0001
217	M11283	Aplysia californica FMRFamide mRNA, partial cds, clone FMRF-2.	0.007	3874685	(Z78539) Similarity to S.pombe hypothetical protein C4G8.04 (SW:YAD4_SC HPO); cDNA EST EMBL:D27846 comes from this gene; cDNA EST EMBL:D27845 comes from this gene; cDNA EST yk202h7.3 comes from this gene; cDNA EST yk202h7.5 come...	9e-013
218	J03998	P.falciparum glutamic acid- rich protein gnen, complete cds.	0.003	<NONE>	<NONE>	<NONE >
219	Z23143	M.musculus ALK-6 mRNA, complete CDS	0.002	2393890	(AF006064) protein kinase homolog [Fowlpox virus]	1e-011

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
220	AB007914	Homo sapiens mRNA for KIAA0445 protein, complete cds	0.001	2136964	cysteine-rich hair keratin associated protein - rabbit >gi 510541 emb CAA56339 (X80035) cysteine rich hair keratin associated protein	1.9
221	AB012105	Brassica rapa mRNA for SLG45, complete cds	0.0008	3687246	(AC005169) putative suppressor protein [Arabidopsis thaliana]	5.5
222	L41608	Methylbacterium extorquens (clone pDN9, HINDIIIAB) mxaS gene 3' end, mxaA, mxaC, mxaK, mxaL and mxaD genes, complete cds.	0.0008	3024235	NERVOUS-SYSTEM SPECIFIC OCTAMER-BINDING TRANSCRIPTION FACTOR N-OCT 3 PROTEIN)	5.1
223	AB007914	Homo sapiens mRNA for KIAA0445 protein, complete cds	0.0008	2136964	cysteine-rich hair keratin associated protein - rabbit >gi 510541 emb CAA56339 (X80035) cysteine rich hair keratin associated protein	2.5
224	AC002293	Genomic sequence from Human 9q34, complete sequence [Homo sapiens]	0.0008	2789557	(AF034316) MHC class I antigen [Triakis scylium] scylium]	0.0002

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
225	L16013	Rattus norvegicus Q-like gene sequence	9e-005	<NONE>	<NONE>	<NONE>
226	AF148512.1	Homo sapiens hexokinase II gene, promoter region	9e-005	<NONE>	<NONE>	<NONE>
227	U94776	Human muscle glycogen phosphorylase (PYGM) gene, exons 6 through 17	9e-005	4759138	solute carrier family 7 transporter 3 [Homo sapiens]	5.4
228	X56030	H.sapiens IAPP gene for amyloid polypeptide, exon 1	1e-005	<NONE>	<NONE>	<NONE>
229	U36515	Human CT microsatellite, clone GM5927-CT-2-3, from the tandemly repeated genes encoding U2 small nuclear RNA (RNU2 locus)	4e-007	2435616	(AF026215) No definition line found [Caenorhabditis elegans]	0.85
230	AB011119	Homo sapiens mRNA for KIAA0547 protein, complete cds	4e-007	4758508	airway trypsin-like protease protease [Homo sapiens]	3e-031
231	NM_000521 .1	Homo sapiens hexosaminidase B (beta polypeptide) (HEXB) mRNA	5e-008	2119379	slow muscle troponin T - chicken T [Gallus gallus]	2.8
232	X13895	Human serum amyloid A (GSAA1) gene, complete cds	4e-008	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.7

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
233	AB009288.1	Homo sapiens mRNA for N-copine, complete cds	4e-008	4520342	(AB008893) N-copine [Mus musculus]	3e-006
234	AB011119	Homo sapiens mRNA for KIAA0547 protein, complete cds	4e-008	4758508	airway trypsin-like protease protease [Homo sapiens]	1e-028
235	X13895	Human serum amyloid A (GSAA1) gene, complete cds	5e-009	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.8
236	X13895	Human serum amyloid A (GSAA1) gene, complete cds	2e-009	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.2
237	U64997	Bos taurus ribonuclease K6 gene, partial cds	2e-009	3914810	RIBONUCLEASE K6 PRECURSOR (RNASE K6) >gi 2745760 (AF037086) ribonuclease k6 precursor	3e-018
238	J02635	Rat liver alpha-2-macroglobulin mRNA, complete cds.	2e-009	112913	ALPHA-2-MACROGLOBULIN PRECURSOR precursor - rat >gi 202592 (J02635) prealpha-2-macroglobulin [Rattus norvegicus]	4e-019
239	Z78141	M.musculus partial cochlear mRNA (clone 29C9)	5e-010	3219569	(AL023893) /prediction=(method:;	4e-009

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
240	AF060917	Gambusia affinis microsatellite Gafu6	2e-010	3874618	(Z48241) similar to coiled coil domains; cDNA EST yk302g12.5 comes from this gene; cDNA EST yk365d10.5 comes from this gene; cDNA EST yk461c1.5 comes from this gene [Caenorhabditis elegans] coil domains; cDNA EST yk302g12.5 comes from this gene; cDNA EST	0.096
241	U68138	Human PSD-95 mRNA, partial cds	2e-010	4521241	(AB024927) CsENDO-3 [Ciona savignyi]	2e-022
242	U88827	Aotus trivirgatus ribonuclease precursor gene, complete cds	6e-011	3914810	RIBONUCLEA SE K6 PRECURSOR (RNASE K6) >gi 2745760 (AF037086) ribonuclease k6 precursor	1e-016
243	AF045573	Mus musculus FLI-LRR associated protein-1 mRNA, complete cds	2e-012	3025718	(AF045573) FLI-LRR associated protein-1 [Mus musculus]	3e-016

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
244	NM_001365 .1	Homo sapiens discs, large (Drosophila) homolog 4 (DLG4) mRNA > :: gb U83192 HS U83192 Homo sapiens post-synaptic density protein 95 (PSD95) mRNA, complete cds	2e-012	4521241	(AB024927) CsENDO-3 [Ciona savignyi]	5e-020
245	U28049	Human TBX2 (TXB2) mRNA, complete cds.	7e-013	2501115	TBX2 PROTEIN (T-BOX PROTEIN 2)	2e-011
246	M23404	Chicken erythrocyte anion transport protein (band3) mRNA, complete cds.	2e-013	726403	(U23175) similar to anion exchange protein [Caenorhabditis elegans]	1e-025
247	AF005963	Homo sapiens XY homologous region, partial sequence	1e-014	104270	Ig heavy chain - clawed frog	1.9
248	M29863	Human farnesyl pyrophosphate synthetase mRNA	9e-015	182405	(M29863) farnesyl pyrophosphate synthetase [Homo sapiens]	0.005
249	D28126	Human gene for ATP synthase alpha subunit, complete cds (exon 1 to 12)	3e-015	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
250	Z80150	H.sapiens CACNL1A4 gene, exons 41 and 42 > :: emb[A70716.1] A70716 Sequence 37 from Patent WO9813490	3e-015	3387914	(AF070550) cote1 [Homo sapiens]	3.5
251	U28049	Human TBX2 (TXB2) mRNA, complete cds.	4e-016	2501116	TBX2 PROTEIN (T- BOX PROTEIN 2) tbx gene [Mus musculus]	6e-009
252	U31629	Mus musculus C2C12 unknown mRNA, partial cds.	1e-017	3024998	HYPOTHETIC AL HEART PROTEIN	3e-017
253	J05262	Human farnesyl pyrophosphate synthetase mRNA, complete cds.	1e-018	182405	(M29863) farnesyl pyrophosphate synthetase [Homo sapiens]	0.0001
254	D28126	Human gene for ATP synthase alpha subunit, complete cds (exon 1 to 12)	5e-019	<NONE>	<NONE>	<NONE >
255	D28126	Human gene for ATP synthase alpha subunit, complete cds (exon 1 to 12)	5e-019	3219984	HYPOTHETIC AL PROTEIN MJ1597.1 region MJ1597.1 [Methanococcus jannaschii]	5.7

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
256	NM_004587 .1	Homo sapiens ribosome binding protein 1 (dog 180kD homolog) (RRBP1) mRNA > :: gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds	2e-019	4759056	ribosome binding protein 1 (dog 180kD homolog) >gi 3299885 (AF006751) ES/130 [Homo sapiens]	0.004
257	U89915	Mus musculus junctional adhesion molecule (Jam) mRNA, complete cds	5e-020	3462455	(U89915) junctional adhesion molecule [Mus musculus]	2e-005
258	AF045573	Mus musculus FLI-LRR associated protein-1 mRNA, complete cds	5e-020	3025718	(AF045573) FLI-LRR associated protein-1 [Mus musculus]	9e-025
259	NM_004587 .1	Homo sapiens ribosome binding protein 1 (dog 180kD homolog) (RRBP1) mRNA > :: gb AF006751 AF006751 Homo sapiens ES/130 mRNA, complete cds	2e-020	4759056	ribosome binding protein 1 (dog 180kD homolog) >gi 3299885 (AF006751) ES/130 [Homo sapiens]	0.0008

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
260	AF051098	Mus musculus seven transmembrane domain orphan receptor mRNA, complete cds	2e-021	3858883	(U67056) myosin I heavy chain kinase [Acanthamoeba castellanii] >gi 4206769 (AF104910) myosin I heavy chain kinase [Acanthamoeba castellanii]	0.002
261	AF051098	Mus musculus seven transmembrane domain orphan receptor mRNA, complete cds	2e-021	3858883	(U67056) myosin I heavy chain kinase [Acanthamoeba castellanii] >gi 4206769 (AF104910) myosin I heavy chain kinase [Acanthamoeba castellanii]	0.001
262	M13519	Human N-acetyl-beta-glucosaminidase (HEXB) mRNA, 3' end.	2e-021	4504373	hexosaminidase B (beta polypeptide) >gi 123081 sp P07686 HEXB_HUMAN BETA-HEXOSAMINIDASE BETA CHAIN PRECURSOR beta-N-acetylhexosaminidase (EC 3.2.1.52) beta chain - human >gi 386770 (M23294) beta-hexosaminidase beta-subunit [Homo sapiens]	2e-007

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
263	Z81014	Human DNA sequence from cosmid U65A4, between markers DDX366 and DDX87 on chromosome X *	2e-022	<NONE>	<NONE>	<NONE>
264	AF147311.1	Homo sapiens full length insert cDNA clone YA82F10	2e-022	3875904 (Z70207) predicted using Genefinder; similar to collagen; cDNA EST EMBL:D65905 comes from this gene; cDNA EST EMBL:D65858 comes from this gene; cDNA EST EMBL:D69306 comes from this gene; cDNA EST EMBL:D65755 comes from this gen...		0.07
265	AF037088	Gorilla gorilla ribonuclease k6 precursor, gene, complete cds	9e-024	3914791 RIBONUCLEA SE K6 PRECURSOR (RNASE K6) > gi 2745752 (AF037082) ribonuclease k6 precursor		3e-019
266	Z81014	Human DNA sequence from cosmid U65A4, between markers DDX366 and DDX87 on chromosome X	8e-024	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
		*				
267	AF037088	Gorilla gorilla ribonuclease k6 precursor, gene, complete cds	9e-025	3914810	RIBONUCLEA SE K6 PRECURSOR (RNASE K6) >gi 2745760 (AF037086) ribonuclease k6 precursor	4e-018
268	AF147311.1	Homo sapiens full length insert cDNA clone YA82F10	1e-026	131413	PULMONARY SURFACTANT -ASSOCIATED PROTEIN A PRECURSOR (SP-A) (PSP-A) (PSAP) precursor - rabbit >gi 165706 (J03542) apoprotein of surfactant [Oryctolagus cuniculus]	0.059
269	Z46786	D.melanogaster mRNA for acetyl-CoA synthetase	1e-027	1079042	acetyl-CoA synthetase - fruit fly	4e-025
270	NM_004039 .1	Homo sapiens annexin II (lipocortin II) for lipocortin II, complete cds	4e-028	450448	(M33322) calpactin I heavy chain [Mus musculus]	0.1
271	X53064	Homo sapiens SPRR2A gene encoding small proline rich protein	1e-028	134846	SMALL PROLINE- RICH PROTEIN II rich protein [Homo sapiens]	0.005

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
272	M29863	Human farnesyl pyrophosphate synthetase mRNA	1e-028	4503685	farnesyl diphosphate synthase dimethylallyltransf erase, geranyltranstransferase) bp313 to bp1374 is almost identical to human farnesyl pyrophosphate synthetase mRNA. [Homo sapiens]	2e-008
273	Z18950	H.sapiens genes for S100E calcium binding protein, CAPL, and S100D calcium binding protein EF- Hand patent US 5789248	5e-029	2493898	DOPAMINE-BETA-MONOXYGENASE PRECURSOR (DOPAMINE BETA-HYDROXYLASE) (DBH) 1.14.17.1 precursor - mouse >gi 260873 bb s 119249 621 aa] [Mus sp.]	1.4
274	M19481	Human follistatin gene, exon 6.	5e-030	<NONE>	<NONE>	<NONE>

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
275	AF007155	Homo sapiens clone 23763 unknown mRNA, partial cds	2e-032	4502641	chemokine (C-C) receptor 7 TYPE 7 PRECURSOR (C-C CKR-7) (CC-CKR-7) (CCR-7) (MIP-3 BETA RECEPTOR) (EBV- INDUCED G PROTEIN-COUPLED RECEPTOR 1) (EBI1) (BLR2) > gi 1082381 pir B55735 lymphocyte-specific G-protein-coupled receptor EBI1 - human > gi 468316 (L3158)	1.6
276	M99624	Human epidermal growth factor receptor-related gene, 5' end.	8e-034	294845	(L13655) membrane protein [Saccharum hybrid cultivar H65-7052]	9e-014
277	U49082	Human transporter protein (g17) mRNA, complete cds	8e-035	1840045	(U49082) transporter protein [Homo sapiens]	1e-014

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
278	D50369	Homo sapiens mRNA for low molecular mass ubiquinone-binding protein, complete cds	9e-036	3024781	UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX UBIQUINONE-BINDING PROTEIN QP-C PROTEIN) (COMPLEX III SUBUNIT VII) ubiquinone-binding protein [Homo sapiens]	0.0002
279	AF086313	Homo sapiens full length insert cDNA clone ZD52B10	9e-036	2832777	(AL021086) /prediction=(method:; comes from the 5' UTR [Drosophila melanogaster]	1e-039
280	NM_004074.1	Homo sapiens cytochrome c oxidase subunit VIII (COX8), nuclear gene encoding mitochondrial protein, mRNA > :: gb J04823 HU MCOX8A Human cytochrome c oxidase subunit VIII (COX8) mRNA, complete cds.	1e-038	2499854	PROBABLE PEPTIDASE Y4SO > gi 2182630	2
281	AB024436.1	Homo sapiens mRNA for beta-1,4-galactosyltransferase IV, complete cds	2e-041	3132900	(AF038662) beta-1,4-galactosyltransferase [Homo sapiens] beta-1,4-galactosyltransfe	4e-016

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
				galactosyltransfe rase IV [Homo sapiens]		
282	AF057734	Homo sapiens 17-beta- hydroxysteroid dehydrogenase IV (HSD17B4) gene, exon 16	2e-043	2842416	(AL008730) dJ487J7.1.1 (putative protein dJ487J7.1 isoform 1) [Homo sapiens]	3e-062
283	Z69650.1	Human DNA sequence from cosmid L69F7B, Huntington's Disease Region, chromosome 4p16.3 contains Huntington Disease (HD) gene	2e-044	1872200	(U22376) alternatively spliced product using exon 13A	1e-008
284	NM_003938 .1	Homo sapiens adaptein, delta (ADTD) mRNA > :: gb U91930 HS U91930 Homo sapiens AP-3 complex delta subunit mRNA, complete cds	2e-044	3478639	(AC005545) delta-adaptein, partial CDS [Homo sapiens]	3e-016
285	AF026029	Homo sapiens poly(A) binding protein II (PABP2) gene, complete cds	8e-045	1916930	(U88570) CREB-binding protein homolog [Drosophila melanogaster]	7.6
286	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	1e-045	73404	E2 protein - human papillomavirus type 5	0.11

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
287	U90918	Human clone 23654 mRNA sequence	1e-048	3877568	(Z70208) similar to collagen	0.042
288	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	1e-049	73404	E2 protein - human papillomavirus type 5	0.11
289	AL049258.1	Homo sapiens mRNA; cDNA DKFZp564E173 (from clone DKFZp564E173)	1e-050	<NONE>	<NONE>	<NONE >
290	AF022367	Homo sapiens beta-1,4- galactosyltransfe rase mRNA, complete cds	5e-051	3132900	(AF038662) beta-1,4- galactosyltransfe rase [Homo sapiens] beta- 1,4- galactosyltransfe rase IV [Homo sapiens]	6e-019
291	AF057734	Homo sapiens 17-beta- hydroxysteroid dehydrogenase IV (HSD17B4) gene, exon 16	7e-053	2842416	(AL008730) dJ487J7.1.1 (putative protein dJ487J7.1 isoform 1) [Homo sapiens]	6e-055
292	AF097709	Homo sapiens serine protease (PRSS11) mRNA, partial cds	8e-055	4506141	protease, serine, 11 (IGF binding) > gi 1513059 d bj BAA13322 (D87258) serin protease with IGF-binding motif [Homo sapiens] protease, PRSS11 [Homo sapiens]	2e-017

Table 2

		Nearest Neighbor (BlastN vs. Genbank)		Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
293	U31629	Mus musculus C2C12 unknown mRNA, partial cds.	9e-057	3025215	HYPOTHETIC AL 81.0 KD PROTEIN C35D10.4 IN CHROMOSOM E III >gi 2146877 p ir S72572 probable ABC1 protein homolog - <i>Caenorhabditis</i> <i>elegans</i> protein (Swiss-Prot Acc: P27697) [<i>Caenorhabditis</i> <i>elegans</i>]	5e-033
294	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	8e-057	73404	E2 protein - human papillomavirus type 5	1.7
295	AF025439	Homo sapiens Opa-interacting protein OIP3 mRNA, partial cds	4e-059	<NONE>	<NONE>	<NONE >
296	M99624	Human epidermal growth factor receptor-related gene, 5' end.	1e-060	123364	SEGMENTATI ON PROTEIN EVEN- SKIPPED fly (<i>Drosophila</i> sp.) >gi 157387 (M14767) even- skipped gene [<i>Drosophila</i> <i>melanogaster</i>]	5.3
297	AF045573	Mus musculus FLI-LRR associated protein-1 mRNA, complete cds	5e-061	3025718	(AF045573) FLI-LRR associated protein-1 [Mus musculus]	7e-029
298	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	2e-062	2119133	ribosomal protein S17 - cat (fragment) [Mus musculus]	2e-015

Table 2

		Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
299	M30702	Human amphiregulin (AR) gene, exon 5, clones lambda-ARH(6,12).	2e-063	4502199	amphiregulin (schwannoma-derived growth factor) > gi 113754 sp P15514 AMP_R_HUMAN_AMPHIREGULIN_PRECURSOR_(AR)(COLORECTUM_CELL-DERIVED_GROWTH_FACTOR)(CRDGF) > gi 107391 pir A34702 amphiregulin precursor - human > gi 178890 (M30703) amphiregulin [Homo sapien]	0.0002	
300	L38847	Mus musculus hepatoma transmembrane kinase ligand Sequence 1 from patent US 5624899	6e-064	3861228	(AJ235272) unknown [Rickettsia prowazekii]	2.9	
301	L38847	Mus musculus hepatoma transmembrane kinase ligand Sequence 1 from patent US 5624899	6e-064	3861228	(AJ235272) unknown [Rickettsia prowazekii]	2.9	
302	Z78141	M.musculus partial cochlear mRNA (clone 29C9)	8e-066	1490324	(Z78141) unknown [Mus musculus]	8e-019	

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
303	X12650	Mus musculus gene for beta- tropomyosin	2e-072	833602	(X54277) cardiac tropomyosin [Coturnix coturnix]	7e-022
304	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	2e-084	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	5e-019
305	M13364	Rabbit calcium- dependent protease, small subunit mRNA, complete cds.	2e-084	115611	CALCIUM- DEPENDENT PROTEASE, SMALL NEUTRAL PROTEINASE) (CANP) > gi 108563 pi r A34466 calpain (EC 3.4.22.17) II light chain - bovine 3.4.22.17) [Bos taurus]	1e-058
306	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	3e-088	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	9e-028
307	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	5e-092	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	2e-035
308	X85992	M.musculus mRNA for semaphorin C	8e-097	2137756	semaphorin C - mouse (fragment) musculus]	2e-048

Table 2

		Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
309	M24103	Bovine ADP/ATP translocase T2 mRNA, complete cds.	e-103	113463	ADP,ATP CARRIER PROTEIN, LIVER ISOFORM T2 (ADP/ATP TRANSLOCASE 3) (ADENINE NUCLEOTIDE TRANSLOCATOR 3) (ANT 3) >gi 86757 pir S03894 ADP,ATP carrier protein T2 - human	2e-035	
310	U48852	Cricetulus griseus HT protein mRNA, complete cds.	e-107	1216486	(U48852) HT protein [Cricetulus griseus]	3e-057	
311	X76168	R.norvegicus mRNA for connexin 30.3	e-112	544118	GAP JUNCTION BETA-5 PROTEIN (CONNEXIN 30.3) (CX30.3) >gi 481577 pir S38891 connexin 30.3 - rat >gi 431204 emb CAA53762 (X76168) connexin 30.3	1e-063	
312	X76168	R.norvegicus mRNA for connexin 30.3	e-115	461864	GAP JUNCTION BETA-5 PROTEIN junction protein Cx30.3 - mouse >gi 192647 (M91443) connexin 30.3 [Mus musculus]	7e-064	

Table 2

	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
313	AJ009634.1	Mus musculus fjx1 gene	e-137	4138203	(AJ009634) Fjx1 [Mus musculus]	5e-065
314	X76168	R.norvegicus mRNA for connexin 30.3	e-130	544118	GAP JUNCTION BETA-5 PROTEIN (CONNEXIN 30.3) (CX30.3) >gi 481577 pi r S38891 connexin 30.3 - rat >gi 431204 e mb CAA53762 (X76168) connexin 30.3	2e-074

Table 4
PairAB-test

SEQ ID	CLUST ID		CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
4	819498	_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
8	728115					
		_15,16 (Normal Colon vs. Colon Tumor)	0	7	6.62	
		_16,17 (Colon Tumor vs. Colon Metastasis)	7	0	7.11	
9	372700					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	3	50	11.93	
		_19,20 (Colon Tumor vs. Colon Tumor Metastasis)	8	0	5.98	
12	729832					
		_15,16 (Normal Colon vs. Colon Tumor)	0	11	10.41	
		_16,17 (Colon Tumor vs. Colon Metastasis)	11	0	11.17	
13	505514					
		_23,24 (Normal Lung vs. Lung Tumor)	26	10	2.63	
17	549934					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8	0	7.87	
		_16,17 (Colon Tumor vs. Colon Metastasis)	3	20	6.56	
25	450399	_15,16 (Normal Colon vs. Colon Tumor)	11	3	3.88	

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
		_15,16 (Normal Colon vs. Colon Tumor)	28	68		2.3
		_15,17 (Normal Colon vs. Colon Metastasis)	28	117		3.89
26	450982					
		_16,17 (Colon Tumor vs. Colon Metastasis)	14	32		2.25
28	379302					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8	1	7.87	
43	817503					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	4	4.43	
48	830085					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		9.15
52	830931					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12
55	819046					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	13		6.61
58	728115					
		_15,16 (Normal Colon vs. Colon Tumor)	0	7		6.62
		_16,17 (Colon Tumor vs. Colon Metastasis)	7	0	7.11	
65	553242					

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
		_16,17 (Colon Tumor vs. Colon Metastasis)		0	6	5.91
71	820061					
		_21,22 (Normal Prostate vs. Cancerous Prostate)		1	20	20.33
78	220584					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)		1	12	8.59
80	549934					
		_16,17 (Colon Tumor vs. Colon Metastasis)	3	20	6.56	
		_15,16 (Normal Colon vs. Colon Tumor)	11	3	3.88	
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8	0	7.87	
86	819460					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	1	17.7	
95	551785					
		_21,22 (Normal Prostate vs. Cancerous Prostate)		0	6	6.1
96	17092					
		_03,04 (Breast, High Metastatic Potential vs. Breast, Non-Metastatic)	0	25	25.62	
99	745559					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	1	9	9.15	

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
101	379879					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	9	9.15	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	13	9.3	
107	268290					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	33	69	2.13	
108	818043					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
114	450247					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	23	8	2.83	
115	819273					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
116	587779					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
118	615617					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7	7.12	
121	818682					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	2	5.41	

Table 4

SEQ ID	CLUST ID	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
123	484413					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
124	819273					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
127	818682					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	2	5.41	
131	819273					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
147	820061					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	1	20	20.33	
153	375958					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	11	5.59	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	9	6.44	
155	831049					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	11	11.18	
157	553200					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	6	6.1	

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
158	139677					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
159	139677					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
163	375958					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	9	6.44	
168	831812					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	11	5.59	
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7	7.12	
176	193373					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
177	400619					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	6	0	8.38	
178	831149					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7	7.12	
180	817503					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	4	4.43	

Table 4

SEQ ID	CLUST ID	PairAB-test	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
187	648679					
		_23,24 (Normal Lung vs. Lung Tumor)	11	1	11.11	
		_16,17 (Colon Tumor vs. Colon Metastasis)	79	0	80.23	
		_15,17 (Normal Colon vs. Colon Metastasis)	7	0	7.51	
		_15,16 (Normal Colon vs. Colon Tumor)	7	79	10.68	
190	373928					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
195	373928					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
198	372700					
		_19,20 (Colon Tumor vs. Colon Tumor Metastasis)	8	0	5.98	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	3	50		11.93
204	379105					
		_15,16 (Normal Colon vs. Colon Tumor)	0	8		7.57
205	831188					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	8		8.13
209	831812					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12

Table 4

SEQ ID	CLUST ID	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
213	831026					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	10	10.17	
215	380207					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	6	6.1	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	8	5.72	
216	819460					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	1	17.7	
224	819201					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	6	0	5.9	
225	374826					
		_15,17 (Normal Colon vs. Colon Metastasis)	5	20	3.73	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	38	132	2.49	
		_15,16 (Normal Colon vs. Colon Tumor)	5	18	3.41	
231	553242					
		_16,17 (Colon Tumor vs. Colon Metastasis)	0	6	5.91	
246	220584					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	1	12	8.59	
248	819498					

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
253	819498		6	0	5.9	
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
256	831160		6	0	5.9	
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
259	831160		0	12	12.2	
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
262	373298		0	12	12.2	
		_15,17 (Normal Colon vs. Colon Metastasis)				
270	450262		126	42	3.22	
		_15,16 (Normal Colon vs. Colon Tumor)				
271	484703		126	59	2.26	
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
272	819498		0	8	8.13	
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
		_21,22 (Normal Prostate vs. Cancerous Prostate)				
			28	0	27.54	
			6	0	5.9	

Table 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
273	406043					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	6	6.1	
274	817500					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	18	9.15	
275	818180					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	10	5.08	
280	429009					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8	1	7.87	
284	383021					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	3	12	4.07	
289	831580					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	6	6.1	
311	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	1	10.82	
312	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	1	10.82	
314	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	1	10.82	
315	10154					
		_3,4 (Breast,High Metastatic Potential vs. Breast, Low Metastatic)	3	317	108.1	

Table 7

Library No.

Clones

es75	M00063947D:D01 M00063158A:A01 M00063517A:A04 M00063520D:E11 M00063638C:G12 M00063642B:A08 M00063686B:E07 M00063689D:E12 M00063781B:B10 M00063826A:D03	es79	M00064003B:C10 M00064302A:D10 M00064309C:H09 M00064310D:F03 M00064322C:A10 M00064359B:H12 M00064390A:C05 M00064404A:B05 M00064404C:G05 M00064404D:A06
es76	M00063838B:G08 M00063838B:G08 M00063841A:B09 M00063886A:B06 M00063910D:A12 M00063912A:D06 M00063920D:H05 M00063928A:G09 M00063934B:E04 M00063945A:C03	es80	M00064429D:B07 M00064446A:D11 M00064457D:C09 M00064476D:C04 M00064506A:C07 M00064514A:G10 M00064520A:F08 M00064579D:E11 M00064620C:D01 M00064624D:C09
es77	M00064032D:G04 M00064046A:G02 M00064053C:G04 M00064053D:F02 M00064082A:A08 M00064089B:F09 M00064132B:B07 M00064138A:F11 M00064161B:G04 M00064175B:B09	es81	M00064633C:A03 M00064637B:F03 M00064690A:C04 M00064690A:C04 M00064714A:G03 M00064723D:H11 GKC10154-1 GKC10154-3
es78	M00064178C:C04 M00064179A:C04 M00064200D:E08 M00064248A:E02 M00064270B:B03 M00064271B:D03 M00063580C:A06 M00063594B:H07 M00064002C:F06 M00064002C:H09		

es82	M00063151A:G06	M00063852D:F07
	M00063151D:B10	M00063888D:D05
	M00063152C:B07	M00063888D:F02
	M00063156D:H10	M00063890A:F11
	M00063158A:E11	M00063890A:H04
	M00063158A:E11	M00063891A:F11
	M00063452A:F08	M00063892B:G02
	M00063453B:F08	M00063898A:A10
	M00063462D:D07	M00063915C:E01
	M00063463D:B05	M00063919C:E07
	M00063466C:C11	M00063920D:H02
	M00063467D:H07	M00063922B:A12
	M00063478C:D01	M00063925B:F04
	M00063482A:A08	M00063926A:H04
	M00063482A:F07	M00063931B:E10
	M00063485A:E05	M00063931B:F07
	M00063487C:C02	M00063932D:G08
	M00063514C:D03	M00063934C:C10
	M00063514C:E08	M00063938B:H07
	M00063515B:F06	M00063939C:D06
	M00063515B:H02	M00063939C:H01
	M00063518D:A01	M00063940D:F09
	M00063520D:D08	M00063940D:F09
	M00063604A:B11	M00063941B:C12
	M00063606C:B04	M00063943B:G12
	M00063610D:C11	M00063949D:A05
	M00063613D:C11	M00064021D:H01
	M00063617D:F09	M00064025D:E07
	M00063627C:F06	M00064025D:H12
	M00063636A:E01	M00064033C:C11
	M00063681B:C02	M00064033D:B01
	M00063682A:C04	M00063843B:D07
	M00063685A:C02	M00063848C:G11
	M00063774A:D09	M00063852B:D08
	M00063784A:H12	M00063818C:A09
	M00063784C:E10	M00063828A:H12
	M00063785C:F03	M00063828D:E05
	M00063795C:D09	M00063839A:F01
	M00063801B:D04	M00063841A:E08
	M00063804C:A11	
	M00063805D:E05	
	M00063807A:D12	
	M00063810C:E03	

es83	M00064043D:C09	M00063577C:C02
	M00064048C:G12	M00063578B:E02
	M00064053B:D09	M00063578C:A06
	M00064057C:H10	M00063580D:B06
	M00064059A:C11	M00063593A:D03
	M00064060B:D03	M00063600C:C09
	M00064079C:A10	M00063955C:F07
	M00064082D:D10	M00063955D:F05
	M00064083D:E05	M00063956A:F05
	M00064086C:E01	M00063957A:E02
	M00064090C:A02	M00063957A:E02
	M00064090D:D09	M00063967C:A12
	M00064105B:A03	M00063967D:G02
	M00064106C:G03	M00063968D:G08
	M00064113B:C04	M00063972C:E10
	M00064115B:E12	M00063978B:B06
	M00064119B:H10	M00063981D:A06
	M00064119C:D12	M00063990A:D05
	M00064122C:B06	M00063990A:D05
	M00064126C:C02	M00063997C:B12
	M00064126C:F12	M00063998C:E09
	M00064136C:D12	M00064000B:C03
	M00064144D:A07	M00064001A:B03
	M00064151B:C07	M00064005D:A08
	M00064159A:H03	M00064008A:B01
	M00064165A:B12	M00064009A:C01
	M00064171D:E05	M00064014D:H05
	M00064171D:E05	M00064018C:E07
	M00064172C:A02	M00064293D:B12
	M00064173B:E01	M00064294D:F01
	M00064176D:H10	M00063557D:C07
	M00064178B:A05	M00063559D:G03
	M00064178B:A05	M00063571B:G03
	M00064180A:G03	M00063575B:G02
	M00064186C:B03	M00063555B:D01
	M00064188B:G08	M00063533A:C12
	M00064194C:D02	M00063534C:A02
	M00064212D:E04	M00063538D:B01
	M00064260C:E05	M00063539C:C11
	M00064268D:G03	
	M00064272C:G01	
	M00063163A:G04	
	M00063165A:C09	

es84	M00064307B:G02	M00064564A:C02
	M00064307C:G03	M00064568A:H06
	M00064310C:A10	M00064569B:A09
	M00064328B:H04	M00064569B:A09
	M00064328B:H09	M00064571C:C04
	M00064337D:F01	M0064577C:B120
	M00064341A:C02	M00064579A:C06
	M00064345A:A03	M00064593A:A05
	M00064346C:B09	M00064593D:C01
	M00064349D:H01	M00064601C:G07
	M00064352C:H01	M00064601D:B05
	M00064354A:A10	M00064605C:G05
	M00064358A:G03	M00064610D:H01
	M00064358C:D09	M00064620D:G05
	M00064375B:G07	M00064624C:B03
	M00064376A:A05	M00064631A:C07
	M00064385D:C11	M00064631A:C07
	M00064386B:C02	M00064631C:H11
	M00064386B:C02	M00064636B:A04
	M00064393B:H04	M00064649A:E04
	M00064399A:E01	M00064650B:B07
	M00064405B:C04	M00064652B:D09
	M00064406B:H06	M00064675C:E09
	M00064414D:D06	M00064678D:F05
	M00064415B:G03	M00064693D:F08
	M00064424B:C12	M00064723C:H04
	M00064428B:A12	M00064723D:H03
	M00064447B:A07	M00064723D:H03
	M00064447B:C06	M00003773D:H02
	M00064450C:E07	M00021929A:D03
	M00064452D:E11	M00043134A:A05
	M00064454A:H10	M00064534D:F06
	M00064454C:B06	M00064550A:A07
	M00064460C:B01	M00064554D:A03
	M00064467B:D06	M00064526D:F05
	M00064481C:F03	M00064527A:H07
	M00064508A:B09	M00064530B:H02
	M00064514D:F11	M00064532D:G06
	M00064517B:F04	M00064520A:E04
	M00064517B:F10	M00064520A:E04
	M00064517C:F11	M00064524A:A09

Path Patient ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnod e Met	Regional Lymphnod e Grade	Distant Met & Loc	Descrip Distant Met	Dist Met Grade	Comment
15 21	Ascending colon	4.0	T3	G2	extending into subserosal adipose tissue							invasive adenocarcinoma, moderately differentiated; focal perineural invasion is seen
52 71	Ascending colon	9.0	T3	G3	Invasion through muscularis propria, subserosal involvement; ileocecal valve involvement	positive	3/8	N1	negative	MX		Hyperplastic polyp in appendix.
121 140	Sigmoid	6	T4	G2							M0	Perineural invasion; donut anastomosis negative. One tubulovillous and one tubular adenoma with no high

Table 8 Patient ID	Path Report n	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion Met	Lymphnode Met	Incidence Lymphnod e Met	Regional Lymphnod e Grade	Distant Met & Loc Distant Met	Descrip	Dist Met Grade	Comment	
													grade dysplasia.	
													patient history of metastatic melanoma	
125	144	Cecum	6	T3	G2	Invasion through the muscularis propria into suserosal adipose tissue. Ileocecal junction.								
128	147	Transverse colon	5.0	T3	G2	Invasion of muscularis propria into percolonic fat								
130	149	Splenic flexure	5.5	T3		positive	1/5	N1	negative			M0		
						through wall and into surrounding adipose tissue								
						positive	10/24	N2	negative			M1		

Path Patient ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Descript Met	Dist Met Grade	Comment
133	152	Rectum	5.0	T3	G2	Invasion through muscularis propria into non-peritonealized pericolic tissue; gross configuration is annular.	negative	0/9	N0	negative	M0	Invasion through muscularis propria into non-peritonealized pericolic tissue; gross configuration is annular.
141	160	Cecum	5.5	T3	G2	Invasion of muscularis propria into pericolonic adipose tissue, but not through serosa. Arising from tubular adenoma.	positive	7/21	N2	positive (Liver)	M1	Perineural invasion identified adjacent to metastatic adenocarcinoma. adenocarcinoma consistsant with primary

Path Patient ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Descript Met	Dist Met Grade	Comment
156	175				Invasion through muscularis propria into subserosa/pericolic adipose, no serosal involvement. Gross configuration annular.							Separate tubulovillous and tubular adenomas
228	247	Rectum	3.8	T3	G2	positive	2/13	N1	negative	M0	Hyperplastic polyps	

Table 8 Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc Distant Met	Descrip	Dist Met Grade	Comment
						Invasion through muscularis propria into subserosal adipose tissue.							Tubulovillous adenoma with high grade dysplasia
264	283	Ascending colon	5.5	T3	G2	Invades through muscularis propria to involve pericolonic adipose, extends to serosa.	negative	0/10	N0	negative	M0		
266	285	Transverse colon	9	T3	G2	Invades full thickness of muscularis propria, but mesenteric adipose free of malignancy	negative	0/15	N1	positive replaced (Mesenteric deposit)	MX		
268	287	Cecum	6.5	T2	G2		negative	0/12	N0	negative	M0		

Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Descrip Distant Met	Dist Met Grade	Comment
278	297	Rectum	4	T3	G2	Invasion into perirectal adipose tissue.						M0	Descending colon polyps, no HGD or carcinoma identified..
295	314	Ascending colon	5.0	T3	G2	Invasion through muscularis propria into percolic adipose tissue.	positive	7/10	N2	negative		M0	Melanosis coli and diverticular disease.
339	358	Rectosigmoid	6	T3	G2	Extends into perirectal fat but does not reach serosa	negative	0/12	N0	negative		M0	1 hyperplastic polyp identified
341	360	Ascending colon	2 cm invasive			Invasion through muscularis propria to involve pericolonic fat. Arising from villous adenoma.		0/6	N0	negative		M0	
							negative	0/4	N0	negative		MX	

Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Descript Distant Met	Dist Met Grade	Comment
						Through colon wall into subserosal adipose tissue. No serosal spread seen.							
356	375	Sigmoid	6.5	T3	G2	Invasion thru muscularis propria to pericolonic fat	negative	0/4	N0	negative	M0		
360	412	Ascending colon	4.3	T3	G2	Invasion through muscularis propria into subserosal adipose tissue, not serosa.	positive	1/5	N1	negative	M0	Two mucosal polyps	Tumor arising at prior ileocolic surgical anastomosis.
392	444	Ascending colon	2	T3	G2								Macrovesicular and microvesicular steatosis M1

Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Distant Met	Dist Met Grade	Comment
						Cecum, invades through muscularis propria to involve subserosal adipose tissue but not serosa.							
393	445	Cecum	6.0	T3	G2		negative	0/21	N0	negative	M0		rediagnosis of oophorectomy path to metastatic colon cancer.
413	465	Ascending colon	4.8	T3	G2	Invasive through muscularis to involve periserosal fat; abutting ileocecal junction.				adenocarcinoma in multiple slides	M1		
							negative	0/7	N0	positive (Liver)			

Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnod e Grade	Distant Met & Loc	Descrip Distant Met	Dist Met Grade	Comment
						Invasion through muscularis propria involving pericolic adipose, serosal surface uninvolved					moderately differentiated adenocarcinoma, consists with primary	M1	Anatomical location of primary not noted in report. Evidence of chronic colitis.
505	383		7.5 cm max dim	T3	G2		positive	2/17	N1	positive (Liver)		M1	No mention of distant met in report
517	395	Sigmoid	3	T3	G2	penetrates muscularis propria, involves pericolonic fat.				6/6	N2	negative	M0

Path Patient ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc Distant Met	Descrip	Dist Met Grade	Comment
534 553	Ascending colon	12	T3	G3	Invasion through the muscularis propria involving pericolic fat. Serosa free of tumor.	negative	0/8	N0	negative	M0		Omentum with fibrosis and fat necrosis. Small bowel with acute and chronic serositis, focal abscess and adhesions.
546 565	Ascending colon	5.5	T3	G2	Invasion through muscularis propria extensively through submucosal and extending to serosa.	positive	6/12	N2	positive (Liver)	metastatic adenocarcinoma	M1	

Table 8 Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc	Descript Distant Met	Dist Met Grade	Comment
577	596	Cecum	11.5	T3	G2	Invasion through the bowel wall, into suberosal adipose. Serosal surface free of tumor.	negative	0/58	N0	negative	M0	tubular adenoma and hyperplastic polyps present, moderately differentiated adenoma with mucinous differentiation (% not stated)	Appendix dilated and fibrotic, but not involved by tumor
695	714	Cecum	14	T3	G2	extending through bowel wall into serosal fat	negative	0/22	N0	negative	MX	invasive poorly differentiated adenosquamous	
784	803	Ascending colon	3.5	T3	G3	through muscularis propria into pericolic soft tissues	positive	5/17	N2	positive (Liver)	M1		

Table 8 Patient D	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc Met	Descrip Distant Met	Dist Met Grade	Comment
													carcinoma
786	805	Descending colon	9.5	T3	G2	through muscularis propria into pericolic fat, but not at serosal surface							moderately differentiated invasive adenocarcinoma
791	810	Ascending colon	5.8	T3	G3		negative	0/12	N0	positive (Liver)	M1	M1	poorly differentiated invasive colonic adenocarcinoma

Table 8 Patient ID	Path Report ID	Anatomical Loc	Primary Tumor Size	Primary Tumor Grade	Histopath Grade	Local Invasion	Lymphnode Met	Incidence Lymphnode Met	Regional Lymphnode Grade	Distant Met & Loc Distant Met	Descrip Met Grade	Comment
						into muscularis propria						well- to moderately-differentiated adenocarcinoma; this patient has tumors of the ascending colon and the sigmoid colon
888	908	Ascending colon	2.0	T2	G1		positive	3/21	N0	positive (Liver)	M1	moderately differentiated adenocarcinoma
889	909	Cecum	4.8	T3	G2	through muscularis propria int subserosal tissue	positive	1/4	N1	positive (Liver)	M1	

We Claim:

1. An isolated polynucleotide comprising a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ ID NOS: 1-316.
5
2. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOS:1-316, a degenerate variant of SEQ ID NOS:1-316, an antisense of SEQ ID NOS:1-316, and a complement of SEQ ID NOS:1-316.
10
3. A polynucleotide comprising a nucleotide sequence of an insert contained in a clone deposited as clone number xx of ATCC Deposit Number xx .
15
4. An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence of a sequence selected from the group consisting of SEQ ID NOS:1-316.
20
5. The isolated cDNA of claim 4, wherein amplification is by polymerase chain reaction (PCR) amplification.
25
6. An isolated recombinant host cell containing the polynucleotide according to claims 1, 2, 3, or 4.
30
7. An isolated vector comprising the polynucleotide according to claims 1, 2, 3, or 4.
35
8. A method for producing a polypeptide, the method comprising the steps of: culturing a recombinant host cell containing the polynucleotide according to claims 1, 2, 3, or 4, said culturing being under conditions suitable for the expression of an encoded polypeptide; recovering the polypeptide from the host cell culture.
9. An isolated polypeptide encoded by the polynucleotide according to claims 1, 2, 3, or 4.
10. An antibody that specifically binds the polypeptide of claim 9.
11. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of:

detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene comprising an identifying sequence of at least one of SEQ ID NOS:1-316;

5 wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

12. A library of polynucleotides, wherein at least one of the polynucleotides comprises the sequence information of the polynucleotide according to claims 1, 2, 3, or 4

10 13. The library of claim 12, wherein the library is provided on a nucleic acid array.

14. The library of claim 12, wherein the library is provided in a computer-readable format.

15. A method of inhibiting tumor growth by modulating expression of a gene product, the gene product being encoded by a gene identified by a sequence selected from the group consisting of SEQ ID NOS:1-316.

1 CCCAGATTCGGCACCGAAGGGGCTAAGACCCCTCCAGGCCAGGTGGATATACTCTCGTGTGGCCGTTTTAACCGG 0
 60
 1 GCTGAAAGCGCAATATTGGGAGTCACCCATTCCAGGCTGCTATCCATGCCAGGGCAACAGCTGCCT 0
 160
 1 ATTCGCTCTTGGAACCCCTGGCTTCTTATGCCAGAACACAGTTGATTCGATGTCATCAGTCCCCTGOTGGAGCCCTGG 0
 240
 1 AGACACATTCAGCTTATACTGCCACACTCATTAAGTGTCTAAACATTAAACACTGCCCTGACAAATGGAGGGAAAG 0
 320
 1 TGGTGAATCAGCTGACAGGCACRCTGCCCTCAGGTTGACAGAGATGATGTTGCCATCCACAGTAATTCAAGGGGAGT 0
 400
 1 CCTTGTTGGTCCAGGCATCATCACAGTTGACACGGAAACCGTTGCCAGAGGGGCTGGCTTGACTGAGGATTCGA 0
 480
 1 CAGTGATGGCATTTGGCCCCACTTCCCTGCCATGAGAACCCAGTGTGCAATGGCTTTAACACAGTGGAAAGCTTC 0
 560
 1 TAGTCACACAGACACCCCTGGCATGCTTCTGCTTCCAAATCTGACTCATCTTGGCTTCCATCACAAATGCT 0
 640
 1 GTCCACCATCTGATACTCTTCAAGGGAGAAACTGAGCCAAAGTACAGGACATCTGCTTCAGCCATGACTGGCTG 0
 720
 1 CCTTGTTGGTCACTCTCCGGGTTCTTCCAGGTTCCACCTTATGGTGGCCAGGCTTGTTGGTACAC 0
 800
 1 ATATGTCACCACGGAGTAGTGAATGGCATGAGGGTTCCAGGAAAGTGTGGACTGGAGAGATTAACAGAACTGAG 0
 880
 1 TCTTAAAGCAAGGAGGTGGCTTACCCCTGTTCCAGGCTATCAAGCAACCCCTCTGGTCAACCTTGGCAATGGAACTGAA 0
 960
 1 CACCCAGACTCTAAACAAATTTACCMACMCMCCCTGGCAACCCCTGGCTCTCTCTCCACCTGAGGGAG 0
 1040
 1 TGAGCCCTTTCACAAATCAGCACCCATGACATTGGGACCAACCCAAACGAAACGGGCTTATCTCTTGGCAATGGAACTGAG 0
 1120
 1 CGGTGTTTTCATTAAGCCCCATGAGTTAACCTCCACAAATTACCCAGCAAAATTGATGGGCGAGAAATT 0
 1200
 1 TTGTGTGGCTGCTATCTTCAAGAACATCCAGGTCAAGGTTGCAAATAATGCAAGGTCTGAAAAGACGAAAGATCACTCCA 0
 1280

FIGURE 1A

FIGURE 1B

FIGURE 1

SEQUENCE LISTING

<110> Williams, Lewis T.
Escobedo, Jaime
Innis, Michael A.
Garcia, Pablo Dominguez
Sudduth-Klinger, Julie
Reinhard, Christoph
He, Zhijun
Randazzo, Filippo
Kennedy, Giulia C.
Pot, David
Kassam, Altaf
Lamson, George
Drmanac, Radoje
Crkvenjakov, Radomir
Dickson, Mark
Drmanac, Snezana
Labat, Ivan
Leshkowitz, Dena
Kita, David
Garcia, Veronica
Jones, Lee William
Stache-Crain, Birgit

<120> Human Genes and Gene Expression Products XVI

<130> PP-01625.001PC

<150> 60/192,583
<151> 2000-03-28

<160> 324

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 214
<212> DNA
<213> *Homo sapiens*

<400> 1
tttagtactgc atatgtaaat actacccttt caatgagcta tataaacaat gatagcacat 60
ccttccttt actatgtctc acctccctta ggagagaact tccttaaagt agtgctaaac 120
atacatatac ggaacttgaa agctttggtt agccttgccct taggtaatca gactagttta 180
cactgtttcc agggagtagt tgaattacta taag 214

<210> 2
<211> 353
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(353)
<223> n = A T C or G

<400> 2
ggcacgagga gagaactaga aaatatgtat attggatata ctatgtccca ggcacgattc
caagccccctg atacattctc tannnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn
nnnnnnnnnnn nnnnnnnnnn nnaaagtggaa acactgggat ttgaacaagg ttttgggttgg
ccatcttttc ctatggggac tcagaaaatata ctgttgtcta gccccttctc agcctcccaa 60
120
180
240

ccttctcggt tccttaccta tgtcacagct gactttgagc taaagtcatc tcggggcagc	300
tagtgcccta tgtgagctgg cgttcatttc tcactgttac tccttccaaa tac	353
<210> 3	
<211> 399	
<212> DNA	
<213> Homo sapiens	
<400> 3	
ggcacgagcc caccaagagc tgcatagagc acgttttagct agagtaggag tttgcagtgc	60
tcatatggga aatgctgctg ctatactttt aggaatttct gagtgcatt tagaaacatc	120
tagcacactt gaaacactgc gtatcatttt cctcaactcat gaatatagtc atcagaattc	180
ataaaatagtt tacctgagcc cttaacaac ctcaaataagg ccataattct ctctctgggt	240
gatggcatgg accctacagg aaaaaccaca ctttaccgct tctgaccagc atcactacaa	300
aaaggagtgc tgaagccaat caccatgtaa gcaagataaa agcaaagggg gtcttgccctg	360
cccatctctg ttccatacat tcttaccagg cactgagag	399
<210> 4	
<211> 389	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(389)	
<223> n = A,T,C or G	
<400> 4	
ggcacgagga gagggtggtg ggtccctgag ttgggtggaaa gggatacgagn nnnnnnnnnnn	60
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn	120
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn	180
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn	240
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nngagtagag gatgcctggat atgaggcaat	300
atttggata gggaaaggaa gcttggatt ttagctacgt agagacactt gaaaattgga	360
gggaggaaag gagtgggtgg ctggagn	389
<210> 5	
<211> 279	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(279)	
<223> n = A,T,C or G	
<400> 5	
cctctccccct tggAACCCAA agagGAACGG ggCCGAACtt tataAAACTtt aggCAAGGGC	60
aaAGGGCGTG nnnnnnnnnn nngggccaa gggcatttc ccaAGCGATT aaaatttggg	120
aaccttttgt tacaaaaatt gcggggaaaa ttatTTCGG gagcaatttt ccctttaaaa	180
atttgagaat tcttaccccc agagtgtgac ataatttaag gcgcctctgc ccaaagaggc	240
catgtgcgtg agggaaatac cgcgttaat tatcacaaaa	279
<210> 6	
<211> 388	
<212> DNA	
<213> Homo sapiens	
<400> 6	
ggcacgaggc agaggcctcc ctgcactggc cctggcctca ctctttcccc tgacccttgg	60
ggcccaggc catggaggga cccttaggag ttcaatgaga gagaccatga ggccactggg	120
ctttccctt cccaggcctc ctgggtgccca cccccctacg ttattcttgg gcctctaata	180
agtgtcccac aggtgcctgg ccagccccac ctgctgcaga tgtggtctgt gtgtgtgcata	240

gtgtgggtgt	gtgtgggcac	aggtgtgagt	gtgtgagcaa	cagtacccca	ttccagtcgt	300
ttccgtctgt	gactaagtca	gcaacacagt	tcctctgaca	tggccttgg	ctgtgtttct	360
ttgggggtga	agagattgcg	gaggaagt				388
<210> 7						
<211> 410						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(410)						
<223> n = A,T,C or G						
<400> 7						
ggcacgaggg	gaagtcgcgc	atgcgcgagt	gtacgcgttg	ccggcgaaga	ggggagcctg	60
acgactcgga	aatttgaata	ccacagttagc	atggagtggt	acctcatgga	gactgacatc	120
ttggagtcgt	tggaagatct	aggttacaag	ggcccatgtt	tggaagatgg	agcgctctct	180
caggcagtct	ctgctggagc	cagtcccccc	gagtttacca	aactctgtgc	ttggctggtg	240
tctgaattaa	gagtgcctg	taaactagag	aaaaaacgtgc	aagcaactaa	cagtcccgagt	300
gaagctgaag	aattccagct	tgaggtgagt	gggctactag	gggagatgaa	ctgcccgtat	360
cttctactga	catctgnnga	tgtgaccaag	cgccttctca	ttcagaaaaaa		410
<210> 8						
<211> 229						
<212> DNA						
<213> Homo sapiens						
<400> 8						
ctaacaaaaa	acactaaaaaa	aaaataaaag	aaattaattt	aaactgacct	aactcgtggc	60
agggggact	cggctataag	accacaaaac	cctgctgact	cataacaaac	tgagttgtaa	120
gacattcattc	gccgcgatata	cctttagttaa	agaatgaact	ctggaagccc	acccacggac	180
aatgcacctt	cacaaagatt	ctgcactaat	ctgagtgaag	gtcttttgtt		229
<210> 9						
<211> 380						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(380)						
<223> n = A,T,C or G						
<400> 9						
ggcacgagag	tagttggaa	atctttata	aatccaccta	ttactaccta	ttggtagggg	60
agattaaatt	tctacaggtt	tggagagtcg	gtttgactac	actgtgtgg	gcaagttttt	120
aagaagcaaa	ggtatagcag	ttccaagttt	nnnnnnnnnn	nnnnnagacc	aaactctaga	180
tctgccccaa	aatggacggc	cgcggcattt	aatgaagaa	agatttattt	ttcctttttt	240
cttttaagaa	aaattttttt	aaaaattttt	gattnnnnnn	nnnnnnnnnn	nnnnnnnnnn	300
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	360
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	380
<210> 10						
<211> 317						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(317)						
<223> n = A,T,C or G						

<400> 10
 cacacacaca catccactct ctcttttgc tctcttcata cacacacata tctcccttac 60
 tcacacactc tctctcacac accccctctt tctttccccc cgcaacttct ttctctcacg 120
 cgcgcgcga ctcactctct tttttctct ctctctcaact ctctctctcc ggcgcgtctc 180
 tcacacgctt tatatctctc tctctgaggg acttctctct cctctcaact ttatcttttt 240
 gttgtttt atagegtctc tctttccct nnnnnnnnnn ntctatatat acagagagag 300
 atctctctgc tctctcc 317

<210> 11
<211> 391
<212> DNA
<213> Homo sapiens

<400> 11
 ggcacgagag aatttagctga aaccaccaa gagctgcata gagcacgttt agcttagagta 60
 ggagtttgcgtgctcatat gggaaatgct gctgctatac ttttaggaat ttctgagtgc 120
 aatttagaaa catctagcac acttggaaaca ctgcgtatac ttttcctcac tcatgaatat 180
 agtcatcaga attcataaat agtttacctg agccctttaa caacctcaaa taggccatat 240
 ttctctctct ggtttagtggc atggacccta caggaaaaac cacaccttac cgcttctgac 300
 cagcatcaact acaaaaagga gtgctgaagc caatcaccat gtaagcaaga taaaagcaaa 360
 gggggtcttg cctgccccatc tctgttccat a 391

<210> 12
<211> 280
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(280)
<223> n = A,T,C or G

<400> 12
 tgtcgccgc ccccccggggc gctctctctc tacactcgta cgctcccccc tctgtctgtc 60
 tctctctcta gagtcacggc tccctacacg ggcgcacat gcgaggggca ctnnnnnnnnn 120
 nnngctcnnc nnnnnnnnnnn nnnnnnnnnnn cgnnnnnnnnn nnnnnnnntcc cttgtataact 180
 ctctgtgtgc gcggggacan nnnnnnnnnnn nnntgcgcgc gcgagagcgc gcgcgcacaca 240
 caagagagag cgcgcctnn nnnnnnnnnn naccgcgaac 280

<210> 13
<211> 311
<212> DNA
<213> Homo sapiens

<400> 13
 cgcttttttg ggaacccaaa cctttttgg ctggccggaa aaaatttcca cgggaagggt 60
 aaagggtttt attaattttt ttggcaaaac aggggttaag aaaccttccc tcccgcccta 120
 aggggtggct aggctttgga aaggctaaaa gggggaaaatt tctggccctt gttccaagg 180
 aaacatgggc tagggggaaa ccccacccct tcagggccctt taaaaggc ccccaaaaaa 240
 agaaccctt tattaagggt taaaagggt taaaagggt gggacacta tgggccaagg 300
 caaatttttg t 311

<210> 14
<211> 387
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(387)
<223> n = A,T,C or G

<400> 14

ggcacgaggt	ctttctgcc	cacatctcac	acaatttggg	tgtctgaaca	agcttgggga	60
gggtctataa	ggggtaggct	ccccnnnnnn	nnncccat	gaaaaggcg	ttttccaac	120
ccaaggggct	tttttagccg	attttnnnn	nnnnnnccgg	acttggtaat	tggctttgg	180
ctttttaaag	cccaaaaaat	aataattaag	gggc当地	taaggaaggg	aaaaaaaaagc	240
ctttactccc	cctgccttcc	aaaaagaaaa	ggaaaaaccg	ccccccctt	aataatttgc	300
acccctaaaa	aaaggggtt	aaaaaaaaagc	aaaaaacaaa	agggccttgg	aaaaaatttt	360
gactttttt	aaccggaaac	ctggaa				387
<210> 15						
<211> 273						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(273)						
<223> n = A,T,C or G						
<400> 15						
ctgtctctct	ctctcccccc	ctctccctcc	cgcgcgcga	cgctctttca	tctctctctc	60
tacagacagg	gggggggttt	ctctctccct	ctcgagaggg	accgcttttt	ttttctcccc	120
ctctctcaca	ctcgggggtgt	gcgcgcctcc	tttgggggct	tttctatagg	gcgcgcctcta	180
aagaaaagccc	gcctttctcc	tctgggtgcc	tcctcccaca	cccggtttt	ctccccgct	240
gtttttgaag	aaactccctcc	tggctccctt	atn			273
<210> 16						
<211> 283						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(283)						
<223> n = A,T,C or G						
<400> 16						
ctctctctct	ggccccccccc	ctctctttac	acacactttc	tctctctct	ctcgctctct	60
ctttttttt	ctctctcccc	tcgtctcttc	tgtgtgtctc	tatctcggt	ctctctctgc	120
gtgtccctca	cacacactcg	cgcgagagat	ctctctctat	atctctcttt	tgtctgtgtc	180
tctctctcgc	gcgcacacac	atctatatat	ttttgcgcgc	acacgcgaga	gtgtccct	240
ctctctctct	gcacnnnnnn	nnnnnnnnnn	cacaccctcc	ccc		283
<210> 17						
<211> 392						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(392)						
<223> n = A,T,C or G						
<400> 17						
ggcacgagat	gactccttcc	ttaaaatcca	gctcaaattct	ccccctttt	ggggctttc	60
tctgacactc	catcataaag	ctaattgtt	aagtatgatc	cagtggcaca	gtttatttct	120
acttcataac	tttatctca	ctatgttgta	agatattagg	tatgtttctt	ctactaccag	180
taattttcaa	agatgtttaagg	aagaaggata	gaagacagca	gtataggtga	atgtgtgcata	240
gtgttnnnnn	nnnnnnnnnc	catatggcc	aaaatttttgc	gactggctgg	aaaacaaaag	300
gcttttcaaa	ttttcaaata	cctttaaaaaa	aaacctggaa	attgttttgt	nnnnnnnnnn	360
cgc当地	aaaattttgg	gcctgggggg	ga			392
<210> 18						
<211> 385						

<212> DNA

<213> Homo sapiens

<400> 18

ggcacgaggc	agaggcctcc	ctgcactgg	cctggcctca	ctctttccc	tgacccttgg	60
ggcccaggc	catggaggga	cccttaggag	ttcaatgaga	gagaccatga	ggccactgg	120
ctttccccct	cccaggcctc	ctgggtgcc	cccccttacg	ttattttgg	gcctctaata	180
agtgtcccac	aggtgcctgg	ccagggccac	ctgctgcaga	tgtggtctgt	gtgtgtgcat	240
gtgtgggtgt	gtgtgggac	aggcgtagt	gtgtgagcaa	cagtacccca	ttccagtcgt	300
ttccctgtgt	gactaagtca	gcaacacagt	ttctctgaca	tgggccttgg	ctgtgttct	360
ttgggggtga	agagattgct	gaggg				385

<210> 19

<211> 383

<212> DNA

<213> Homo sapiens

<400> 19

gaaggcgtgc	ggagagaaaa	ccctggagcc	atcttcata	gaagaggaaa	ggaaactgt	60
tgacaggaga	atgaatcaag	tttgggctc	aaggtgcgg	ccactggaa	aaacagctgc	120
cccgagttgc	aaaactctgg	gtccatatat	tataaactat	gccctgagga	aggaatctca	180
ggcgatctt	aggagaaaaat	gttctagctt	gggaaacaaa	cacaacagga	ccgtgaatcc	240
aaatatttca	agtgggtta	gaggactgga	gttctaaacg	ctgctttac	tgttaagtgtat	300
cacgccccgg	aatgtgctga	agaaaggaaa	atgagccagt	atcggcgagg	actatgggca	360
aggaaaacg	gagtgtgcga	tgt				383

<210> 20

<211> 313

<212> DNA

<213> Homo sapiens

<400> 20

ctctcccccg	cgctcttgc	atatgcgcgc	cccttttttc	ttctacacgg	ggggggggcgc	60
gcctcttttt	ctcgcgcgccc	cccctctc	tcttttgtgc	gcacgcgcgc	gcgcgggggg	120
gttctttttt	tgtgcggaga	gagagtctgt	ctcagggggtt	tttttgtttt	cttcacgac	180
acacactttc	tcccctgtgc	atgtgtttt	atgctctctc	gagatatgtc	tctctctctc	240
tgtgtgtgt	tgttgtgcgc	ccccctggg	gagagcgcctc	ttctctctct	cctcatata	300
cgcgcgcgcgc	cga					313

<210> 21

<211> 396

<212> DNA

<213> Homo sapiens

<400> 21

ggcacgaggg	gacccccc	acctctgtct	agagagctgg	gtagatcaga	aacttggt	60
cacctggcta	gcacagagca	ggctca	tcttggtccc	actaccaga	ttcctgcaga	120
cattgcaaac	caa	ttgttgaat	acccctgtcc	ccagccactt	gttttggat	180
catctgctct	gcagtggaa	gcctgtgtgt	ttgagttcac	tctgcac	tatatttgag	240
tatagaaacc	gagtcaagt	atcatgtgca	tccagacaca	ctgtgtcacc	tgagccac	300
agcaaata	cttaacgatc	tggaaatgaaa	ctgtgaccag	tgccccc	ttctgttct	360
gagagactgc	cgtcttctt	tttggccata	ggtgcg			396

<210> 22

<211> 310

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(310)

<223> n = A,T,C or G

<400> 22
tgaatatcatg ggcctgaac atcttcacg cccgtttctt aaaaagagaag aaaaaaaacgc 60
gcccgggtt tttctcttc tcagagggtt gaaacacaca atatctcggtt gggccgggg 120
agagcccgct ctctctgcgt gtaaaacaca cagaagtgcg ctcacgcctt ggcggggagc 180
ccacagactt ttttttaaaa caaaaagtat attgggggtt gtttaatct ccctctccgc 240
tccttagaggg gggcgnnnn nnnnnnnnnn ntttttaaat agggggccc gagtctcacc 300
caatagaagg 310

<210> 23
<211> 375
<212> DNA
<213> Homo sapiens

<400> 23
ggcacgagcc ggcgaagagg ggagcctgac gactcgaaa tttgaatacc acagtagcat 60
ggagtgtac ctcatggaga ctgacatctt ggagtcgtt gaagatctag gttacaagg 120
cccattgtt gaaagatggag cgctctctca ggcgtctct gctggagcca gttccccca 180
gtttacaaa ctctgtgtt ggctgtgtc tgaattaaga gtgctctgt aactagagga 240
aaacgtgaa gcaactaaca gtccgagtga agctgaagaa ttccagctt aggtgagtgg 300
gctactaggg gagatgaact gccgttatct ttcactgaca tctgggatg tgaccaagcg 360
ccttctcatt cagaa 375

<210> 24
<211> 477
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(477)
<223> n = A,T,C or G

<400> 24
gctcccttctt cttttgttg atccatcga tccgaattcg gcacgagagc acctctgtgc 60
ctctctgaga gcactcacag ccaaaagtac acagctgcc ccaggcttag agtgcttgat 120
acacccttga atccccctt atatgtgcc ccagccagg agagataaaa gcatcagcac 180
catgagattc acctgcctt ggtgtttttt nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnact cttagacagc aaaaatgttt 360
tctcccttgtc ttgttccctt gtttcgtttt cccacccctgc ctggataact actgttctt 420
gtttttttttt nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 477

<210> 25
<211> 265
<212> DNA
<213> Homo sapiens

<400> 25
cgccgggggg ggacccctct ctctctctt gttgcgcgcg ctctctcacc ccgtgtgtcg 60
cccccgatat tgcagagag accccctatt ttttctccc gccccacaca catctatgt 120
taaaaatgtgc gtgtctgtcg cgacaccca cacactctcc ccgggggggtt tataaaatac 180
tcgcgcgtta tattttcgcc ccccttttg tgtgtggcg ccacaaaaac accacacgct 240
ctccccctgt tctctcgccgt gtgttt 265

<210> 26
<211> 388
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(388)
<223> n = A,T,C or G

<400> 30
 ggcacgagac tacacccgt tcgatgactg gtacctgtgg gttcagatgt acaaggggac 60
 tgttccatg ccagtcttc agtccttgg ggcctactgg cctggcttc agaggctcat 120
 tggagacatt gacaatgcca tgaggacctt cctcaactac tacactgtat ggaaggcgtt 180
 tgggggctc ccggaattt acaacattcc tcagggatac acagtggaga agcgagagg 240
 ctaccactt cgcccagaac ttatgaaag cgcaatgtac ctctaccgtg coacggggga 300
 tcccaccctc ctagaactcg gaagagatgc tgtggaatcc attgaaaaaa tcagcaaggt 360
 ggagtgcgga tttgcaacaa tcaaagatct gcg 393

<210> 31
<211> 459
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(459)
<223> n = A,T,C or G

<400> 31
 gcaatcgcat tgtcttttg aggatnnnat naatgtcaat tcggcacgag ctttgtggat 60
 gtttccagct gccatcgta ccctctgtc tgctccctgg accagctca ggacttgaag 120
 gcccctcggtt ctgagatcat cacacatttgc caggggtgc agagggactt atctctagca 180
 gtctccatc gcaggctcca ttccctcagac tggaatctgt gtactgtatt tggatcctc 240
 ctgggctatc ctgttcccta taccttac taccaaccagg gagatgacaa ctgcttagct 300
 ctgactccac tacgagtatt cactgcccgg atctcatggt tgcttagtca acccccaatc 360
 ctgtctatt ctttttagtgc cccagagagt ttgttccac gcctgaggga cattctgaac 420
 acctgggaga aagacctcag aacccgattt atgactcac 459

<210> 32
<211> 445
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(445)
<223> n = A,T,C or G

<400> 32
 ggcacgagat ggagagcacc tctgtgcctc tctgagagca ctcacagcca aaagtacaca 60
 gctgccccca ggctgagagt gcttgataca cccttgaatc cccttcttata tgatgcccc 120
 gcccaggaga gataaaagca tcagcaccat gagattcacc tgcctctggc cgtnnnnnnnn 180
 nnn 240
 nnn 300
 nnnnacttctt agacagcaaa aatgtnttc tccagtcttt gttccttggc ctcaagggtcc 360
 acccttgctg gataactact ggtcttgggt tcctgggta aagatggaac ttgagtaagc 420
 tcgacccaaa tccaaaatca atccg 445

<210> 33
<211> 429
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(429)
<223> n = A,T,C or G

<400> 33
 ggcacgagcg cctgccctgc atcagggaga catgtcagct gaggagtaat tgaccagatt 60
 tctgttttag aaatatggca gtggaggcag gagatggcat ctgaggccca ggctggggag 120
 aagggtgctg ggatgagaac ctggagttca gaccagggaa gggatgagag cctaagaaga 180

ggagctctca	ccctgagaca	ggctggtgca	ggagtctgtc	cgatccaggc	ctgggtccct	240
ggttccctct	gagcttggga	ggactatgtg	agacagaaca	ggaccagggg	cctgcattc	300
cccttgtatt	attcatcnm	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	360
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnnna	420
tgtatggccc						429
<210> 34						
<211> 439						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(439)						
<223> n = A,T,C or G						
<400> 34						
gttctgtggg	aatacgagggt	ccctggtgac	agggcagggc	tagatctgga	gcctgcactt	60
ggctgtgac	atactgtctt	gtttctgaga	atccctccct	acttcctctag	ttaatctcca	120
gagacttctg	tgactactta	atcacaaagg	aaattttcaag	aatatttatac	aaatactatt	180
ttagaaaaaa	aaagagaagg	gatttgaatg	tttcagttc	agtttagnta	tcnnnnnnnn	240
nnnnnnnccc	caaacttcaa	aatggaggcc	ccccctctct	ttaacccccc	taaaaaaaaaat	300
tctgatgttt	gagggttttgt	tgccaattaa	ccaaacccccc	aaaaaaaaag	gggggttaaac	360
cccattggaa	agttttcccta	attttggggg	gtgcccttgc	agtgacccc	gttccctgc	420
cctgggaaag	gccccaaag					439
<210> 35						
<211> 440						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(440)						
<223> n = A,T,C or G						
<400> 35						
ggcacaggg	gaagtccctgg	ttccagactc	cccttttgc	cgggacatga	tggatctgtc	60
agctgggcc	tatagtccta	gagagctaga	gatggaggga	aattcagatc	atctaaaccc	120
ttcacggccctt	cactggacag	aagaggaaac	tgaggctcca	tctgcatgac	gttcccagag	180
tcacggcaca	aattcatgga	agaagcagca	ggaaaactcag	ttctccagtc	tgggtccaat	240
gtgtgtttta	gaaatatatc	cacagggtta	atgactcaat	ttttcatgca	tgattgtca	300
taatgacaat	catgttatgt	ttgtttctgt	agctttggaa	atcactccctt	ccacttgagt	360
ttcaggteccc	aactgtccac	acctgcagga	gtgagggttt	gctgagactg	ataaggcact	420
cacattntgt	gggagttgaa					440
<210> 36						
<211> 423						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(423)						
<223> n = A,T,C or G						
<400> 36						
acgagcgcnn	nncctgcattc	agggagacat	gtcagctgag	gagtaattga	ccagatttct	60
gcttagaaa	tatggcagt	gaggcaggag	atggcatctg	aggcccaggc	tggggagaag	120
ggtgctggga	tgagaacactg	gagttcagac	cagggaaagg	atgagagcct	aagaagagga	180
gctctcaccc	tgagacaggc	tggtcagga	gtctgctcga	tccaggcctg	gttccctgg	240
tccctctgag	cttggggagga	ctatgtgaga	cagaacagga	ccagggccct	gcattccccc	300
ttgtattatt	catcnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	360

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnatga	420
tgg	423
<210> 37	
<211> 424	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(424)	
<223> n = A,T,C or G	
<400> 37	
ggcttgtaga nctcgagggt tngcaagaat cgcatcggc acgagctggg acacagtng	60
ctctttata ttgttgcgt gaataaatga atgaactaag gcagtcgtt agggatttac	120
tgttaaccac catgggaaaa ttaaataaaat gcggggaaagg aaaacgttct aaaatttagaa	180
gactactttc tactctcagc ttctgattcc ctctgagcta agaaccagac agccttaggc	240
tggtaactcc tataagctgg tcctcctccc atgctgaccc catcttact gtacaattca	300
cttttcatgg actgaaggca ccaccaagat agatccagga gtgacaactc cagtgttaggt	360
gtccactgtt cccttaatct ctgtcctgct ccaagtataa ataaatcggt gcccatttcct	420
taga	424
<210> 38	
<211> 434	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(434)	
<223> n = A,T,C or G	
<400> 38	
ggcacgaggt acacagctgc ccccaggctg agagtgcgtt atacaccctt gaatcccctc	60
ttatatgtat ccccagccca ggagagataa aagcatcagc accatgagat tcacctgcct	120
ctggcgttnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnnn	180
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnnn	240
nnnnnnnnnn nnnnnnnnnna ctcttagaca gcaaaaatgc tttctccag tcttgttccc	300
ttgttcttagt ttcccacccct gcctggataa ctactgttct tggtttnnnn nnnnnnnnnnn	360
nnnnnnnnnn agtctcgatc cagattcaa aatcgtcaa ctacttcaa aacaatgaca	420
tgctggctac ttaa	434
<210> 39	
<211> 428	
<212> DNA	
<213> Homo sapiens	
<400> 39	
ggcacgagct ttgtggatgt ttccagctgc cagcgtcacc cttctgtctg ctccctggac	60
cagcttcagg acttgaaggc cctcgtggct gagatcatca cacatttgcg ggggctgcag	120
aggacttat ctcttagcgt ctccatcagc aggctccatt cctcagactg gaatctgtgt	180
actgtatttg ggatcctct gggctatcct gttccctata ctttcaccc tgaaccaggaa	240
gatgacaact gcttagctt gactccacta cgagtattca ctgccccgat ctcatggttt	300
ctaggtcaac ccccaatctt gctctattct tttagtgc cagagagttt gttcccaggc	360
ctgaggggaca ttctaaacac ctgggagaag gacctcagaa cccgatttag gactcagaat	420
gactttgc	428
<210> 40	
<211> 429	
<212> DNA	
<213> Homo sapiens	

```

<220>
<221> misc_feature
<222> (1)...(429)
<223> n = A,T,C or G

<400> 40
ggcacgagtg gagagcacct ctgtgcctct ctgagagcac tcacagccaa aagtacacag      60
ctgccccccag gctgagagtg cttgatacac ccttgaatcc cctcttatat gatgccccccag    120
cccaggagag ataaaagcat cagcaccatg agattcacct gcctctggtc gtttagggAAC      180
aatggaggcc tgcgattttgg agttaaactc tcaagtatct ctgtgttgac aacacccaaAG      240
ctagaggaat ccagtaggat gtgggcattgg ttttcccgaa aggctgactg agcagttctg     300
caaatgtttg caagtacagg gcagaatttc atccagccctc agaaccttga gccaagactc     360
agcatcagca aagccaaaAG tttcattttc ttgactgtgg gagtgtactt cccaacctt      420
agatggccn                                         429

<210> 41
<211> 430
<212> DNA
<213> Homo sapiens

<400> 41
actctgcAAA cagctacttg tgctgattgc aggagaccca taaattcgaa cgaggaacAA      60
ccgagacctg aaggggctGA cgaacgcgt ttctgataAG tatgggtcc ctgaagagAA     120
catttacAA gcctacaATA aatgcacGCG aggaatCTTA tgcaacatGG acaacaACAT     180
cattcagcat tacagcaACC acgtcgccTT cctgctggAC atggcggAGC tggacggCAA     240
aattcagatc atccttaAGG agctgGAAGG CCTCTCGAGC atacAAACCC tcacgacCTG     300
catggggcCA gcagggacGT ggccccacGC cacacacaAC ctctccacAT gcctcaacGC     360
tgttacttGA atgccttCCC tgagggAAAGA ggcccttGAG tcacagacCC acagacGTCA     420
ggaccatGGG                                         430

<210> 42
<211> 437
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(437)
<223> n = A,T,C or G

<400> 42
ggcacgaggc gcccctctGCC cccctcagAG ggtctctcct ctgcacCCCC aaattcccc      60
agcatctcaa tcccttgcAT ggggagcaAG gcctcgagCC cccatggTTT gggctccCG     120
ctggggcTT ctccaaAGACT ggagaAGCGG ctggggagGG tggcccaca gccccccAGC     180
aggatctctG tgctgtcAGC cagcccaGtg tctgatgtCA gctatatgtT tggaaAGCAGC     240
cagtccctcc tgcactccAG caactccAGC catcagtCAT cttccagATC cttggaaAGT     300
ccagccAACT cttccctccAG cctccacAGC cttggctAG tgcctctgtG tacaAGACCC     360
agtacttcc aggctccAG AAACCCCAcc ctaaccatGG gccaacCCAG aacacCCAC      420
tctccaccAC tgggcan                                         437

<210> 43
<211> 432
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(432)
<223> n = A,T,C or G

<400> 43
ggnnncagtGA ccaccaggAC ctgggtgtCTG tgcacatcta catcacCCAG ctggctgAGA      60
agttcgacCT caggaccACT atgctgtACA tctgtgAGCG gcacttccAG aaggTTCTGA    120

```

accggagtct attcacaggc ctgcgctcca tcacccactt tggccgtccc ccctttgagc	180
ccttttcaa ctcctgcag gaggtccacc cccaggtccg gaagatcgaa gtgttagct	240
gtggccccc tggcatgacc aagaatgtgg aaaaggcctg tcagctcata aacaggcagg	300
accggactca cttctccac cattatgaga acttcttaggc cccttccgg gggttctgcc	360
cactgtccag ttgagcagag gttgagccc acacctcacc tctgttcttc ctatttctgg	420
ctgcctcagc cc	432
<210> 44	
<211> 436	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(436)	
<223> n = A,T,C or G	
<400> 44	
ggcacgagcc gaggcgccg tttccgtgg ccgttccag ggccgcgcgg cggtgatcaa	60
gcacccgttc cccaagggtt accggcaccc ggcgctggag gcgcggcttgc gcagacggcg	120
gacgggtcag gaggccccgg cgctccctccg ctgtcgccgc gctggaatat ctgccccagt	180
tgtttttt ttggactatg cttcaactg cttatatatg gaagaaattt aaggctcagt	240
gactttcga gattatattt agtccactt ggagactgaa aaaactcccc agggtctctc	300
caacttagcc aagacaattt ggcaggttt ggctcgaatg cacatgaag acctcattca	360
tggtgatctc accacctcca acatgctcct gaaacccccc cttgaacagc tgaacattgt	420
gctcatagac tntggg	436
<210> 45	
<211> 300	
<212> DNA	
<213> Homo sapiens	
<400> 45	
tctctctctc tctctctcac agacactttt accccatata tacacataaa atgtgtgcgc	60
gagagagaga gagccctctc gctctatata tatcccccg gggggagat aaaaatatat	120
atccccacac ttatagggc gggctccccct ctctatcctg tttgttagaga gaaatatata	180
tatatctgtg gggggagaga gagatctctc accccccccgc acacgcgagc tctttcttaa	240
gatgtgttag cggcccccccccttggatataaaaaagaga ggggtatata tattgggggg	300
<210> 46	
<211> 191	
<212> DNA	
<213> Homo sapiens	
<400> 46	
caaaacaaaa ccatgttccc actggtgatg cctgtctgac acgttttgtt atttagtagg	60
aatgaaggg tcttcaagct tcgagagaac cttcaaaatt gtcacaattt ctgaaaacag	120
aatgaatcg gaacattatc tcaatatttt gcataataga caacaccaca gtgttttgtt	180
tccctgacct g	191
<210> 47	
<211> 302	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(302)	
<223> n = A,T,C or G	
<400> 47	
gccccggcgt gtgtgtatgt gtgtacacgc ccccggtggc tctctgtcgc atcttgnnnn	60
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnncaca tagcgcgcgc gctcgcgcgc	120

acggagctat agagacacca ctctctctct gagatacacg cgcgccaca cactctgcgc	180
gccccgcgctc ttctttgtct cgcgccgcgc cccgctatgt ggagggtata tgtggggaa	240
aatagcgagg tgtgcgcgca cccgcccacg cgccgtctat atctctatata cttcagcgcg	300
cg	302
<210> 48	
<211> 411	
<212> DNA	
<213> Homo sapiens	
<400> 48	
ggcacgaggc ttgcggggca ttaggactag agggttgggtg aaaattcaga cagaatgtaa	60
cttgacaaag agaagacacg aacaactgt acaattatct tatgaatatt tgcaaaactc	120
aaagggatct gattgggtac ctctggcctt tatcaaattt acatcacaac ttctagaaga	180
aagtcaacct tcatactttt caatagaaat catatgtttt gctaaccat tcctatttag	240
gctgaaaaca attaagagtt atgggtactt aaaaaaatca ttatgtttt aaaaatttagt	300
atagaaggag catagtgttc tatacagtca cacacataca cttccattt tcttttattt	360
aaacttttag taacatagca gtctatgttt gggtcagttt tccctttttt g	411
<210> 49	
<211> 408	
<212> DNA	
<213> Homo sapiens	
<400> 49	
ggcacgaggc acacaaagcc aaggcatac cctatagagt aaagctgcag ccaccctgt	60
tctcatgtgc agctgaaata gtgatctgct tctgtcaactg tcacatagac agccctgcat	120
gccccctgtc tcacacagtt ttaatgaag acagctcctt ctcatcttc cataaggcctg	180
agatacaagt tcagggactc agcaatgcac ttttagactg agctaggagg caaatatctg	240
aagcttgcta tgctgttctt tccattcctt ttccctctga aacacacaaa ataccaaagg	300
aaccttacgca tcacaccact gagtcctcta actaatcata tttgtcaga cacagctcaa	360
gcacacccct tagttaagag agaacctcca tatacattaa tttttttc	408
<210> 50	
<211> 407	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(407)	
<223> n = A,T,C or G	
<400> 50	
agagaaaacat ccactcgaat tcggcacgag gacagggcag ggctagatct tttttctgca	60
cttggcctgt gacatactgt ctgggtctg agaattcctt cctacttctc tagttatct	120
ccagagactt ctgtgactac ttaatcaca aggaaatttt caggaatattt atcaaataact	180
attttagaaa aaaaaagaga agggatttga atgtttttag ttcaagttttag ttatcnnnnn	240
nnnnnnnnnn ncccaaactc aagtatggag gccccccctt cttaaacc accaaaaaaaa	300
ttttttgggg ttcaagggtgg gttggccaac tacccaaacc cccaaagaaa atgggggtta	360
accccttga aaaagtttc ttactttggg gggctccct tgagccg	407
<210> 51	
<211> 312	
<212> DNA	
<213> Homo sapiens	
<400> 51	
ccccgggggc gctctctttt tttttccccc caagtgagag agccccgcgc gcgtctctct	60
ctcgatctt ttcgacaccc ccctgtgtg gggcgccgc cgcgtctgtg tgtgatacac	120
agaatgtgcg tgggtgtct gagagacact ctccgcgtt gtgtgtgaga cacagactt	180
tcttttttta gggggcgggg ggggagttt atgtgtgcca catgtttct gtgtataaaa	240
agagcgcaca gagtgtttt tatatctgtg agagagacct ctctgtatatacagctc	300

agaggggaga gg	312
<210> 52	
<211> 420	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(420)	
<223> n = A,T,C or G	
<400> 52	
acgagggnnn nnaagcaccc cggttacccc atgagggcct acaagctggc caccctggcc	60
atgacccatc tcaacctgag ctacaatcag gacacacacc ctgcattaa tgatgttttg	120
tggcctgtg cgcttagcca ctcccttgtt aaaaatgagc ttgcagctat aatacctctg	180
gtggtaaga gtgtcaagtg tgcaacggta ctgtcagaca ttttgcgcag atgcactctg	240
accactcctg gcatggtggg acttcatggg aggaggaact ctggtaagct catgtcactg	300
gacaaaagccc ctttgggca acttggat gccacgatcg gggctacat caacacaacg	360
cactcacggc tcacacacat cagtccctgg cactatagtg agtttataga gttcctcagc	420
<210> 53	
<211> 394	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(394)	
<223> n = A,T,C or G	
<400> 53	
ggcacgaggt gtggatgaca gagcgagacc ctgcctcatn nnnnnnnnnnnnnnnnnnc	60
ccccccnnnn nnnnnnnnaaa aaccgggttggcccccgggt gttctttagg gcccctaaaaaa	120
ttggcccaaa aaaaattggc cggggccctaa aaaaaccccg gttttttggg gagaattcaa	180
aaaagggtcg gtnnnnnnnnn nntttttaaa cttccaaaccg gcctcagggg gaaaaaaacct	240
ggaaaaactca atgggggttg gaacaaaatc aatatttggt cttaccggaa agcgtaaga	300
ttttaaacca gtaaaaatgg ccaannnnnnnnnnnnnnnnnnnnnaacagg gccccccgggg	360
taagggctaa aaattttcag atttgaacct tttt	394
<210> 54	
<211> 390	
<212> DNA	
<213> Homo sapiens	
<400> 54	
ggcacgagat tttcttggca ataagcggac tctggactc cggctcccta ccccaaactg	60
aagcgcttcc gtgaacaccc ccgttctccg tagggggagg ggagcaggcg ggatcctgg	120
tccctcataa gcacttttgtt tttaccgcct gcaacctcac tgtgcggcc cccgaccatag	180
ccctagcccc aggtctagcc gggcccattg cagggggcag cactttgggg catctccggc	240
acttgggtgg gaccaaggag atgccaccat agacctttcc ctcgccttct tcctccctag	300
tccgggttcc attctttca ccagcaccca tcgccccagg ggtaccgagg gggggcaggg	360
ggtgtcaat tcaaacccaa ccccgctcg	390
<210> 55	
<211> 280	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(280)	
<223> n = A,T,C or G	

<400> 55
tctctctc tctctgcgcc cacacctctc tcannnnnn nnngcacgtg tatatctnnn 60
nnnnnnnnnnn ttttttttag agagacatct cgcgcgtgtc tctcttttc cggcccgccg 120
ctctttc ggcgcgcgc gcacccccc tttgtggggc ggcgcgtctc ttttttttg 180
tgcgcgcan nnnnnnnnnnt ctctctgt ggcnnnnnn nnnnnntctc ttattnata 240
ttttgggggg cggggggcct cccctccccct ctgtgtgcct 280

<210> 56
<211> 398
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(398)
<223> n = A,T,C or G

<400> 56
ggcacgaggt ccaccta cgc tcagcaatct catgccgggtt ggcaattagt cagcataa 60
cgatgcctgc ccatcagttc tttactctga ggtgttagag tggaaaaaaa atataaataac 120
ttacnnnnnn nnnnnnnncat accaacc ccctccatt nnnnnnnnnn nnngccgc 180
cccttaaaat tcatggagag gccttattcg tagccagcca ctatataaac cctgctgg 240
ggccgggnnnn nnnnnnnnngt gaaggggggaa aaaaaaagcc ttttttgaa aaaatttagtc 300
atttttgtct ttttttgac acatttgcg ggacaaagaa ccctgtaaaa ccccccatt 360
cnnnnnnnnnn nnnnnnaacc tcaacgaggg gggggcgg 398

<210> 57
<211> 386
<212> DNA
<213> Homo sapiens

<400> 57
ggcacgagat tttttggca ataagcggac tctgggactc cggctcccta ccccaaactg 60
aagcgcctcc gtgaacaccc ccgtccctcg tagggggagg ggagcaggcg ggatcctgg 120
tccctcataa gcacttttgtt tttaccgcct gcaacctcac tttgtccgc cccgaccat 180
ccctagcccc aggtctagcc gggccattt cagggggcag cacttgggg catctccggc 240
acttgggtgg gaccaaggag atgcaccat agacctttcc ctcgccttct tcctccctag 300
tccgggttcc attctttca ccagcacca tcgcccagg ggtaccgagg gggggcagg 360
gggggtcaag tccaggccca cccccc 386

<210> 58
<211> 202
<212> DNA
<213> Homo sapiens

<400> 58
cacttttct atatgaatat cttggccgt a tcatagactc aaaaaagaaa ttatgcaagt 60
tctttctgcc cccacctgcg ccaggggaga agtttacatt cgggaactcc agagttaaag 120
cagttgtgtt gataattttt tatgtgaac acaccacgt ataaaaaaca acattcacgt 180
gttttatattt tgttatgtgtt tt 202

<210> 59
<211> 394
<212> DNA
<213> Homo sapiens

<400> 59
ggcacgagtc tgcttctgtc actgtcacat agacagccct gcatgcccc ttttcacac 60
agtttgaat gaagacagct ctttctcatc tttccataag cctgagatac aagttcagg 120
actcagcaat gcacttttagg actgagctag gaggcaataa tctgaagctt gctatgctgt 180
tctttccatt cttttccct ctgaacaca caaaatacca aaggaactta cgcaacacac 240
cactgagtcc tctaactaat catatgtgtc cagacacagc tcaagcacac cccttagtta 300
agaaagaacc tccatataaca ttaatttttt tctgcctaaa aataaaaattt cgttgtggca 360

gcaatttggaa aactacagca aagtctccaa aaaa	394
<210> 60	
<211> 246	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(246)	
<223> n = A,T,C or G	
<400> 60	
cccccccttt tttaggcctg aatacaaagt agaagatcac tttccttcac ttgtctgaga	60
atttcttagat actacagntc ttactcctct cttecccttg ttattcaggg tgaccaggat	120
ggcgaggagg gatctgtgtc actgttagta ctgtgcccaag gaaggctggg tgaagtgacc	180
atctaaattt caggatggtg aaattatccc catctgcctt aatgggctta cctcctctt	240
gccttn	246
<210> 61	
<211> 395	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(395)	
<223> n = A,T,C or G	
<400> 61	
ggcacgagct tgcttccctc tcaccctctg cagttccnn nnnnnnnnnn nnnnnnnnnn	60
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	120
nnnnnnnnnn nnnnnnnctc catatcgtaa actgccttg aaccaattac cactaccagg	180
gagacaaaact attgcttaga ggatgctgac aggagcagca tgccaaaatt ggaagaagga	240
gaaagttaa gctctcctca ctatgagttt tcaagtataa aagactttt cttccacgat	300
tttggagaaca actgaggact cttgtgacca ggacaacagg gaagcttgca gcaagatagc	360
tccagggttgg attcatgctt cgccacccaa aggct	395
<210> 62	
<211> 387	
<212> DNA	
<213> Homo sapiens	
<400> 62	
ggcacgagc ttgcggggca ttatgactag agggttgggt aaaattcaga cagaatgtaa	60
cttgcacaaag agaagacacgc aacaactgtaa acaattatct tatgaatatt tgcaactc	120
aaaggatct gattgggtac ctctggctt tatcaaatta acatcacaac ttctagaaga	180
aagtcaacct tcatcttttta caatagaaat catatgtttt gctaaccat tcctatttt	240
gctgaaaaca attaagagtt atgggtactt aaaaaaatca ttatgtttttaaaatttagt	300
atagaaggag catagtgttc tatacagtca cacacataca cttccttatt tcttttattt	360
aaacttttagt taacatagca gtctatg	387
<210> 63	
<211> 401	
<212> DNA	
<213> Homo sapiens	
<400> 63	
ggcacgaggg aaactgtatg acaggagaat gaatcagggtt tggggctcaa ggtgccggcc	60
actggggaaa acagctgccc cgagttgcaa aactctgggt cctatatgtaaactatgc	120
cctgaggaag gaatctcagg cgtatcttag gagaaaaatgt tctagcttgg gaaacaaaca	180
caacaggacc gtgaatccaa atattcaag tgggtttttaga ggactggagt tctaaacgct	240
gttttactg taagtgtatca cgcccccggaa tttgtctgaaagaaat gagccagttat	300

cggcaggac tatgggcaag gaaaacgaga gtgtgcgtat tgtcaaagca agacatctgt
gtatagtaat ataaccaagt aatagatgt catagaatca a 360
401

<210> 64
<211> 274
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(274)
<223> n = A,T,C or G

<400> 64 60
cacgcacccg cctgtgtgtg tgcgcacaca cgctccctct ctctatagac agacacacac
tgcgctcg ctctctcttt tggcgctc ctccgtgtc cccccctetc tctctttttt
ctctatatnn nnnnnnnnnn nnnnntctga gagctcgcbc gtcagcgtt ctattcacac
gcgcgttttt ttatata tattttgtgc gcgcgggggg gggcgcacac actctcttt
tttgtgggt tcgctgtccg cgtccctcct ttg 120
180
240
274

<210> 65
<211> 279
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(279)
<223> n = A,T,C or G

<400> 65 60
cccttttttt tatacaccccc cccttgcgtg tctgttttggt gtgtctgccc cccttctctc
gttgtatct ccctctctct tttttctccc cccgcgtct ctctctcttg cggggaggct
cacataccccc ctctctctct ctttttgaa ccacacattc cgtttctttt ttttttatct
ctaccctct ctgcgtgtgta ccccccacan nnnnnnnnnn nnnnnnnnnn nnagagtag
atggcgttc cccactctcc nnnnnnnnnn gtgggggtgc 120
180
240
279

<210> 66
<211> 311
<212> DNA
<213> Homo sapiens

<400> 66 60
caaaacaaaa attaaaaatg accccccctt aaaattttag ggggtccatt tttaaaaacc
ttaacagttt aaagggttctt ggtagtttgg gggacccca ctttagatg ggagcaaaaa
aggggatttt tttccaacat agcgagcggt ttagatttt tttgtccctt tagatgtcc
ctgtgcacca cgcacccacc tccagaggtc ttctttttt acacacccctg tctgggggtg
tttctcagaa gattaacaca ggcgcgtgggg gtttaaggga ggggtgacct cgcaggaca
ttatgggct t 120
180
240
300
311

<210> 67
<211> 386
<212> DNA
<213> Homo sapiens

<400> 67 60
ggcacgagg aatctcaggc gtatctttagt agaaaatgtt ctagcttggg aaacaaacac
aacaggaccc tgaatccaaa tatttcaagt gggtttagag gactggagg ctaaacgctg
cttttactgt aagtgtatcac gccccggaaat gtgtcgatgt aaggaaaaatg agccagtatc
ggcgaggact atgggcaagg aaaacgagag tttgtcgatgt gtcaaaagcaa gacatctgt
tatagtatata taatcaagta atagatgtc atagaatcaa gctgtatgtat ttggcagggg
ccgcggggagg atgaggcaac tcccatcaga ttagaaagat gttacactg taacaaaagt
qqqqctcqag qaagggggaaa agcgca 120
180
240
300
360
386

<210> 68
<211> 396
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(396)
<223> n = A,T,C or G

<400> 68

ggcacgagga	ggcagctgcc	tttgttgcc	atggatgggt	aggggctgca	ctgagcagca	60
cccggttct	tcatccgct	gcaccccaa	cagacttct	tcttccccag	atccctttta	120
cagttggatt	ctcccttgg	gatctggctc	tgccttagtc	cgacctagag	ggatcagctt	180
cgcccacgcc	cactctcacc	cggaacctt	catcttttat	tgaaggcttt	taggcccatt	240
gggatgttca	ttagaactct	gaaaactaca	gttctccctt	ttatgaggac	tgcaccacag	300
ctcgccctct	cctgggttcc	gcctgggtgc	agagtgagcc	catggacag	ccctctgaaa	360
ttatactgtt	tacaaccatg	ctgagtcgtc	aaggan			396

<210> 69
<211> 397
<212> DNA
<213> Homo sapiens

<400> 69

ggcacgagtc	ttagtcaaca	tggacaacaa	catcattca	cattacagca	accacgtcgc	60
cttcctgctg	gacatggggg	agctggacgg	aaaaattca	atcatcccta	aggagctgta	120
aggcctctcg	agcatccaaa	ccctcacgac	ctgcaagggg	ccagcaggga	cgtggcccca	180
cgccacacac	aacctctcca	catgctcag	cgctgttaact	tgaatgcctt	ccctgaggga	240
agaggccctt	gagtcacagenta	cccacagacg	tcagggccag	ggagagacct	agggggtccc	300
ctggcctgga	tccccatggt	atgcttgaat	ctgctccctg	aacttcctgc	cagtgcctcc	360
ccgtacccca	aaacaatgtc	accatggta	ccaccta			397

<210> 70
<211> 394
<212> DNA
<213> Homo sapiens

<400> 70

ggcacgagcc	aaacctagca	aaaaacgggg	ttcacaagcc	atggtcgggg	tccgggggggg	60
acagaaatgg	attttcttgg	caataagcgg	actctggac	tccggctccc	taccccaaac	120
tgaagcgtt	ccgtgaacac	ccccgtcctc	cgtagggggg	ggggagcagg	cgggatcctg	180
ggtcctcat	aagcacttttgc	gttttaccgc	ctgcaacctc	actgtgcccc	ccccgcacca	240
tgccttagcc	ccaggtcttag	ccgggccccat	tgcagggggc	agcacttggg	ggcatctccg	300
gcacttgggt	gggaccaagg	agatgccacc	atagaccttt	ccctcgccctt	tttcctccct	360
agtccgggtt	ccattctttt	caccagcacc	catc			394

<210> 71
<211> 389
<212> DNA
<213> Homo sapiens

<400> 71

ggcacgagga	aagttaagca	tctacagggtt	atggctttgg	gagttccaat	atcagtctat	60
cttttattca	acgcaatgac	agcactgacc	gaagaggcag	ccgtgactgt	aacacctcca	120
atcacacagccc	agcaaggtaa	ctggacagtt	aaaaaacacag	aagctgacaa	catagaagga	180
cccatagcct	tgaagtttgc	acaccttgc	ctggaagatc	ataacagtta	ctgcatcaac	240
ggtgcttgtt	cattccacca	tgagctagag	aaagccatct	gcaggtgtct	aaaattgaaa	300
tgccttaca	atgtctgttc	tggagaaaaga	cgaccactgt	gaagcccttg	tgaagaattt	360
tcatacaaggc	atctgttagag	atcagtgtag				389

<210> 72
<211> 396

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(396)

<223> n = A,T,C or G

<400> 72

ggcacgaggc ctggcccac acgcgggcag caggatctct gtgtgtca	ccagccccagt	60
gtctgtatgtc agctataatgt ttggaaagcag ccagtccttc	ctgcactcca gcaactccag	120
ccatcagtca tcttccagat ccttggaaag tccagccaac	tcttcctcca gcctccacag	180
ccttggctca gtgtccctgt gtacaagacc cagtgacttc	caggctccca gaaacccccac	240
cctaaccatg ggccaaccca gaacacccc	ctctccacca ctggccaaag aacatgccag	300
cagctgcccc ccatccatca ccaactccat ggtggacata	cccattgtgc tgatcaacgg	360
ctgcccagaa ccagggtctt ctccacccca gcggan		396

<210> 73

<211> 386

<212> DNA

<213> Homo sapiens

<400> 73

ggcacgaggc cacctgttgc cctaacaccc tgcgtgactc tctccgctg cagcagccag	60
tccctcctgc actccagcaa ctccagccat cagtcatttt ccagatcctt gaaaagtcca	120
gccaactctt cctccagcct ccacagcctt ggctcagtgt ccctgtgtac aagacccagt	180
gacttccagg cttccagaaa ccccaccta accatggcc aacccagaac accccactct	240
ccaccactgg ccaaagaaca tgccagcgc tgcccccatt ccatcacca ctccatggtg	300
gacataccca ttgtgttat caacggctgc ccagaaccag ggtttctcc accccagcgg	360
accccaggac accagaactc cggtca	386

<210> 74

<211> 390

<212> DNA

<213> Homo sapiens

<400> 74

ggcacgagct cagatccggg gactgcggat aaatggcctt aggccgcggg cagcgagatg	60
ttgcgttccg gtgtgggtgt gggtgtgcct ccgacggcgt ctcgggtcca gtgtcgaggt	120
tctttctgtc tagtaccccg gagccacta cggaggagga cacctgagtt tacgtctttt	180
ccatctgtc ctcgcctcag ctgcctgggt ccccgacgag agccaggta cacttaactc	240
cgccatctgc gttttgagca ctgttctcat aatggagttt cctgatttg ggaaggattt	300
ttcagaaaag acttgcaagc agctagattt tttccagta aaatgtgatg catgtaaaca	360
agatttctgt aaagatcatt ttccatacgg	390

<210> 75

<211> 399

<212> DNA

<213> Homo sapiens

<400> 75

ggcacgagaa atggccttag gccgcggca gcgagatgtt gcgttccgggt gtgggtgtgg	60
gtgtgcctcc gacggcgtct cgggtccagt gtcgagggttc tttctgttta gctacccgga	120
gcccactacg gaggaggaca cctgagtttta cgtcttccat atctgtgtc cgcctcagct	180
gcctgggtcc ccgacgagag ccaggtgaca cttaaactccg ccatctgcgt tttgagcact	240
gttctctataa tggagtttcc tgatgggg aagcattgtt cagaaaaagac ttgcaagcag	300
ctagattttc ttccagtaaa atgtgatgca tgtaaacaag atttctgtaa agatcatttt	360
ccatacgtct cacataagtg tccgtttgca ttccagaag	399

<210> 76

<211> 386

<212> DNA

<213> Homo sapiens

<400> 76		60	
ggcacgagca aaggctcgca	gccccccagaa accccggctcc	gagcggcggc ggcccccgtt	120
ccgctgccc	tgagctaagg acggctcgct	cccttatatcc agctccgaat	180
gcggggggcca	ggggcccccgc	gcctcccccgc tgaggaccga	240
agccgcttt	ctaaaacatt cataccaaag	aagaatatcc ctgatggatc	300
gaactctaa	aacatgcaga	tcatcaatgc ggaactctta	360
ttgcctgagg	gagaggatct	aatgtatgg agtgcgcga	386
cagcaacaac	atgggttttg	acacctgggg attctttac	
ggaact			
<210> 77			
<211> 395			
<212> DNA			
<213> Homo sapiens			
<400> 77			
ggcacgagc catctccaaa	tactgcggtt gttcagaagc	tcttagtttg tgggctgtcc	60
ttgttatttc	acttgaccat	ctgtacaaca ttacctgtgg	120
tttcaagcta	cagcttcgtg	agtacaacat tgatgagcat	180
gccagaccca	aatactattt	tttttttttttcaatgc	240
tttggttca	gagggtatga	tgcatggacg ctagctgtat	300
agaattcaac	aaatagagat	ccattaataaa tgctgcaggc	360
cagacagtc	tttggctcaa	cgaaaatgga gcagctcgct	385
		gggacttaat ttccaatttg	
		ttccaatgtt tggaatatt	
<210> 78			
<211> 389			
<212> DNA			
<213> Homo sapiens			
<400> 78			
ggcacgagc aggccggat	gttcgtccctg	gtggaaatgg tggacaccgt	60
ccttggcagt	tttagaggaa	ccggatcccc gctcaacgac	120
gccaacaagg	tcgtgtacaa	tccattgccc aggagctgaa	180
gaggatgcct	atgtattccc	caagaagtgg cgatggactc	240
gtgggttttc	atccattctt	tgcatttgc tgtttgatata	300
gaaggagtg	acgtctctt	ccacaaactg cccatggatggc	360
cagcagccag	ccaagttcga	ccaaagtccat tttcgctgc	389
		ctgcagccca agatcaaagg	
		tcatcccccc agagtcactg	
<210> 79			
<211> 365			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> misc_feature			
<222> (1)...(365)			
<223> n = A,T,C or G			
<400> 79			
ggcacgagaa aacatttcat	cttgattttt	attaaggta tatgtatgtt	60
tgtataatac	acatttgcac	acttaacagc	120
gatgtatctg	tgacctcaac	tttttttttgc	180
ttttatcccg	cccccccccc	tttttttttttgc	240
nnnnnnnnnn	cccccccccc	tttttttttttgc	300
nnnnnnnnnn	cccccccccc	tttttttttttgc	360
caggggcgga	atctgggtt	tttttttttttgc	385
ctcac			
<210> 80			
<211> 376			
<212> DNA			
<213> Homo sapiens			
<400> 80			
ggcacgagct ggaaaccaggc	ccctaagctg	cttcacccattt ctcactagcc	60

agcctctccc	acggccccc	cagtttcttc	aaatacaccc	cctccactat	tcaccatact	120
gccaccgtga	tttatTTACA	actTTTGTc	cgattacCC	cAGTAGCCT	ctaATTGTC	180
ccttgcac	taaAGTAGCC	cCTCtCATCC	CCCAAAATCTT	accATGTCAC	tCTTCTACAT	240
aattctggct	ttccatgacc	cataAAACCAC	atttCTCAAG	tGTGCTCTAT	GTGGCTTGA	300
atATGTTAAT	gATCTTAATT	CTACTTTAG	TGCAATTTC	TTAGAGCTGG	CATCACTTTC	360
atcatgacgt	gagaac					376
<210> 81						
<211> 384						
<212> DNA						
<213> Homo sapiens						
<400> 81						
ggcacgagag	gattgtgtga	aattgtgcaa	atgcataaat	gtgggctggg	atagtAAAAG	60
ggaggggcccc	ggagcagcccc	acctggggtc	ctatcttagta	gacgcggcccg	gtgcccaccc	120
attgtgtga	tgccagcagc	ccactycaag	catccttcc	ctttccaagg	ttctgtctgg	180
tacatgaata	ggtgtggcag	gggtgggggc	tcctgaagac	caactagggg	tactaggggac	240
cttagactct	tgcagagacc	tgcaccccat	atcaggtggg	gtcaatagat	aaataccccc	300
gcctccttgc	cccttagttc	tgggtgtgtg	ggcaagttag	aggaactgtt	cttctcacac	360
tttcacgtgc	tctcggtgga	gatc				384
<210> 82						
<211> 383						
<212> DNA						
<213> Homo sapiens						
<400> 82						
ggcacgagca	aaggctcgca	gcggccagaa	acccggctcc	gagcggcggc	ggcccggttt	60
ccgcgtcccg	tgagctaagg	acggtccgct	ccctcttagcc	agctccgaat	cctgatccag	120
gcggggggcca	ggggccccc	gcctccctc	tgaggaccga	agatgagctt	ccttccagc	180
agccgcttct	ctaaaacatt	caaaccaaag	agaataatcc	ctgaaggatc	tcatcagtat	240
gaactcttaa	aacatgcaga	agcaactcta	ggaagtggg	atctgagaca	agctgtttag	300
ttgcctgagg	gagaggatct	caatgaatgg	attgtgtga	acaactgggg	atttctttac	360
caggatcaca	atggtaatat	ggg				383
<210> 83						
<211> 358						
<212> DNA						
<213> Homo sapiens						
<400> 83						
ggcacgagca	gggcccgcgc	gcccgtatca	agcaccgcctt	ccccaaagggc	taccggcacc	60
cggcgttgc	ggcggggctt	ggcagacggc	ggacgggtca	ggaggcccgg	gcccgttcc	120
gctgtcgccg	cgctggata	tctccccag	ttgtctttt	tgtggactat	gttccaact	180
gcttatataat	ggaagaaatt	gaaggcttag	tgactgttc	agattatatt	cagtccacta	240
tggagactga	aaaaaaactcc	ccagggtctc	tccaacttag	ccaagacaat	tggcaggtt	300
ttggctcgaa	tgcacgtata	agacccatt	catggtgatc	tcaccaccc	caacatgc	358
<210> 84						
<211> 338						
<212> DNA						
<213> Homo sapiens						
<400> 84						
aagatggctg	agagggacag	aatgtttat	tttggagaga	aacaatgttc	taggtcaaac	60
tgagtctacc	aatgcacac	tttcacaatg	ggtctagaag	aaatctggac	aagtcttttc	120
atgtggttt	tctacgcatt	gattacatgt	ttgctcacag	atgaagtggc	cattctgcct	180
gcccctcaga	acctctctgt	actctcaacc	aacatgaagc	atctcttgc	gtggagccca	240
gtgatcgcc	ctggagagac	agtgtactat	tctgtcgaat	accaggggg	gtacgagagc	300
ctgtacacga	gccacatctg	gattcccagc	agctgggt			338
<210> 85						
<211> 475						

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(475)
<223> n = A,T,C or G

<400> 85

gtcgctcaat aggcaaggagt ccatcgattc gaattcgca cgagnnnnn nnnnnnnnn
nnnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn
nnnnnnnnnc gctccactgt gcactcctga cacatactt ccccgctaca ctctctattc
tccccctctt gtgtctctc tctatagcg tagatagaga gccctgtgt tagataataa
acgtgtgtgt gtgtgtaa aaggagacac aaacacgccc acnnnnnnnn nnnttgggc
cttttttctt tttgagccct ttggggaaaa aaccgggaa aacacagccc tacccactat
ttggggcgcg ccaaaaaacc ttctttaaaaaaa aaatgtgtt aatgttaaa ttttttagga
acannnnnnn nnnngcaaaa aatagcaccc caaaagcagg gtttttacat ttttgc
60
120
180
240
300
360
420
475

<210> 86
<211> 467
<212> DNA
<213> Homo sapiens

<400> 86

gagcgatttt ctgcaggattt ctatcgattc gaattcgca cgagccatgg tctcagttag
ggcttggaaatt tacagagaag ttggccagg ggttccacca tgctgccagt cagtttggga
aggaaaacaga gaagctcgcc catggggtcc accatgggt taatgaggcc tggaaggaag
cagagaagtt tggccagggt gtccaccatg ctgcctcgca gttggggaaag gaggaagaca
gagtggttcca aggctccat catggcgtta gtccaggctgg aagggaggcg gggcagtttgc
gccacgacat tcaccacaca gcagggcagg ctggggaaaga gggagacata gcagtcatg
gtgtccaacc tggggtccac gaggccggga aggaggcagg gcaatttggc caggagttc
accataccct tgaacacaggcc gggaaaggaag caaacaaagc gttccag
60
120
180
240
300
360
420
467

<210> 87
<211> 449
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(449)
<223> n = A,T,C or G

<400> 87

cgggggtggga aaccngannt tnannaancg gacggattct cccgttccga atagcctttt
acagaagatt cttcacagct atgtgcctga agagatcang gatggaaatc aagttcgagt
tacctcatgg gatggcagga aatggggaga actggagggg gacacctatg accgggtgct
ggtggatgtg ccctgtacca cagaccgcca ctcccttcat gaggaggaga acaacatctt
taagcggtca aggaagaagg agcgacagat attgcctgtg ctgcaagtgc agtttcttgc
ggctggactc cttgccacca aaccaggagg ccatgttgc tattctacct gctcaactc
acacttacag aacgagttatg tggtgcaagg tgccatttag gtcctggca atcaatacag
catccaggtca caggtggaaat atctgactg
60
120
180
240
300
360
420
449

<210> 88
<211> 439
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(439)
<223> n = A,T,C or G

<400> 88
 gtagtgtatg tgcagcctcc catcgattcg aattcggcac gagatcccct cttatatgtat 60
 gccccagccc aggagagata aaagcatcg caccatgaga ttcacctgcc tctggtcgtt 120
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240
 nnnnnnnnnn actcttagac agcaaaaatg ctttctccca gtcttggtcc ctgtttctca 300
 gttcccaccc tgcctggata actactgttc ttggtttnnn nnnnnnnnnn nnnnnnnnnn 360
 nagtctcgta ccagattcaa aaatcagtca actacttcaa aaacaatgac atgctggcta 420
 cttagataga agaggaggc 439

<210> 89
<211> 436
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(436)
<223> n = A,T,C or G

<400> 89
 ggcacgagca tcaaataatgt aatatacgat ttatgctgga aatgtcaacc tccctggcag 60
 ctgttaacgcc catcattgaa agggaaagcg gaggacacca ttatgttaat atgactttac 120
 ctgtcgatgc agttatatact gttgctccag aagaaacatg gggaaaaagtt cgtaaactcc 180
 tggttgcattgc aattcataact caactaactg acatggaaaa atgtatTTTaaatataatga 240
 aaggAACATC tattgtggtc cctgaaccac tgcaactttt attaccaggg aaaaaaaaaatc 300
 ttgttacaat ttcatatcct tcagaatac cagatggcca gctgcaggcc tataggaagg 360
 agttacatga tctttcaat ctgcctcactg acagacccta tttcaaaagg tctaattgttt 420
 atcactttcc agatgn 436

<210> 90
<211> 437
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(437)
<223> n = A,T,C or G

<400> 90
 ggcacgagag atcatgcact accacatgca gcacgagcag taccggcagg tcatacgcgt 60
 gtgtgagcgc catggggagc aggacccctc cttgtggag caggccctca gctacttcgc 120
 tcgcaggag gaggactgca aggagtatgt ggcagctgtc ctcaagcata tcgagaacaa 180
 gaaccttcatg ccaccttc tagtggtgca gaccctggcc cacaactcca cagccacact 240
 ctccgtcactc agggactacc tggtccaaaa actacagaaaa cagagccagc agattgcaca 300
 ggatgagctg cgggtgcggc ggtaccgaga ggagaccacc cgtatccgccc aggagatcca 360
 agagctcaag gccagtccta agatTTCCA aaagaccaag tgcagcatct gtaacagtgc 420
 cttggagttg ccctcan 437

<210> 91
<211> 437
<212> DNA
<213> Homo sapiens

<400> 91
 ggcacgagct tcagtcttat gtcatttact cttaggaca acctcttggaa aaactaaatc 60
 atttcttgc aggtgttgaa gctcgctgg cacagggcat aaggaggagg gaagtaagt 120
 accaacttgc atttaacaaa caagaacttc gtaaagtcat taaggagtac cctggaaagg 180
 aagtaaaaaaa aggtcttagat aacctctaca agaaagtgtg taaacattta tgtgaagaag 240
 agaacttact tcaggtgggtg tggcaactcca tgcaagatgtg atttatacgc cagtataagc 300
 actttgaagg tttgatagct cgctgttatac ctggatctgg tgttacaatgt gaattcacta 360
 ttcaaggacat tctggattat tggtccagca ttgcacagtc ccactaaacc ttgtgaaaga 420

agaaaagata actgaat	437
<210> 92	
<211> 427	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(427)	
<223> n = A,T,C or G	
<400> 92	
aacggctt ctnctttga ggagcccatc gagtcgaatt cggcacgagg cgagtctctg	60
ggtcgcacg ggaaggagtg aaacacctct ctgcgcctgc gcgcctcggtg cctgcgaagc	120
aaacctccggcc tcaccttttc ctgcccgaag cagaagattc tcgcaggcct ggtttctccc	180
tccagaagac cccccaccca aatcccttgt agtccttggg agtgccttga cccctgtgc	240
caccgtcctt cagagagcaa cggaagagct tcccgaggg cgagaaaaag agggaaaagta	300
gccagcaatg tcgaaacgcag tgtataataa gatgtggcat cagacccaag aagccctcg	360
tgctttactc gatgaagagc ctcagacgtt gattgaacca cacagaaatc aggttttcat	420
ctttcaa	427
<210> 93	
<211> 429	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(429)	
<223> n = A,T,C or G	
<400> 93	
gtgacgatcc catcattcaa ttcggcacga gtcacagcc aaagttcctt ctgccccca	60
gctgagagtg cttgatacac ccttgaatcc cctttatat gatgcggccag cccaggagag	120
ataaaaagcat cagcaccatg agattcacct gcctctggc gttagggAAC aatggaggcc	180
tgcattttgg agttaaactc tcagtgtatct ctgtgttgac aacaccaaaag cttagaggaat	240
ccagtaggat gtgggcattgg ttttccggaa aggctgactg agcaggcttg caaatgtttg	300
caagtacagg gcagaatttc atccagcctc agaaccttga gccaaagactc agcatcagca	360
aagccaaaag tttcattttc tcgactgtgg gagtgctagt cccaacctt agatggccat	420
tcagttnta	429
<210> 94	
<211> 421	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(421)	
<223> n = A,T,C or G	
<400> 94	
ggcacgagat tatttacttg gtgtgtggtc accactgttt tttaaatgag tgttttcatt	60
tgtatcaaac tggacactgtct ttcctcaagg attgccccaa aggagacaca aatttactaa	120
acacttatca ataatacgttcc accgtgcttag gcaatttcca tataacttata atttaatcc	180
cacaataact ttgaaagaca gaaagtattt tctctgannnnnnnnnnnnnnnnnnnnnnnnnn	240
nn	300
nn	360
nn	420
atcctctgtc tccaaaggct gtacttcatt caggacactt tcccccacat	421
tttagaaaagc tgtaattatc ttccagtgag acagcatagc acatgtgatc actgtccctt	
c	
<210> 95	

<211> 421
 <212> DNA
 <213> Homo sapiens

<400> 95

```

ggcacgagat gagaagataa aattcagcgt tggccttag actttccat ccttaaggag   60
tgcacggaa gc caagtgaaca agcctcagtg acacaagtca aattcatagt ttcaactctgg
gtttttgtt gttgtgttgt tattatttc actacagaaa gactgagtt catgcctcg
gctatgtcag atgtgaattt tcatggtaa ctggacagtt aacaaaacag aagctgacaa
catagaagga cccatagcct tgaagttc acacccttgc ctggaaagatc ataacagtta
ctgcatcaac ggtgcttgc cattccacca tgagctagag aaagccatct gcaggtgtt
tactggttat actggagaaa ggtgtctaaa attgaaatcg cttacaatg tctgttctgg
a
  
```

<210> 96
 <211> 418
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(418)
 <223> n = A,T,C or G

<400> 96

```

tggatccatc gattcaattc ggcacgaggt tatttttaag aactttgct tactatattg   60
gatttacctg cggtgtgagt agcttaaat gtttgcgtt atacagataa gaaatgctat
ttcttcgttgg ttcctgcagc cattgaaaaa ccttttcct tgcaaattat aatgttttg
atagattttt atcaactgtg gggaaacccaaa cacaagctg ataacccccc ttaaaaaacga
cccagtcaaca gtaaagaaga cacaagannn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnng
  
```

<210> 97
 <211> 418
 <212> DNA
 <213> Homo sapiens

<400> 97

```

atgctacatt gctactttgt tgcattgatc gccagacgac cactagatc gaaactgagc   60
gcgagatgtt gaatctgtgt gttatgaaaa tgcattgtac cagtataaaa tgacattctc
tattaataac atctgcgggtg cgacacacat aattgtccca atttttaata ttgatgggaa
gcatgaagca ttttttaat gtgttgcag gccccattaa atgcataaac tgcattaggac
tcatgtggtc tgaatgtatt ttagggctt ctggaaattt tcttgcacaga gaaacctcagc
tggacaaggc agcctgtatc tgagtggact aactgacaca atgaaactgt caggcatgtt
tctgtccctc tctctggctc ttttctgtt ttttgcgtt ttttgcgtt gtcttcgtc agggaggg
  
```

<210> 98
 <211> 417
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(417)
 <223> n = A,T,C or G

<400> 98

```

catcgatcg aattcggcac gaggccaagt ggacaggcca tagccccac agactggagg   60
gacgcccgtt gggaaatgtcc cacagagtgg ccaggatcc ctgagagaaa gagcagggtt
tagcggagac tctggggctg ctttagaata tggtgggtgt gtggggcaaa agggacaccc
aggggtgtat caagaggtca tnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
  
```

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnn	360 417
 <210> 99	
<211> 416	
<212> DNA	
<213> Homo sapiens	
 <400> 99	
ggcacgagct acctcagccc tgctccagga gacaccagca gctgggccag tggccctgag agatggcccc gaagggagca tgtggtaca gtcagcaaga ggaggaacac atctgtggac gagaactatg agtgggactc agaattccct ggggacatgg aattgttgcac ctgggcttgg ccagctcccg gctcagacct gaagctgagc cagagctagg tgtgaagact ccagaggagg gctgcctcct gaacactgcc catgttactg gccctgaggc ccgcgtgtc gcccttcggg aggaattcct ggccttcgc cgccgcccag atgctactag ggctcggcta ccagcctatc gacagccagt cccccacccc gaacaggcca ctctgttg aacatt	60 120 180 240 300 360 416
 <210> 100	
<211> 417	
<212> DNA	
<213> Homo sapiens	
 <400> 100	
ggcacgaggg aaaatgttagg ctaccatgg aaaatgacat tctctattaa taagatctga ggtgcgacac acataattgt cccaaatttt aagattgtt gggagcatga agcattttt taatgttgtt gcaggccccca ttaaatgcat aaactgcata ggactcatgt ggtctgaatg tattttaggg ctttctggga attgttgcata cagagaacct cagctggaca aagcagcctt gatctgatgt agctaactga cacaatgaaa ctgtcaggca tgttctgtc cctctctctg gctctttct gcttttaac aggtgttttc agtcaaggag gacaggttga ctgtggtag ttccaggaca ccaaggtcta ctgcactcgg gaatctaacc cacactgtgg ctctgtat	60 120 180 240 300 360 417
 <210> 101	
<211> 412	
<212> DNA	
<213> Homo sapiens	
 <220>	
<221> misc_feature	
<222> (1)...(412)	
<223> n = A,T,C or G	
 <400> 101	
ggcacgagga aagtaaacgt gtatctcttg ttcattttta tagaactttt gcatactata ttggatttac ctgcgggtgtg actagcttta aatgtttgtg tttatacaga taagaaatgc tattttttc tggttctgc agccattgaa aaacatttt ctttgcataat tataatgttt ttgatagatt ttatcaact gtggaaacc aaacacaaaag ctgataacct ttctaaaaaa cgacccagtc acagtaaaaga agacacaaga nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn	60 120 180 240 300 360 412
 <210> 102	
<211> 414	
<212> DNA	
<213> Homo sapiens	
 <400> 102	
ggcacgaggt cttgctcaca tggctacta ctctctccgt gatgtcactt gtcacccctca ccagccctcc tttctccaga tggcttcttc ataaccacca ggtcagaaga ggatccgttc caatgattt cctaaaacaa tggaaagtgtt ttccaaagag cttataaggc attgttaggat ctggcctgcc ctgactccac ttaccagaa ccatctgtc ctcttctc ttgtgttact caaggattt gctgctgtgg caaatcaact ctgaaatctc cgtgacttaa tacaagagag gttattttct tactcacgtt ggggtcactg ccacttgta acagaggagc tatggaaact tgagacctaa gcagaaatga gttcaataat attgtcacac tctaggactt tctc	60 120 180 240 300 360 414

<210> 103
<211> 410
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(410)
<223> n = A,T,C or G

<400> 103
ggcacgagga agagccggga ggtatgtattt gttgttagga aaatgttaggc taccagttaga 60
aaatgacatt ctctattaat aagatctgag gtgcgacaca cataattgtc ccaattttta 120
agattgtatgg ggagcatgaa gcattttttt aatgtgttgg caggccccat taaaatgcata 180
aactgcata gactcatgtg gtctgaatgt attttagggc ttctggaa ttgtcttgac 240
agagaacctc agctggacaa agcagcctt atctgagtga gctaactgac acaaatgaaac 300
tgtcaggcat gtttctgtc ctctctctgg ctctttctg cttttaaca ggtgtcttca 360
gtcaaggagg acaggttgac tgtgtgtgagt tccaagacac ccaaggctan 410

<210> 104
<211> 411
<212> DNA
<213> Homo sapiens

<400> 104
ggcacagat acgaatgggg tgtatTTTC gactgctcg aggcccccc aggttatgtg 60
gacagagcta agccaaagt tgtgatTTTc cactctgttc tgtccatgtc gaggaaagat 120
aagttagaaag tgacacagta agagccagaa tacaccaggta gaaggagaga attgcattgt 180
gttttgagaa gtttcaactga caagttatcc tgggctgtgg gacatcaacta gctttgaaag 240
tgttagctggc acctcggtcca tctaatttga tgggtgtgtg tgggtgttg tgcacgcgtc 300
ggctcaacat atctgaaccc aggtgatttc tggcttcagg acgcttttag gtgacaaggaa 360
tcaggcatgt gaacaaataa ccatactgt aagctggctg tgctgggtct c 411

<210> 105
<211> 413
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(413)
<223> n = A,T,C or G

<400> 105
ggcacgagga agattctcg agtcctggtt tctccctcca gaagcccccc cacccaaatg 60
ctctgtatgt cctggtagtg ccctgacccc tgctgccacc gtccttcaga gagcaacgga 120
agagcttccc ggagggcgag gaaaagaggg aagtagcca gcaatgtcga acgcaatgt 180
taataagatg tggcatcaga cccaaagaagc cctcggtgt ttactcgata aagagcctca 240
gaagatgatt gaaccacaaa gaaatcaggt tttcatctt caaacattag ccaccttcta 300
cgtaaaagtat gtgcagatct ttagaaacct agagaatgtc tacgaccagt tcgtccaccc 360
ccagaaacgaa atactgatca gaaaaatcct ggacggngtg atggccgca tcc 413

<210> 106
<211> 412
<212> DNA
<213> Homo sapiens

<400> 106
aggatccat cgattctaat tcggcacgag ctccataagg cagaggtctt tgcgaggacg 60
ccggcgtgga ccacgagacc gcccattgtat tgctggaa caagaattcc ttatcttgg 120
aggcagtgaa acgactaata gctaaaggtt atacagaaga actacgaaaa tgttttgggg 180
tccgaatgga gtttgtgaca gctggcctcc gagtgcata gggacctgga atttctcgta 240
tgaatgactt gaccatcatc cagactacac agggattttt cagatacctg gaaaaacaat 300

tcagtgactt atagcagaaa ggcacatccgga tcagttatga cgcccgagct catccatcca	360
gagggggttag catcaaaagg tttgcccgac ttgctgcaac cacatttac ag	412
<210> 107	
<211> 408	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(408)	
<223> n = A,T,C or G	
<400> 107	
ggcacgagga aaaaccagtt tctctttat tgtctgttac taatctctat tctaaagatt	60
cagctcaatt ctcaaccata ctccaaactc tctctttcc agtacacctt actccctctc	120
cttcaattcc actttcctct gcttacnnnn nnnnnnnncnn nnnnnnnnnnn nnnnnnnnnnn	180
nnnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnngnn	240
nnnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn	300
nnnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn naatgtttt	360
tttcattaaa gagagaaaatc acctattcag gaccggcccc cacctttg	408
<210> 108	
<211> 405	
<212> DNA	
<213> Homo sapiens	
<400> 108	
ggcacgaggc ttacagggg gaccagggcc cttcctaact cgaccgcatt tggattgggt	60
gctggcttgg gagggaggct gtccgatgct gacattcccc ttaacatggc cctgaccgtg	120
gctgtcaggc gccaccttgc ctcaccaggc cagccccact ggaaatgggg tcagtcacag	180
cagaaccgtc caaagggtgga cctgatgtgg gcccgtccgg gggcgcttgg cctcagcggg	240
ccatggaga cccagtaaaa cgactcttagt gtgaggcagt ggtccctgcca ctgactgaca	300
aaccctctt gtaagcaaac ttgacaaata atgaatctac tgaactctgt tatagaacaa	360
gctattctg catgaacttc tcttattgaa gcagaagcca cgtca	405
<210> 109	
<211> 403	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(403)	
<223> n = A,T,C or G	
<400> 109	
ggatcccatc gnntcgnatt cggcacgagg caaccagctc gtccagcgcg tggccctgct	60
gctcaaggag cagactgcgt acccccccac acactacate cggagggtgc cccagaggaa	120
gatccactac ttcacgggcc tgcaggcgct tcagctgctg ctgctgtgt cttccggcat	180
gagctccctg ccctacatga agatgatctt tcccctcatc atgatcgcca tgatccccat	240
ccgctatatac ctgctgcccc gaatcattga agccaagtac ttggatgtca tggacgctga	300
gcacaggcct tgactggcag accctgcccc cccccccatc gccagccctc cacgtactcc	360
caagctggct ctggaaactgt gaggggaagg ggaagatgtg tgg	403
<210> 110	
<211> 397	
<212> DNA	
<213> Homo sapiens	
<400> 110	
ggcacgagtc tgcttctgtc actgtcacat agacagccct gcatgcccc tggatgtcacac	60
agggtgtaat gaagacagct cttctcatc ttccataag cctgagatac aagttcagg	120

actcagcaat	gcactttagg	actgagctag	gaggcaaata	tctgaagctt	gctatgctgt	180
tctttccatt	ccttttcct	ctgaacaca	aaaatacca	aaggaactta	cgcaacacac	240
cactgagtcc	tctaactaat	catatgtgct	cagacacagc	tcaagcacac	cccttagtta	300
agaaagaacc	tccatatata	ttaatttttt	tctgcctaaa	aataaaattt	cgttgtggca	360
gcaatttgg	aactacagca	aagtctccaa	aaaaatc			397
<210> 111						
<211> 401						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(401)						
<223> n = A,T,C or G						
<400> 111						
ggcacgagag	ccggtgcctt	caccggccctt	tctcctttta	tcctttttta	aacgctcttg	60
ggggtttatgt	ccgctgttcc	ttgggtgccg	agacatata	atgggtgtct	ccccccagcc	120
ccttcctcc	ccgccttctg	ggaggaggag	gtcacacgt	gatgggcact	ggagaggcca	180
gaagagactc	acaggagccgg	gtgccttcc	gcctggggct	ccctgtgacc	tctcgtccc	240
ctggcccggc	cagccaccgt	ccccagcacc	caagcatgca	attgcctgtc	ccccccggcc	300
agctccccca	acttgatgtt	tgcgtttgt	ttggggggat	attttcata	attattnnn	360
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn			401
<210> 112						
<211> 401						
<212> DNA						
<213> Homo sapiens						
<400> 112						
ggcacgaggg	cagtccagca	acaagccttt	catttacatt	aaattataac	tttctattca	60
ttccctaaacc	aaacttaaaa	ttctgctttc	ctttgagtag	aaggatattt	acttgtttt	120
tttttccttc	agaaggaatt	taatgcaaac	ggattgcagt	cagcacttcc	tgaatgtttt	180
cacacagtat	gcaaagctt	catcatacca	aggagtggag	agttgaagtt	tcctcccagt	240
gactccagtg	acagaccaca	cctagaaagc	gtttctcttc	ctgagttttt	caaaaagatg	300
taaaagagct	ggggagagta	tggaaagaaa	caatacagga	ttgccttta	ttaattaaga	360
atgcctcct	gataaaagga	aaaagaaatt	aatgctggag	g		401
<210> 113						
<211> 401						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(401)						
<223> n = A,T,C or G						
<400> 113						
ggcacgaggc	cccacgggcc	ccatctcccc	acaggcattt	agggttaactt	ggtaggctc	60
ctggagcagg	tgggcacca	ttttgtgg	ggccagccaa	gggaaaagga	ggtgctttag	120
aggaaaagg	cagtggat	gcggagagg	gttgtggaa	aaaggagcg	agccctggag	180
gaggtggaaa	ggccatctt	ggagatgaag	tggaaaggta	gggctgagaa	ggaggcatgc	240
cagcgggaga	aagagctgcc	tgcagcagta	catcccttcc	attttgttta	aattgggctt	300
ggagaatcta	ttctgaaaac	attgactcta	gacttgtaga	anagagccat	ttaattttc	360
acttcaatg	gtaaaagcaa	gggttaattt	gttgacattt	t		401
<210> 114						
<211> 399						
<212> DNA						
<213> Homo sapiens						

<400> 114

ggcacgagag	cagaagattc	tctcagtccct	gttttctccc	tccagaagac	ccccccaccca	60
aatccctgt	agtcctcggt	agtgcctga	cccctgtgc	caccgtcctt	cagagagcaa	120
cggaaagact	tcccggaggg	cgaggaaaag	agggaaaagta	gccagcaatg	tgcgacgcaa	180
tgtataataa	gatgtggcat	cagacccaag	aagccctcg	tgcttaactc	gataaagagc	240
ctcagaagat	gattgaacca	caaagaaaatc	aggtttcat	tttcaaaca	ttagccacct	300
tctacgtaaa	gtatgtgcag	atcttagaa	acctagagaa	tggctacgac	cagggtcgcc	360
accccccagaa	acgaatactg	atcagggaaag	tcctggacg			399

<210> 115

<211> 399

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(399)

<223> n = A,T,C or G

<400> 115

ggcacgaggc	tttttccaaac	tttaaggat	atcaggagag	aagacactct	tgatgtggag	60
gtttctgcca	gtggctcacac	aaaggaaatg	caggcagat	atgaactgt	tcatccatta	120
ggtcagat	ataaaaatata	tgaacaaaaa	gaggatctg	aattctcatt	ttcagatgg	180
gaagtggcag	aaaaagcaga	gttttacagg	tcaaaaaatg	aaagtgaacg	gaactgtcta	240
gaagaatcag	aggcgtcta	ttcagatca	tctggagacc	ctgaacaaat	aaagggaaagac	300
agtttatcag	aagagagtgc	tgatgcacgg	agttttgaaa	tgactgaatt	caatcaagct	360
ttataagaaa	taaaaggcga	ggttgtgaa	aacaactcn			399

<210> 116

<211> 400

<212> DNA

<213> Homo sapiens

<400> 116

ggcacgagcg	gaccggggccg	agccgggccc	ccggggcgca	gtcttaacc	atggcgccc	60
tcttcaagaa	aaaaactgtg	gatgtatgaa	taaaggaaca	aatcgagag	ttacgaggta	120
cacaggggc	tataatcaga	gatcgagcag	ctttagagaaa	acaagaaaaa	cagctggaaat	180
tagaaaattaa	aaaaatggcc	aagattggta	ataaggaagc	ttgcaagtt	ttagccaaac	240
aacttgtca	tctacggaaa	cagaagacga	gaactttgc	tgtaagttca	aaagttactt	300
ctatgtctac	acaaacaaaa	gtatgtgaaatt	cccaaatgaa	gatggctgga	gcaatgtcta	360
ccacagcaaa	aacaatgcag	cgagttaca	agaagatggg			400

<210> 117

<211> 402

<212> DNA

<213> Homo sapiens

<400> 117

ggcacgaggg	gagatcgctc	agctggccgt	gtcctggca	gccacggcat	atgcctccaa	60
ggacggggtc	ctcaactgagg	ccatgatgga	ccctgtgtg	caagatgtcg	tccagcagta	120
ccgacagaag	atgcgctggc	tgaaggcgg	ggggcctgg	cgcgggtcg	agcacccccct	180
atccggagtc	caaggcgaga	ccctcacctc	atggagcctg	gccacggacc	cctccttaccc	240
ctgccttgc	ggccctgtca	catttaggat	atgcctctgg	atggggactg	ggctgtgccc	300
agggcctctg	tcccccaagga	tgtcttgcgg	tggcggtcg	ccgttctgccc	ccccaggggca	360
ccccctgttg	taggcactgg	ctctaggagg	gcaggccccc	tt		402

<210> 118

<211> 395

<212> DNA

<213> Homo sapiens

<400> 118

ggcacgaggt	agagatacga	atggggtgta	gtagccgact	gtcgcaggc	accccccaggt	60
------------	------------	------------	------------	-----------	-------------	----

tatgtggaca gagctaagcc caaagttgtg atttccact ctgttctgtc catgtcgagg	120
gaagataagt agaaaagtgc acagtaagag ccagaataca ccaggtgaag gagagaattg	180
cattgtgttt tgagaagtt cactgacaag ttatcctggg ctgtgggaca tcactagctt	240
tgaaaagtgt a gctggcacct cgtccatcta atttgcgtt tttgtatggg gtgtgtgggca	300
cgcgtcgccc tagcagatc gaaccagggt gatttctgtt ctcaggaagc ttttaggtga	360
caaggatcag gcatgtgaac aaataaccat actgg	395
<210> 119	
<211> 144	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(144)	
<223> n = A,T,C or G	
<400> 119	
ccggtaagga atataacttct tctgatacta aatatgccaa tatttaaat gtaatattca	60
gggattacaa ctgtgagggc taaacacacg gaattaccca ccaattcctc ttagttctc	120
tactaattca atttgcatac ctca	144
<210> 120	
<211> 392	
<212> DNA	
<213> Homo sapiens	
<400> 120	
ggcacgagac caggtcataa gaggatccgt tccaaatgatt ttcctaaaac aatggaaatg	60
ttttccaaag agcttataag gcattgttagg atctggccctg ccctgactcc actttaccag	120
aaccatctgc tgctcttctc tcttgttta ctcaaggat tagctgctgt ggcaaataa	180
ctctgaaatc tccgtgactt aatacaagag aggtttattt cttaactcacg ctgggtgcac	240
tgccacttgg taacagagga gctatggaaa cttgagaccc aagcagaaat gagttcaata	300
atattgctac actctaggac tttccaaa attaacaaca gaacaaaagt gcaaggcagt	360
gataacccat ctgacagcat ttggggagt tt	392
<210> 121	
<211> 395	
<212> DNA	
<213> Homo sapiens	
<400> 121	
ggcacgagat caatcacaaa agtttatcct taagacttcc cttcagctgc tggaggcag	60
tcatcacatc tggaaaaaga gtgcttagtta taacaaaatga gatcacaat ttgaccattt	120
tattagacac cctctattag tggtaacaga caaagatgaa ggttaagttt aaatcaaatt	180
gaaatcatct tccctctgtt cagattgca tatctgataa taccctcaac tttcttgggt	240
caaattaatt gcctggtact cacagtccag tggtaacagg caataatggt gtgattccag	300
aggagaggac tagtggcag gaaaataaat gagatttaca gtatttgatt ggagccataa	360
gcataattt gttccggcgg cggcaggaa taaaa	395
<210> 122	
<211> 288	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(288)	
<223> n = A,T,C or G	
<400> 122	
cccccgcccc tctctgttct ctctcgcccg cgggtctct ctcgatagag tgcgcgaccc	60
gcacacccttc tgggtgggt tctcgctccc cgtgtgcgcg cgccgcgcgt ctctgtggg	120

ctgcacaca ccgcgcgcgc gcgcgtctc tttggggggg ccctccccgc accttgtgt	180
tgtgtgtctg ttttatctt gtggatgtg cgtgnnnnn nnnnnntctgt gtgtgtgtct	240
ccctcccgcc cggtgtctgt tatatatgcg ctgcgtcgct gggcgccg	288
<210> 123	
<211> 393	
<212> DNA	
<213> Homo sapiens	
<400> 123	
ggcacgagga tccattcttc gaccccaaga ttgtactcta aagaaggctg aaaaattttt	60
tccaaattgc catgcagata tcttaacag caggacattt gcaggccctt tctactggac	120
ttttctccca aacaggacaa gcccaggcag ggctgcattt agaggaatgg aacctggac	180
tagaattaat tgcccaactt cccaccctac cagtgcagcc cggcaaggcc aggaatttgg	240
aggcctaagg tgggcatgaa agcttggaa gcaactgtcg tctcagaca ggcgtcctaa	300
agacctctag gctggaaagct tgggcttgca agtggatccg ggaccgaggg tggctctt	360
gacaacccca ggaacttggaa ccaaggcaga gcc	393
<210> 124	
<211> 394	
<212> DNA	
<213> Homo sapiens	
<400> 124	
ccgcgacgag atgatgatct gcttcttcca ttatgccag atgataaaaa ggattgatac	60
aaaagaggga tctgaattct catttcaga tggagaatgt gcccgggggg cagagggttt	120
caggtcgaa aatgaaatgt aacggaaactg cctagaagaa tcagagggtt gctattgcag	180
atcatcttggaa gaccctgaac aaataaagga cgacagttt tcagaagaga gtgtgtatgc	240
acggagttt gaaatgactg aactcaatca agcttttagaa gaaataaaa ggccggctgt	300
tgaaaacacc tctgttactg aattttcttga ggagaaacac cgaacttggaa attcacaccg	360
gcctaattgtc caagaattca aggggggttc cttc	394
<210> 125	
<211> 390	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(390)	
<223> n = A,T,C or G	
<400> 125	
ggcacgagcc cttataaaaa catatatgaa catatataact tttttgttg tataaaaaaca	60
ggatcacatt atagatatta ttctgttaact ttctgtttt accccaaaata cagcagagca	120
ctattttcca gaagcacgta gttctaactt nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	180
nnnnnnnnnn nnnnnnaactt tattcaagta cttcacattt taatggaca ttccattttgt	240
ctgtataat ttacaattt agcaataactt tgagaaagggt ctgtcaagt atatccatat	300
gaactaatgt ctatgttagaa gatatgtgg ctcaaataattt atgtacattt aatgtctt	360
taaacaccgc tagattactt tccaggaagc	390
<210> 126	
<211> 388	
<212> DNA	
<213> Homo sapiens	
<400> 126	
ggcacgaggc cagcacacat tacttaaca ctttggactt gaaattctga aagatcagaa	60
attccttaact gtttggatgtt attaggtttt aggacttagc cattttatct cacatgactc	120
aggccttaat gctccattgc taatagctaa atgtggaaaa gtttagaattt acatthaatt	180
tagtcaactg tttaggctgca atcattttt tttaaaaatc tgcttatggc attattcgag	240
ataacttgac caactctaaa atatatatgt aattacttct agatgtaaatg agtttttcat	300
attaacaaca caatcaggct ctgtttcagt tagttcttag agtggtaaaa aaaaatctt	360

acagtaagtgc	caaaattata	atccaagg	388
<210> 127			
<211> 388			
<212> DNA			
<213> Homo sapiens			
<400> 127			
ggcacgagag	ttaatccaaa	agacttccct tcagctgctg gaaatcagtc atcacatctg	60
tgaaaagagt	gcttagttata	acaaatgaga tcacaaattt gaccattta ttagacaccc	120
tctattagtg	ttaacagaca	aagatgaagg ttaagttgaa atcaaattga aatcatcttc	180
cctctgtaca	gattgcaata	tctgataata ccctcaacctt tcttggtgca aattaattgc	240
ctggtaactca	cagtccagtg	ttaacaggca ataatggtgt gattccagag gagaggacta	300
ggggcagga	aaataaatga	gatttagcagt atttgactt gagccatagg catcaattct	360
gctccagctg	tcgaccaggt	tctaaaaaa	388
<210> 128			
<211> 267			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> misc_feature			
<222> (1)...(267)			
<223> n = A,T,C or G			
<400> 128			
actgtgtgt	tgtctgtttt	ctctctctct cttctcagtc acactttttt tttgggacac	60
accctccatc	cgcggggggg	ttttttccc ggcgcgcgcc cttttttttt gtgtgtttct	120
ctgcgcgcct	ctttttttc	tctctttcc cccccccgtt annnnnnnnnnnnnnnnngcg	180
ggggggtttt	cgcgcgttccn	nnnnnnnnnnnnnnnccttccg cccccccaca ggggggtgct	240
gttttattatc	tttctttctc	cctgagc	267
<210> 129			
<211> 389			
<212> DNA			
<213> Homo sapiens			
<400> 129			
ggcacgagct	tgactgcaaa	cttgctgaag gtagggactg tttgtcttgg acttcgctgc	60
cagtccttag	aacagtgtct	gggacacagt gtgttctcaa atatttggat ctggataaaa	120
tgaatgaact	aaatcagtc	tttagggatt tactgttaac caccatggga aaattaaata	180
aatgcgggaa	agggaaaacgt	tctaaaaattt gaagactact ttctactctc agcttctgat	240
tccctctgag	ctaagaacca	gacagcctt ggctggtaac tcctataagg tggactcctt	300
cccatgctga	ccccatctt	actgtacaat tcactttca tggactgaag gcaccaccaa	360
gatagatcca	ggagtgacaa	ctccagttgg	389
<210> 130			
<211> 319			
<212> DNA			
<213> Homo sapiens			
<400> 130			
tgttgtaact	gggagtggag	gcccaagtggc tggggagaca ttaggtggtg gggcccgcc	60
cgaccccttag	gttcttcctt	ctcccttagct gtgtcttgg tctggccact cccagcccc	120
ttgtccccctt	ggaagcttgc	cctgccctca tcttggccat gccttctact gccaggagac	180
ttgcacccat	ttcaacccta	gggcggggca aagtggggca aggatggacc agcagaagg	240
gggttaaggct	ctgttcactt	ccccctgcct ccacagaacg aagccacggg ttccgttattc	300
ttcctccatgt	tttggttcct		319
<210> 131			
<211> 385			
<212> DNA			

<213> Homo sapiens

<400> 131

ggcacgagaa	acgtttcagc	tacgaaaagtg	agcttttcc	aacttttaag	gatatcagga	60
gagaagacac	tcctgatgtg	gaggttctg	ccagtggcta	cacaaggaa	atgcaggca	120
atgatgaact	gcttcatcca	ttaggtccag	atgataaaaa	tattgaaaca	aaagagggat	180
ctgaattctc	atttcagat	ggagaagtgg	cagaaaaagc	agagtttac	aggtcagaaa	240
atgaaaagtga	acggaactgt	ctagaagaat	cagagggctg	ctattcaga	tcatctggag	300
accctgaaca	aataaaggaa	gacagtttat	cagaagagag	tgctgatgca	cggagtttg	360
aatgactga	attcaatcaa	gcttt				385

<210> 132

<211> 383

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(383)

<223> n = A,T,C or G

<400> 132

ggcacgaggg	aatagaggg	tccctggtga	cagggcaagg	ctagatctgg	agcctgcact	60
tggcctgtga	catactgtct	tgtttctgag	aatcctcccc	tacttctcta	gataatctcc	120
aaacacttct	gtgactactt	aatcacaag	gaaattttca	ggagatataa	tcgattctta	180
ttttacaaaa	aaaaagagaa	gggatctgaa	tgttttagt	tcacgctagg	gatcnnnnnn	240
nnnnnnnnnc	ccaaacctga	cgttgagga	ccgccttt	tttcagccaa	tttaaaagat	300
tttttaaggt	ttagggttgg	ttggccatta	aaccatcccc	ggaaagaaaa	tggggtaaa	360
agaccaagaa	ggaggtcgcc	aag				383

<210> 133

<211> 382

<212> DNA

<213> Homo sapiens

<400> 133

ggcacgagat	aagatctgag	gtgttacaca	cataattgtc	ccaattttta	agatttgatgg	60
ggagcatgaa	gcattttttt	aatgttgtgg	caggccccc	taaatgcata	aactgcata	120
gactcatgt	gtctgaatgt	attttagggc	tttctggaa	ttgtcttgc	agagaacctc	180
agctggacaa	agcagccctg	atctgagtga	gctaactgac	acaatgaaac	tgtcaggcat	240
gtttctgctc	ctctctctgg	ctctttctg	ctttttaaca	ggtgtttca	gtcaggggagg	300
acaggttgac	tgtggtgagt	tccaggacac	caaggtctac	tgcactcggg	aatctaacc	360
acactggggc	cttgaatggc	ca				382

<210> 134

<211> 375

<212> DNA

<213> Homo sapiens

<400> 134

ggcacgagca	agcctttcat	ttacattaaa	ttataacttt	tcattcattc	ctaaaccaaa	60
cttaaaattc	tgcttcctt	tgagtagaag	gtatTTTact	tgTTTgttt	ttccttcaga	120
aggaatttaa	tgcaaacgga	ttgcagtca	cactttctga	atgtttcac	acagtatgca	180
aagcttacat	cataccaagg	agtggagagt	tgaagttcc	tcccagtgc	tccagtgaca	240
gaccacacct	agaaagcggt	tctttcctg	agtatttcaa	aaagatgtaa	aaagagctgg	300
gagagtatgg	gaagaaacaa	tacaggattg	cTTTAATT	attaagaatt	gcctcctgat	360
aaaaggaaaa	agaaa					375

<210> 135

<211> 376

<212> DNA

<213> Homo sapiens

<400> 135
 ggcacgagac ctgtttgagg tggaactcca agcagctcg accttgagc gactggagct 60
 ccagagtctg gaggcagctg agatagagcc ggaggccag gcccagaggt cgcccaggcc 120
 cacgggctca gatctgctcc ctggagcccc catcctcagt ctgcgttct cttacatctg 180
 ccctgaccgg cagttgcgtc getattttgt gctggagct gatgccacg cagctgtcca 240
 ggagctgctt gccgtgttga cccccagtac caatgtggct gttccctgc aggtctgaa 300
 tggcatatag ctgggcctgg cagggcagag cctcggcta gagtggcag ctggggcggg 360
 ccgctgtgtg ctgctg 376

<210> 136
<211> 371
<212> DNA
<213> Homo sapiens

<400> 136
 ggcacgaggt cacctctacc agccctcctt tctccagatg gcttcttcat aaccaccagg 60
 tcagaagagg atccgttcca atgattttcc taaaacaatg gaagtgtttt ccaaagagct 120
 tataaggcat tgttaggatct ggcctgccc gactccactt taccagaacc atctgctgct 180
 cttctcttctt gtgttactca aggtttagc tgctgtggca aatcaactct gaaatctccg 240
 tgacttaata caagagaggt ttatttctta ctcacgctgg gtgcactgccc acttggtaac 300
 agaggagcta tggaaacttg agacctaagc agaaatgagt tcaataatat tgctacactc 360
 taggactttc t 371

<210> 137
<211> 258
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(258)
<223> n = A,T,C or G

<400> 137
 cagtttcttt gtgcgcgcgc cccccctttt ttctctctt ctccgcgcgg gcgtgtccct 60
 ccnnnnnnnn nnctgtgtgt ggcctcttc cgcggccat atattgtttt tttctctgtg 120
 gannnnnnnnn nntctctta gagtttttc tctccctcg cgcgcacatt gttatacact 180
 cctccctctt ctttttttt acacacat atatattgcg cccctctccc cccacacatt 240
 tatatctctc tcacatct 258

<210> 138
<211> 368
<212> DNA
<213> Homo sapiens

<400> 138
 ggcacgagac attttgagac ttcttccaaa ttggccctta gaaagttaca ctggtttggta 60
 ctctcaactt tgcactgtt tataccacca ctgactgtc cctgccttat tatttcttta 120
 atgagttgga ctgaacagt gttaatccctg actctgtttt tgactgacag ttaacagtta 180
 catgaaccat tcataattaca gctcttactt aaatttgacc aagccaggat atatctgtta 240
 ggccacattt cttttttcc aaaggcagggtt tgggcaaaat taatcccacag 300
 gactgaaagg tatacatctg tgagtttgt tctcaacttcc acctctaatt tgaagaacac 360
 tttaattt 368

<210> 139
<211> 372
<212> DNA
<213> Homo sapiens

<400> 139
 acggcacgag ctggctccctc gttttctttt tggacagttt cattaccaac atcctcggttc 60
 gggcttagga tgcctttctg ctcgaggggaa ccaacgcggc gattcgctat gccttggcca 120
 ttatcttggta caacgagaag gacatcttga ggctacagaaa tggcctggaa atctaccagg 180

acctgcgctt	cttcaccaat	accaactcca	tcaagccggaa	gctgatgaac	attgccttca	240
atgacatgaa	ccccttccgc	atgaaactat	tgccggagct	gtgcattggcc	caccgtgagc	300
ggctggaggc	tgatctgccg	gagctggagc	aacttaaggc	aaagtacctg	gttaggcagg	360
catcccgcg	ca					372
<210> 140						
<211> 365						
<212> DNA						
<213> Homo sapiens						
<400> 140						
ggcacgaggc	tgagagtgt	tgatacaccc	ttgaatcccc	tcttatatga	tgccccagcc	60
caggagagat	aaaagcatca	gcaccatgag	attcacctgc	ctctggtcgt	taggaaacaa	120
tggaggcctg	cgatttggag	ttaaactctc	agtatctct	gtgttgacaa	caccaaagct	180
agaggaatcc	agtaggatgt	gggcatggtt	ttcccggaag	gctgactgag	cagttctgca	240
aatgtttgca	agtacagggc	agaatttcat	ccagccttag	aaccttgagc	caagactcag	300
catcagcaaa	gccaaaagtt	tcatttctt	gactgtggga	gtgctagtcc	caacctttag	360
atggc						365
<210> 141						
<211> 353						
<212> DNA						
<213> Homo sapiens						
<400> 141						
ggcacgagaa	acaaaagaga	gcaagagaga	agacagtggg	tgaagtccctg	gttccagact	60
cccccttttg	ccgggatatg	atggatctgt	cagctggta	ggcccctcta	agaggggtgg	120
tatttcggg	ccaggtgcct	aggtcctag	agagctagag	atggagggaa	attcagatca	180
tctaaaccct	tcagcccttc	actggacaga	agaggaaact	gaggctccat	ctgcatgacg	240
ttcccagagt	cacggcacaa	attcatggaa	gaagcagcag	gaaactcagt	tctccagtct	300
gggtccaatg	tgtgttttag	aaatatctcc	acagggttaa	tgactcaatt	ttt	353
<210> 142						
<211> 352						
<212> DNA						
<213> Homo sapiens						
<400> 142						
ggcacgaggc	cactcggggg	cccaggaacc	cctcagttag	ggcttctcag	tcactgagcg	60
gaaggtgccc	ccagaggggg	cagccgcctg	tgaggagcag	gcgtgtctgg	gttaaccatgt	120
ggctcctgt	ggcctccct	gcctgtcccc	aaagcacagg	gctcagctcc	agagggagac	180
gggtgggct	gtcagtggtc	ccaggtgcat	cccactttcc	agcagactt	ggtgccagca	240
gaggctgcag	gtgtggcagg	agggggccca	gccgtgaggg	caccaggttc	aggcccggca	300
tctcagggtg	gagagccagg	gctgtcctga	acctccagag	ggggtgagct	gg	352
<210> 143						
<211> 470						
<212> DNA						
<213> Homo sapiens						
<400> 143						
gacttctgtc	tttttagat	cccatcgact	tcaattcggc	acgaggtcat	gagaaaggaa	60
ccaatggagt	atgagaagtt	tccagtgtaaa	aacagaaaaga	atccagttaga	atttatttttag	120
ggaagaggaa	aagatgtgtt	cggggtggcc	ttggaagtgta	acgttgaagg	actactgaga	180
ttggttcaag	aaactgtgaa	gggaaagaaa	gggttataact	gagaatggta	agagataatt	240
ttagaaactt	gcgaaaaatg	gcttaatcta	aatgagtgtt	agggggagata	cagctgtgat	300
gataggttga	gctcacatgg	tggagagcca	cagttgcggg	tgcttgcact	gataatgtga	360
gggcatggag	acagacaata	agttgaatgc	tcttttttta	acaaaggaag	ctaaaaggga	420
ggggatgtct	aatttgatca	atacgtttgg	gaaaacttat	attttcttgg		470
<210> 144						
<211> 456						
<212> DNA						

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(456)

<223> n = A,T,C or G

<400> 144

tagcacttt	gtttaggagg	accccatcg	ttcgaattcg	gcacgagctg	cactgagcag	60
caccgggtt	cttcatccgg	ctgcaccccc	aacagagctc	tttctccccc	agatccctt	120
tacagttgga	ttctccctct	tggatctggc	tctgccttag	tccgacctag	agggatcagc	180
ttcgcccacg	cccaactctca	cccgaacct	tcatctctt	attgaagct	tttagggcca	240
ttgggatgtt	cattagaact	ctgaaaacta	cagttctccc	ctttatgagg	actgcaccac	300
agctcgccct	ctcctgggtt	ccgcctgggt	gcagagttag	cccatgggac	agccctctga	360
aattatactg	cttacaacca	tgctgagtt	gcaaggactt	cgtccaagcc	tttccgtcca	420
ggacctcaaa	cagatccaa	cacaagaaga	gagatn			456

<210> 145

<211> 464

<212> DNA

<213> Homo sapiens

<400> 145

atcgcccata	cggcgagccc	accgacgcga	attcggcacg	aggggaaaca	caggcctctt	60
ctgccttttag	gaccctcccc	ctgccttgca	gggggctcg	ggagagcaat	atcaggagct	120
agggcttgc	gctgcccaca	ctccctgctt	ttgggatatc	taactgctaa	ggagggagtt	180
gacatcccc	ttctggctca	tgtgtctgac	accaacaaca	tgggctctgt	ccctctctct	240
ttgactctcc	ctttgtccctc	cccatacagc	ttgggtgggg	tggatcccta	tacctggggc	300
aggcagcccc	aaagtgggtt	agggggatgg	caaagactgt	ataggcgcca	ctggactctg	360
gcaaggcctt	tattacctt	actcccttc	ctctccatc	accagctca	aggcctgagg	420
tgtgcagggg	ctcctggcag	ctactgagtg	agggttcctg	gtcg		464

<210> 146

<211> 448

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(448)

<223> n = A,T,C or G

<400> 146

ggcacgagct	gcactgagca	gcacccgtgt	tcttcatccg	gctgcacccc	caacagagct	60
ctttcttccc	cagatccctt	ttacagttgg	attctccctc	ttggatctgg	ctctgcctta	120
gtccgaccta	gagggatcatg	cttcgcccac	gccactctc	acccggaacc	tttcatctct	180
tattgaagcc	ttttagggcc	attggatgt	tcatagaaac	tctgaaaact	acagttctcc	240
cctttatgag	gactgcacca	cagctcgccc	tctctgggt	tccgcctgg	tgcaaggatg	300
gccccatggga	cagccctctg	aaattatact	gcttacaacc	atgctgagtc	tgcaaggact	360
tcgtccaagc	ctttccgtcc	aggacctaa	acagatccaa	tcacaagaag	agagatttca	420
ggaaagagaa	nattattcct	atcatcgn				448

<210> 147

<211> 439

<212> DNA

<213> Homo sapiens

<400> 147

ggcacgagga	aagttaagca	actacaggaa	atggctttgg	gagttccaaat	atcagtctat	60
cttttattca	acgcaatgac	agcactgacc	gaagaggcag	ccgtgactgt	aacacctcca	120
atcacagccc	agcaagctga	caacatagaa	ggacccatag	ccttgaagtt	ctcacacctt	180
tgccctggaaag	atcataacag	ttactgcata	aacgggtc	gtgcattcca	ccatgagcta	240
gagaaaagcca	tctgcagggt	ttttactgggt	tatactggag	aaagggtgta	gcacttgact	300

ttaacttcat atgctgtgga ttcttatgaa aaatacattg caattggat tggtgttgga	360
ttactattaa gtggtttct tgttatttt tactgctata taagaaagag gtgtctaaa	420
ttgaaatcgc cttacaatg	439
<210> 148	
<211> 334	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(334)	
<223> n = A,T,C or G	
<400> 148	
ccccgcgcgc gctcccttc tatctttat aaaaaatata gagagcgac atctctgtgt	60
gtgagagagt ctgtgcgcgc gcgcataatat atatggagg ggtgtctccc cccatctgtg	120
tgtctctcct cttgcggggc atatgcgtgc gcacacccgc gcgcgtgttc tttttgtgc	180
cnn	240
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnncg cgcgacacaca cccacacacc	300
gtgtgttcta cagcgcgata aagagagaca caca	334
<210> 149	
<211> 428	
<212> DNA	
<213> Homo sapiens	
<400> 149	
ggcacgaggt cctgagcgc ctcatggag gtgaattaga gaaaacaaaa gagagcaaga	60
gagaagacag tgggtgaagt cctggttcca gactcccctt tttgcggga tatgtatggat	120
ctgtcagctg gtgccttagag tcctagagag ctagagatgg agggaaattc agatcatcta	180
aacccttcag cccttcactg gacagaagag gaaactgagg ctccatctgc atgacgttcc	240
cagagtcacg gcacaaattc atgaaagaag cagcaggaaa ctcagttctc cagtctgggt	300
ccaatgtgtg ttttagaaat atctccacag gttaatgac tcaattttc atgcattgatt	360
gctagtaatg acaatcatgt tatgttttgt tctgttagtt tggaatcac tccttccact	420
tgagtttc	428
<210> 150	
<211> 427	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(427)	
<223> n = A,T,C or G	
<400> 150	
cgcggccaaan nnnaatctt aaagggtaa gggagataacc tacttgtct ggttagggag	60
atgtttcggtt ttcatgtttt accagaaaat ccacttcctt gccgacctta gtttcaaagc	120
ttatttcttaa ttagagacaa gaaacctgtt tcaacttcaa gacaccgtat gaggtgaatg	180
gacagccagc caccacaatg aaagaaatca aaccaggaat aacctatgtc gaacccacgc	240
ctcaatcggtc cccaaagtgtt tcctgacacg catctttgt tacagtgcac cacaactgaa	300
gaatgggtt caacttgacg cttgaaaat taccaaataa cgagctgcac ggccaagaga	360
gtcacaattc aggcaacagg agcgacggc cagggaaagaa caccaccctt cacaatgaat	420
ttgacac	427
<210> 151	
<211> 437	
<212> DNA	
<213> Homo sapiens	
<220>	

```

<221> misc_feature
<222> (1)...(437)
<223> n = A,T,C or G

<400> 151
ccgagccgga tgnccctnnn gagtatngca angattccaa ttcggcacga gagacagtgg      60
catggagctt taaaagacga gtagtgttta gcaaggaaat aaggaggaac ggggttacg      120
ggcagaggag aaagcacatg ccaagtcaac aaagaaaaat agaattcgaa aacttttaa      180
aatattact aaggatttc acaatgctgc actgggctag aaactgaagc taaaacagat      240
acgtggtccc tgctgtatg gggcttacgt tctacaggca aggacagggt gtgatgaggg      300
ttctgaagga tagagaccaa gcatggaggg tggtgaggag gcttcgcga gacctaata      360
atgggaagcc acgaagtggg aggggtgggg gtccaggctg gaggggccca atgtatgt      420
agagggacta cagccct      437

<210> 152
<211> 425
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(425)
<223> n = A,T,C or G

<400> 152
ggcacgagct gcactgagca gcaccggtgt tttcatccg gtcgcacccc caacagagct      60
ctttttccc cagatccctt ttacagttgg atttccctt ttggatctgg ctctgcctta      120
gtccgaccta gaggatctag cttccccac gcccacttc acccgaacc tttcatctc      180
tattgaagcc ttttagggcc attggatgt tcattagaac tctgaaaact acagttctc      240
cctttatgag gactgcacca cagctgccc ttcctgggt tccgcctgg tgcagagtga      300
gccccatggga cagccctctg aaattatact gttacaacc atgctgatc tgcaaggact      360
tcgtccaagc cttccgtcc agggaccta acagatccaa tcacaagaag agagattca      420
ggaan      425

<210> 153
<211> 421
<212> DNA
<213> Homo sapiens

<400> 153
ggcacgagcc gtggctgcct cgtgagccct ccagagccca ggcctccgtg gcctccctc      60
gtgtgatcc caccaggagc cacgtgcctc gccttgcctt caaggattt tgctttctc      120
ctgtgcacct ggcgaggctg aaggcgaggg gtggaggagg ccccgacaca gcctcatctc      180
catgtgtacg cgtgtgtacg tggatgcg tggatgtacg tggatgcg tggatgtacg      240
cgtgtgtacg tgcgtgtta cacatgcgtg gccgcctgtg gtgtgcacgt gtgtctggg      300
tcccgaggct tctccagagc tggagctgg ctggcgtgg aaggcatgc tctggggcag      360
tggatccctc aggaaccagg gtcctccctc cccttctgc ctggcagcc ccgtggccctc      420
t      421

<210> 154
<211> 423
<212> DNA
<213> Homo sapiens

<400> 154
ggcatgagtg gaagggagggc agctgcctt gtttgcattt gatggtagg ggctgcactg      60
agcagcagcg gtgttcttca tccgctgca ccccaacag agctcttct tcccccagatc      120
ccttttacag ttggattctc cctcttggat ctggctctgc cttagtccga cctagaggga      180
tcagcttcgc ccacgcccac ttcacccgg aaccttcat ctcttattga agccttttag      240
gcccattggg atgttcatta gaactctgaa aactacagtt ctcccttta tgaggactgc      300
accacagctc gcccctctcct gggttccggc tggatgcaga gtgagccat gggacagccc      360
tctgaaattha tactgcttac aaccatgctg agtctgcaag gacttccggc aaggcttcc      420
gtc      423

```

<210> 155						
<211> 312						
<212> DNA						
<213> Homo sapiens						
<400> 155						
tctgtca	acaaaacaca	gtgcgcgcac	atagcggggg	gggagcacac	acacaagatg	60
tgtgtata	caacccgcgc	gcgagagagc	gctctttt	gtggggggga	aaaaaaactct	120
tatacacaca	cgtgtgtgt	tgtcgctctc	cgaaaataca	cactataaca	aacgcactgt	180
gtgtgtgaga	cacacactcc	tctctccgag	tggggagaga	gagatgcgc	tccactctta	240
aacacatatg	cgctcacaga	gagcatatat	atgtttttt	tgagagaaga	gagagatctc	300
tttgtggttt	ct					312
<210> 156						
<211> 428						
<212> DNA						
<213> Homo sapiens						
<400> 156						
tgaccttcca	ggctacctac	gcaggtgtcg	gggccaacaa	gcacctgcag	gagctggccc	60
aggaggagt	gaagcagcat	gccaggaac	tctgggctgc	ctacaggggt	ctgctgcag	120
ttgccttaga	gcgcaagggc	caggccctgg	aggaggatga	agacacagag	acaagggacc	180
tccaggtgca	tggattgtg	ctgccccctca	tgctgcccag	cttctactca	gagctttca	240
cgctctacct	gctgcttcat	gagccggagg	acagttcta	cagccagggc	attgccaact	300
tgagccttctt	tcctgatacc	caactgctcg	agttcctgga	tgtcagaag	cacttgtgc	360
ccctcaagga	cctcacgtg	acgagcaatc	agaggtactc	cctggtcagg	gacaagtgtt	420
tcctgtca						428
<210> 157						
<211> 430						
<212> DNA						
<213> Homo sapiens						
<400> 157						
ggcacgagag	gactttgagc	ccagagagat	gaagtcat	gctcaaggca	gcagtcagtg	60
gaaggggcttg	gagaaggaga	aggggtctga	aggtgtgtg	ggacacatga	gagtgtatctc	120
gcagcttgg	ttgctgcagc	agactcggac	aagcattgtt	tcagtgctg	gtttctccct	180
ccacttgatg	ggggccaact	ccaaaccaat	gtccccattcc	tatcctgaaa	tgcttctaaa	240
ggcagtgccc	tgagaacacc	caacctcaca	gcctgtctcc	attttattgt	cttctggaa	300
cttcccttctt	ctgtctagca	cctgtttgca	ctgggattgt	cctgtctg	cttcagttgg	360
atctgggtt	gcacccatgt	aggatttagc	aattttaggc	tgtcattcg	caaaggccaa	420
ctcacaatgg						430
<210> 158						
<211> 405						
<212> DNA						
<213> Homo sapiens						
<400> 158						
ggcacgaggg	aagatttcca	gtggtctcaa	ttgtgtgaat	cctatgaagg	tgtcttattt	60
gttgaattag	aggtgaaagc	ctccttcctc	actttttt	agaaacagtt	tagttttatt	120
attatgcaga	atttgtttag	caaattgcaa	cagcccaagc	cacagctagc	tccacaagag	180
cccttccatg	agccctcaac	ctggatctc	gtgtatctt	gttgaatgg	acattaggtt	240
tccaaagtcca	ggcctgtat	ttagaagggt	caggtgggt	aggagagagg	agagtcttgg	300
aggggctgt	ccatgggggt	cacacctctc	tcctgtgggt	tttcgttggt	gattgagttc	360
tgaggcattt	gctgcattga	ctgtgttagc	tttaactct	gtgca		405
<210> 159						
<211> 403						
<212> DNA						
<213> Homo sapiens						
<400> 159						

ggcacgagcc	tgactcaagg	ggtttggaa	gatttccagt	ggtctcaatg	gtgtgaatcc	60
tatgaagggt	tcttatttgt	tgaatttagag	gtgaaagcct	ccttcctcac	tcttttttag	120
aaacagttt	gttttattat	tatcagaat	ttgttgagca	aattgcaaca	gcccaagcca	180
cagctagctc	cacaagagcc	cttccatgag	ccctcaacct	gggatctcg	gtatctttgt	240
tggaatggac	attaggttc	caagtccagg	cctgtgattt	agaagggtca	ggttgggttag	300
gagagaggag	agtcttggag	gggctgctcc	atgggggtca	cacctctc	ctgtgggttt	360
tgcgttgta	ttgagttctg	aggcatttgc	tgcattgact	gtg		403
<210> 160						
<211> 417						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(417)						
<223> n = A,T,C or G						
<400> 160						
gttctgtggg	aatacgagggt	ccctggtgac	agggcagggc	tagatctgga	gcctgcactt	60
ggctgtgac	atactgtctt	gtttctgaga	atcctccctt	acttctctag	ttaatctcca	120
gagacttctg	tgactactta	atcacaaagg	aaattttcag	aatattatc	aaatactatt	180
ttagaaaaaa	aaagagaagg	gattgaatg	ttttcagttc	agtttagtta	tcnnnnnnnnn	240
nnnnnnnnccc	caaactccag	aatgggggccc	cccccttctt	taaccacc	taaaaatttt	300
tcggagggttc	agggttgggtt	ggcaattac	aaaaacccca	aaagaaaatg	ggggtaacc	360
cccttggaaa	agtttctta	cttgggggg	tggcccttgc	acgtngggccc	gggttac	417
<210> 161						
<211> 300						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(300)						
<223> n = A,T,C or G						
<400> 161						
ctatatctct	ctgcgccttc	tccccctctt	gtgtttccc	ccgcccctct	agagatatct	60
ctctcactcg	cgggcgcaca	cccccttta	caaaatagg	ggctctctgt	gtgtgggttt	120
tttcttgggc	ccccctctt	ttttttctt	tttgcggggc	ccccctgtg	tgtctctctc	180
tagacacacc	cccccgcgcg	tgtttttat	aaatatctgt	ctctcacaca	ccccctactg	240
cccccctgtg	tgtgggcgcg	ttccccccca	cacacacaga	gtgtgtgnnn	nnnnnnnnnnn	300
<210> 162						
<211> 411						
<212> DNA						
<213> Homo sapiens						
<400> 162						
ggcacgaggg	caccgagcct	cctgtggag	gtcccggaggc	agcttcgcct	gctggccctg	60
gctgcagccc	tcacctgccc	cagccttagc	tgagcagccc	ccgccactgg	gcgcgggggg	120
ctccccactt	cgccagcgcc	cgctcctcg	ctcgccccgg	gttagttgt	agggacgcag	180
ctctccacgt	gcccgcactgc	gaggctggac	gctacgggct	cctggaaagg	agcagacacc	240
agcatttgcc	acaatgtgt	catccactga	ctttacattt	gcttcctggg	agcttgggt	300
cccggttgac	catcccaatg	aagagcaggc	agaaagacgt	ccgcactgag	aggattctgg	360
agacccttca	cgttggaaagg	agtgtatgtc	aaggtagta	gaacagatca	a	411
<210> 163						
<211> 412						
<212> DNA						
<213> Homo sapiens						

<212> DNA

<213> Homo sapiens

<400> 167

ggcacgaggg ggcacaagct gttggagctg caatgggccg cggctgggg ttcttgggg	60
gcctcctggg cgccgtgtgg ctgctcagct cggggccacgg agaggagcag ccccccggaga	120
cagcggcaca gaggtgcttc tgccaggtta gtggttactt ggatgattgt acctgtgatg	180
ttgaaaaccat tgatagattt aataactaca ggctttccc aagactacaa aaacttcttg	240
aaagtgacta ctttaggtat tacaaggtaa acctgaagag gccgtgtcct ttctgaaatg	300
acatcagcca gtgtgaaaga agggactgtg ctgtcaaacc atgtcaatct gatgaagttc	360
ctgatgaaat taaatctgct agctacaagt attctgaaga agccaaat	407

<210> 168

<211> 416

<212> DNA

<213> Homo sapiens

<400> 168

ggcacgagac acaactttga gacaccccaa gtgctttctg cagaggttgt cgttggaaaa	60
ctgtcacctt ctagaaggcca attgcaagga ctttgcgtct gtgttgggtt tcagccggaa	120
gctgacacac ctgtgcttgg ccaagaaccc cattggaaat acaggggtga agtttctgtg	180
tgagggcttg aggtcccccg agttaaact gcagacctt gtgctttggaa actgcgcacat	240
aactagcgat ggctgctgcg atctcacaaa gttctccaa gaaaaatcaa gcctggttg	300
tttggatctg gggctgaatc acataggagt taaggaaatg aagttcctgt gtgaggctt	360
gaggaaacca ctgtgcaact tgagatgtct gtgggtgtgg ggatgttccaa tccctc	416

<210> 169

<211> 386

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(386)

<223> n = A,T,C or G

<400> 169

ggcacgagga atctcgccctc tgtctgggtgt gttacctact gggggcacag gaacaatttc	60
ctcaaggaga cagtggcatg gagcttgaa agacgatgt gtgttagcaa ggaaataagg	120
aggaacgggg gttacggca gaggagaaag cacatgccaa gtcagcaaaag aaaagttagaa	180
ttcgaaaaact ttttaaaaat attactaagg atttcacaa tgctgcactg ggctagaaac	240
tgaagctaaa acagataacgt ggtccctgct gctatgggc ttccgttcta gaggcaagga	300
cagggtgtga tgagggttct gaaggataga gaccaagcag ggagggtgtt gaggaggctt	360
ctgcgagacc tgaaggatgg gaagcn	386

<210> 170

<211> 391

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(391)

<223> n = A,T,C or G

<400> 170

ggcacgagaa tagagggtcc ctggtgacag ggcagggtca gatctggagc ctgcacttgg	60
cctgtgacat actgtcttgt ttctgagaat cctccctac ttctctagtt aatctccaga	120
gacttctgtg actacttaat cacaaggaa atttcagga atattatcaa atactattt	180
agaaaaaaaaa agagaaggaa tttgaatgtt ttctgttca gtttagttatc nnnnnnnnnnn	240
nnnnncccaa aactcaagat tggggcccccc ccctccctta accccgcctaa aaagttttt	300
gggggtttag ggtgggttgg caaataacaa aacccccaaa agaaaagggg ggtaaacccc	360
cttggaaaag tttccctaact ttggggggcg c	391

tgtttata cagataagaa atgcatttc tttctggtc ctgcagccat tggaaaaact	360
tttttcttg gaaataataa ggttttcat agat	394
<210> 175	
<211> 387	
<212> DNA	
<213> Homo sapiens	
<400> 175	
ggcacgaggc cagtttagggc tgccatgtgc tggagctgt gtgtctgctc tccttcgtcc	60
gctccccca ggcagtgtgg tagcacatcc cattgttagag atgagggcac cgaggcttcc	120
tggagcatac cacctggtcc cgttcatgag tggggcaaa gctagcactc tcacttgtcc	180
attctgcctt cctggagacc agtggatgg gtcagtagac cccaccacac cattagcccc	240
aggaacataa ggctgtggct agacagcagg ggtctcaggt tcatacatga ggactggctt	300
gtccttgagc acccactcac ctgttatgt ggggaggaat cctacaatag gtcaccatgg	360
caggctgggg cttgctgacc ctgcccc	387
<210> 176	
<211> 395	
<212> DNA	
<213> Homo sapiens	
<400> 176	
ggcacgagca gacctccatt acctccatcc ctgttgatt atttaaagaa agcctcagac	60
agtaaggcct tttttaaaaa gaataaaatg acttggtttgcgcttggaaag caggggaagc	120
attcagatga gcggttctg cattaaccctt gcctatcacg catctcgatgt cctgtgtggc	180
tggcgagccc cccttggaaag gttctggtgc ttcaagtcgc tcctgcagag tccaccggc	240
ctcggttgg gaatgcagag cccttgcattt tccttcttgc cgcctgcattt ctgttctgg	300
ggaccggctg ggcctttggct ctgcattcccc tggccaggtc cctcagggtt gatgcgcgtt	360
gaaggacttt gagcagtggt ggcagcactt gccct	395
<210> 177	
<211> 388	
<212> DNA	
<213> Homo sapiens	
<400> 177	
ggcacgaggc acgctcgccgaa gcccgtcac ccgcgtccctg tacgtgaaca tgactagcgg	60
cccggttggg ccggccggccg ccggggccgg caggaaggag aaccaccagt ggtatgtgt	120
caacagagag aaattatgcg aatcaactcca ggctgtcttt gttcaaggtt accttgatca	180
aggaacacag atcttcttaa acaacagcat tgagaaatcg ggctggctat ttatccaattt	240
atatcatttctt tttgtgtcat ctgttttag cctgtttatg tctagaacat ctatcaatgg	300
gttgcttagga agaggctcaa tggggatgtt ttcaccagat cagttcaga gactgcttaa	360
aattaatcca gactggaaaa cccacaga	388
<210> 178	
<211> 397	
<212> DNA	
<213> Homo sapiens	
<400> 178	
ggcacgagca ggatccctca gatctgtggc gcagatccga tggagaggct gagctgctcc	60
aggacttggg gtgttatcac ggcaacctca cacccatgc tgctgaagct cttctcctct	120
caaatggatg tgacggcagc taccttctga gggacagcaa tgagaccacc gggctgtact	180
ctctctctgt gaggggccaaa gattctgtta aacacttca tggatatat actggatatt	240
catttaaattt tggctttaat gaattctcat ctttgaagga ttttgcataag cattttgca	300
atcagccctt gattggaaagc gagacaggca ctctgtatgt tctaaaacat ccctacccaa	360
aaaaagtggaa agaaccctcc atttatgaat ctgtccg	397
<210> 179	
<211> 397	
<212> DNA	
<213> Homo sapiens	

<400> 179						
ggcacgaggc	gtggggcgac	aagctgccgg	agctgcaatg	ggccgcggct	ggggatttctt	60
gtttggcctc	ctgggcgccc	tgtggctgct	cagctgggc	cacggagagg	agcagcccc	120
ggagacagcg	gcacagaggt	gcttctgcca	ggttagtggt	tacttggatg	attgtacctg	180
tgtatgttga	accattgata	gattnaataa	ctacaggctt	ttcccaagac	tacaaaaact	240
tcttgaaaagt	gactactta	ggtattaca	ggtaaacctg	aagaggccgt	gtccttctg	300
gaatgacatc	agccagtgt	gaagaaggga	ctgtctgtc	aaaccatgtc	aatctgatga	360
atgtcctgtat	ggaattaaat	ctgcgagcta	caagtat			397
<210> 180						
<211> 399						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(399)						
<223> n = A,T,C or G						
<400> 180						
ggcacgaggc	cacccctttt	gcctccatcc	tcaaagacct	ggtcttcaag	tcatccgtca	60
gctgccaagt	gttctgttaag	aagatctact	tcatctgggt	gacgcggacc	cagcgtcagt	120
ttgagtggct	ggctgacatc	atccgagagg	tggaggagaa	tgaccaccag	gacctggtgt	180
ctgtgcacat	ctacatcacc	cagctggctg	agaagttcga	cctcaggacc	actatgttgt	240
acatctgtga	gcccgcacttc	cagaagggtc	tgaaccggag	tctattcaca	ggcctgcgt	300
ccatcaccca	ctttggccgt	cccccccttg	agcccttctt	caactccctg	caggaggtcc	360
accccccacgt	ccggaagatc	ggagtgttta	gctgtggcn			399
<210> 181						
<211> 402						
<212> DNA						
<213> Homo sapiens						
<400> 181						
ggcacgaggc	tacttcgctc	gcaaggattt	gtactgcaag	gagttatgtgg	cagctgtcct	60
ggagcatatc	gagaacaaga	acctcatgcc	acctcttcta	gtgggtcaga	ccctggccca	120
catctccatc	gcccacactt	gcgtcatcg	ggactacactg	gtccaaaaac	tacagaaaaca	180
gagccagcag	attgcacagg	atgagctgcg	ggtgcggcgg	taccgagagg	agaccacccg	240
tatccgcac	gagatccaag	agctcaaggc	cagtcctaag	attttccaaa	agaccaagtg	300
cagcatctgt	aaacatgcct	tggagatgcc	ctcagtcac	tccctgtgt	gccactccctt	360
ccaccaacac	tgctttgaga	gttactcgga	aagcgaagct	ga		402
<210> 182						
<211> 384						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(384)						
<223> n = A,T,C or G						
<400> 182						
ggcacgagag	caactcaggc	ctgctgggtt	aactgcttac	accattttcc	ttccccctct	60
cttccttgc	ttcgacactc	ttaacctgga	aaaagcacta	atttgcctc	cataatctgt	120
gttttgtcat	ttggaaaggt	tgttagaaatc	ctagagtatg	tgaccttttta	agatgcactt	180
tttagaaaaac	tcaacatgtt	gctcttgggt	taatgtttt	ttcttttttag	tgttcggtat	240
tctcttgtgt	ggtcatgccc	cagttttat	aaccatccca	tagatgttta	ttttcccttg	300
taaagtgggt	tagcatgtan	nnnnnnnnnn	nnnnnnggga	aactcatttct	cnnnnnnnnnn	360
nnnnnnnnnn	nnnnnntgccc	cttg				384
<210> 183						
<211> 384						

<212> DNA

<213> Homo sapiens

<400> 183

ggcacgaggg	aaggtagaggg	ctgagaagga	ggcatgccag	cgggagaaaag	agctgcctgc	60
agcagtacat	cccttcatt	ttgtttaaat	tggcttggaa	gaatctattc	taaaaacatt	120
gactctagac	ttgttagaaaa	gagccatttt	agtttcaact	caaatgtaaa	gcaaggtagt	180
ttggtgacat	tttgctttt	tgtgaaatag	tgcacagtat	gagttaatct	gagcaggct	240
gaattgacca	aatgcttatac	tacgagggttc	ctagagctct	gctgaccctt	gccccaaact	300
ctaaaatgt	cctattaaag	ataaatgctt	ctaccaaagt	aaaactctgt	gagtttttc	360
agggcagaat	gtaccagcca	gtca				384

<210> 184

<211> 379

<212> DNA

<213> Homo sapiens

<400> 184

ggcacgagct	tcctccagcc	tccacagcct	tggctcagt	tccctgtgt	caagaccccag	60
tgacttcagg	gctcccgaaa	accccccctt	aaccatgggc	caaccaggaa	caccccaactc	120
tccaccactg	gccaaagaac	atgcaggcag	ctgcccccca	tccatcacca	actccatgg	180
ggacatacc	attgtgctga	tcaacggctg	cccagaacca	gggtttctc	caccccaagcg	240
gaccccgagg	caccagaact	ccgtcaacc	tggagctgt	tctccagca	acccctgtcc	300
agccaccagg	agcaacagcc	agaccctgtc	agatcccccc	tttaccacat	gccccagaggg	360
taagtctgaa	accaatatt					379

<210> 185

<211> 368

<212> DNA

<213> Homo sapiens

<400> 185

ggcacgagac	ccggtccagg	tgccctacgt	cgcgcgagc	gchgcccagg	tggagcacgt	60
gttgtcgctg	ctgcgaggac	gccccggaaa	aacggtgat	ctgggtct	gchgacggcag	120
gatcgtgctg	gccccccaca	ggtgcggcct	ccgccccggcc	gtgggctacg	agctgaaccc	180
ctggctggtg	gcgctggcgc	ggctgcacgc	ctggaggccc	ggctgtgccc	gagcgtctg	240
ctatcgccgc	aaggatctt	ggaaggtaac	ctggggatcc	ctggccaccc	gctgacagcc	300
caaggtgcgg	ctgacacctg	cgagggtctgg	gggccccggac	tggaaagctg	cgatgaccgg	360
gtgccccac						368

<210> 186

<211> 375

<212> DNA

<213> Homo sapiens

<400> 186

ggcacgaggt	ctcacagagc	gagaagggt	caggagcagc	ccattttgt	ctctctctct	60
acctctgtga	agggcgcgaa	tggccagagc	agaacttcta	gaaggaaaga	tgagcaccca	120
ggatccctca	gatctgtgga	gcagatccga	tggagaggt	gagctgtcc	aggacttggg	180
gtggtatcac	ggcaacctca	cacccatgc	tgctgaagct	cttctctct	caaatggatg	240
tgacggcagc	taccttctga	gggacagcaa	tgagaccacc	gggctgtact	ctctctctgt	300
gagggccaaa	gattctgtt	aacactttca	tgttgaatat	actggatatt	catttaaatt	360
tggctgtat	gaatt					375

<210> 187

<211> 368

<212> DNA

<213> Homo sapiens

<400> 187

ggcacgaggc	cgtgcagagc	ctgtatggta	agccccctagg	gggctcaaag	gccccccagc	60
tcccaggaaa	gatgtgact	gactttgaaa	cctgggactc	ctacagcccc	caaggaaggc	120
gcccctgaaac	gcagggccct	aaatactgcc	actcttcctt	cgatgccatc	actgtagaca	180

ggcaacagca	actgtacatt	tttaaaggga	gccatttctg	ggaggcggca	gctgatggca	240
acgactcaga	cccccgcca	ctgcaggaaa	gatgggtcgg	gctgcccccc	aacattgagg	300
ctgcggcagc	gtcattgaat	gatggagatt	tctacttctt	caaagggggg	cgatgctgga	360
ggatccgg						368
<210> 188						
<211> 436						
<212> DNA						
<213> Homo sapiens						
<400> 188						
ggcacgagaa	ggggctgggg	tgggctcagg	caaggcctgg	ggccctggcc	ttcttcctgg	60
cagggggagg	caggggactg	tgcagggct	cagggaggcc	tcccccacct	gccccctgac	120
cacacccact	ctgatgagggc	tcatggcctc	ctggcagggtc	gacggaggag	atcatcgccc	180
tcttcatttc	catcacgtt	gtgctggatg	ccgtcaagg	cacggttaaa	atcttctgga	240
agtactacta	ttggcattac	ttggacgact	atcacacaaa	aaggacttca	tcccttgtca	300
gcctgtcagg	cctcggcgcc	agcctaaccg	ccagcctcca	cactgcccctc	aatgccagct	360
tcctcgccag	ccccacggag	ctgcctcgg	ccacacactc	aggccaggcg	accgcccgtgc	420
tcagcctct	catcat					436
<210> 189						
<211> 435						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(435)						
<223> n = A,T,C or G						
<400> 189						
ggcacgagac	agacccttc	ttcctaaagg	ctttgtggca	tcagacacat	aaagggtata	60
tgttagtgtgg	agcactaacc	atggcagggt	aatttattcc	aggcacagag	tcataattct	120
ggaaacatct	agactcactg	cattaacaga	gcattttgtt	tctaaagtag	acctcttatg	180
tcatccagat	ttcactcatt	ctgaccacag	ccaggaagct	gagggtgaag	ccagaattag	240
ctgaaaccca	ccaagagctg	catagagcac	gtttagctag	agtaggagtt	tgcagtgctc	300
atatggaaa	tgctgtctgt	atacttttag	gaatttctga	gtgcaattta	gaaacatcta	360
gcacacttga	aacactgcgt	atcatntcc	tcactcatga	atatagtcat	cagaattcat	420
aaatagttt	cctga					435
<210> 190						
<211> 437						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(437)						
<223> n = A,T,C or G						
<400> 190						
ggcacgagat	taggaccctt	ccttggcaca	ggggtgagaa	agagcttggg	gaacgcttgg	60
cattatggag	ggcttggagg	ggctcaaccc	cgatttggag	agaagtttgg	gatggagtgg	120
gcgagagatt	gagagagcga	gcagaaaaag	aggcttgg	gcctggact	gatgggtggat	180
aaggcctgga	aagaagatga	cgaggaggag	gagagaggg	agtggggtgg	atgaggagca	240
ggctgacacc	tgggctgccc	tcaatcccc	aggccaggga	gggcggngct	ggcccccctggg	300
aagaactggg	tctctgggt	ccctatgcac	tgcctaaact	ggctgagcca	ggagtggggc	360
aggaagttag	agtcaaggcc	cagcaaaagg	agggggagga	gctgccaatt	ataaccttgt	420
gganggaccg	gttttng					437
<210> 191						
<211> 434						
<212> DNA						

<213> Homo sapiens

<400> 191

ggcacgagaa	gaaaactgtga	agggaaagaa	aggtttatac	tgagaaatgg	aagagataat	60
ttagaaaaact	tgtaaaaaat	ggcttaatct	aatgagtgt	tagggagat	acagttgtga	120
tgataggtt	agctcacatg	gtggagagcc	acagttgcgg	gtgctgcac	tgataatgtg	180
agggcatgga	gacagacaat	aggtgaatg	ctctttttt	acaaaaggaa	gtagaaaggg	240
agggggatgt	aaatttgata	aataggttgg	tgaaaactta	tatTTCTTg	taaagagaga	300
gaactgagca	tgtttaggt	ataaggtaaa	aaggcgtgaa	gaggaatatt	tcgttgataa	360
tgaaagttag	cagctaggaa	agaaaactcc	cagaggaaga	gggaggcaag	gaaatcaaga	420
acacacttaa	agtg					434

<210> 192

<211> 323

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(323)

<223> n = A,T,C or G

<400> 192

gggtctctcg	ccccctctc	tctctttgt	gtgtctctc	ctctgtccc	tgtgtgnnnn	60
nnnnnnnnnnt	ctctctata	ctcgccgcgc	cgca	ctcc	tgaccccgcc	120
ccctatgcg	ctctctcatt	tgtggagaga	gagaccgcta	tctatctc	tctcccccgc	180
cctatacaca	tctccctctc	tgtgaaagag	acgtgtgtgt	gtctccacac	cccttggcg	240
cgcgccgcgc	acccctctc	ctgggggggg	tgtctctct	gtatatatat	atgtgcacac	300
acgcgcgcgc	gctctgtt	gtt				323

<210> 193

<211> 412

<212> DNA

<213> Homo sapiens

<400> 193

ggcacgagaa	ggggccgtga	cagccgttgc	catctgctgc	cggagccggc	acctggcgca	60
ggctccca	gagctccagt	gacagcccc	tcccaggatg	ggtgtctggg	gagggtcaag	120
ggctggggct	gagctttaaa	atgggtccga	cttgccttc	tctcagccct	ccatggcctg	180
gcacgaggg	atggggatgc	ttccgcctt	ccggggctgc	tggcctggcc	cttgagtggg	240
gcagccct	tgcctggAAC	tcactca	tgggtgcctc	ctccccaggt	ggaggtgc	300
ggaagctcc	tccctca	tggggcattt	caccattcaa	acaggtcgag	ctgtgctcgg	360
gtgtgccag	ctgtcccaa	tgtggcgtat	tccgtggca	aatgacttt	ta	412

<210> 194

<211> 405

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(405)

<223> n = A,T,C or G

<400> 194

cgttgctgtc	ggtcagcaat	gaaataaata	tcttgtagaa	tgttccccnn	nnnnnnnnnnnn	60
nngaaccctc	ggggccctt	ttttccgaa	accccaactg	aaaaaaaacc	cttgggggggt	120
tggcaaaacc	ccccataaaa	agggggggaa	aaaaaggctt	ttttggaaa	aatgggggggg	180
tcttgcttt	ttttggaccc	ctttaagcg	ggggaaacca	gttaacccc	ccccaggggc	240
nnnnnnnnnn	gtttcaggc	cnnnnnnnn	nnnnnnnnnn	ttttccctn	tctcccttct	300
gtctcgccct	gctgcgtgc	cgtttctcg	ttccactccc	cccgttttg	tactcccccc	360
gtgccgttga	cggtccaccc	tatttttcg	cgccgggtgca	cccc		405

<210> 195
<211> 400
<212> DNA
<213> *Homo sapiens*

```
<220>
<221> misc_feature
<222> (1)...(400)
<223> n = A, T, C or G
```

<400> 195

ggcacgagat	taggaccctt	ccttggcaca	ggggtgagaa	agagcttggg	gaacgcttgg	60
cattatggag	ggcttggagg	ggctcaaccc	cgatttggag	agaagtttgg	gatggagtgg	120
gcgagagatt	gagagagcga	gcaggaaaaag	aggcttttgg	gcctgggact	gatgttggat	180
aaggccttga	aagaagatga	cgaggaggag	gagagagggg	agtggggtgg	atgaggagca	240
ngctgacacc	tgggtgtgcc	tcaatccccca	aggccaggga	gggcggngct	ggccccttggg	300
aagaacttggg	tctctttggct	cccttaggcac	tgcctaaact	ggctgagcca	ggagtggggc	360
aagaatatgg	atgttcaggcc	caacacaagg	agggggagggg			400

<210> 196

<211> 402

<212> DNA

<213> Homo sapiens

<400> 196

ggcacgagat	taggaccctt	ccttggctca	ggggtgagaa	agagcttggg	gaacgcttgg	60
cattatggag	ggcttggagg	ggctcaaccc	cgatttggag	agaagtttgg	gatggagtgg	120
gcgagagatt	gataagcga	gcaggaaaag	aggcttggg	gcctgggact	gatgggtggat	180
aaggccttgg	aagaagatac	taggaggagg	agagagggaa	gtgggggttgg	tgaggagcag	240
gctgacacct	gggtggccct	caatccccaa	ggccaggggag	ggcggggctg	gcccccttggga	300
agaactgggt	ctctgggctc	ccttaggcact	gcccaaactg	gctgaaccag	gagtggggca	360
agaagtgaga	gtcaaggccc	aacaaaagga	gggggaggag	ct		402

<210> 197

<211> 401

<212> DNA

<213> Homo sapiens

<400> 197

<210> 198

<211> 397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1) . . . (397)

<223> n = A, T, C or G

<400> 198

tgcataattag	acattcttaa	caggcgcca	gtctagtgtt	gaaagttta	tttttcatt	60
tttcttttaa	gcaaattttt	tttaaaaaat	tctgatnnn	nnnnnnnnnn	nnnnnnnnnn	120
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	180
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	tctgattaa	240
ttcttttatt	tatcataagg	ggtttaattc	ctgaagtaaa	ggtttgccacc	tattaaactt	300

aaaactgcc aatgattttt gttctttat gtgcgcgata gaaatacataa gaatggagtg	360
gccacctcct cccttcaga ctagggcagc agggacg	397

<210> 199

<211> 398

<212> DNA

<213> Homo sapiens

<400> 199

ggcacgagaa gaaagggtta tactgagaaa tggaaagagat aattttagaa acttgtgaaa	60
aatggcttaa tctaaatagag tggtagggga gatacagtt tgatgatagg ttgagctcac	120
atgggtggaga gccacagttt cggtgtctt cactgataat gtgaggcat ggagacagac	180
aataggttga atgctctttt ttacaaaag gaagtagaaa gggaggggta tgtaaatttg	240
ataaataggt tggtaaaaac ttatattttc ttgttaaagag agagaactga gcatgttga	300
ggtataaggt aaaaaggcgt gaagaggaat atttcgttga taatgaaagg gagcaactta	360
ggggaaaaaaa cttcccaagg aggaggggag cagggaaa	398

<210> 200

<211> 394

<212> DNA

<213> Homo sapiens

<400> 200

ggcacgagca gaaggcagcg gtctaggcga ggacgccccg ctggaccagg agaccgcccc	60
gtggctgcgc tggacaaga attcctaact tttggaggca gtgaaacgac taatagcaga	120
aggtataaaa gaagaactac gaaaatgttt tggggcccgatggagtttggacagctgg	180
cctccgagct gctatggac ctggaaatttc tcgtatgaat gacttgacca tcatccagac	240
tacacaggga ttttgcagat acctggaaaa acaattcagt gacttaaagc agaaaggcat	300
cgtgatcagt tttgacgccc gagctcatcc atccagtggg ggtagcagca gaaggtttgc	360
ccgacttgc gcaaccacat ttatcagtca gggg	394

<210> 201

<211> 391

<212> DNA

<213> Homo sapiens

<400> 201

ggcacgagca ggcgtgtctg ggtaaccatg tggctcctgc tggccctcccc tgcctgtccc	60
caaagcacag ggctcagtc cagagggaga cgggctggc tgcgtggcgtt cccaggtgc	120
tccactttc cagcagcaact tgggtccagc agaggctgca ggtgtggcag gaggggggccc	180
agccgtgagg gcaccagtt cagggccggc atctcaggtt ggagagccag ggctgtcctg	240
aacctccaga ggggggtgagc tggaaacttg tgcgtggg cttttccaa aaggaaaacg	300
ggagcttact ggctcacggc tgcgtggg cttttccaa gacagcctcg aggatctgca ggtccccaga	360
caccaagcct ggggtctc cagcagacgg c	391

<210> 202

<211> 392

<212> DNA

<213> Homo sapiens

<400> 202

ggcacgagat tctcagtaca ctaaacactt gttaagagtg ttgttaagag ccagagttag	60
tatcatgtgg gacacagacc cttttttctt aaaggctttg tggcatcaga cacataaagg	120
gtatatgttag tggggagcac taaccatggc agggtaattt attcaggcata cagagtata	180
attctggaaa catctagact cactgcatta acagaggatt ttgtttctaa agtagacctc	240
ttatgtcatac cagatttcac tcattctgac cacagccagg aagctgaggg tgaagccaga	300
attagctgaa accccaccaag agctgcatac agcacgttta gctagacttag gagtttgcag	360
tgctcatatg gggaaatgtc ctgtataact tt	392

<210> 203

<211> 392

<212> DNA

<213> Homo sapiens

```

<220>
<221> misc_feature
<222> (1)...(392)
<223> n = A,T,C or G

<400> 203
ggcacgagga ggagccgc ccggaggctg aggctctggc cgtagccccgg gacggagca      60
gccgttctt gagcggcctg gagctggta agcagggtgc cgaggcgccgtg tttatccgtg      120
gccgttcca gggccgcgcg gcgggtatca agcaccgctt ccccaagggc taccggcacc      180
cggcgctgaa ggcgcggctt ggcagacggc ggacggtgca ggaggccccgg gcgctccctcc      240
gctgtcgccg cgctggata tctccccag ttgtctttt tgtggactat gcttccaact      300
gcttatatat ggaagaattt gaaggttcag tgactgttcg agattatatt cagtccacta      360
tggagactga aaaaactccc cagggctct cn      392

<210> 204
<211> 386
<212> DNA
<213> Homo sapiens

<400> 204
ggcacgagaa gccttaaacc gggaaatttc catgtatct agaggtttt gatgtcatct      60
taagaaacac acttaagagc atcaattta ctgattgtat tttatgtttt aagtacgaaa      120
gggttgtgc caatatttc tacgtattat gcagtattta tatctttgt atgtaaaact      180
ttaactgatt tctgtcattc atcaatgagt agaagtaaat acattatagt tgatggct      240
aaatcttaat taaaaggctt catttccta gaaatctaatttcaat tttcgttta ttcatgacaa      300
tatttttaa aagtaagaa attctgagtt gtcttcttgg agctgttaggt cttgaaggcag      360
caacgtctt caggggttgg agacag      386

<210> 205
<211> 295
<212> DNA
<213> Homo sapiens

<400> 205
gcgtctctt cacacacaaa agatatatat atagaaagggtt agtgtggata tcccccttaa      60
atatgtgagc gtgtctctt cgaccgtctc ccccaagagaa aatatctcta gagagagcac      120
aagtgtgttc tctgtgtttt gtgtgtgaga aaaaataagt gcccgcgcac acatagattt      180
ttatatcgct ccccccgcgcg cctttatata ttgtttttgtt gtgtatataat attttataca      240
aaaacatgtt tctttttttagt gccccttaca aaaaaattt ttgttctttt gaacc      295

<210> 206
<211> 383
<212> DNA
<213> Homo sapiens

<400> 206
ggcacgaggta taccatcaag cccttgc aaaggccctctgg aagggtccagg      60
gatgggctctt gatgagaggg taaaagatgc tcaggaaac acaggcctca gctgcctaga      120
ggaccctccc cctgccttc agtgggctcg ggttagagcag tatcaggagc taggggttgc      180
tgctgcccac actcctgtt tttggatat ctaactgtca aggaggaggat tgacatcccc      240
cttctggctc atgtgtctga caccacaaac atggctctcg tccctctctc ttgactctc      300
cctttgtctt ccccatagag ctgggttggg gtggatccctt atacctgggg caggcagccc      360
caaagtgggg gaggggatg gca      383

<210> 207
<211> 385
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(385)
<223> n = A,T,C or G

```

<400> 207
 ggcacgagct tcaggataag aagctcatgg ccatgttctt agagtataac aaagccatcc 60
 ggaactacac ccgcttcgtat gactggtacc tttgggttca gatgtacaag gggactgtgt 120
 ccatgccagt ctccatgtcc ttggaggcct actggcctgg ttttcagagc ctcattggag 180
 acattgacaa tgccatgagg accttcctca actactacac ttttatggaa cttttgggg 240
 ggctcccgaa attctacaac attcttcagg gatacacagt ggagaagcga gagggttacc 300
 cacttcggcc agaacttatt gaaagcgc aa tgtaacctcta ccgtgccacg gnggatccca 360
 ccctccatgtt acttcggaa gatgg 385

<210> 208
<211> 374
<212> DNA
<213> Homo sapiens

<400> 208
 ggcacgagcc tcagctgcctt agaggaccct cccctgcctt tgcagtggc tcgggttagag 60
 cagttatcagg agctagggtt gtctgtgtcc cacactccgtt cttttggga tatcttaactg 120
 ctaaggaggg agttgacatc ccccttctgg ctcatgtgtc tgacaccaac aacatggct 180
 ctgtccctctt ctctttgact ctccctttgtt cttccatata gagctgggtt ggggtggatc 240
 cctataccctg gggcaggcag ccccaaagtgtt ggggaggggg atggcagaga ctgtaaaggc 300
 gcccactggac tctggcaagg ctttattttt ctttactccc cttccatcc catcaccagc 360
 ctcaaggcctt gagg 374

<210> 209
<211> 425
<212> DNA
<213> Homo sapiens

<400> 209
 ggcacgagcc caagtgcattt ctgcaggggt tttcggttggaa aaactgtcac cttacagaag 60
 ccaattgcataa ggaccttgctt gctgtgttgg ttgtcagccg ggagctgaca cacctgtgt 120
 tggccaagaa ccccatgggg aatacagggg tgaagtttctt gtgtgagggtt ttgagggtacc 180
 ccgagtgtaa actgcagacc ttgggtgtttt ggaactgcga cataactagc gatggctgt 240
 gcgatctcac aaagcttctc caagaaaaat caagcctgtt gtgttggat ctggggctga 300
 atcacatagg agttaagggaa atgaagttcc tttcggttgggatggatccatccctcc gttcagttgt 360
 actttagatg tctgtgggttgggatgtt ccattccatcc gttcagttgtt gaagacctct 420
 gctctt 425

<210> 210
<211> 396
<212> DNA
<213> Homo sapiens

<400> 210
 ggcacgagga gcaagggaaat aatattgtca tatttgcgtt tgagaatgtt ccctgagtct 60
 cggttttctt atctatggaaa tgaggctaaat aataataaaa tagagaatata aatggatata 120
 tgcctgtaaa cagtgcctgg catatagctt attattcatc cagcttgcgc gcccattccat 180
 atgtgaagct ttgtgtgttgg aggtctgtat tacaatcaca ttcaattttata gctaatttt 240
 tacttatgtt gctatctctg aaacttagaa atgaaatcat cgaggaaaaa ggccattttct 300
 tgatccctgtc ttgtgttccctt gttccctggca taaaggctaa cacgtttagt gctaattgtca 360
 ccgagcaaaat aaagcatcaaa agtggcggtt cggggcc 396

<210> 211
<211> 267
<212> DNA
<213> Homo sapiens

<400> 211
 tctctagaga cacacagaga gggtgagcgg ctctctcaca cgcaccccaag agtcaggcgc 60
 gcacgcgttcc tctctcttc tctatccctc agaaaatgtt ttccctttcc ctctccctgt 120
 gatgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt 180
 ctgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt gatgtgtgtt 240
 acttttttttataatgtgtgtt cagttcc 267

<210> 212
<211> 396
<212> DNA
<213> Homo sapiens

<400> 212
ggcacgagcc aggaggaccc tcgccttcctc tccgcacatgc ttgccacctc ttgtcttctga 60
gagtccatct cagttcgtag ttctgtact tgcatgtacc tggctcaat caagctacaa 120
ctcaaggcagt cacggggaga aggattgttag atggggccagt gactcacagg gtcaggcact 180
cgggggagcc tgagtcaagga ggtcagtggg ccctggaaagg gagggggcaa gcctgggtgg 240
gtaaggttct gggccccagg caagaaggca gagttctcc gcaggggtgt gtgcaagagc 300
tagctgcgca gaaggtctcc gctggctctc caagccggc ttgtgaaata ggaacgccaa 360
catccttcctc cacaggcagt ggcaggcacc tcctcc 396

<210> 213
<211> 284
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(284)
<223> n = A,T,C or G

<400> 213
tggctgtct cgcccttcct ccctctctct ttgtactcac agtaaaaat tatagtgttc 60
gcgtgcgggg cgcgctcttt actttttttt ctctctaca catatttata tatatagaga 120
gaggctccga ggcgtctgcc ccccttcctct ctctctcttc tcacgtgtgt gcatcaccca 180
ctcnnnnnnn nnnnctttc cagagatacg ggggttgtt tcctccgctc tctctcacac 240
gtctgtgcag cagaggacta ttttttttctt tcccccgctg cttn 284

<210> 214
<211> 440
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(440)
<223> n = A,T,C or G

<400> 214
ggcacgaggg attgcagtca gcactttctg aatgttttca cacagtatgc aaagcttaca 60
tcataccaag gagtggagag ttgaagtttc ctcccagtga ctccagtgc agaccacacc 120
tagaaaagcgt ttctcttcct gatgtttca aaaagatgtt aaagagctgg ggagaggtatg 180
ggaagaaaaca atacaggatt gccttaatt attaagaat tgcctctga taaaaggaaa 240
aagaaaattaa tgctggagta tgggggggtg ataaccttaa agattataaa tatttgttgt 300
ctataaatac ttataaattaa taaacacaaat ataattaaaa ttagaacatc aggaaaagaa 360
ttaaaatctt caggttgcac aacccaaatg ttaacccaaa caaatactca tgagattcaa 420
ctttgttcac ctatagaaan 440

<210> 215
<211> 439
<212> DNA
<213> Homo sapiens

<400> 215
ggcacgagtgc cacaggggac acttacggac acagaaatgc acagggggagg ccgagcataa 60
ccaggggtga ggggcagca gcagttgttag ttactgccgc ggggcactgc tatgtgcagg 120
gacagccagc accccagccca tcaccactcc ctgggctgac tggcaggat ggcaccctgg 180
gagccccggca tataccccagg gcacccctac ggctgccccc agtctcatgc ccaggtgggt 240
gctctggctt ggagcggagg ccaggttttgc ggccgaggct tccccaggca atcctgtgag 300
ctcccttcata gcctctgacc cagtcgtgc tggcttgcat ggatgttaggg cttgggtgg 360

gaagttcagg	tcctggctt	gccttgcc	gatgtggatg	agcagctcac	atgctcagg	420
ccacctgaga	ctgtcactg					439

<210> 216

<211> 392

<212> DNA

<213> Homo sapiens

<400> 216

ggcacgagga	gacagagaag	tttggccagg	gggtccacca	tactgctgg	caggttgg	60
aggaggcaga	gaagttggc	caggtggg	aggaggaaga	cagagtggc	caaggcctc	120
atcatggcg	tagtcaggt	ggaagggg	cggggcagg	tggccacgac	attcaccaca	180
cagcagggca	ggctgggaaa	gagggagaca	tagcagtta	tggtgtccaa	cctggggtcc	240
acgaggccgg	gaaggaggca	ggcagttt	gccagggagt	tcaccatacc	cttgaacagg	300
ccgggaagga	gcagacaaa	gcccgtcca	ggttccacac	tgggtccac	caggctgg	360
aggaagcaga	gaaaccttgc	ccagggg	tc			392

<210> 217

<211> 394

<212> DNA

<213> Homo sapiens

<400> 217

ggcacgagcc	catctgggc	agcaccacgt	ggatctctcc	ctcgtcacct	tcaactgg	60
cctcgtggc	tttgcggaca	gtctcattag	caacatcctc	cttcgggtct	gggatgcct	120
cctgtacgag	gggacgaagg	tggtgttgc	ctatgccttgc	gccatttca	agtacaacga	180
gaaggagatc	ttgaggctac	agaatggcct	gaaaatctac	cagtagctgc	gcttcttcac	240
caagaccatc	tccaacagcc	ggaagctgat	gaacatcgcc	ttcaatgaca	tgaaccctt	300
ccgcatgaaa	cagctgcggc	agctgcgc	ggtccacccgg	gagcggctgg	aggctgagct	360
gcgggagctg	gagcagctta	aggcagagta	cctg			394

<210> 218

<211> 432

<212> DNA

<213> Homo sapiens

<400> 218

acacccactt	gtttgaggac	accatcgatt	cgaattcggc	acgagccctag	ccagccccct	60
acgtgccta	caggagtct	tccagacacg	ccaaaagtga	cttggactca	aagttaaagg	120
caaacctgca	gaaaatgtat	ttaagcttgc	agctctcaaa	ctgaaaaccac	atactaataat	180
catgaggatg	gcatctcgag	aggagagctt	ggaagatgtc	ttaggtccac	cccctgacaa	240
tgtatgatgtt	gttaatgact	ttgatattga	agatgaagta	gttgaagtag	aaaataggga	300
agaaaaccta	ctgaaaattt	ctcgcagacg	gaaagagtagc	aaagtggaaa	ttttgaatcc	360
tccaggggaa	ggggaaaagc	ttttggtgct	agatgttat	tatacattat	ttgaccacag	420
gtcttgcga	ag					432

<210> 219

<211> 395

<212> DNA

<213> Homo sapiens

<400> 219

ggcacgagcc	ctttactcct	ctacccaaga	tcttgcttgc	ttctttctaa	gttgcctctc	60
tatctagctt	gcaggatttgc	agttgaggaa	aacacagact	tccatgagg	tgggaactac	120
gagagaaaag	acagacagag	tcaaattctac	agcatatctc	tcacccagg	aactggaa	180
tgtattttat	caatatgatg	taaagtctga	aatatacagc	tttggatctcg	tcctctgg	240
aatcccaact	ggagatatcc	cggttcaagg	ctgttaattct	gagaagatcc	gcaagctgg	300
ggctgtgaag	cggcagcagg	agccactggg	tgaagactgc	ccttcagac	tgcgggagat	360
cattgatgag	tgccgggccc	atgatccctc	tgtgc			395

<210> 220

<211> 487

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(487)

<223> n = A,T,C or G

<400> 220

tgcttttg atgatccat cgattcgaat tcggcacgag cagctagctc agttcaaggt	60
ggaaatggct taacgagagg aacggcaaca gcaggtggct gaggactacg agctcagact	120
ggccgggag caagcgcag tgcgaact gcagagtggg aaccagcagc tggaggagca	180
gcgggtggag ctggggaaa gactgcagc catgctgcag gcccactggg atgaggccaa	240
ccagctgctc agcaccactc tccccccccc caaccctcca gtcctccctg ctggaccctc	300
cagcccccggg ctcaggagc ccgagaagga ggagaggagg gtctgacta tgccctccat	360
ggccgtggcc ctgaagcctg tattcagca gagccgggaa gcaaggacg agtacacctgg	420
agcgcctcct gtttttgca gntccctcctc agatcttagc ctccctggg gcccctctt	480
tcagagc	487

<210> 221

<211> 365

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(365)

<223> n = A,T,C or G

<400> 221

ggatgccagt ggtgaggctg taagcgaaac ttttcagttt aaagctcaag atctcttaag	60
ggcagtccca agatccagag cagagatgtc tgatgacgtc cacagcgatg gcagatactc	120
cctcagtgga tctgttagtc actctagaga tgccggaaga gaaggcctga gaagtgacgt	180
atttccaggg ctttccttca gatcaagcaa cccttccatc agtgatgaca gctactttcg	240
caaagaatgt ggccgggatc tggaattttc tcactctgtat tctcgggacc aggtcattgg	300
ccaccggaaa ttggggcatt tccgttctca ggactggaaa ttgcgcctcc gtggttcttg	360
ggaan	365

<210> 222

<211> 376

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(376)

<223> n = A,T,C or G

<400> 222

ggcacgagga gatcccccgg cgggtcccggt cctctgcgtg cacgcgcctg cgtgctcgcg	60
ctcgccgttc tggcgctgt nnn	120
nn	180
nn	240
nn	300
nn	360
nn	376
nnntgatggc agcagtggcc tgcctgaagc agccactgcc aagaatctag	
ctgcagtnnn nnnnnnnnnnnnnnnnnca tgctccacac agccaccggg agccaagaac	
gcaccctcct ggtacagct gcaagccgcc accgaggct gcggaccggg gcctccctgg	
tgctctgggg gttggg	

<210> 223

<211> 399

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(399)

<223> n = A,T,C or G

<400> 223

ggcacgaggg	gtgacagagc	ggctggcgca	tgctcagtag	agcaggctac	ggcaagcagc	60
ctccctcagg	gaacatcaca	ggaagcagct	gcaggacctg	agtggacagc	accagcagga	120
gctggccagt	cagctagctc	agttcaaggt	gaaatggca	gaacgagagg	aacggcaaca	180
gcaggtggct	gaggactacg	agctcagact	gccccggag	caagcgcag	tgtgcgaact	240
gcagagtggg	aaccagcagc	tggaggagca	gcgggtggag	ctggtgaaa	gactgcaggc	300
catgctgcag	gcccactggg	atgaggccaa	ccagctgctc	agcaccactc	ttccgcccgc	360
caaaccttca	gcttcttctg	cttgaccctc	cagccccgn			399

<210> 224

<211> 402

<212> DNA

<213> Homo sapiens

<400> 224

ggcacgaggg	cagttcagta	tcgatggaca	gatcttctta	ctctttgact	cagagaagag	60
aatgtggca	acggttcatc	ctggagccag	aaagatgaaa	gaaaagtggg	agaatgacaa	120
ggatgtggcc	atgtccttcc	attacatctc	aatgggagac	tgcataaggat	ggcttgagga	180
cttcgtatg	ggcattggaca	gcacccctgga	gccaaatgca	ggagcaccac	tcgccatgtc	240
ctcaggcaca	acccaactca	gggcacacgc	caccaccctc	atccttgct	gcctcctcat	300
catcctcccc	tgcttcatcc	tccctggcat	ctgaggagaa	tcctttagag	tgacaggtt	360
aagatgatac	aaaaagccc	ctgtgagcac	ggtcttgatc	ag		402

<210> 225

<211> 270

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(270)

<223> n = A,T,C or G

<400> 225

ctctctttct	ttctccctcc	ccccccgggc	gcgcgtcattt	atctcgcttc	ttatgtctct	60
ctctctgtgt	ctgtgacaga	cacactctt	ttcatatagc	gcgcctccctt	ttctttgctc	120
tcgggggggg	tctctctgtt	cgcgtgtgtt	ctctctccag	tgagtgtgca	cgccttaggt	180
agagagatn	nnnnnnnnnn	nnnnntgtgt	gtgaattttt	tatatttcta	tatctctcac	240
tctctgggtg	tcacactctc	cgtgtgtggg				270

<210> 226

<211> 404

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(404)

<223> n = A,T,C or G

<400> 226

ggcacgagaa	ccctcccagg	ctaagccca	atttggggct	gcgcctgcct	gcatcaggga	60
gacatgtcag	ctgaggagta	attgaccaga	tttctgtctt	agaaatatgg	cagtggaggc	120
aggagatggc	atctgaggcc	caggctgggg	agaagggtgc	tgggatgaga	acctggaggtt	180
cagaccagg	aagggtatgag	agcctaagaa	gaggatctt	caccctgaga	caggctgg	240
caggagtctg	ctcgatccag	gcctgggtcc	ctgggtccct	ctgagcttgg	gaggactatg	300
tgagacagaa	caggaccagg	gcgcgtcatt	cccccttgtt	ttattcatct	tcnnnnnnnn	360
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnn		404

<210> 227

<211> 389
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(389)
<223> n = A,T,C or G

<400> 227
ggcacgagaa gtcactcaac ctctctgagc ctttcttca cctataaaagt ggggatagta 60
actacacctt ttatggaaagc atatgaggat tgggtgaat catccatgtt gcccctccac 120
cgccacgtgg agtttggcat ggaggagttt ctaaatggaa gtcatcttga tcaggtggc 180
tgccaacctc tctgagcctc agtttgcctt tcttagggat ggggacaatg caatggaaat 240
ctgaggattt gttgaaattt tgcaaatgca tgaatgtggg ctgggatagt aaaaggagg 300
gccccggagc agcccacctg gggtcctatc tagtggacgc gcccgtgcc cacccattgc 360
tgtatgcca gcagccactt gcaagcatn 389

<211> 228
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(384)
<223> n = A,T,C or G

<400> 228
ggcacgagct gccaccctcta gaaagctgct ttcttctatc accgcttgcc cttgaattat 60
tccctgaatg aaggccaagaa ccctccagg ctaagccccca atttggggct cgccctgcct 120
gcatcaggga gacatgtcag ctgaggagta attgaccaga tttctgcctt agaaatatgg 180
cagtgaggc aggagatggc atctgaggcc caggctgggg agaagggtgc tgggatgaga 240
acctggagtt cagaccaggg aaggatgag agcctaagaa gaggagctt caccctgaga 300
caggctggtg caggagtcgt ctcgatccag gcctgggtcc ctggatccct ctgagcttgg 360
gaggactatg tgagacagaa cagn 384

<211> 229
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(292)
<223> n = A,T,C or G

<400> 229
gggtctctc tctcgaaaaa gccccccctc tctctatttt tttttgcgcg cacactcact 60
ctctctctc tttttccccc ggcgcgcgc acgcgccttt tttttctttt ttctnnnnnn 120
nnnnnactct ctctctttt tcttttgcgtt gggggctcc ggcgcgccttc tctctctc 180
tctcacccac agacactctc tctgtgtgcg cacctctctc tctcgaaaaa ccggatctct 240
ctccccccctc tctatctctg ttatgggg ggtccctcc ggcgccttc ca 292

<211> 230
<212> DNA
<213> Homo sapiens

<400> 230
ggcacgagggt gggacagaag tagaagaggg tgaatggccc tggcaggcta gcctgcagtg 60
ggatggagt catcgctgtt gagcaacctt aattaatgcc acatggcttg tgagtgtgc 120
tcactgtttt acaacatata agaacccctgc cagatggact gttcccttg gagaacaat 180

aaaacctcg	aaaatgaaac	gggtctccg	gagaataatt	gtccatgaaa	aatacaaaca	240		
cccatcacat	gactatgata	tttctttgc	agagtttct	agccctgttc	cctacacaaa	300		
tgcagtagat	agagtttgc	tccctgatgc	atcctgttag	tttcaaccag	gtgatgtgat	360		
gttgtgaca	ggatttgag	cactgaaaaa	tgatggttac			400		
<210> 231								
<211> 332								
<212> DNA								
<213> Homo sapiens								
<220>								
<221> misc_feature								
<222> (1)...(332)								
<223> n = A,T,C or G								
<400> 231								
tatata	gaca	ccccgccttt	tttctctctc	tctctata	aca	ccccgtct	ctctcccccg	60
tgtgtctc	tc	ccctctcttt	tgctcata	tatatac	ta	ca	tgtggggac	120
tctctctagc	gctccctctc	ttttgtgtgg	gctctcac	acacacac	nnnnnnnnnn		180	
nnggagactc	c	tttctctgt	ggagaatatg	tgtgcgcacc	atctctct	ctcttatttt	240	
tccctcg	g	gctcgctctg	tgagagagac	tctctgttct	ca	acatatg	300	
ccctccc	c	tctcacactc	gtgccccg	cn			332	
<210> 232								
<211> 407								
<212> DNA								
<213> Homo sapiens								
<220>								
<221> misc_feature								
<222> (1)...(407)								
<223> n = A,T,C or G								
<400> 232								
ggcacgagaa	ctccggctac	gtttgtgtc	ccaacaaata	gaccagggtt	ccctaagtgt		60	
cgcttcctcc	aagaagccct	ccctgatgag	ttgagccact	ttagttgtg	ctcaggctca		120	
ccctgcacgt	cttgggtgt	ctcatca	taatgatcta	aaacacacgt	ctgctcatga		180	
gaccgcata	ccaccccca	tgctggggcc	gctctggat	tttcatgcct	gctgccagca		240	
cccaggggga	gctccggaaa	tgtctgtgg	gggctcgaa	tacccac	tctggtaatg		300	
cagccccagcg	gttcccagcc	tcgtttcca	gccctca	anaatggagt	cgctctgg		360	
cgaacgc	c	tgancagtgt	gtacctacgt	gtcaggccca	tccttcc		407	
<210> 233								
<211> 406								
<212> DNA								
<213> Homo sapiens								
<400> 233								
ggcacgagga	aagacccacg	tgctgcctca	tgtggccgac	atcctcagca	agtcttgc		60	
ggcacccagg	tgagcctctg	gtgggggtgg	gtatcacca	ctcggtctg	gaggatgagg		120	
cctggccat	aatccagg	tgatccat	ctcgaagg	ccagaggtaa			180	
ctgcgttgc	ccatcctca	ggcatccc	gcccgtctg	ccaagtgcgt	gctggccgag		240	
gtcccgaa	agggtgg	gtactacagc	cacagagg	tgccccgag	aagcctgg		300	
gtccctgccc	gagaggccag	cccaggctgc	acaccgtgaa	aatgtggagg	gcgtaaagg		360	
ggggcccaga	aagaaagtgt	cccacacaac	ctctgttgc	acatgg			406	
<210> 234								
<211> 380								
<212> DNA								
<213> Homo sapiens								
<400> 234								
ggcacgagga	gggtgaatgg	ccctggcagg	ctagcctgca	gtggatggg	agtcatcgct	60		

gtggagcaac	cttaattaat	gccacatggc	ttgtgagtgc	tgctcaactgt	tttacaacat	120
ataagaaccc	tgccagatgg	actgcttcct	ttggagtaac	aataaaacct	tcgaaaatga	180
aacggggct	ccggagaata	attgtccatg	aaaaatacaa	acaccatca	catgactatg	240
atatttctct	tgcagagctt	tctagccctg	ttccctacac	aatgcagta	cataagagttt	300
gtctccctga	tgcatcctat	gagttcaac	caggtatgt	gatgtttgtg	acaggatttg	360
gagcactgaa	aatgtatgtt					380
<210>	235					
<211>	410					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(410)					
<223>	n = A,T,C or G					
<400>	235					
ggcacgagct	gagcaggact	tagaggaact	ccggctacgt	ttgctgtccc	aacaaaataga	60
ccagggttcc	ctaagtgtcg	cttcctccaa	gaagccctcc	ctgatgagtt	gagccacttt	120
agtttgtct	caggctcacc	ctgcacgtc	tggttgctct	catcaactgta	atgatctaaa	180
acacacgtct	gctcatgaga	ccccatccc	accccccgtat	ctggggccgc	tcttgattt	240
tcatgcctc	tgccagcacc	cagggggagc	tccggaaatg	tctgctgggg	gctcggaaata	300
cccacccccc	tggtaatgca	gcccagcggg	tcccagcctc	gtntccagc	cctcaactcan	360
aatggagtctg	ctctggttcg	aacgcctctg	acaagtgtgt	acctacgtgt		410
<210>	236					
<211>	394					
<212>	DNA					
<213>	Homo sapiens					
<400>	236					
ggcacgagac	tccggctacg	tttgctgtcc	caacaaatag	accagggttc	cctaagtgtc	60
gcttcctcca	agaagccctc	cctgatgagt	tgagccactt	tagttgtgc	tcaggctcac	120
cctgcacgtc	ttgggttgctc	tcatcaactgt	aatgatctaa	aacacacgtc	tgctcatgag	180
acccgcaccc	caccccccgtat	gctggggccgc	ctcttgattt	ttcatgcctg	ctgccagcac	240
ccagggggag	ctccggaaat	gtctgctgggg	ggctcggaaat	acccacccctt	ctggtaatgc	300
agcccagcgg	gtcccagcct	cgttttccag	ccctcaactca	aatggagtc	gctctggttc	360
gaacgcctct	gacaagtgtg	tacctacgtg	tcag			394
<210>	237					
<211>	428					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(428)					
<223>	n = A,T,C or G					
<400>	237					
ttccggcacga	nnnaagaaga	ggccctcaga	gatctgacag	cctatgagtg	cgtggacacc	60
acctcagccc	actgagcagg	agtcaacagca	cgaagaccaa	gcgaaagcg	acccctgccc	120
tccatcctga	ctgctccctc	taagagagat	ggcacccggc	agagcaggat	tctgccccct	180
tctgctgctt	ctgctgctgg	ggctgtgggt	ggcagagatc	ccagtcagtg	ccaagcccaa	240
gggcatgacc	tcatcacagt	ggtttaaaat	tcagcacatg	cagcccgagcc	ctcaagcatg	300
caactcagcc	atgaaaaaca	ttaacaagca	cacaaaacgg	tgcaaagacc	tcaacacccctt	360
cctgcacgag	cctttctcca	gtgtggccgc	cacctgccag	acccccaaaa	tagcctgcaa	420
gaatggcc						428
<210>	238					
<211>	432					
<212>	DNA					

<213> Homo sapiens

<400> 238

tctcatggag	gaacccatcc	attcgaattc	ggcacgagga	tcaactggct	atcatatatctg	60
tttaatacat	ttactggagc	cagaaaccta	ggccatcatc	gaaccccagc	ccttggtctg	120
agcctgcggc	tgttagatgtg	gaactcacag	catatgcatt	gttggccag	cttaccaagc	180
ccagcctgac	tcacaaggag	atagcgaagg	ccactagcat	ataggcttg	ttggccaagc	240
aacgcaatgc	atatggggc	ttcttctta	ctcacgatac	tgttagttct	gtacaagctc	300
ttgccaaata	tgccactacc	gcctacgtgc	catctgagga	gatcaacctg	gttgtaaaat	360
ccactgagaa	tttccagcgc	acattcaaca	tacagccagc	taacagattt	gtatccagc	420
aggataccct	gc					432

<210> 239

<211> 373

<212> DNA

<213> Homo sapiens

<400> 239

ggcacgagggc	aggacctct	ctcccgagtc	gcccgagctgc	aggaggagaa	caagcagctc	60
atgaccaacc	tctcccacaa	ggatgtcaac	ttctcgagg	aggagttcca	gaagcatgaa	120
ggcatgtcg	agcgggagcg	acaggtgtat	aacaagctg	aggaggtgg	ggacaaacaa	180
cgcgacgaga	tccgcgccaa	ggacagggag	ctggccctg	aaaatgagga	cggtgaggct	240
ttacagcagc	agcagacacg	gctgtatgaag	atcaaccatg	accttcggca	ccgggtcact	300
gtggtggagg	cccaggggaa	agccctgatc	gaacagaagg	tggagctgga	ggcagacactg	360
cagaccaagg	agc					373

<210> 240

<211> 392

<212> DNA

<213> Homo sapiens

<400> 240

ggcacgagag	ctgaccgaga	tggacgtttt	ctacatcg	tcgcttgtgg	gccacgagtt	60
cgagcgggtc	attgaccacg	acgggtgtta	ggccatcg	cgcctcatgc	ccaaggtcgt	120
gcmcgtctg	gagatcttgg	aggtgtctgg	cagtgc	cacgtcg	ccgagctgg	180
cgatctgcgc	ctggagcagg	acctcctctc	ccagatcg	cagctgtgg	aggagaacaa	240
gcagctcatg	accaacctt	cccacaagga	tgtcaacttc	tcaaggagg	agttccagaa	300
gcatgaaggc	atgtcagagc	gggagcaca	ggtgtatgaag	aagctgaagg	aggtggtgga	360
caaacaacgc	gacgagatcc	gcccacagga	cg			392

<210> 241

<211> 434

<212> DNA

<213> Homo sapiens

<400> 241

gatcccatcc	attcgaattc	ggcacgagga	ttgattcacc	ttcacctgtg	ctgcactcca	60
gctgacccaa	gttaggaagcc	ggacgagctg	taaaacatg	acgaaagagt	ggattatttg	120
gtcaactgagg	aagagatcaa	tcttaccaga	ggggccctag	ggctgggctt	caacatcg	180
ggggggacag	atcagcagta	tgttccaac	gacagtggca	tctacgtcg	ccgcatcaa	240
aaaaatgggg	ctggccct	ggatgggccc	ctccaggagg	gtgataagat	ccttcggta	300
aatggccaag	acctaaagaa	cctgtcgac	caggatctg	tagacctt	tctgtatgca	360
ggctatgt	tgttctgt	agtgcagcac	aggttacagg	tgcagaatgg	acctatacg	420
catcgaggt	aagg					434

<210> 242

<211> 385

<212> DNA

<213> Homo sapiens

<400> 242

ggcacgagga	gagcgcgcac	acctcctcaa	cccactgaac	aggagtcaca	gcacgatgac	60
cattcgaaa	gcgacccctg	ccctccatcc	tgactgctcc	tcctaaagaga	gtggcaccg	120

gccaaaacag	gattatgcc	ccttctgctg	cttctgctgc	tgccgcttag	tgtggcagag	180
atcccactca	gtgccaaacc	caaggcatg	acctcatcac	agtggtttag	aattcagcac	240
atgcagcccc	gcccctcaagc	atgcaactca	gccatgaaaa	acattaacaa	gcacacaaaa	300
cggcggcaaa	acctcaaacac	cttccctgcac	gagccttct	ccagtgtggc	cgccacactgc	360
cagaccccca	aatagcctg	caaga				385
<210> 243						
<211> 388						
<212> DNA						
<213> Homo sapiens						
<400> 243						
ggcacgagag	aaggcctgcg	gcaaagagat	gagcttattg	acaaacatgg	cttagttata	60
atccccgatg	gcactccaa	tggtgatgtc	agtcatgaac	cagtggctgg	agccatcaact	120
ggtcgtctc	aggaagctgc	tcaggtcttg	gagtcaccag	gagaagggcc	attacatgtt	180
tggctacgaa	aacttgcgtgg	agagaaggaa	gaactactgt	cacagattac	aaaactgaag	240
cttcagttag	aggaggaacg	acagaaatgc	tccatgactg	atggcacagt	gggtgacctg	300
gcaggactgc	agaatggctc	agacttgcag	gtcatcgaaa	tgcagagaga	tgc当地ataga	360
caaattagcg	aatacaaatt	taagcttg				388
<210> 244						
<211> 388						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(388)						
<223> n = A,T,C or G						
<400> 244						
ggcacgaggt	cactgttcaa	gagtcaatc	ttaccagagg	gccctcagg	ctgggcttca	60
acatcgccgg	tgggacagat	taccagtatg	tctccaacga	cagtggcattc	tacgtcagcc	120
gcatcaaaga	aatatggggct	gcggccctgg	atgggcccgt	ccaggagggg	gataagatcc	180
tttcggtaaa	tggccaagac	ctaaagaacc	tgctgacca	ggatgctgaa	cacctctttc	240
gtaatgcagg	ctatgctgtg	tctctgagag	tgcagcacag	gttacaggcg	cagaatgtac	300
ctataggaca	tcgaggtgaa	ggggacccaa	gcggattccc	atatttattg	tgctgggtgcc	360
cgnngctggc	ctctccctgg	tattcgcg				388
<210> 245						
<211> 390						
<212> DNA						
<213> Homo sapiens						
<400> 245						
ggcacgaggc	tgtgtgtctc	ttttctcacc	ccagggcctg	gccatgtccc	ctttgggaag	60
cctgttccct	tacccctaca	cgtacatggc	cgcagcggcg	gccgcctctt	ctgcggcagc	120
ctccagctcg	gtgcaccgccc	acccttcct	caatctgaac	accatgcgcc	cgcggctgcg	180
ctacagcccc	tactccatcc	cggtgcgggt	cccggacgjc	agcagtctgc	tcaccaccgc	240
cctgcccctcc	atggcggcgg	ccggggggcc	cctggacgjc	aaagtcggcg	ccctggccgc	300
cagccccggcc	tcgggtggcag	aggactcggg	ctctgaactc	aacagacgct	cctccacgct	360
ctccctccagc	tccatgtct	tgtcggccag				390
<210> 246						
<211> 397						
<212> DNA						
<213> Homo sapiens						
<400> 246						
ggcacgagac	cactgggacc	tcctgctcct	cgccatcatc	aacacaggjc	tgtctctgtt	60
tggctgcct	tggatccatg	ccgcctaccc	ccactcccc	ctgcacgtgc	gagccctggc	120
cttagtggag	gagcgtgtgg	agaacggaca	catctatgac	acgattgtga	acgtgaaggg	180
gacgcggctg	acctcgctgg	gcccacgcgt	cctggtgggc	ctgtccctgt	tgctgctgcc	240

ggtcccgctt cagttggatcc ccaagccccgt gctctatggc ctcttcctct acatcgcgct
 caccccccgc gatggcaacc agctcgcca gcgcgtggcc ctggtggttc aggaacccaa
 ctggggAAC ccccgacaca ctacatcccc gaggggg 397

 <210> 247
 <211> 471
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <222> (1)...(471)
 <223> n = A,T,C or G

 <400> 247 60
 ttacggcgcg ttttgttaggg gacccccacccg attcgaattc ggcacgagct ctttttattt
 tcgctgatata cttttttta ctaaatgcac ccatecttac ctgttcgggt gtctgcgtgc 120
 ctaatttttc ctggctgtta cacaagaacc cgatgttttag ttgaactctg gagcaaaaat 180
 cctgcattcat ttgttaggtgg gtgtcattgt gactggctgc tacctccca tgagtcttct 240
 aaaataaaaac ctgcaaaattc acatcttccc catgcttcca gagaatgcat attcttcctt 300
 tgaaaaaaaga aaacnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnn 360
 nnnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnn 420
 nnnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnngat g 471

 <210> 248
 <211> 403
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <222> (1)...(403)
 <223> n = A,T,C or G

 <400> 248 60
 ggcacgaggt acagacatct agttggcagg agccaaagat gttgccaaac atgttagtann
 nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 120
 nnnnnnnnnngat gtagaggatg cctggtatga ggcaatattt gggataggaa agggaaagctt 180
 gggattttag ctacgttagag acacttgaaa attggaggaa ggaaaggagt gggtggcttt 240
 ggagatgttc tggatatgt gaatgagggg agtggagggg ncctgnnnnc tctgnngaag 300
 gccangcccg gtttcctgtc ttccancctc ttccagggaa attacggca gaaaggaggct 360
 gagaaaagtgg tccccgggaa ggccgtttat gaagagctt gtg 403

 <210> 249
 <211> 316
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <222> (1)...(316)
 <223> n = A,T,C or G

 <400> 249 60
 ccgcattaaag gcgccttctt ttaatgcaat cattttgaac atgtgcgaca gtcgagaata
 ctaattgtat caatcttgcatactctacc taaagacagt ctagaaacct gggggagaaa 120
 gaactcacgg cacaacacat tggcccgaga acggaaattct ctgtaaagctt agttgtgtgg 180
 acttccctgt gtaaccagaa gcccgttttctatcggtc actgaaacac ccactgtgtgg 240
 ttgtctactc cctcactcactc cgaacanaac ctgttacactc cgcataatc tactagtgtcc 300
 gataaaactat atcaga 316

 <210> 250
 <211> 419

<212> DNA

<213> Homo sapiens

<400> 250

ggcacagat	atcagtcaag	ggcttcaa	gacacagcag	aaacctcacc	gggcctcg	60
ctgcctccca	ctgggtccca	tggccaccac	cttgacctt	gaaagctctg	ttatatggaa	120
ggttagggagg	acactattc	cctcaactac	ttctagtaaa	aagctcagtt	ctctccccag	180
cagcaagagg	gcacctgtga	acacctgagt	cacagcgcat	tcctcctctg	cttagaaacat	240
tcgatggctc	ccaccttact	tgcagtaaat	gctgagggtcc	ttcctgtggc	ccccggggcc	300
ctgcatgatc	tgatccatcc	cttacctacc	ctcatctctc	cactggcctc	cccacacttg	360
ctcccctccg	gacactctgg	actacttgct	gctatctgaa	cataccaggc	ccctgcccc	419

<210> 251

<211> 434

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(434)

<223> n = A,T,C or G

<400> 251

ggcacgagg	ggcctccacc	ggtgactcg	gcctggattc	cacggccatg	gcctctg	60
ctgcggcgca	gggactgtcc	ggggcg	cgacaccc	gccctccac	ctccagc	120
acgtcctggc	ctctcagg	ctggccatgt	cccctt	aagctgtt	ccttaccc	180
acacgtacat	ggacgc	ggccgc	cctctgc	agcctcc	tcgg	240
gccacccctt	cctcaatctg	aacaccatgc	gcccgc	gctacagc	ccctact	300
tcccggtgcc	ggtcccgg	ggcagc	tgctaccac	cgccctg	tccatgg	360
cggccgcgn	gcccctgg	ggcaaagac	ccgcctgg	cgccagcc	gcctcg	420
cagtggactc	ggcg					434

<210> 252

<211> 425

<212> DNA

<213> Homo sapiens

<400> 252

ggcacgagaa	agca	ctgggaat	aactct	caat	gatgtgacc	60
actcccccga	gagagt	ttt	gaagagg	tcgg	cagg	120
ccttggagga	gg	gtgc	ccct	caat	ggc	180
ggacggac	ggagg	gt	gaat	ttt	gg	240
gcgggcaccc	tt	gtc	tagcc	gaga	gg	300
acagtacccc	ggc	at	gat	gtac	gg	360
caagatgagc	gg	gat	gac	ca	gg	420
gcggccctgc	cc	gg	gg	aa	cc	425
gcagg						

<210> 253

<211> 395

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(395)

<223> n = A,T,C or G

<400> 253

ggcacgagca	gacatctgt	tggcagg	caaagatgtt	gccaaacatg	tagtannnnn	60
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	120
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	180
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	240
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	300
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	

aagcccgttt	tcctgtcttt	caacctcttc	cagggaaaatt	acgggcagaa	ggaggctgag	360
aaagtggccc	gggtgaatgc	gctatatgac	gagct			395
<210> 254						
<211> 307						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(307)						
<223> n = A,T,C or G						
<400> 254						
agtctgtcttc	ttttaatgtatc	atcattttga	acatgtgtga	aagttgatca	tacgaattgg	60
atcaatcttg	aaataactcaa	ccaaaagaca	gtcgagaagc	cagggggaga	aagaactca	120
ggcacaaaat	attggctctga	aatggaaatt	ctctgtaa	ctagttgctg	aaatttcctg	180
ctgttaaccag	aagccagttt	tatcta	acgg	ctactgaa	acccactgtg	240
tccctcactc	accgatcaaa	acctgctacc	tccccaa	agac	tttacttagtg	300
ttctcan					ccgataaaact	307
<210> 255						
<211> 312						
<212> DNA						
<213> Homo sapiens						
<400> 255						
agtctgtcttc	ttttaatgtatc	atcattttga	acatgtgtga	aagttgatca	tacgaattgg	60
atcaatcttg	aaataactcaa	ccaaaagaca	gtcgagaagc	cagggggaga	aagaactca	120
ggcacaaaat	attggctctga	aatggaaatt	ctctgtaa	ctagttgctg	aaatttcctg	180
ctgttaaccag	aagccagttt	tatcta	acgg	ctactgaa	acccactgtg	240
tccctcactc	accgatcaaa	acctgctacc	tccccaa	agac	tttacttagtg	300
ttctcaaaga	gc				ccgataaaact	312
<210> 256						
<211> 415						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(415)						
<223> n = A,T,C or G						
<400> 256						
ggcacagca	ggagcagctg	gcaaggaga	aggacacgg	gaagatgctg	caggaacagc	60
tggaaaaggc	agcgcgtgcc	tggccaaa	gcagggcgg	aggagtgcag	ctgcccggag	120
ccccggggag	gcaggaccgg	gagaggcaga	gctggcgg	gtcgta	tgctggagc	180
gctgggctgg	gagccccagg	ggaggcagag	ctggcgg	gtatgtgg	cagagacttc	240
ctaacgaggg	cttcagccca	cccggccac	cacccac	tctgggttc	ccttgctgg	300
aagcgagtgt	ctgatcccc	tgctggccca	ggtc	tact	ttgcacctgt	360
tagccagtgc	tccagccct	gccctgcagg	atgatggtt	cccctcagct	cccan	415
<210> 257						
<211> 396						
<212> DNA						
<213> Homo sapiens						
<400> 257						
agaaaagggtg	agtgagggtgc	tgtcctgggg	ttctcca	agt	ggatgc	60
ggtttgaagc	tgaagtggc	ctggggaa	gggttga	agg	cagaagca	120
ggaaggcatt	tggatatcca	gcccttctc	tgtggc	ttc	gccc	180
cccccacca	tacctgtctg	ctgc	actc	tgt	ttctgtt	240
					gcttctggcc	

ttaaaagttg gcaaggggag gttaataaagc acctagggtgg ctgagtgtct ctgtcttctg	300
gctgttcac aggacttcga gtaagaaggt gatttacagc cagccatgtg cccgaagtga	360
aggagaattc aaacagacct cgtaattcct ggtgtg	396
<210> 258	
<211> 431	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(431)	
<223> n = A,T,C or G	
<400> 258	
gnnggagggc ctgcggcaaa gagatgagct tattgagaaa catggcttag ttataatccc	60
cgtggact cccaatgtgt atgtcagtca tgaaccagt gctggagcca tcactgttgt	120
gtctcaggaa gctgctcagg tcttggagtc agcaggagaa gggccattag atgtaaggct	180
acgaaaactt gctggagaga aggaagaact actgtcacag attagaaaaac tgaagcttca	240
gttagaggag gaacgacaga aatgtccag gaatgatgac acagtgggtg acctggcagg	300
actgcagaat ggctcagact tgcagttcat cgaaatgcag agagatgcca atagacaaat	360
tagcgaatac aaatttaagc tttcaaaagc agaacaggat ataactacct tggagcaaag	420
tattagccgg c	431
<210> 259	
<211> 404	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(404)	
<223> n = A,T,C or G	
<400> 259	
ggcacgagca ggagcagctg gcaaggggaga aggacacggt gaagaagctg caggaacagc	60
tggaaaaggc agcgcgtgcc tggcgccaaa gcagggcggg aggagtcgag ctgccggag	120
ccccggggag gcaggaccgg gagaggcaga gctggcgga gtcgtcaagc tgctggagc	180
gctgggctgg gagccccagg ggaggcagag ctggcgagat gtatgggaa cagagacttc	240
ctaaccgggg cttcagccca cccggccac caccacccct tctgggttc cttgctggg	300
aagcgagtgt ctgatcccc tgctggccca ggtcctact ttgcacctgt gtggccccc	360
tagccagtgc tccagccct gccctgcagg atgatggttt cccn	404
<210> 260	
<211> 402	
<212> DNA	
<213> Homo sapiens	
<400> 260	
ggcacgagat ctccctgcct tgtgagcagc tggccggcg ctctggaca ggcggggatg	60
ggagggagtc taccggggca ctgttagagct ggtagctgg agctggagct gtagagttcc	120
aggctggagag ctggagagcc ctgggtgaga gggagcccta tagggcccc gggggacaca	180
ccaggcttga gggtagtagg tgctggaggc agagcctggc ctgtccaggg tgggacctca	240
cgaccaccc tgcgtccggcc ccagctcgga ggagcttcta cgtgtatgac ggcacccctgg	300
cactgctcaa cctactgcag gggctggggaa gtgagctgt gtgcttcgac atcatcgagg	360
ggctctggtg cgtggggggcc gcagggagtc tgcctcgtgg gg	402
<210> 261	
<211> 402	
<212> DNA	
<213> Homo sapiens	
<400> 261	

ggcacgagat	ctccctgcct	tgtgagcagc	tggccggcg	ctctggaca	ggcgggatg	60
ggagggagtc	taccggcca	ctgttagagct	ggtagctgg	agctggagct	gtagagttcc	120
aggctggag	ctggagagcc	ctgggtgaga	gggaggccta	gagggcccc	gggggacaca	180
ccaggcttga	gggttagtagg	tgctggaggc	agagcctggc	ctgtccaggg	tgggacactca	240
cgaccaccc	tgtccggccc	ccagctcgga	ggagcttcta	cgttatgcg	ggcatcctgg	300
cactgctcaa	cctactgcag	gggctgggg	gtgtgctgt	tgcttcgac	atcatcgagg	360
ggctctggtg	cgtgggggcc	gcagggtgtc	tgccctcgta	gg		402
<210>	262					
<211>	151					
<212>	DNA					
<213>	Homo sapiens					
<400>	262					
ggccaatatg	aagctacgtc	cggtatccg	ggttccctgt	aattgctttc	tgatccctgg	60
tacttagatt	tgattaccta	tggaccacat	tggtagaact	actatatggg	ggaacccctcct	120
gattttggc	ggtctcaaaa	acaaaaaaaaa	c			151
<210>	263					
<211>	404					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(404)					
<223>	n = A,T,C or G					
<400>	263					
ggcacgaggg	aacgtgaaag	gactagactg	cctgagtctt	ctgannnnnn	nnnnnnnnnn	60
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnt	120
ggacctaccc	cccgagtgg	ttgcagggg	ctctcagggc	ttcggctaca	gactgagggc	180
tgcattatca	gcttcctac	tttgaggtt	ttgggactt	actggcttc	ttgctcctca	240
acttcagat	ggcctgttgc	gggacctcac	cttgcata	tgtatcatgag	gaaatacac	300
accctccca	gggatgtatgg	aaggtaagg	tcctaacacc	tcctgcacat	ctgacatgc	360
gcacattgaa	ccagatagtc	ctggaatgtg	ggaaaacaga	ggcn		404
<210>	264					
<211>	380					
<212>	DNA					
<213>	Homo sapiens					
<400>	264					
ggcacgaggg	gaacggaaag	ccgggaccca	gaactcttgt	cttcaggat	aaagtggcca	60
gggtgtacga	agccccgggc	ttttcctgg	acctggagcc	catccggga	gccttggacg	120
ctgtcgaaaa	gatgaacgac	ctacggaca	cgcaggctt	catctgcacc	agccccctgc	180
tgaagtacca	ccactgtgt	ggtgagaagt	accgctgggt	ggagcagcac	ctggggcccc	240
agttcgatca	acgaattatc	ctgacaaggg	acaagacggt	ggtctgggg	gacctgtca	300
ttgatgacaa	ggacacagct	cgaggccagg	aggagacccc	aagctggag	cacatcttgt	360
tcacctgtcg	ccacaatcg					380
<210>	265					
<211>	440					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(440)					
<223>	n = A,T,C or G					
<400>	265					
ggcagaggcg	tggacaccac	ctcagccac	tgagcaggag	tcacagcacg	aagaccaagc	60

gcaaaagcgac	ccctgcctc	catcctgact	gttcctccta	agagagatgg	caccggccag	120		
agcaggattc	tgc	cccccttc	tgctgcttct	gtgcgtggg	ctgtgggtgg	cagagatccc	180	
agtca	gtgcc	aagcccaagg	gcatgac	ctc	atcacagtgg	ttaaaattc	agcacatgca	240
gccc	agcc	caagcatgca	actcagccat	gaaaaacatt	aacaagcaca	caa	aaaacggtg	300
caa	agac	ctc	aacac	cttcc	tgac	ccgagcc	tttctcc	360
cccc	aaaata	gc	ctgcaaga	atggcgataa	aaactgccc	caaa	gcccacg	420
cctg	accatg	tga	gactccn				gcccgtgtt	440
<210>	266							
<211>	396							
<212>	DNA							
<213>	Homo sapiens							
<220>								
<221>	misc_feature							
<222>	(1)...(396)							
<223>	n = A,T,C or G							
<400>	266							
gcacgaggag	gaacgtggaa	ggactagact	gcctgagact	tctgannnnn	nnnnnnnnnnnn	nnnnnnnnnnnn	nnnnnnnnnnnn	60
nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnn	nnnnnnnnnnnt	120
tggacctacc	ccccgagttg	tttgc	ccaggg	gctctcaggc	cttcg	ctac	agactgagg	180
ctgcattatc	agcttcc	ta	ctttgaggt	tttggactt	tactg	cttt	cttgc	240
aacttgcaga	tggc	cgtt	tg	ggac	ctca	c	tgtgatc	300
cacc	ccccc	cc	cc	cc	cc	cc	cc	360
tcac	atgt	gt	ggat	gt	ctt	cc	tc	420
tgca	catt	tg	gat	at	cc	cc	cc	440
cac	atgt	cc	gat	cc	cc	cc	cc	
<210>	267							
<211>	429							
<212>	DNA							
<213>	Homo sapiens							
<400>	267							
ggcacgagga	tctgacagcc	taggagtgcg	tggacaccac	ctcagcc	ccac	tgagcaggag		60
tcac	acgc	gc	aa	ggc	cc	cc	cc	120
agag	atgg	cc	cc	cc	cc	cc	cc	180
ctgtgg	ttt	cc	cc	cc	cc	cc	cc	240
ttt	aa	cc	cc	cc	cc	cc	cc	300
aaca	ggc	cc	cc	cc	cc	cc	cc	360
gtgg	cc	cc	cc	cc	cc	cc	cc	420
caga	cc	cc	cc	cc	cc	cc	cc	429
<210>	268							
<211>	405							
<212>	DNA							
<213>	Homo sapiens							
<400>	268							
ggcacgaggc	ggcttcc	cccg	ccg	ccg	ccg	ccg	ccg	60
taa	gtgt	gt	gt	gt	gt	gt	gt	120
agc	ttgg	ac	cc	cc	cc	cc	cc	180
cag	cc	cc	cc	cc	cc	cc	cc	240
cct	gg	gg	gg	gg	gg	gg	gg	300
gg	ac	cc	cc	cc	cc	cc	cc	360
gcac	at	cc	cc	cc	cc	cc	cc	405
<210>	269							
<211>	372							
<212>	DNA							
<213>	Homo sapiens							
<400>	269							
ggcacgagaa	ccctgaggcc	tggctatgg	accacgggt	ggtaggt	gcc	cagcg	ctg	60

ccatcgtgga caccttctgg caaacagaga caggtggcca catgttact ccctttcctg	120
gtgccacacc catgaaaccc gtttctgcta ctttcccatt ctttgggtta gctcttgca	180
tccatgttgcgtccgggaa gagtttggaaag gcgaagctga aggttatctg gctgccagcg	240
ggaccaggat ggcttattact ggatcactgg caggatttat gacatgctca atgtatctgg	300
acacctgctg agtacagcag aggtggagtc agcacttgttgc gaaatgagg ctgttgcata	360
ggcacctgttgc gg	372
<210> 270	
<211> 411	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(411)	
<223> n = A,T,C or G	
<400> 270	
ggcacgagag ctctcggcgc acggccccagc ttcccttcaaa atgtctactg ttcacgaaat	60
cctgtcgaag ctcagcttgg agggtgatttgc tccaggaagt tattccagat gaagacttat	120
acnn	180
nn	240
nn	300
nn	360
nn	411
<210> 271	
<211> 302	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(302)	
<223> n = A,T,C or G	
<400> 271	
ctgagtgtga cactcagaga gtgtgttata tagacagaga gagagcgccgc gcctctgttcc	60
ccccccctgt gtgtgccccca ctccagtgccg cccagatccg tgccccccccc cggagcgccg	120
tgtccctnn nnnnnnnnnnag tgcacacc cccctccccc tctcatgatg gcccacataat	180
atattctgt gtgacccttc cccccccctg ccagttagtgc tccccccccc agcgcgagtc	240
actgttttat tttttctcgc ccccaagaag ggatagcgtat gtgtctctcc cttccctccca	300
ca	302
<210> 272	
<211> 429	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(429)	
<223> n = A,T,C or G	
<400> 272	
ggcacgagat gtggtagaca catcttagttg gcaggaggcca aagatgttgc caaacatgtt	60
gtann	120
nn	180
nn	240
nn	300
nn	360
nn	420
tcttgcggat	429

<210> 273
<211> 471
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(471)
<223> n = A,T,C or G

<400> 273

tgttgtgcat	ttgggcattcc	caccgattcg	aattcggcac	gagaaagcat	tgaagagacc	60
tcaaggctt	aagaaatgag	taggcaaaaa	tctaagtcaa	aggagaatct	gtactggggc	120
ccccctgtcc	ctgaggtcat	tggccaagcc	aagccgaacc	tgagcttga	tcctgatgg	180
ttggggagtg	aggaagacag	aagtggaaagc	ccagttctca	ccccaaagagg	ggacacaaaat	240
ggatgaccct	cccatgtatgc	tgagacccc	aaaggctaca	cactcaagct	aaaagccaga	300
ggaatccca	tcctgccacc	cacaagactt	caagggaaagt	tgttttggtg	ctgagcagag	360
caggggaga	agggaaaacag	cccttaagga	gctccagcca	ctggccagcc	ttcatgtgac	420
tctagccaa	attcattccc	atcacctggg	gtggaaagggc	cagaatctc	n	471

<210> 274
<211> 391
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(391)
<223> n = A,T,C or G

<400> 274

ggcacgaggt	aaactctcta	taagtgttca	gtgttgcacat	agccttgg	catagnnnnn	60
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnntt	tttgcaccc	ctggaaaaaa	ggggatgcnn	120
nnnnnnnnng	ggggaaaaac	aattcttaag	ggccctttgg	ccataaactt	ttttccgggc	180
caccttgg	acttttggtc	ctggaaagggg	tttttttgg	ggcccacgg	ggaggggccc	240
cataggtaaa	ctcggaaaac	ttttcttaac	ccgggttagt	gttttaatt	aaaacccaaa	300
annnnnnnnn	nnttggaaatc	ctttcttta	aaaaaattaa	tctctcaaag	aaaaacaaag	360
nnnnnnnnnn	nggggggccc	cttgcgttta	g			391

<210> 275
<211> 339
<212> DNA
<213> Homo sapiens

<400> 275

cactccgggg	gctctattt	tgtgctctgc	acccagttt	ttatacactc	cacgctttgg	60
atataacatc	tagcgccacg	gtgcctatgt	gtacacaccc	tctctctata	tatagataacc	120
tctgtgcgca	catatagagg	ggaaaagaga	gatatatcta	tttatataac	atttctacac	180
aactgtctct	gggggtcag	agaacgcgcg	cacccctctc	ttttgagaga	aggagactct	240
gtccccccctc	tctggggcgc	agggaggccc	catggcatga	agaaaaataac	tcacttataat	300
ctctctctct	cactctctgt	ttgcggaaaa	acacacagg			339

<210> 276
<211> 434
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(434)
<223> n = A,T,C or G

<400> 276

cccttagctac	ttgctcttgc	tgcaggatgc	catagattcg	tgggctcctg	ccttttctca	60
accccggagt	gcctgaccag	ttctaccgccc	tgtggctatc	cctcttcctg	cacgcccggga	120
tcttgcactg	cctgggtgtcc	atctgcttcc	agatgactgt	cctgcgggac	ctggagaagc	180
tggcaggctg	gcaccgcata	gccatcatct	acctgctgag	tggtgtcacc	ggcaacactgg	240
ccagtgcctat	cttcctgcca	taccgagcag	aggtgggtcc	tgctggctcc	cagttcggca	300
tcctggctgt	cctcttcgtg	gagctcttcc	agagctggca	gatcctggcg	cggccctggc	360
gtgccttctt	caagctgtg	gctggggagg	cttttcttcc	cacctttggg	ctgctgccgt	420
ggattgacaa	cttn					434
<210>	277					
<211>	378					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(378)					
<223>	n = A,T,C or G					
<400>	277					
ggcacgagaa	aaagtaccgc	tccagagcag	gagcctaggc	agccgagagg	gtgcccgaac	60
ctgagtctga	gttgcggcca	cttcaggagc	ttagaggagc	aggatggaaac	tgcaggatcc	120
aaagatgaat	ggagccctcc	cttcggatgc	tgtgggctac	aggcaagaac	gtgagggctt	180
cctgcccagt	cgtggccctg	ctccctggag	caagccggtc	cagttcatgg	atttcgaggg	240
gaagacatcg	tttggaatgt	cagtgttcaa	cctcagcaac	gccatcatgg	gcagcggcat	300
cctggggctg	gcctatgcca	tggccacac	gggggtcatt	ttcttctgg	gcctgctgct	360
gnccatcg	cttctgcc					378
<210>	278					
<211>	302					
<212>	DNA					
<213>	Homo sapiens					
<220>						
<221>	misc_feature					
<222>	(1)...(302)					
<223>	n = A,T,C or G					
<400>	278					
cccccnctct	cggccnnnnnn	nnnnncgttt	tcactcccg	gagtccccctt	gtttttggcc	60
cggatccggg	ttctttcttt	cccgtggc	cgcgggttgg	agtgttttat	cttttcttca	120
catggggggc	tggggagttc	cccagaaccc	ccagggggaa	accccccctcc	tatgaaaatg	180
acacatgagc	ccctccctcc	ggtgccgggg	acctgtctct	ctaagaccct	tttctggaa	240
agggtcttt	gtttgtatga	ccccacccac	gcggggggct	ttctatggc	cgccccccccc	300
cg						302
<210>	279					
<211>	405					
<212>	DNA					
<213>	Homo sapiens					
<400>	279					
ggcacgaggc	ctcattggag	acattgacaa	tgccatgagg	accttcctca	actactacac	60
tgtatggaa	cagtttgggg	ggctcccgga	attctacaac	attcctcagg	gatacacagc	120
ggagaagcga	gagggctacc	cactcggcc	agaacttatt	gaaagcgcaa	tgtacctcta	180
ccgtgccacg	ggggatccca	ccctccctaga	actcggaaaga	gatgctgtgg	aatccattga	240
aaaaatcacc	aagggtggat	gcccatttgc	aacaatcaa	gatctgcgag	accacacgct	300
ggacaaccgc	atggagtcgt	tcttcctggc	cgagactgt	aaatacctct	acctcctgtt	360
tgacccaacc	aacttcatcc	acaacaatgg	gtgcacccctc	gacgc		405
<210>	280					
<211>	415					
<212>	DNA					

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(415)

<223> n = A,T,C or G

<400> 280

ggcacgaggg	tcacctgtgc	tgcccctcct	taatctcgta	tgatggtcac	agtccgggtgg	60
ccgtgggggt	gctctgcctt	ccctgggtccc	cactgcccatt	atctgtggac	tgccccttcc	120
aaagaccctt	gggggggggtt	ganananattc	aatcttacca	aactcaacga	tccatccatt	180
tcatgttact	gatattacat	gccccacaccc	ctggatcata	ttatttcaaatt	ccagtcatct	240
attctgcatt	catgacccctt	tgataactcc	atcatgaccc	acttgacgggt	cactgaccat	300
gcttacttgg	ttccgccttg	taacaataaa	atctatattaa	actnnnnnnnn	nnnnnnnnnnnn	360
nnnaccagcc	cacataaaaat	atgattgaat	caatttctta	taccttcaact	agaat	415

<210> 281

<211> 389

<212> DNA

<213> Homo sapiens

<400> 281

ggcacgaggt	agactggggg	ctcactgatt	gcattgacac	ttttcatcat	gggtccccgg	60
gggctcacgt	ggaggctgtac	acatgaatac	atggctatca	tgtctgtcac	cttcaatggg	120
gaaaaacaaac	ttttaatgg	tagggaaacac	aacaggtaca	ataatttaca	aaaatatgtt	180
tgccacattt	cagggcaagg	caaaatgcag	aggagacata	tgttaaaatc	ttatcattca	240
catttgttct	ttttatcttt	aagatgaagc	tcttacacca	agtgtcacga	gtctggagaa	300
catatgggtt	gaagagctgt	tcttataaaa	taagatctgg	ggaacacaat	cctttatata	360
tcaacatcac	agtggatttt	tggattggg				389

<210> 282

<211> 371

<212> DNA

<213> Homo sapiens

<400> 282

ggcacgagat	agaatccgag	gcattgatat	cattaaatgg	atggagcgt	accttaggga	60
taagaccgtg	atgataatcg	tagcaatcg	ccccaaatac	aaacaggacg	tggaaaggcgc	120
tgagtcgcag	ctggacgagg	atgagcatgg	cttacatact	aagtacattc	atcgaatgat	180
gcagatttag	ttcataaaaac	aaggaagcat	gaatttcaga	tccatccctg	tgtctttccc	240
aaatgctaag	aggagcatg	tgcccacctg	gcttcagaac	actcatgtct	acagctggcc	300
caagaataaa	aaaaacatcc	tgctgcggct	gctgagagag	gaagagtatg	tggctcctcc	360
acggggccct	c					371

<210> 283

<211> 413

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(415)

<223> n = A,T,C or G

<400> 283

ggcacgaggt	gggagacacc	acttgtcttt	atgtgggtct	caaagatgtat	gtagaatttc	60
ctttaatttc	tcgcagtcctt	cctgaaaat	attttcctt	gagcagcaaa	tcttgttaggg	120
atatcagtga	aggtctctcc	ctccctcctc	tcctgnnnnn	nnnnnnnnngga	aacaaagttt	180
tgcttttgtt	ccccagcctg	aagggaagg	gctcaatttt	ggttaaccaa	aaccttggcc	240
tccgggtta	aagcaattct	ccggcctaac	cctttggaga	acctgggtta	ataggcgcag	300
gcccccaggc	cgggttaatt	ttgggtttta	agaaaaaaaca	gggttctca	atgtggggca	360
ggcgtggcca	aaaccccccac	cctaaggggta	tcggccctcc	ttggcctccc	aan	413

<210> 284

<211> 409

<212> DNA

<213> Homo sapiens

<400> 284

ggcacgaggc	ctggggatgc	tccctgctaa	gtgggcctgc	tcaccacccctt	gccataaagc	60
tctaggcgag	cctgagcctg	ccgtgggggc	cccactgtga	ccctgcccga	gtcttcctgg	120
gtccctgcgt	cctcttaagg	ggcaigtgaca	cctgcctcgc	tggccctgtg	tgggtggca	180
gccccactgt	ttgggatatac	acatggccag	gcacgtggtg	agcctgctca	gggcggacgc	240
ctgcaggcgc	gtgctcggtc	acacactgac	ttgtgtggcc	ctccctgtccg	gtgcagcctg	300
gacctggacg	cctggatcaa	tgaggccactc	tcggacagcg	agtcaagagga	cgagaggccc	360
aggccgtct	tccacgagga	ggagcagcgg	cgtcccaagc	accggccgt		409

<210> 285

<211> 404

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(404)

<223> n = A,T,C or G

<400> 285

ggcacgagcc	acttcacccc	cttggggct	gcttattcac	tctgggatt	cgccatggac	60
acgtctcaac	tgcgcaagct	gctgcccatt	tttccctgcc	cctccagatt	gcctggagat	120
ctattttgtt	tccttttgtt	tttcttttc	tgtttttagt	gtcttcttt	gcaggtttct	180
gtagccggaa	gatctccgtt	ccgctccca	cggtccca	gtaaattccc	cttccccctg	240
ggaaaatgca	ctacctgtt	ttggggggtt	taggggttt	tttgggggtt	agnngnntttg	300
nttttttgggn	nnnnnnnnnn	gnnttgactt	ttttnnctt	tatttggag	gtaatggaa	360
agaataggaa	aatcaggcag	gggggagaat	ggttgtttat	tctt		404

<210> 286

<211> 441

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(441)

<223> n = A,T,C or G

<400> 286

ggcacgagg	aagcggtgg	tgtgtgtccc	ctgttactt	ttagctgagc	tggggttggg	60
tgtacgggtt	ctgttccct	gagccctgcg	gcccaccta	tgttacgtg	tgtgtgtgag	120
ggggggcggc	gctncncnn	cacccccc	nggccttat	ccttgtgaag	ctctcctcaa	180
tctaatactt	attgcccctg	actccaaatc	ttccacctt	tgcctcttat	tatatctatg	240
ttcattacct	taggtcagct	gttctctatt	atgacactga	ttcatacttt	tgttttttga	300
taagtactt	tttcctctt	cattgttgct	aatatccctt	tcctttttt	cttggctac	360
tctcaactca	tctataaaac	tcttacat	ctctccacta	atttctttga	actaacaatt	420
tttatataaga	atttaaggct	g				441

<210> 287

<211> 387

<212> DNA

<213> Homo sapiens

<400> 287

ggcacgagca	gcccgttgaat	tccgcaagca	cccgaggccc	gggggtctc	cgcgggcgtc	60
ccatgcggag	gacatgggtgc	gcccgtgtact	tttccccacg	acctcaggga	ccggcccc	120
cgcggact	gcttcctacc	tggtccggtc	ccggcagctg	aatctggcca	ccccaacctc	180
ccggtcgcta	tggcaccac	aggcctaaca	ttcgcgagtc	cacccctccgc	cgtccgcgag	240

gaaaacctga ttggcgccct cttggcgate ttcgggcacc tcgtggtcag cattgcactt	300
aacctccaga agtactgcc a catccgcctg gcaggctcca aagatccccg ggcattttt	360
aaagaccaaa actggtggt tggcct	387
<210> 288	
<211> 439	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(439)	
<223> n = A,T,C or G	
<400> 288	
ggcacgagg aggctgaaag cgggtggtgt gtgtccctg tttactttta gctgagctgg	60
ggttgggtgt acgggttctg ttccctctag ccctgcggcc cacctgatgt ttacgtgtgt	120
gtgtgagggg gggcggcgg nncannnnnn nnnnnnnngan tcttttcca ataacaatat	180
taattaatcc aatctttttt ctcttctct tctttctact cttttcctc cttttttttt	240
atttactttt actcatcc tc ttcttcat ttactctgtc ttttgatttta cttagttctt	300
ctcttcgca attttccctt attttgtca ctctttggg aataacgtac tcttatgaga	360
agtgtttcc tcttttatttta cattgggtt tcttctcctt tcataattta ttttacgtat	420
gtttgtggag ttttttctt	439
<210> 289	
<211> 170	
<212> DNA	
<213> Homo sapiens	
<400> 289	
atgagtggtc ttttaattttag gaacaaatct aatggaaagg agagttgact gaagttggcc	60
cacaggattt tgagctggc agaggcttca tgaaggcttg ccaccccttggg acgcccattt	120
taatgggggg gcctgctgttta aggcaaaagg ctttttggca aattgctggg	170
<210> 290	
<211> 393	
<212> DNA	
<213> Homo sapiens	
<400> 290	
ggcacgaggt agactggggg ctcactgagt gcagtgcac ttttcatcat gggccccgg	60
gttctcacgt ggagtctgac acatgaatac atggctatca tgtctgtcac cttcaatggg	120
gaaaacaaac tttgtaatgg tagggaaacac aacaggtaca ataatttaca aaaatatgtt	180
tgcacacattt cagggcaagg caaaatgcag tggagacata tgtaaaatttca ttatcattca	240
catttgcattt ttttatctt aggtgaagc tcttacacca agtgcacga gtctggagaa	300
cagatgggtt gagtagttgt tcttataat tagtatctgt ggaacacaat ctttatata	360
tcaacatcac agtggatttc tggcttggtg cat	393
<210> 291	
<211> 430	
<212> DNA	
<213> Homo sapiens	
<400> 291	
ggcacgaggg atagaatccg aggcatgtt atcattaaat ggatggagcg ctacctttagg	60
gataagaccg tggatgataat cgtagcaatc agcccaaat acaaacagga cgtggaaaggc	120
gctgagtcgc agctggacga ggatggacat ggcttacata ctaagtagat tcatcgaatg	180
atgcagattt agttcataaa acaagggaaatc atgaatttca gattcatccc tggctcttc	240
ccaaatgcta agaaggagca tggccacc tggcttccaga acactcatgt ctacagctgg	300
cccaagaata aaaaaaaacat cctgctgcgg ctgctgagaa aagaaaaaga tggctccct	360
tcacgggggc ctcttgcac ccttcaagtg ggtcccttgt gacacccgtc aatcccagat	420
cactgaggcc	430

<210> 292

<211> 423

<212> DNA

<213> Homo sapiens

<400> 292

atcccatcg	ttcgaattcg	gcacgaggga	agcaaggcca	cccgccttat	ggatggaatt	60
gaggggaaagg	cacccggggc	tcctgcacg	agcttccctc	ctatattcaa	tgaggaaatg	120
accctgcaga	aggctggctg	cagatgcccc	tgcctcccg	ctttgcctgc	ttggagtttg	180
atgacacgt	ggtcctgtca	ggctacagc	aggctatgg	tctttggtaa	cggaaagcgc	240
tggtaaaca	gtgagcttc	ccgtgggtgc	ttttccctga	cgccaaacaac	caggcaagc	300
tgcctgtct	gctgcttggc	cgctccctag	agctgcggcc	gggagagttc	gtggtcgcca	360
tcggaagccc	gtttccctt	caaaacacag	tcaccacccg	gatcgtgagc	accacccagc	420
gag						423

<210> 293

<211> 409

<212> DNA

<213> Homo sapiens

<400> 293

ggcacgaggc	taggagtact	ggcttagatg	gttatagaag	tccatgccag	gaggcgtct	60
gcagtcagag	ggtgtttctg	ggctggactc	cagcccctc	ctgtcgagg	ccaatgccga	120
gcggattgtg	cagaccttat	gtacagttcg	agggccgc	ctcaaggttg	gccagatgct	180
cagcatccag	gacaacagct	tcatcagccc	tcaagtcag	cgcatcttg	agcgggtccg	240
ccagagcgc	gacttcatgc	cccgtggca	gatgctgaga	gttcttgaag	aggagctcgg	300
cagggactgg	caggcaagg	tggctccctt	ggaggaggtg	cccttgccg	ctgcctcaat	360
tggcaggtg	caccagggcc	tgctgaggga	cgggacggat	gtggcgtg		409

<210> 294

<211> 369

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(369)

<223> n = A,T,C or G

<400> 294

ggcacgaggc	cagctgctgg	tggagcggca	ctggggactg	gaggctggaa	gcgggtggtg	60
tgtgtccct	gtttactttt	agctgagctg	gggttgggtg	tacgggtct	gttcctctga	120
gccctgcggc	ccacctgatg	tttacgtgtg	tgtgtgaggg	ggggcggngn	nnnnnnnnnn	180
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	240
nnnnnnnnnn	ntnaatatat	tttttggttt	aatgggtnnn	nnnnnnnnnn	nnnnnnnnnn	300
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnataaaatt	360
attaaaattt						369

<210> 295

<211> 403

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(403)

<223> n = A,T,C or G

<400> 295

ggcacgagt	cttctctagc	tctctaggcc	tctccagttt	gcacctgtcc	ccaccctcca	60
ctcagctgtc	ctgcagcaaa	cactccaccc	tccacctcc	attttcccc	actactgcag	120
cactccagg	cctgttgcta	taggcctac	ctgtatgtca	ataaacaaca	gctgaagcn	180
nnnnnnnnnn	nnnnncccc	cccctaaaa	acaatgggg	gccgttacc	aaaaacccaa	240

actggaaaaa acccttggtg gagttggacc acccccccacc taaagggcgg gaaaaaaaaag	300
gctttattgg aaaaatttggg gaggcttgg tttaattgga acccataaaa gccggcaaaa	360
aacaggttaac caccaccatt ggcttcttt ttagtttcag ggg	403
<210> 296	
<211> 384	
<212> DNA	
<213> Homo sapiens	
<400> 296	
ggcacgagga gaacttctgg atcgggccc gctcgaggc cctcatccac ctgggcgcca	60
agtttgcgc ctgcatgcgc caggaccgc aggtgcacag cttcatcg tcggcgcgc	120
agcgcgagaa gcactccgccc tgctcggtgc gcaacgcacag gtcggctgc gtgcagacct	180
cggaggagga gtgcgtccta acaggattt tgccgtcaaa ctcccttcca cgctggcagt	240
gtgggtgaag tggcccatcc atcccagcgc cccagagctt gcggggccaca agagacagtt	300
tggctctgtc tgccaccagg atcccagggt gtgtgtatgag ccctctccg aagaccctca	360
tgagtggcca gaagacatca ccaa	384
<210> 297	
<211> 401	
<212> DNA	
<213> Homo sapiens	
<400> 297	
ggcacgagat taagtgaatt gcgttatatt tatgaccttta aggaccagat acaggaggta	60
gaagggagat acatgcaggg gcttaaagaa ctaaaggaat ctttgtctga aagtggaa	120
aaatacaaga aagccatgtt ttccaatgca cagtttagaca atgagaagaa caatttgatc	180
taccatgttag acaactcaa ggatgttattt gaagagcagg aggaacagat ggcagaattt	240
tatagagaaa atgaagaaaa atcaaaggag tttagaaaggc agaaacatat gtgtgtatgt	300
ctgcagcata agatggaaaga acttaaagaa ggcctgcgc aaagagatga gcttattttag	360
aaacatggct taagtataat ccccgatggc actcccaatg g	401
<210> 298	
<211> 430	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(430)	
<223> n = A,T,C or G	
<400> 298	
aaatgggaga actctgaggt ncccaacgat tcgcattcgg cacgaggcca gctgctgggg	60
gagcggctct ggggacttgg ggcttggaaac ggggtgggtgt tgccttctgt ttacttttag	120
ctgagctggg gttgggtgtt cgggttctgt tcctctgagc cctgcggccc acctgtatgtt	180
tacgtgtgtg tttgggggg ggcgggnnac gntatanacc catcttattt tcaaattaca	240
aaatcccant aataggtatc tccatcaagc tgcangagga ggagagagaa atgagagaca	300
attatgttcc tttgggtctca gccttggatc aggagattt tgaatgtat tcttgcctca	360
aggagatgtt gttttttttt gactttgggg gtctgttcaa ctttcatgtt acttcaactt	420
cagctggaa	430
<210> 299	
<211> 387	
<212> DNA	
<213> Homo sapiens	
<400> 299	
ggcacgaggt ttcatacattt ctcagaattt gtatatacaag acacattttaa atataagccc	60
tctggaaatg gttttatata cagtcatcat aattcccccc ttagaaattt gtaatatttt	120
atagccaggt tttagtttag tgtcaagtat agtgtatgtt ggtctatcac tactcatgaa	180
gtggaaaccccttctactcat aaaaacccca atcagacata tagatgaata gaaccttgc	240
aacatttagaa tgccttggtc tctgaaggct tacaagacta tacgtcagga tatattaagg	300

agaagctgag	gaacgaaaaga	aacttcgaca	agagaatgga	aatgtacatg	ctatagcata	360
actgaagaat	aaaatacagg	tttgagg				387
<210> 300						
<211> 373						
<212> DNA						
<213> Homo sapiens						.
<400> 300						
ggcacgagac	tagtccgact	ttttatgtgc	tatgcaaaat	agacatctt	aacatagtcc	60
tgttactatg	gtAACACTT	GTTCCTGAA	TTGGAAGGGA	AAAAAATGTA	ACGACAGCAT	120
tttaagggtt	ccatggtaac	cagccacagt	acatatgtaa	ttctttccat	caccccaacc	180
tctcctttct	gtgcattcat	gcaagagttt	cttgtaagcc	atcagaagtt	acttttagga	240
tgggggagag	gggcgagaag	ggggaaaaatg	ggaaatagtc	tgatttaat	gaaatcaaata	300
gtatgtatca	tcagttggct	acgttttgtt	tctatgctaa	actgtgaaaaa	atcagatgaa	360
ttgataaaaag	agt					373
<210> 301						
<211> 369						
<212> DNA						
<213> Homo sapiens						
<400> 301						
ggcacgagac	tagtccgact	ttttatgtgc	tatgcaaaat	agacatctt	aacatagtcc	60
tgttactatg	gtAACACTT	GTTCCTGAA	TTGGAAGGGA	AAAAAATGTA	CGCACAGCAT	120
tttaagggtt	ccatggtaac	cagccacagt	acatatgtaa	ttctttccat	caccccaacc	180
tctcctttct	gtgcattcat	gcaagagttt	cttgtaagcc	atcagaagtt	acttttagga	240
tgggggagag	gggcgagaag	ggggaaaaatg	ggaaatagtc	tgatttaat	gaaatcaaata	300
gtatgtatca	tcagttggct	acgttttgtt	tctatgctaa	actgtgaaaaa	atcagatgaa	360
ttgataaaaag						369
<210> 302						
<211> 399						
<212> DNA						
<213> Homo sapiens						
<400> 302						
ggcacgaggc	agcagacacg	gctgatgatg	atcaaccatg	accttcggca	ccgggtcact	60
gtgtggagg	cccaggggaa	agccctgatc	gaacagaagg	tggagctgga	gcgcagacctg	120
cagaccaagg	agcaggagat	ggcagcctg	cgagcagacg	tggggaaagt	gcgcagagagg	180
ctgcaggggg	agcacagcca	aatggggag	gaggagcctg	agacggagcc	gtgtggagag	240
gagagcatct	ccgacgcaga	gaaggtggcc	atggatctca	aggaccccaa	ccgcggccgg	300
ttcacccctgc	aggagctgcg	ggacgtgctg	cacgagagga	acgagctcaa	gtccaaagggt	360
ttcttgctgc	aggaggagct	ggcttactat	aagagttag			399
<210> 303						
<211> 391						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (1)...(391)						
<223> n = A,T,C or G						
<400> 303						
ggcacgagca	cagccccctga	ctgccccgac	ccccacagag	cccgccgcgc	accccacgtc	60
ccccacgcca	gcgcggcc	atggaggcca	tcaagnnnnn	nnnnnnnnnn	nnnnnnnnng	120
acaaggagaa	tgccatcgac	cgcgcggac	aggcgagggc	ggataagaaa	ccgcgtgagg	180
acaagtgcac	gcaggtggag	gaggagctga	cgcacactca	gaagaaaacta	aaagggacag	240
aggacgagct	ggataaaat	tccgaggacc	tgaaggacgc	gcaggagaag	ctggagctca	300
cggagaagaa	ggccctccgac	gctgaagggt	atgtggccgc	cctcaaccga	cgcacccagc	360
tcgttggaga	ggagttggac	agggctcang	a			391

<210> 304
<211> 418
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(418)
<223> n = A,T,C or G

<400> 304
ggcacgagtg ccgcagcccc cacagagccc gccgcgcacc ccacgtcccc caccgcagcg 60
cccagccatg gaggccatca agnnnnnnnn nnnnnnnnnn nnnnnngaca aggagaatgc 120
catcgaccgc gcggagcagg cgaggcggta taagaaagcc gctgaggaca aytgcgaagca 180
ggtggaggag gagctgacgc accttccagaa gaaactaaa gggacagagg acgagctgga 240
taaatattcc gaggaccta accacgcgcgca ggagaagctg gagctcacgg ayaagaaggc 300
ctccgacgct gaaggtgatg tggccgcct caaccgacgc atccagctcg ttgaggagga 360
gttggacagg gctcangaaac gactggccac ggccctgcag aagctggagg aggcagaa 418

<210> 305
<211> 420
<212> DNA
<213> Homo sapiens

<400> 305
ggcacgagga ttccggcaac aatttacaca gctggctgga ccagacatgg aggtgggtgc 60
cactgatctg atgaatattc tcaacaaagt ctttctaaag cacaagatc ttaagactga 120
cggttttagt cttgacacct gccggagcat tgtgtctgtc atggacagtg acacgactgg 180
taagctgggc tttaagaat ttaagtatct gtggaaacaac atcaagaat ggcagtgtgt 240
ttataagcag tatgacaggg accattctgg gtctctggta agttctcagc tgccggggagc 300
tctgcaggcc gcaggcttcc agctaaatga acaactttac caaatgatttgc tccgcggta 360
tgctaatgaa gatggagata tggattttaa caatttcatac agctgcttgg tccgcctgga 420

<210> 306
<211> 399
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(399)
<223> n = A,T,C or G

<400> 306
ggcacgagcc acgtccccca cgccagcgcc cagccatgga ggccatcaag nnnnnnnnnnnn 60
nnnnnnnnnnnn nnnggacaag gagaatgcca tcgaccgcgc ggagcaggcg gaggcggata 120
agaaagccgc tgaggacaag tgcaagcagg tggaggagga gctgacgcac ctccagaaga 180
aactaaaagg gacagaggac gagctggata aatattccga ggacctgaag gacgcgcagg 240
agaagctgga gctcacggag aagaaggcct ccgacgctga aggtgatgtg gccgcctca 300
accgacgcac ccagctcggtt gaggaggagt tggacagggc tcaggaacgca ctggccacgg 360
ccctgcagaa gctggaggag gcagaanaag ctgcagatg 399

<210> 307
<211> 438
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(438)
<223> n = A,T,C or G

<400> 307

atccccatcg	ttcgaattcg	gcacgagccc	ccacagagcc	cgccgtgcac	cccacgtccc	60
ccacgcccagc	gcccagccat	ggaggccatc	aagnnnnnnnn	nnnnnnnnnnn	nnnnnnngac	120
aaggagaatg	ccatcgaccg	cgcggagcag	gcggaggcgg	ataagaaaagc	cgctgaggac	180
aagtgcAACG	aggtggagga	ggagctgacg	cacctccaga	agaaactaaa	agggacagag	240
gacgagctgg	ataaatatTC	cgaggacctg	aaggacgcgc	aggagaagct	ggagctcacg	300
gagaagaagg	cctccgacgc	tgaaggtgat	gtggccccc	tcaaccgacg	catccagctc	360
gttggaggagg	agttggacag	ggctcatgaa	cgactggca	cggacctgca	gaagctggag	420
gagggcagaa	aaagctgc					438
<210>	308					
<211>	419					
<212>	DNA					
<213>	Homo sapiens					
<400>	308					
ggcacgagct	ttggcctgcc	cgctcccttc	ctttctggcg	acccgactct	ggctacgcaa	60
cggggccccc	gtcaatgcct	gggcctactg	ccacgtgcta	cccactgggg	acctgctgt	120
gttggcacc	caacagctgg	gggagttcca	gtgctggta	ctagaggagg	gcttccagca	180
gctggtagcc	agctactgccc	cacaggtgg	ggaggacgcgc	gtggcagacc	aaacagatga	240
gggtggcagt	gtacccgtca	ttatcagcac	atcgcgtgt	agtgcaccac	ctggtgccaa	300
ggccagctgg	ggtgcagaca	ggtcctactg	gaaggagttc	ctggtgatgt	gcacgctctt	360
tgtgctggcc	gtgctgtcc	cagtttatt	cttgctctac	cggcacccgga	acagcatgg	419
<210>	309					
<211>	415					
<212>	DNA					
<213>	Homo sapiens					
<400>	309					
ggcacgaggc	ttagccagag	acgcctcca	ttctctcttc	gcccggctc	tccggctggc	60
ctcccgatgc	gctgcccgc	ctgcaccat	gacggAACAG	gccatctctt	tcgacaaaaga	120
cttcttggcc	ggaggcatcg	tcgcctgtat	cttcaagacg	gacgtggctc	ctatcgagcg	180
ggtcaagctg	ctgctgcctgt	ccagcacgc	agcaagcaga	tcgcgcgcga	ctagcagtac	240
aaggcatcg	tggactgtat	tgtccgcata	cccaaagagc	atggagtgct	gtccttctgg	300
aaggcaacc	ttgccaacgt	caatcgatc	ttccccactc	aaggcctcaa	tttcgtcttc	360
aaggataatg	acatcgatc	cttactgggg	ggcgtggaca	aacacacgca	ggtct	415
<210>	310					
<211>	396					
<212>	DNA					
<213>	Homo sapiens					
<400>	310					
ggcacgagcg	ggtcctggcg	gtgccacatg	gggtaccagg	gcccgtgtg	.cactgactgc	60
atggacggct	acttcagctc	gctccggAAC	gagacccaca	gcatotgcac	agcctgtgac	120
gagtccctgca	agacgtgtc	gggcctgacc	aacagagact	gcggcagtg	tgaagtgggc	180
tgggtgtgg	acgaggggcgc	ctgtgtggat	gtggacgagt	gtgcggccga	gcccgcctccc	240
tgcagcgctg	cgcagttctg	taagaacgccc	aacggctct	acacgtgcga	agagtgtgac	300
tccagctgtg	tgggctgcac	agggaaaggc	ccaggaaact	gtaaagagt	tatctctggc	360
tacgcgaggg	agcacggaca	gtgtcgatgt	gtggac			396
<210>	311					
<211>	394					
<212>	DNA					
<213>	Homo sapiens					
<400>	311					
ggcacgaggc	ctctggggcc	tacagctcat	cctggtcacg	tgcccctcac	tgctcggtt	60
catgcacgtg	gcctaccgcg	aggaacgcga	gwgcaagcac	cacctgaaac	acggggcccaa	120
tgccccgtcc	ctgtacgaca	acctgagcaa	gaagcggggc	ggactgtgg	ggacgtactt	180
gctgagcctc	atcttcaagg	ccgcgtgg	tgctggcttc	ctctatatct	tccaccgcct	240
ctacaaggat	tatgacatgc	cccgctgtgt	ggcctgctcc	gtggagcctt	gcccccacac	300
tgtggactgt	tacatctccc	ggcccacgg	gaagaagg	ttcacact	tcatggtgac	360

cacagctgca tggagatctt cggccccagg cacc	394
<210> 312	
<211> 384	
<212> DNA	
<213> Homo sapiens	
<400> 312	
ggcacgaggc gaggaacgcg agcgcaagca ccacctgaaa cacggccca atgccccgtc	60
cctgtacgac aacctgagca agaagcgggg cggactgtgg tggacgtact tgctgagcct	120
catcttcaag gccgcgtgg atgctggctt cctctatatc ttccaccgccc tctacaagga	180
ttatgacatg ccccgcgtgg tggctgctc cgtggagcct tgcccccaca ctgtggactg	240
ttacatctcc cggcccacgg agaagaaggt cttcacctac ttcatgtga ccacagctgc	300
catctgcata ctgctcaacc tcagtgaagt cttcacctg gtggcaaga ggtgcattgaa	360
gatcttcggc cccaggcacc ggcc	384
<210> 313	
<211> 430	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> misc_feature	
<222> (1)...(430)	
<223> n = A,T,C or G	
<400> 313	
ggcacgagcc ggctcgtaag caacctttc agtctgcagt gggacccgcg cgcatgcag	60
cgtgccagca gcaacctgca ccgcggtccg ggcggggcgc tggctttct ggacaatgag	120
gcgggcttgg tgcacggcta ccggtagca ggcattgtggg acaagtataa cgagccgctg	180
ttgcagtcag tgcgtgtt ccgcgcgg accgcgcggc gcgtctggc gtcgcaccgc	240
ggacaggacg ccgcggcccg gctgctgcgc ctctaccggc gccacagacc tcgcttcccc	300
gagctggccg cccttgcaga ccccacgct cagtcgtac agcgcgcct cgacttccct	360
gccaaggcaca ttttgcactg taaggccaag tacggccggc ggtctggac ttatgtcac	420
cgggaggaan	430
<210> 314	
<211> 408	
<212> DNA	
<213> Homo sapiens	
<400> 314	
ggcacgagag cagaaggact ttgtctgaa caccaagcag cccggctgcc ccaacgtctg	60
ctatgacgag ttcttccccg tgcctccacgt gcgcctctgg gcccatacgc tcatctgg	120
cacgtgcccc tcactgctcg tggctcatgca cgtggctac cgcgagggac gcgcgcgca	180
gcaccacctg aaacacgggc ccaatgcccc gtccctgtac gacaacctga gcaagaagcg	240
ggcggactg tggggacgt acttgcgtag cctcatcttc aaggccggc tggatgtctgg	300
cttcctctat atttccacc gcctctacaa ggattatgac atgccccgcg tggggccctg	360
ctccgtggag ctttgcaccc acactgtgaa ctgttacatc tcccgcc	408
<210> 315	
<211> 412	
<212> DNA	
<213> homo sapiens	
<400> 315	
tccggccca tgcgcagccg ggcgcgttag ctgcgcgtct tcctgacccc cgatccctgg	60
ggcgaggatc ctttgacagg agcgtgaccc tgctggaggt gtgcgggagc tggcctgagg	120
gcttcgggct gcggcacatg tcctccatgg agcacacggg ggaggccctc cgggagcgcac	180
ttgccgcacgc catggccgag tcacccatgg gggacgtcg gggatccgga acagaacttc	240
agcgagaggg aagcatcgag actctgagta acagctcagg ctccaccagg gcgcgcatac	300
caagaaacctt tggatggctac cgatctccgc tgcccccaccaa tgagagccag cccctcagcc	360
tcttcccgac tggcttccccg taggtaccag caacctgctt ctgactggcc ag	412

<210> 316

<211> 300

<212> DNA

<213> homo sapiens

<400> 316

gccagccct	cagcctttc	ccgactggct	tcccgttaggt	accagaacc	tgcttctgac	60
tggccagcc	cctccccctgc	tggaggaggg	gagaagcccc	gctctggtc	tacccttcag	120
tctctgtct	tccttcatca	accaccttc	ccaagcttag	tgacagcagc	cgtccatcct	180
acctggatgg	agaagagacc	cttctccaag	cacccatcagc	cacttgcct	ctgcccacacc	240
tgtcggtgga	ggctgtggcc	aggagagact	gtagaagctc	ggtccctgtg	tatgtttgca	300

<210> 317

<211> 2064

<212> DNA

<213> homo sapiens

<400> 317

acctcagcca	atttcggcac	gagggcgta	ggaccctccg	agccaggtgt	gggatatagt	60
ctcggtgtc	gccgttttt	aagccgtct	aaaaagcga	atattcggt	gggagtgacc	120
cgattttcca	ggctgtatc	catgtccagg	ccaaacatg	aatccattt	ctttgggaa	180
gccgctggct	tgcttatgca	aaaaacaagt	tgattcgat	tcatcgtcc	cgtgggtggag	240
cctgtggaga	caacatttc	tcttatactg	ccacagtc	tagtgcgt	aaaacattga	300
aaagtggct	gacaatggta	gggaaagtgg	tgactcagct	gacaggcaca	ctgccttcag	360
gtgtgacaga	agatgtgtt	gccatccaca	gtaattcacg	gcggagtcct	ttggtcccag	420
gcatcatcac	agttatttgc	accggaaaccg	ttggagaggg	ccaggtgttt	gtgagtgagg	480
attctgacag	tgtggcatt	gtggccact	tccctgcca	tgagaagcca	gtgtgctgca	540
tggctttaa	tacaagtgg	atgcttctag	tcacaacaga	cacccttggc	catgactttc	600
atgtcttcca	aattctgtact	catccttgg	cctcatcaca	atgtgtgtc	caccatctgt	660
ataactcttca	caggggagaa	actgaagcca	aagtacagga	catctgttc	agccatgact	720
gtcgctgggt	tgtggtcagt	actctccgg	gtacttccc	cgttttcccc	atcaaccctt	780
atggtggcca	gccttgtgtt	cgtacacata	tgtcaccacg	agtagtgaat	cgcgtgagcc	840
gtttccagaa	aagtgtgtt	ctggaaagaga	ttgaaacaaga	actgacgtct	aagcaaggaa	900
gtcgctgtag	ccctgttcca	ggtctatcaa	gcagcccttc	tgggtcaccc	ttgcatggga	960
aactgaacag	ccaagactcc	tataacaattt	ttacaacaaa	caacccttggc	aacccttggc	1020
tcttcctct	tcccagctt	atggtagtga	tgccttggc	acaatcaag	cagccaatga	1080
cattggggac	catcacaaa	cgaaccggca	aagttaaacc	tcctccacaa	atttcaccca	1140
gcaaatacgat	ggggcgagaa	tttttgttgg	ctgtctatctt	cggaacatcc	aggtcatgg	1200
ttgcaaataa	tgcaggctg	aaaagagaaa	agatcagtc	caaacaagtt	gtagttgagt	1260
ccctgtacat	tatcgttgc	tatggcacct	tagtggaaaca	catgtggag	ccgcgacccc	1320
tcagcactgc	acccaagatt	agtgtacgaca	caccactgg	aatgtacaca	tcgcctcgag	1380
ccagctggac	tctggttaga	acccctcaat	gaaatgaatt	gcagccaccg	ttaatgca	1440
accaccctct	gctcctcgct	gcagatgcag	tacagtatta	tcagttcctg	tttgctggcc	1500
tggttcccc	tggaaagtct	gggcccatta	ctcgacatgg	gtcttacgac	agtttagctt	1560
ctgaccatag	tggacaggaa	gatgaagaat	ggctttccca	ggttgaattt	gtaacacaca	1620
ctggacccca	tagacgtctg	tggatggtc	cacagttcca	gttcaaaacc	atccatccct	1680
caggccaaac	cacagttatc	tcatccagtt	catctgttt	gcagtcacat	ggtccgagtg	1740
acacccacaca	gcctttttt	gatttgata	cagatgtat	tgatctcaac	agtctcagga	1800
tccagccagt	ccgcctctgac	cccgtcagca	tgccagggtc	atccctcca	gtctctgatc	1860
gaaggggagt	ttccacagt	attgtatctg	cctcaggtac	ctttgacagg	agcgtgaccc	1920
tgtctggaggt	gtgcgggagc	tggcttggagg	gcttcgggtc	gccccacatg	tcctccatgg	1980
agcacacacgg	ggagggccctc	cgggagcgcac	ttggcgcacgc	catggccgag	tcaccttagcc	2040
gggacgtcgt	gggatccgg	acag				2064

<210> 318

<211> 1365

<212> DNA

<213> homo sapiens

<400> 318

cgagaactct	gagtaacacgc	tcaggctcca	ccagcggcag	cataccaaga	aactttgtat	60
gctaccgatc	tccgctgccc	accaatgaga	gccagccct	cagcctttc	ccgactggct	120
tcccgttaggt	accagcaacc	tgcttctgac	tggccagccc	cctccctgc	tggaggaggg	180

gagaagcccc	gctctggtcc	tacccttcag	tctctgtct	tccttcatca	accacccccc	240
ccaagcttag	tgacagcagc	cgcccatcct	acctggatgg	agaagagacc	cttctccaag	300
cacctcagcg	cacttgcct	ctgccacacc	tgtcgggtgg	ggctgtggcc	aggagagact	360
gtagaagctc	ggtccctgtg	tatgtttgca	tatgacatcc	tgcattggat	ccgctttgt	420
attttttaac	catacccacg	gtggggcggg	tggggggagc	ctggAACAGT	gaccagatct	480
ggggcctga	gtggggacag	agtgtatcg	ccacccccc	attttgcacc	tgagtggaca	540
gtcacagect	cagctcatgt	ctggctgtga	cacacactgc	ccccagcttc	ccttggtcag	600
cccactcca	gcacgggg	aacggaggcc	cagactata	ggaaaggagg	aaggaggagac	660
atgcctcttc	ttcctcctt	ctttcccat	ctgttcctgg	gaagagttt	tctttcttat	720
ctttaagccc	ctttaccctg	gtccctgtact	gatcgtgaa	ggaaaccgtg	tttactgagg	780
ccctgttga	aagtgcacgt	cttgcataat	aaatcacgt	gcagttggaa	aaaaaaaaaaa	840
aaaaaaaaaaag	gatcttaat	taagcggccg	caagcttatt	ccctttagtgc	agggttaatt	900
ttagcttgc	actggccgtc	gtttacaac	gtcgtactg	gtaaaccctg	gcgttaccca	960
acttaatcgc	cttgcagcac	atccccctt	cgccagctgg	cgtaatagcg	aagaggcccc	1020
caccgatcgc	ccttcccaac	agttgcgcag	cctgaatggc	gaatgggacg	cgccctgttag	1080
cggcgatttca	agcggggcgg	gtgtgtgtgt	taccgcgcag	cgtgaccgct	acacttgcca	1140
gcgccttagc	gcccgttct	ttcgtttct	cccccttcct	ttttcgcac	gttcgcggc	1200
ttttccccgt	caagctctaa	atcggggct	cccctttagg	gttcccgatt	tagtgcctta	1260
ccggcacctc	gaccccaaaa	aacttgatta	gggtgtatgt	tcacgtatgc	ggccatcgcc	1320
ctgataagac	ggttttcgc	ccttgcacgt	tggagttccac	gttct		1365

<210> 319

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> synthesized primer

<400> 319

tgggatatacg tctcgtggtg cg

22

<210> 320

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> synthesized primer

<400> 320

tgattcgtatcg tcatcagtcc cg

22

<210> 321

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> synthesized primer

<400> 321

tgtgtcacag ccagacatga gc

22

<210> 322

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> synthesized primer

<400> 322

tgcaaacata cacaggacc g 21

<210> 323
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> synthesized primer

<400> 323
tttagcagca ctaatgactg tggc 24

<210> 324
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> synthesized primer

<400> 324
cgccgtgaat tactgtggat gg 22